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Summary 
The present work intended to evaluate the analysis of forensically relevant drugs in 
blood and urine by conventional and advanced LC-MS/MS methods.  
Chapter I gives a short review of the pharmacology of the drugs studied in this 
thesis (amphetamines, cannabis and hallucinogens) and their effects on human 
behavior and performance. Hallucinogens are psychoactive substances that 
powerfully alter perception, mood, and a host of cognitive processes. They are 
considered physiologically safe and do not produce dependence or addiction. Their 
origin predates written history, and they were employed by early cultures in a variety 
of sociocultural and ritual contexts. Nowadays, cannabis is still Europe’s most 
commonly consumed illicit drug as nearly a quarter of all Europeans have tried 
cannabis in their lifetime. Relaxation, well-being and somnolence are one of the 
effects of cannabis. Moreover, in parts of Europe, use of amphetamines constitutes 
an important part of the drug problem. They stimulate the CNS, increasing the heart 
rates and blood pressure and decreasing appetite, among other effects. 
LC-MS(/MS) is a widely used method in forensic laboratories, particularly in 
applications where non-volatile, labile or high-molecular-weight compounds are 
being analyzed. Chapter II aim to give an overview of the current LC-MS(/MS) 
applications in forensic laboratories and detailed information in relation to ionization, 
ion separation, and ion detection, together with tandem mass spectrometry. 
Suppression or enhancement of analyte ionization by coeluting compounds is a well 
known phenomenon in LC-MS(/MS) analysis mainly depending on the sample 
matrix, the sample preparation procedure, the quality of chromatographic separation, 
mobile phase additives, and ionization type. Therefore, common sample preparation 
procedures are protein PPT, LLE and SPE. Optimum sample preparation leads to 
enhanced selectivity and sensitivity. Detailed information about the recent 
applications of LC-MS(/MS) to the analysis of amphetamines, cannabis and 
hallucinogens in blood and urine are included at the end of this chapter.  
However, sample preparation is often regarded as time-consuming, a laborious 
work. Recent developments in on-line SPE aspects of high-throughput quantitative 
bioanalysis of drug and metabolite in biological matrices are described in Chapter 
III. High-throughput analysis is becoming increasingly important in forensic 
laboratories. One commercial automated on-line SPE system is the Symbiosis 
system manufactured by Spark Holland. In on-line SPE sorbents of very small 
particles are packed in a miniature LC column (cartridge) and higher pressures are 
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applied to distribute the SPE solvents. Switching valves direct the flow to the LC 
column or waste, as appropriate. In contrast of traditional off-line SPE, several times 
consuming steps are eliminated. The extracted sample is directly injected to the 
analytical column by a simple valve switch. As a consequence no sample volume is 
lost during transfer, thus increasing the overall assay sensitivity. An extensive 
literature survey is given about the application of this instrument to the analysis of 
drugs in biological matrices.  
Chapter IV presents the objectives of the thesis which are an evaluation of the 
conventional LC-MS/MS technique and the new trend, on-line SPE-LC-MS/MS 
(Symbiosis), for the analysis of:  
a) multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid and metabolites 
in urine using off-line SPE,  
b) THC and metabolites in blood with LLE as off-line sample preparation procedure, 
c) THC-COOH (main metabolite of THC in urine) by on-line SPE, and  
d) 7 amphetamines and metabolites in blood and urine also by on-line SPE. 
Chapter V.I presents the development and validation of a LC-MS/MS method for the 
quantification of hallucinogens and other related compounds in urine. The method 
comprises an off-line SPE procedure, evaporation to dryness and reconstitution in 
mobile phase. The total run time was 20 min. External QCs containing LSD where 
analyzed within each series of analysis. The method was fully validated and applied 
to authentic urine samples (containing psilocin, ketamine, norketamine and 
chlorpheniramine). Chapter V.II describes the validation of the method for the 
analysis of THC and two of its main metabolites in blood. LLE with hexane: ethyl 
acetate was applied as clean-up procedure followed by centrifugation, complete 
evaporation, and reconstitution. The run time was 13 minutes. Two external QCs 
were used within each series of analysis. The method was completely validated in 
terms of precision, accuracy, specificity, recovery, matrix effects and stability. Finally 
the method was applied to authentic blood samples from forensic cases. Chapter 
V.III focuses on the development and validation of a method using the Symbiosis 
system for the analysis of THC-COOH in urine (500 µL). As the THC-COOH is 
glucoronized in urine, a previous hydrolysis was carried out using KOH 10 M. Then, 
the diluted urine was acidified in the LC vials for its direct injection. The method was 
fully validated and applied to authentic samples from cannabis users. Another 
application of the on-line-SPE-LC-MS/MS system is presented in Chapter V.IV for 
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the direct quantification of 7 amphetamines and metabolites in blood and urine. The 
method, completely validated following international guidelines, required a minimum 
sample handling: the dilution of 100 µL blood or 50 µL of urine samples in the 
aqueous mobile phase, spiked with the IS, directly in the LC vials, previous injection. 
HLB cartridges were used for sample clean-up. The method was applied for the 
analysis of blood and urine samples from a MDMA study, and from forensic cases.  
The conclusions in Chapter VI show the advantages of LC-MS/MS and the new 
trend in on-line SPE. The results demonstrated that although conventional LC-
MS/MS methods are still robust and confident, on-line SPE coupled to LC-MS/MS is 
highly effective in terms of time safe and high throughput. 
Chapter VII is focused in the future perspectives in relation to LC-MS/MS 
applications. On-line SPE-LC-MS/MS and the UPLC-MS/MS are potent candidates 
for the analysis of drugs in conventional and alternative matrices (e.g. oral fluid), in 
such a way that the innovative chromatographic technologies are re-shaping the 











L’objet de cette thèse est d’évaluer l’analyse de drogues, pertinentes du point de 
vue médicolégal, dans le sang et l’urine par le biais des méthodes LC-MS/MS 
conventionnelles et avancés. 
Le Chapitre I présente un bref exposé de la pharmacologie des drogues traitées 
dans cette thèse (amphétamines, cannabis et hallucinogènes) et de leurs effets sur 
le comportement. Les hallucinogènes sont des substances psycoactives qui altèrent 
dans une large mesure la perception, l’humeur et la raison. Elles sont considérées 
physiologiquement sans risque parce qu’elles ne produisent pas de dépendance ou 
d’addiction. Leur origine remonte aux cultures ancestrales étaient utilisées dans les 
rituels sacrés et autres contextes socioculturels. Aujourd’hui le cannabis est la 
drogue illicite la plus consommée en Europe, de sorte que près d’un quart des 
européens l’ont goûté au moins une fois dans leur vie. Les effets du cannabis sont la 
relaxation, le bien-être et la somnolence. D’autres drogues problématiques en 
Europe sont les amphétamines. Elles stimulent le CNS en augmentant la pression 
artérielle et diminuant l’appétit, entre autres effets. 
LC-MS/MS est une technique largement utilisée dans les laboratoires médico-
légaux, en particulier dans l’analyse de substances volatiles, thermiquement 
instables ou de poids moléculaire élevé. Le Chapitre II fourni un exposé général des 
applications récentes avec LC-MS(/MS) dans les laboratoires médico-légaux ainsi 
qu’une information détaillée sur l’ionisation, la séparation et la détection des ions, en 
plus de la spectrométrie de masses en tandem. Le phénomène connu comme 
suppression ou augmentation de l’ionisation des ions dans les analyses avec LC-
MS(/MS) dépend principalement de la nature de la matrice, du processus de 
préparation de l’échantillon, de la qualité de la séparation chromatographique, des 
additifs de la phase mobile et du type d’ionisation. Les procédures type de 
préparation de l’échantillon sont la PPT, la LLE, et la SPE. Une préparation optimale 
de l’échantillon entraîne une augmentation de la sensibilité et de la sélectivité. A la 
fin de ce chapitre, on trouvera également des information détaillées sur les 
applications récentes de LC-MS(/MS) pour l’analyse des amphétamines, cannabis et 
hallucinogènes dans le sang et l’urine.  
Cependant, la préparation de l’échantillon est considérée comme une étape 
fastidieuse et nécessitante du temps. Le Chapitre III expose les récents 
développements en SPE on-line à propos de productivité dans les analyses 
quantitatives des drogues dans les matrices biologiques. Ainsi, les analyses de 
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haute production sont en passe de devenir essentiels dans les analyses médico-
légales. Un des systèmes commercialisés avec SPE on-line est le système 
Symbiosis produit par Spark Holland. Dans le système SPE on-line, le matériau 
d’extraction est emballé avec des particules très petites dans des colonnes LC 
(cartouches) qui travaillent à d’haute pression et auxquelles on applique les solvants 
d’extraction. Les valves d’échange dirigent le flux vers la colonne ou l’évacuent, si 
nécessaire. A la différence du SPE off-line classique, le système on-line permet 
d’éviter plusieurs étapes intermédiaires. Ensuite, l‘échantillon extrait est injectée 
directement dans la colonne analytique par le biais d’une simple valve d’échange. 
Par conséquent, il n’y a pas de perte de volume de l’échantillon et cela permet 
d’augmenter la sensitivité. Ce chapitre inclue également une révision 
bibliographique sur les applications actuelles de cet instrument pour l’analyse des 
drogues dans les fluides biologiques.  
Le Chapitre IV présente les objectifs de la thèse qui sont l’évaluation de la 
technique LC-MS/MS conventionnelle ainsi que la nouvelle tendance SPE-LC-
MS/MS on-line (Symbiosis), pour l’analyse de  
a) nombreux hallucinogènes, chlorpheniramine, ketamine, acide ritalinique et 
métabolites dans l’urine avec SPE off-line :  
b) THC et métabolites dans le sang au moyen de LLE off-line comme procédure de 
préparation de l’échantillon,  
c) THC-COOH (principal métabolite du THC dans l’urine) par vu de SPE on-line et  
d) 7 amphétamines et métabolites dans le sang et l’urine avec SPE on-line. 
Le Chapitre V.I. présente le développement et la validation d’une méthode avec LC-
MS/MS pour la quantification des hallucinogènes et d’autres composés analogues 
dans l’urine. La méthode consiste en une LLE off-line, une évaporation à sec et une 
reconstitution dans la phase mobile. La durée totale de l’analyse est de 20 min. 
Avec chaque série d’analyse nous avons analysé des QC externes qui contiennent 
le LSD. La méthode a été entièrement validée et appliquée à l’analyse d’urines 
authentiques (avec de la psilocin, ketamine, norketamine et chlorpheniramine). Le 
Chapitre V.II décrit la validation de la méthode pour l’analyse du THC et deux de 
ses métabolites dans le sang. Comme procédure de nettoyage de l’échantillon nous 
avons utilisé LLE avec hexane: acétate d’éthyle, ensuite une centrifugation, une 
évaporation complète (16 min) et une reconstitution. La durée de l’analyse a été de 
13 min. Nous avons ajouté deux QC externes à chaque série d’analyse. La méthode 
                                                         Résumé 
 
 7
a été entièrement validée en termes de précision, d’exactitude, de spécificité, de 
récupération, d’effet matrice et de stabilité. Finalement la méthode a été appliquée 
aux analyses de sang de cas médico-légales. Le Chapitre V.III est centré sur le 
développement et la validation d’une méthode utilisant le système Symbiosis pour 
l’analyse de THC-COOH dans l’urine (500 µL). Etant donné le THC-COOH est 
glucuronidé dans l’urine, on a effectué une hydrolyse préalable avec KOH 10 M. 
Ensuite, l’urine diluée a été acidifiée directement dans les fioles LC en vue de son 
injection directe. La méthode a été entièrement validée et appliquée à l’analyse 
d’urine de consommateurs de cannabis. Une autre application du système SPE-LC-
MS on-line est décrite dans le Chapitre V.IV. pour l’analyse de 7 amphétamines et 
métabolites dans le sang et l’urine. La méthode, qui a été entièrement validée selon 
les normes internationales, a nécessité moindre manipulations: la dilution en phase 
aqueuse, contenant l’IS, de 100µL sang ou de 50 µL d’urine directement dans les 
fioles LC, avant l’injection. Pour le nettoyage de l’échantillon nous avons utilisé des 
cartouches HLB. La méthode a été appliquée à l’analyse de sang et urine dans une 
étude avec MDMA, et à de cas médico-légaux.  
Les conclusions du Chapitre VI  mettent en évidence les avantages du LC-MS/MS 
et la nouvelle tendance SPE on-line. Les résultats montrent que même si les 
méthodes LC-MS/MS conventionnelles restent fiables, la SPE on-line couplée au 
LC-MS/MS est très efficace et permets de gains de temps et de productivité 
significatifs.  
Le Chapitre VII est centré sur les perspectives futures liées aux applications de la 
LC-MS/MS. Le progrès en SPE on-line et la séparation chromatographique (UPLC) 
sont les candidats potentiels pour l’analyse des drogues dans les matrices 
conventionnelles et alternatives (comme le fluide oral), de sorte qu’on est en train de 
métamorphoser la méthode dans laquelle la séparation et le traitement des 
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Resumen 
El objetivo de esta tesis ha sido la evaluación del análisis de drogas, relevantes 
desde el punto de vista forense, en sangre y orina mediante métodos LC-MS/MS 
convencionales y avanzados. 
El Capítulo I, presenta una breve revisión de la farmacología de las drogas 
incluidas en esta tesis (anfetaminas, canabis y alucinógenos) y sus efectos en la 
actitud y comportamiento humano. Comenzando por los alucinógenos, son 
sustancias psicoactivas que alteran en gran medida la percepción, el humor y la 
razón. Están considerados fisiológicamente seguros al no producir dependencia o 
adicción. Su origen se remonta a las culturas más ancestrales siendo empleados en 
rituales sagrados y otros contextos socioculturales. Hoy en día, el canabis es la 
droga ilícita más consumida en Europa, de tal modo que casi un cuarto de los 
europeos lo han probado alguna vez en su vida. Varios de los efectos del canabis 
son relajación, bienestar y somnolencia. Otras drogas que constituyen un problema 
importante en Europa son las anfetaminas. Estimulan el CNS, aumentando la 
presión arterial y disminuyen el apetito, entre otros efectos. 
LC-MS(/MS) es una técnica ampliamente utilizada en los laboratorios forenses, 
especialmente en el análisis de sustancias no volátiles, térmicamente inestables o 
de alto peso molecular. El Capítulo II tiene como objetivo dar una idea general de 
las aplicaciones recientes con LC-MS(/MS) que existen en los laboratorios forenses 
y dar información detallada sobre la ionización, la separación y detección de iones, 
además de la espectrometría de masas en tandem. El fenómeno conocido como 
supresión o aumento de la ionización de los iones en el análisis mediante LC-
MS(/MS) depende principalmente de la naturaleza de la matriz, del proceso de 
preparación de la muestra, de la calidad de la separación cromatográfica, de los 
aditivos de la fase móvil y del tipo de ionización. Por lo tanto, los procedimientos 
típicos de preparación de la muestra son PPT, LLE y SPE. Una óptima preparación 
de la muestra da lugar a un aumento de la sensibilidad y la selectividad. Al final de 
este capítulo se encuentra información detallada sobre las recientes aplicaciones de 
LC-MS(/MS) para el análisis de anfetaminas, canabis y alucinógenos en sangre y 
orina.  
No obstante, la preparación de la muestra está considerada como un proceso 
laborioso que requiere mucho tiempo. En el Capítulo III se describen los desarrollos 
recientes en SPE on-line (en línea) respecto a la alta producción en los análisis 
cuantitativos de drogas en las matrices biológicas. Los análisis de alta producción 
                                                       Resumen 
 10
se están volviendo primordiales en los laboratorios forenses. Uno de los sistemas 
comercializados con SPE on-line es el sistema Symbiosis fabricado por Spark 
Holland. En el sistema SPE on-line el material de extracción está empaquetado con 
partículas muy pequeñas como las columnas LC (cartuchos) que trabajan a altas 
presiones a las que se les aplican los disolventes de extracción. Las válvulas de 
cambio que posee este sistema dirigen el flujo hacia la columna analítica LC o al 
deshecho, según convenga. A diferencia de la clásica SPE off-line, este sistema on-
line permite ahorrarse varios etapas intermedias. Posteriormente, la muestra 
extraída es inyectada directamente a la columna analítica mediante una simple 
válvula de cambio. Por lo tanto, no hay pérdida de volumen de muestra, aumentado 
la sensibilidad. En este capitulo también se incluye una revisión bibliográfica que 
existe hasta el momento sobre las aplicaciones de este instrumento al análisis de 
drogas en fluidos biológicos.  
El Capítulo IV presenta los objetivos del estudio que son la evaluación de la técnica 
LC-MS/MS convencional y la nueva tendencia, SPE-LC-MS/MS on-line (Symbiosis), 
para el análisis de: 
a) numerosos alucinógenos, clorofeniramina, ketamina, ácido ritalínico y metabolitos 
en orina con SPE off-line,  
b) THC y metabolitos en sangre mediante LLE off-line como proceso de preparación 
de la muestra,  
c) THC-COOH (principal metabolito del THC en orina) mediante SPE on line y  
d) 7 anfetaminas y metabolitos en sangre y orina mediante SPE on-line.  
El Capítulo V.I. ofrece el desarrollo y la validación de un método con LC-MS/MS 
para la cuantificación de alucinógenos y otros compuestos relacionados en orina. El 
método consiste en una LLE off-line, evaporación a seco y reconstitución en la fase 
móvil. La duración total del análisis es de 20 min. Con cada serie se han analizado 
QC externos que contenían LSD. El método ha sido completamente validado y 
aplicado al análisis de orinas auténticas (que contenían psilocina, ketamina, 
norketamina y clorofeniramina). El Capítulo V.II describe la validación del método 
para el análisis de THC y dos de sus metabolitos en sangre. Como proceso de 
limpieza de la muestra se empleó LLE con hexano: acetato de etilo, seguida de 
centrifugación, evaporación completa y reconstitución. El tiempo de duración del 
análisis fue de 13 min. Se añadieron dos QC externos en cada serie de análisis. El 
método ha sido completamente validado en cuanto a precisión, exactitud, 
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especificidad, recuperación, efecto matriz y estabilidad. Finalmente el método se 
aplicó al análisis de muestras de sangre de auténticos casos forenses. El Capítulo 
V.III se centra en el desarrollo y validación de un método utilizando el sistema 
Symbiosis para el análisis de THC-COOH en orina (500 µL). Como el THC-COOH 
esta glucuronizado en orina, se realizó una hidrólisis previa con KOH 10 M. A 
continuación, la orina diluida fue acidificada directamente en los viales LC para su 
inyección inmediata. El método fue validado completamente y aplicado al análisis de 
auténticas muestras de consumidores de canabis. Otra aplicación del sistema SPE-
LC-MS/MS on-line se presenta en el Capítulo V.IV. para la cuantificación directa de 
7 anfetaminas y metabolitos en sangre y orina. El método, que ha sido enteramente 
validado según las normas internacionales, requirió una mínima manipulación: la 
dilución en fase móvil acuosa, conteniendo el IS, de 100 µL de sangre o 50 µL de 
orina, directamente en los viales LC, previa a la inyección. Para la limpieza de la 
muestra se emplearon cartuchos HLB. El método fue aplicado al análisis de sangre 
y orina de un estudio con MDMA y a casos forenses.  
Las conclusiones del Capítulo VI exponen las ventajas del LC-MS/MS y la nueva 
tendencia en SPE online. Los resultados demuestran que aunque los métodos LC-
MS/MS convencionales siguen siendo robustos y seguros, la SPE on-line acoplada 
al LC-MS/MS es altamente efectiva en cuanto a ahorro de tiempo y productividad.  
El Capítulo VII se centra en las perspectivas futuras en relación a las aplicaciones 
con LC-MS/MS. El progreso en SPE on-line y la separación cromatográfica (UPLC) 
son los candidatos potenciales para el análisis de drogas en matrices 
convencionales y alternativas (como la saliva), de manera que está reformando el 
modo en el que la separación y tratamiento de la muestra estas siendo realizadas 
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1. 1. Introduction 
One of the biggest problems facing society today is the abuse and misuse of drugs. 
There are numerous drugs available to the community at large. Many offenders 
charged with violent crimes, or victims of violent crime, may have been under the 
influence of psychoactive drugs at the time a crime was committed. Therefore, it is 
important to understand the possible pharmacological effects associated with the 
use of these drugs. 
The principal drugs of concern can be divided into the categories shown in Table 1. 
Table 1. Principal classes of psychoactive substances (1) 
CNS depressants 
1 Ethanol All alcoholic beverages (alcohol) 
2 Benzodiazepines Alprazolam, diazepam, flunitrazepam, oxazepam, temazepam, etc 
3 Opioids Codeine, heroin, methadone, morphine, oxycodone, pethidine, etc 
4 Antipsychotics Chlorpromazine, clozapine, fluphenazine, haloperidol, olanzapine, etc 
5 Antidepressants Amitriptyline, doxepin, dothiepin, fluoxetine, moclobemide, sertraline, etc 
6 Marijuana Various forms of Cannabis sativa containing tetrahydrocannabinol 
7 Barbiturates Amylobarbital, butobarbital, secobarbital, phenobarbital, thiopental, etc 
CNS stimulants   
8 Amphetamines Speed' (methamphetamine), 'ecstasy' 
9 Cocaine Free base 'crack' and hydrochloride 
10 Other stimulants Ephedrine, pseudoephedrine, phentermine, fenfluramine, etc 
Other substances 
11 Inhalants Petrol, solvents, propane (LPG), paint, butane lighter fluid, etc 
12 Hallucinogens LSD, ecstasy, plant-derived substance such as mescaline, psilocybin, etc 
13 Phencyclidine Usually abbreviated as PCP, and ketamine 
14 Anabolic steroids Testosterone, stanozolol, etc 
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Cannabis in its various forms is arguably the second most 
commonly abused drug after alcohol. Smoked, eaten, 
imbibed –or just talked about- it seems the world has a strong 
appetite for it. An estimated one in five European adults has 
tried cannabis, in such a way that globally, nearly 50 000 tones of cannabis herb or 
resin is produced each year. Little wonder, then, that cannabis has become a 
controversial cultural and commercial phenomenon (2).  
On the other hand, drugs such as MDMA (3,4-MethylenenDioxyMethAmphetamine), 
ketamine and LSD (Lysergic Acid Dietylamide), are typically used 
by teenagers and young adults at bars, clubs, concerts, and 
parties, and the use of these drugs is reported to help maintain 
energy levels for dancing or to enhance an altered state of 
consciousness (3). The use of these called ‘club drugs’ has 
increased significantly over the past 2 decades. One reason for their augmented use 
is the easy availability and low cost.  
In the following, the drugs studied in this thesis are described. 
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1.2. Amphetamines 
In many European countries the second most commonly used 
illegal substance is some form of synthetically produced drug. 
The use of amphetamines and related drugs among the general 
population is typically low, but prevalence rates among younger 
age groups are significantly higher, and in some social settings or 
cultural groups the use of these drugs may be particularly high. 
The amphetamines are central nervous system (CNS) stimulants, with similarities to 
some naturally occurring weak stimulants like ephedrine, a weak stimulant that 
occurs naturally in the branches of a number of an Ephedra species in 
concentrations up to 1.2% (4). The amphetamines are related in structure to the 
legal stimulants. Substitutions on the nitrogen and the ring system account for most 
of the structural variations and differences in stimulating and euphoric effects. Due to 
the chiral carbon atom adjacent to the nitrogen and to which a methyl group is 
attached, stereoisomerism has some serious implications in analytical chemistry and 
forensic toxicology (Figure 1). 
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The abused amphetamine analogues are synthesized in clandestine laboratories by 
a variety of chemical processes from a number of precursor molecules i.e. from 
ephedrine or pseudoephedrine to d-methamphetamine. The presence of significant 
quantities of the starting product and impurities in the street samples allows for 
profiling of the source of drug. MDMA (‘ecstasy’) has become one of the most 
popular recreational drugs among young people visiting raves and mega house 
parties. Although the media often write about a very fast evolution in the choice of 
stimulants: MDEA (3,4-MethyleneDioxy-N-EhylAmphetamine) (‘Eve’), MDA (3,4-
MethylenenDioxyAmphetamine), MBDB (3,4-MethylBenzoDioxolylButanamine), 
PMA (4-Para-MethoxyAmphetamine), etc, our experience in the INCC in Belgium, is 
that amphetamine and MDMA are by far the most popular drugs, with other variants 
popping up only occasionally.  
Physical effects can include reduced appetite, increased/distorted sensations, 
hyperactivity, tachycardia, increased blood pressure, sweating, etc. Psychological 
effects can include anxiety and/or general nervousness, euphoria, creative of 
philosophical thinking, perception of increased energy, increased sense of well 
being, feeling of power or superiority, talkativeness, etc (1).  
The amphetamine-like stimulants have good oral and intranasal bioavailability and 
give maximum blood concentrations (0.1-0.4 µg/mL) within 1-3 h after a normal 
single dose. Proportionally higher concentrations are expected with higher doses, 
although non-linear kinetics of MDMA in humans has been described. The 
amphetamines are metabolized by similar pathways that involve a combination of 
hydroxylation of the ring and the side-chain carbon atom adjacent to the ring, and 
removal of the nitrogen. Drugs with alkyl groups on the nitrogen are dealkylated 
sometimes producing pharmacologically active metabolites: methamphetamine is 
metabolized to amphetamine, MDMA and MDEA are both metabolized to MDA. All 
metabolites with hydroxyl groups are excreted as conjugates (5,8).  
The half-life of amphetamines varies from 3-6 h to more than a day. Drugs with 
relatively long elimination half-lives will often show an accumulation of blood 
concentration with repeated dosing (chronic administration). Their clearance is 
particularly sensitive to the pH of urine. This is due to the basic nature of 
amphetamines, which are excreted rapidly if urine is acidic (increases ionization of 
drug), but only relatively slowly if urine is basic. Detection times in urine range up to 
1-2 days following usual doses. In contrast to many other drugs of abuse, substantial 
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amounts of unchanged drug are excreted in urine. Amphetamine is excreted almost 
completely unchanged when urine is kept acidic, while basic urine will retard 
elimination and allow substantial metabolism to occur. Similar phenomena occur 
with other amphetamine analogues, including methamphetamine and ephedrine. 
(1,9-12). Thus, under normal conditions, methamphetamine is excreted largely as 
the parent drug (40%) following smoked and intravenous single doses, while only 
7% of the dose is excreted as its main metabolite, amphetamine (13,14). Abstinence 
from amphetamine can still result in detection in urine for 2 days. However, high-
dose abusers can have urine positives for up to 9 days after last use (15,16). MDMA 
is metabolized to the demethylated active analogue, MDA. The MDA to MDMA urine 
concentrations are 0.15 or less following consumption of MDMA (17-19). Ephedrine 
is substantially excreted into urine unchanged (70% of dose). A single dose would 
be detectable in urine for 24-36 h (20). 
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1.3. Cannabis 
Cannabis is the collective term for the psychoactive substances of 
the Cannabis sativa plant and one of the most frequently used illicit 
drug in the Western World. Cannabis preparations include 
marijuana plant material, hashish (resin of female flowering tops) 
and hashish oil (extra from the resin). Cannabis is consumed by inhalation by either 
smoking or using a bong or a water pipe, or by ingestion of baked cannabis products 
(21). Cannabis products are mostly smoked in combination with tobacco. Thus, Δ9-
tetrahydrocannabinol (THC), the primary psychoactive analyte, is found in the plant’s 
flowering or fruity tops, leaves, and resin. There are over 421 different chemical 
compounds in cannabis, including 61 cannabinoids, chemical compounds containing 
21 carbons atoms related to THC. During smoking more than 2000 compounds may 
be produced by pyrolysis; nitrogenous compounds, amino acids, hydrocarbons, 
sugars, terpenes, and simply fatty acids, are contributing to known pharmacological 
and toxicological properties of cannabis. The composition of cannabinoids varies 
depending on growing conditions, plant strain and the age of the sample. Smoking 
cannabis produces a much quicker absorption with maximum plasma concentrations 
occurring within a few minutes of smoking. The amount absorbed is also much 
higher than with ingestion; studies show a bioavailability of 14-50%, since THC is 
activated by a heating process through a decarboxylation reaction (22).  
The acute behavioral and physiological effects of cannabis have been well described 
(23-28): euphoria, relaxation, well-being, somnolence, changes in visual and 
auditory perception, altered perception of time and space, short-term memory loss, 
impaired learning, reduced performance, anxiety and panic reactions, disphoria, 
hallucinations, flashbacks, cardiovascular symptoms, red conjuctiva, small increase 
in pupil size, and reduced lacrimation 
There are three metabolites with significance: the 11-hydroxy (11-OH-THC), the 9-
carboxy (THC-COOH) and the glucuronide of THC-COOH (Figure 2). Other 
metabolites found in blood are the 8- and 2-hydroxy-THC metabolites.  
























Glucuronidation Hydroxylation Hydroxylation 
8-OH-THC 












The oral availability of cannabis is about 6%, which means that only 6% of the 
ingested THC is absorbed into the blood stream. The remainder is metabolized prior 
to entry into the blood stream, or is not absorbed. THC is measurable in plasma 
within seconds after inhalation of the first puff of marijuana smoke. Concentrations 
continue to increase rapidly and peak concentrations occur at approximately 9 min. 
Whole blood cannabinoid concentrations are approximately one half of the 
concentrations found in plasma due to the low partition coefficient of drug into 
erythrocytes (THC is 97-99 % protein bound in plasma). Once absorption has taken 
place, THC is rapidly distributed to tissues, concentrations being highest in adipose 
(fat) tissue due to its low water solubility and high affinity for fatty tissues. This 
distribution phase results in a rapid decline in blood plasma THC concentrations. 
THC concentrations greater than 10 ng/mL are uncommon after 1h even after 
moderate to high doses of cannabis (29-35). The terminal elimination half-life of THC 
is reported as 4-5 days, with a range of 3-13 days, although a shorter half-life of 
about 1 day has also been quoted. At first glance, this relatively long half-life 
contradicts the well-known short action of cannabis. However, this half-life is 
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calculated after the process of distribution to tissues has taken place and represents 
the terminal phase of the elimination curve. In high-dose (3.5% cigarette) users of 
marijuana, concentrations of THC can be detected for up to 24h after last use (>0.5 
ng/mL) (32,36-38). 
The metabolite THC-COOH is also found in the blood of cannabis users (39). 
Because of difficulties in measuring THC accurately (because of the low 
concentrations), laboratories frequently measure also this inactive metabolite. 
Plasma concentrations of unconjugated THC-COOH following a 1.97% THC 
cannabis cigarette peak at 43 ng/mL at 20 min after smoking. By 6 h plasma 
concentrations fall to 13 ng/mL. 11-OH-THC is also produced from THC metabolism 
and also exhibits THC-like activity. Blood concentrations are rapidly detected 
following a 1.75% or 3.55% marijuana cigarette within 15-20 min. This metabolite is 
only detectable in blood for 12-24 h after normal-strength marijuana cigarettes 
(40,41).  
The main metabolite of THC in urine is THC-COOH. However, interpretation of 
results in urine is not simple. The amount of time that THC-COOH remains 
detectable in urine depends of the following factors: amount and frequency of use of 
cannabis, the metabolic rage, the body mass, the age, the overall health, the drug 
tolerance and the urine pH. Some researchers have used urinary THC-COOH 
concentrations in excess of 80 ng/mL to imply impairment. However, others have 
found little predictive value in using urinary THC-COOH concentrations, especially 
since 24% of users would have blood THC concentrations of less than 1 ng/mL, a 
concentration that does not normally cause impairment. Many persons with impaired 
THC concentrations, would not be impaired based on urinary THC-COOH 
concentrations (42,43). Gustafson et al (44) demonstrated that the terminal urinary 
elimination of THC-COOH following oral administration was approximately two to 
three days for doses ranging from 0.39 to 14.8 mg/d. 






1.4. Hallucinogens and related compounds 
1.4. 1. Bufotenine 
Bufotenine (Figure 3) is a hallucinogenic substance that exists 
naturally in some plants and in the cutaneous secretions of 
amphibians. (45-47). Although it is used as a therapeutic agent in 
China and other Asian countries, and as an aphrodisiac, ‘love 
stone’ in the West Indies, recent reports indicate its toxicity may carry a significant 
mortality rate (48,49). On the other hand, bufotenine has long been accepted as a 
naturally occurring component of human blood, brain and cerebral spinal fluid. 
However, while its biological presence at low concentrations is acknowledged, the 
biological function remains a mystery (50).  






There is not so many information about the pharmacokinetics of bufotenine. Fuller et 
al (51) administered bufotenine subcutaneously in rats (1-100 µg/kg). It was 
distributed mainly to the lungs, heart and blood, and to much lesser extent, the brain 
and liver. It reached peak concentrations at 1 hour and it was nearly completely 
eliminated within 8 hours. In humans, bufotenine is rapidly absorbed following 
intravenous administration and it is excreted predominantly in the urine (70%).  






Khat (Catha edulis Fosk) is an evergreen plant that grows at high 
altitudes in East Africa and Arabian Peninsula, being used as a 
stimulant plant for centuries. Chewing its fresh leaves is a 
widespread habit in local populations, with several million people 
consuming khat regularly in social sessions that often last for 
hours. Its current use among particular migrant communities in Europe and 
elsewhere has caused alarm among policy makers and health care professionals 
(52,53). A typical dose of 100 g fresh khat leaves contains on average 36 mg 
cathinone (Figure 4), with a higher content of cathinone in young leaves that are still 
growing (54). Users of khat report increased levels of energy, alertness and self-
esteem, a sensation of elation, enhanced imaginative ability and a higher capacity to 
associate ideas (55-57).  






Chewing results in a high extraction of the alkaloids with only 9% remaining in the 
leaf residues. A chewing dose of 45 g khat leaves i.e. 0.6 g/kg of body weight results 
in a mean absoption dose of 45 mg of cathinone. The euphoric effects of khat start 
after about 1h of chewing of 60 g fresh khat leaves per subject. Blood levels of 
cathinone start to rise within 1h and peak plasma levels are obtained 1.5-3.5h after 
the onset of chewing (58). Maximum plasma levels range from 40 to 140 ng/mL after 
1 h chewing. In plasma, cathinone is detectable up to 24h. The elimination half life is 
some 260 min. Only 2% of administered cathinone was found unchanged in the 
urine (53,59).  






Chlorpheniramine is a first generation alkylamine antihistamine 
used in the prevention of the symptoms of allergic conditions such 
as rhinitis and urticarian (Figure 5). Its worldwide popularity as an 
antihistamine is based on effectiveness, low cost (generic) and 
tolerability (60). Adverse side effects have been reported when used alone or in 
combination with other drugs. These side effects include hypertension, arrhythmias, 
seizures, hallucinations, agitation and anxiety, and psychosis (61,62). Many of these 
reported reactions occurred after ingestion of the drug over a prolonged period or in 
dosages in excess of recommended allowances. Ishigooka et al (63) described the 
mental disturbances of 44 abuses cases of “Bron”, an over-the-counter cough 
suppressant solution containing chlorpheniramine and other medicaments. Major 
psychiatric symptoms observed included hallucinatory paranoid state.  






Although its widespread use, surprinsingly little has been reported about its 
pharmacokinetics profiles in man. Chlorpheniramine after oral administration is 
strongly metabolized in the liver by demethylation. Two metabolites have been 
identified: monodesmethylchlorpheniramine and didesmethylchlorpheniramine. After 
a single therapeutic dose, the metabolites cannot be detected in blood. In urine, 
unchanged chlorpheniramine account for about 20% of the dose (64,65).  




1.4.4. Kavain  
Kava-kava is the name given by Pacific islanders to both a shrub 
Piper methylsticum G. Foster belonging to the pepper family and 
psychoactive beverage made from the rhizome (by extraction 
with coconut milk). Kava-kava may have first been domesticated 
less than 3000 years ago in Vanuatu (nowadays called the New 
Hebrides), a group of islands in eastern Melanesia. The use of kava-kava seems 
then to have spread both westwards to New Guinea and part of Micronesia and 
eastward into Fiji and the Polynesia. Locally the plant is known by a number of 
common names, including kawa-kawa, ava ava, awa awa, yati, and yagona. The 
beverage is used in social and ceremonial life because of the narcotic and soporific 
effects and it counteracts fatigue, reduces anxiety and generate state of well being. 
Extracts of kava-kava with 30-70% kavalactones have also been employed in the 
western medicine for the sedative, muscle relaxant, analgesic, anticonvulsive, 
anaesthetic, anti-arrythmic, anti-thrombosis, neuroprotective and anti-spasmodic 
(66-70). However, serious side effects, e.g. hepatitis and acute liver failure were 
observed recently (71). This led to its ban in many countries, which has prompted 
wide discussion in its relative benefits and risks as a social beverage and an herbal 
remedy. 




Only a few methods have been applied for the detection of kava consumption or 
intoxication and are focused on the non-alkaloids kavalactones (72). Koeppel and 
Tenczer identified 10 metabolites of kavain in urine after oral consumption of the 
substance (73). Other more sensitive methods have been developed to investigate 
the pharmacokinetics in blood, urine and hair (74,75).  Most metabolites were mainly 
excreted in the form of their conjugates. All kavain metabolites were detectable in 
serum and urine. Within 1 and 4 h after oral administration, the serum 
concentrations ranged between 40 and 10 ng/mL for kavain (Fiugre 6).  












Ketamine was first synthesized by Calvin Stevens in 1962. Early 
clinical studies on ketamine with human volunteers found it to be 
more effective and shorter acting than phencyclidine, with fewer 
emergence symptoms and less toxicity. The drug was first 
manufactured in the United States in the 1960s as Ketalar. Use of 
ketamine as a surgical anesthetic escalated when it gained popularity on the 
battlefields of Vietnam (1). It was promoted as a dissociative anesthetic because of 
its ability to induce a lack of responsive awareness, not only to pain but also to the 
general environment. 
By the early 1980s a wide range of unauthorized preparations were available in the 
US including capsules, powder, crystals, tablets and solutions, in addition to the 
authorized injectable forms. Solutions sold on the street have gone by names such 
as K, Kay, Jet, Super Acid, vitamin K and Special K (1,9,76,77).  
At low doses ketamine induces distortion of time and space, hallucinations and mild 
dissociative effects. However, at large doses (i.e. over 150 mg) ketamine induces 
more severe dissociation commonly referred to as a ‘K-hole’, wherein the user 
experiences intense detachment to the point that their perceptions appear located 
deep within their consciousness, thus causing reality to appear far off in the distance 
(77,78). Since ketamine is odorless and tasteless, it can be added to beverages, 
without being detected, to induce amnesia. Because of such properties, the drug is 
sometimes misused in a sexual assault, referred as date-rape drug (79). 
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Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist 
which interferes with the action of excitatory amino acids including glutamate and 
aspartate (80). Ketamine has a plasma half-life of 2-4h. It is highly lipid soluble and 
has a distribution half-life of approximately 7-11 min. Ketamine is metabolized to at 
least two compounds: first by N-demethylation, to norketamine, which has 1/3-1/2 of 
the potency of ketamine. Norketamine is further dehydrogenated to produce 
dehydronorketamine (81-83). The parent compound and both major metabolites are 
further transformed by hydroxylation and conjugation prior to elimination (Figure 7). 
About 90% of a dose is excreted in the urine in 72h, with about 2% of the dose as 
unchanged drug, 2% as norketamine, 16% as dehydronorketamine and 80% as 
conjugates of hydroxylated metabolites.  







Ibogaine is a naturally occurring plant alkaloid with a history if 
use as a medicinal and ceremonial agent in West Central 
Africa. It is an indole alkaloid found in the root bark of the 
Apocynaceous shrub Tabernanthe iboga. It is used by native 
Africans to offset hunger and fatigue but when abused, 
ibogaine causes hallucinations (72,84). The onset after ingestion is within 1 to 3 
hours, with a duration of action in the order of 4 to 8 hours. The predominant 
reported experiences appear to involve a panoramic readout of long-term memory, 
particularly in the visual modality, and “visions” or “walking dream” states featuring 
archetypal experiences such as contact with transcendent beings, passage along a 
lengthy path, or floating (85). Recent studies also reported the efficacy of this drug in 
the treatment of drug addiction. Thus, ibogaine attenuate both dependence and 
withdrawal symptoms to a variety of abused drugs including morphine, heroin, 
cocaine, amphetamine, alcohol and nicotine (86). The neurochemical mechanisms 
explaining the antiaddictive properties of ibogaine are not clearly understood. 





Pharmacokinetics data relative to ibogaine in humans are limited (Figure 8). 
Following single doses of ibogaine (500 to 800 mg) to individual subjects, maximum 
ibogaine and noribogaine (its main metabolite) blood concentrations of 30-1250 
ng/mL and 700-1200 ng/mL are obtained approximately 2 and 5 hours after drug 
administration, respectively. Thereafter, ibogaine is cleared rapidly from the blood 
while noribogaine concentrations remain high. Indeed, concentrations of noribogaine 
measure at 24 h postdose were in the range of 300-800 ng/mL (87). It is also 
established that ibogaine is largely deposited in fat and to a lesser extent in brain. 
Ibogaine and noribogaine are excreted via the renal and gastrointestinal tracts, with 
a 60 to 70% elimination in urine and feces within 24 hours (85,88). 






Lobeline is a lipophilic, non-pyridino, alkaloidal constituent of Lobelia 
inflate, also known as Rapuntium inflatum, Indian weed, pokeweed, 
asthma weed, gagroot, vomitwort, bladderpod, eyebright, and Indian 
tobacco (89) (Figure 9). It has many nicotine-like effects, including 
tachycardia and hypertension, hyperalgesia (90). Lobeline was 
previously investigated as a therapeutic agent to treat tobacco 
dependence and it has been demonstrated to inhibit the effect of amphetamines in 
behavioral and neurochemical assays (91,92).  






To our knowledge, there is still no information about the pharmacokinetics of lobeline 
in humans. Just one paper from Song et al (93) identified the parent drug and ten 
metabolites in rat urine 24 h after administration.  
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1.4.8. LSD 
Although drugs producing sensory distortions have been used 
by man for several millennia, many consider the modern era of 
psychedelics to have begun when the psychotropic effects of 
LSD were discovered by Albert Hofmann in 1943. This 
discovery ushered in an era of intense LSD research, with 
nearly 1000 articles appearing in the medical literature by 1961 (94). Most of this 
early research was based upon the drugs’ capacity to produce a “model psychosis” 
(95). By the mid-1960s, LSD and other related drugs had become associated with 
various counterculture movements, depicted as dangerous, and widely popularized 
as drugs of abuse. Accordingly, scientific interest in these drugs faded by the late 
1960s, but human research with related psychedelics has recently experienced a 
slight renaissance (84,96-98). What the experience of the 1960s has pointed to 
many possible therapeutic and non-medical uses. Previous clinical experience, plus 
more recent informal use, has indicated other potential therapeutic uses for cluster 
headaches and addictions, among other conditions. 
The late Daniel X. Freedman made comments consistent with that assessment, 
stating, “one basic dimension of behavior…compel-compellingly revealed in LSD 
states is ‘portentousness’-the capacity of the mind to see more than it can explain, to 
believe in and be impressed with more than it can explicate, to believe in and be 
impressed with mire than it can rationally justify, to experience boundlessness and 
‘boundaryless” events, from banal to the profound” (99). Although these descriptions 
focus on the more spectacular effects that these substances are capable of 
producing, low doses generally elicit less dramatic results. Typical clinical effects of 
LSD and related hallucinogens would include the following: 
• Somatic symptoms: dizziness, weakness, tremors, nausea, drowsiness, 
paresthesias, and blurred visions 
• Perceptual symptoms: altered shapes and colors, difficulty in focusing on 
objects, sharpened sense of hearing, and rarely synesthesias. 
• Psychic symptoms: alterations in mood (happy, sad, or irritable at varying 
times), tension, distorted time sense, difficulty in expressing thoughts, 
depersonalization, dreamlike feelings, and visual hallucinations (100). 
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LSD can induce disturbances of experience, otherwise observed only in psychoses, 
such as alteration of cognitive functions, and depersonalization. However, this drug 
does not appear to produce illness in emotionally healthy persons, but these 
problems seem to be precipitated in predisposed individuals.  
In atypical courses of intoxication, so-called “bad trips”, anxiety and excitement 
predominate. A bad trip is a disturbing experience whose manifestations can range 
from feelings of vague anxiety and alienation to profoundly disturbing states of 
unrelieved terror, ultimate entrapment, or cosmic annihilation. The potential causes 
can be a result of wrong set and settings (101,100).  
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LSD acts as an antagonist of peripheral 5-HT receptors, but acts as an agonist at 
CNS 5-HT receptors. Peak blood concentrations of LSD are typically less than 10 
ng/mL. Maximum plasma concentrations following 70 µg dose range up to 2 ng/mL. 
The maximum blood levels occur around 30-90 min, but psychedelics effects of the 
drug occur within 5-10 min. The elimination half-life is estimated at 3-6h. Blood 
concentrations of drug are therefore quite low by 8h post-dose often less than 1 
ng/mL. The duration of the action of LSD parallels approximately the blood 
concentrations, with ‘trips’ lasting from a few to several hours depending on the dose 
used (1). 
LSD is rapidly metabolized with only about 1-3% of an oral dose excreted in the 
urine as unchanged LSD. The major metabolites in urine are nor-LSD and 2-oxo-3-
OH-LSD (Figure 10). In addition, glucuronide conjugates of 2-oxo-3-OH-LSD are 
also present. Because of the low blood concentrations, LSD is most often measured 
in urine. Peak urine concentrations following oral ingestion of a typical street dose 
are normally less than 10 ng/mL and drop bellow 1 ng/mL within 12-24h. Therefore, 
extremely sensitive analytical methods are required to detect LSD use for more than 
1 day after ingestion of the drug. 2-oxo-3-OH-LSD can be detected in urine up to 
96h after administration, whereas LSD can only be detected for 12-24h post-
administration (102,103).  






Mescaline is one of the classic hallucinogens, which is known as 
the major alkaloid of the cactus peyote (Figure 11) (33,45).  
Peyote grows within a narrow strip of desert along the Texas-
Mexico border. When properly cut, the crown (“button”) is removed 
from the plant leaving the root intact. Peyote is not smoked but eaten as peeled 
fresh buttons, dried whole buttons, dried/ground powder (sometimes also 
reconstituted in water), or is steeped/reconstituted into a warm tea. Peyote is most 
commonly consumed as a sacrament in the all-night ceremonies of the Native 
American Church (104,105). The effects of peyote and mescaline in humans are 
well studied. Native peyote cults used the cactus because it produces rich visual 
hallucinations. These psychoactive effects were used in psychiatric studies as a 
chemically induced model of mental illness (72).  






Typical hallucinogenic doses range from 200 to 500 mg of mescaline with blood 
concentrations of 3.8 mg/L at 2 h and 1.5 mg/L at 7 h after ingestion (106). Following 
intake, mescaline is mainly excreted in the urine unchanged from (55-60%) (107).  





















In recent years, the recreational use of hallucinogenic mushrooms, 
so-called “magic mushroom”, has become an increasing social 
problem in several countries. They are not only naturally occurring 
but also offered as kits for cultivation, and contain the 
hallucinogenic indole derivatives, psilocin and psilocybin (Figure 
12). Differences in the psilocin and psilocybin contents of the fruit 
bodies depends on the factors such as species, developmental stages, climatic 
conditions and the availability of soluble nitrogen and phosphorous in the soil (108). 
Thus, it takes about 30 fruitbodies of Psilocybe semilanceata to produce 
hallucinatory experience. Other large fungi which also contain psilocybin and psilocin 
are Psilocybe cubensis Panaeolus spp, Copelandia spp and Gymnopilus spp (109). 
There are several reports on the contents of psilocin and psilocybin in magic 
mushrooms (110-112) .  






The rapid and extensive cleavage of the phosphoric ester group of psilocybin by 
alkaline phosphatase and unspecific esterases indicates that psilocybin acts as a 
prodrug and that its hydroxyl metabolite psilocin represents the true 
pharmacologically active agent (110,113). Hasler et al (114) compared the 
pharmacokinetic parameters in plasma and urine after an oral administration of 
psilocybin to 6 subjects. Within 24h about 0.9% of the applied dose of psilocybin was 
excreted as free psilocin. However, attention must be paid to the stability of psilocin. 
According to Tiscione et al (115), urine concentrations of psilocin decrease rapidly 
even kept in the refrigerator at 4°C.  In conclusion, we may find psilocin in urine 
during 26-48 hours after administration.  












1.4.11. Ritalinic acid (methylphenidate) 
Methylphenidate (Ritalin) is a phenethylamine derivative used 
in the treatment of depression, narcolepsy, attention-deficit 
disorder, and childhood hyperkinesis (116-119). Recently, 
methylphenidate has become a popular drug of abuse with 
the usual mode of administration being intravenous injection 
of dissolved tablets often in combination with the drug pentazocine. Pentazocine 
(Talwin) is a synthetic benzomorphan derivative that has properties of an analgesic 
and is about one third to one sixth as potent as morphine. The combination of Ritalin 
and Talwin is commonly referred to on the street as “poor man’s heroin’. The fact 
that methylphenidate is commonly prescribed in the treatment of attention-deficit 
disorder provides a likely source for drugs users.  







Methylphenidate is reported to be absorbed quickly and completely from the gut 
after oral administration and it is rapidly hydrolyzed in the methyl ester linkage to its 
metabolite, ritalinic acid (Figure 13). Minor metabolic pathways for both these 
compounds include parahydroxylation of the aromatic ring, oxidation to 6-oxo-
derivates and glucoronide formation. Both methylphenidate and ritalinic acid are 
usually measured in plasma and urine (120,121). Following oral administration of 
methylphenidate peak plasma levels at 2 h. Because about 70% of methylphenidate 
is eliminated in the urine as ritalinic acid, it is obviously a better indicator (more 
prevalent) that the parent methylphenidate for detecting usage (118,122).  









The Datura plants are members of the botanical family 
Solonaceae, which also contains common foods as tomatoes, 
potatoes, eggplants, peppers, and tobacco. This plant is 
originated from the tropical areas of Central and South America 
and it is now a cosmopolitan weed in temperate regions (104). 
The toxicity of Datura species is well known and has been linked deaths and 
poisonings for centuries (123). Traditional preparations include adding roots, leaves, 
or seeds to a fermented drink; drinking an infusion of the leaves or other parts; 
smoking the leaves; or chewing the fruit. When the plant material is taken orally, the 
effects last longer than when smoked and will also be more narcotic and 
hallucinogenic (124,125).  
The main toxic components are tropano alkaloids: hyoscyamine, which forms a 
diastereomeric mixture know as atropine and scopolamine (Figure 14). Scopolamine 
is an antimuscarinic agent (used as analgesic) and a smooth muscle relaxant. It is 
also an antispasmodic agent with antinauseant properties, and is extensively used in 
the treatment of motion sickness and in pre-operative medication (126,127). Weak 
infusions are used as hypnotics by the elderly and as aphrodisiac by adults. Datura 
species have also been used in criminal activities (128).  






Up to now, scopolomine metabolism in man has not been verified stringently. An 
elucidation of the chemical structures of the metabolites extracted from human urine 
is still lacking. Huaixia et al (129) described the determination of scopolamine and its 
main metabolites in rat urine after ingesting 55 mg/kg scopolamine. Eighteen 
metabolites and the parent drug could be detected for up 106 h. In human, 
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pharmacokinetic parameters are dependent on the dosage form. According to 
Renner et al (130), scopolamine has a limited bioavailability if orally administered. 
The maximum drug concentrations occurs approximately 0.5 h after oral 
administration, and only 2.6% of nonmetabolized scopolamine is excreted in urine.  
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2.1. Introduction 
The analysis of drugs of abuse, particularly illicit drugs, is one of the most important 
challenges of forensic and forensic toxicology. As with any other branch of forensic 
sciences, forensic toxicological analysis must also apply and keep particularly high 
standards of quality. This is because the analytical result may have a direct and 
permanent impact on the fate of the person involved. As a consequence, forensic 
toxicological examinations are subjected to very tight scrutiny. This requirement 
should concern not only primarily forensic cases, but also extend to all forensic 
analysis for illicit drugs. It must be kept in mind that each result of drug analysis has 
potential forensic relevance, irrespective of the primary purpose of examination. It 
has often been said that the interpretation of results is the most important and 
difficult part of forensic toxicology. Notwithstanding the value of correct 
interpretation, it must also be said that the correct result enables any further action. 
This is particularly true when the analytical result itself may serve as evidence of 
illegal action. 
The analysis of drugs of abuse is not only important in the enforcement of road 
traffic safety, but also enables the differentiation between the chronic and occasional 
drug user or makes possible the identification of the source of origin of a particular 
batch of illegal drugs. Such an analysis would not be possible without the application 
of chromatography in various forms. Only chromatographic methods successfully 
combine efficient separation of relevant compound(s) from a biological matrix with 
specific detection. Among the chromatographic techniques, liquid chromatography-
mass spectrometry (LC-MS(/MS)) optimally fulfils the requirements of forensic 
toxicological analysis due to its high selectivity, the possibility of detection of active 
metabolites and (emerging in recent years) efficient screening in cases on unclear 
death. For these reasons, this technique is now finding a more and important place 
in forensic toxicological laboratories. 
Thus, LC-MS(/MS) underwent major evolution in the last decade. An expensive, 
difficult and not always reliable hyphenated technique turned into a robust analytical 
tool, applicable in almost all analytical situations.  
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2.2. History 
Beginning in the 1970s, (gas chromatography) GC-MS instrumentation has evolved 
to an essential tool for both biomedical research and some important routine forensic 
chemistry Applicability. However, it was the routine introduction on non-
disintegrating soft ionization techniques as atmospheric pressure ionization (API) 
and sophisticated ion analysis methods in the 1990s that finally made the majority of 
biologically relevant analytes (endogenous metabolites as well as xenobiotics) 
amenable to highly specific mass spectrometry analysis.  
From our current perspective, the hyphenation of LC-MS/MS via an API interface is 
the only LC-soft ionization-MS technique which has been introduced into routine 
forensic laboratories so far (1,2). The use of LC-MS/MS systems in bio-analytical 
research started already in the late 1980s (3,4). Tandem mass spectrometry found 
its way into forensic laboratories in the earlies 1990s when first flow injection 
analysis (FIA)-MS/MS methods were introduced for neonatal screening analysis (5). 
A significant methodological progress was the introduction of LC-MS/MS systems 
featuring API interfaces, which were broadly acknowledge in bio-analysis in the mid-
1990s (6). First implementations in forensic routine laboratories started about a 
decade ago with realizing the first therapeutic drug monitoring (TDM) assay (7,8). 
Consequently, this technology allowed a number of important novel assay 
applicability to be realized in such laboratories, improving their overall quality.  
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2.3. Analytical background 
2.3.1. Ionization 
A LC-MS interface has the double task of eliminating the solvents from the LC and 
producing gas-phase ions from the analyte (9). This can basically be accomplished 
in two ways: 
• the two processes are separated in space, i.e. the analyte is sampled into the 
vacuum region of the mass spectrometer and then ionized at reduced 
pressure 
• ions are created at atmospheric pressure (hence the name API and then 
sampled into the vacuum region). 
The second strategy has been proved to confer much more robustness and 
reliability to the ionization process, and, for this reason, API sources have currently 
almost completely displaced other ion sources that were routinely used previously, 
e.g. thermospray ionization (TSI). 
The family of API sources, originally consisting of electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI), has expanded in recent years to 
include atmospheric pressure photo-ionisation (APPI), atmospheric pressure laser 
ionsation (APLI) and sonic spray ionization (SSI). These have all further increased 
the analytical potential of LC-MS(/MS) in one way or another. Other more obsolete 
ion sources are TSI, particle beam (PBI), fast atom bombardment (FAB) and matrix-
assisted laser desorption ionization (MALDI). 
2.3.1.1. Electrospray ionization 
ESI was the first to be developed in the family of API sources and, at currently, is the 
most frequently used ionization mode in the field of analytical toxicology. An ESI 
source consists of a capillary tube, the ESI probe, to which a voltage (typically 3-5kv) 
is applied (Figure 15). At flow rates of a few microliters per minute, the difference in 
potential between the ESI probe and the orifice opening into the vacuum region of 
the mass spectrometer is sufficient to nebulise the liquid flowing into the capillary. As 
a result of the limitation in the flow rate applied, this device can be directly coupled to 
a nano-or micro-LC apparatus, whereas coupling to a normal LC requires splitting of 
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the eluent. In order to handle higher flow rates, a gas (nitrogen) flowing coaxially to 
the ESI probe is necessary to maintain a stable spray (pneumatically assisted ESI). 




ESI requires the analyte to be ionized in solution. Depending on the voltage polarity, 
nebulised droplets trapping the ionized analyte will be positively or negatively 
charged. The reduction in size caused by solvent evaporation accounts for the 
increase in charge density in the droplet, ultimately leading to its explosion when 
repulsive forces between charges exceed the cohesive forces of the droplet. This 
process occurs repeatedly until gas-phase ions are produced by direct emission 
from the microdroplets (10).  
If a compound can be charged at multiple sites in solution, it will carry multiple 
charges under ESI conditions. This allows the use of mass analysers with limited 
mass-to-charge (m/z) range (e.g. quadrupoles) to achieve the analysis of high-
molecular-weight compounds such as peptides. For example, a compound of 
molecular weight 12000 carrying 20 charges will appear at m/z 600. The 
combination of this feature with the ionization mechanism allowing the formation of 
gas-phase ions from ions in solution makes ESI the best solution for the LC-
MS(/MS) analysis of peptides. 
Typical ions produced under ESI conditions are: 
• in the positive mode: protonated molecular ions [M+H]+, sodium or potassium 
adducts, or solvent adducts 
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• in the negative mode: deprotonated molecular ions [M-H]-, or formate or 
acetate adducts (11) 
Clusters ions may sometimes be formed under ESI or other soft ionization API 
techniques. Adduct formation should be avoided whenever possible, particularly for 
quantification purposes, as it is often irreproducible. This is not always easy to 
accomplish. Some quantitative Applicability, however, exploit adduct formation (12-
14). 
Due to the low amount of energy transferred to the molecule during the ionization 
process, ESI is a mild ionization technique producing very little fragmentation. As will 
be discussed later, this has a positive impact on the sensitivity of LC-MS(/MS) 
analysis as most of the total ion current (TIC) pertains to one ion (the precursor ion 
in MS/MS mode). The flip side is that ESI-MS does not provide as much structural 
information. However, fragmentation can be promoted by imparting kinetic energy to 
the ions of the analyte within the intermediate vacuum region placed between the ion 
source and the mass analyzer. By applying a difference in potential at the two ends 
of this region (this parameter is called the orifice, fragmentor, skimmer or capillary 
voltage, depending on the manufacturer), ions are accelerated and are forced to 
collide with other molecules species (gas molecules, residual solvent, co-eluting 
compounds, etc) and the energy gained as a result of these collisions is dissipated 
by fragmentation (15). The higher the voltage and the length of the path in the 
intermediate vacuum region, the higher the fragmentation rate. This technique is 
called in-source collision-induced dissociation (in-source CID) in order to 
differentiate in from CID obtained under MS/MS conditions (described in the MS/MS 
section).  
In order to correctly select/develop chromatographic separation before ESI-MS, it is 
important to remember the following fact-signal intensity obtained by ESI depends 
on the analyte concentration more than on the analyte mass flow (amount per unit 
time) into the ion source, inferring that better signal-to-noise (S/N) ratios  are 
obtained at lower flow rates. This is said to depend on the solvent evaporation 
process, which is more efficient at lower flow rates. This improves the transmission 
of gas-phase ions into the vacuum region. 
This explains why a drying gas (nitrogen) and a heating device are also included in 
currently marketed ESI sources to assist droplet formation and solvent evaporation. 
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Nevertheless, higher flow rates will certainly result in more frequent servicing of the 
interface. 
In addition to flow rate, the composition of the mobile phase also affects ESI (16,17). 
As a general rule, because ESI requires the analyte to exist in solution as an ion, the 
pH of the LC eluent should be selected accordingly. Should this not match with the 
pH of the mobile phase required for optimal chromatographic separation, it is always 
possible to modify the latter by post-column addition. However, the rule of thumb 
‘basic analyte, acidic mobile phase and vice versa’ has more than one exception 
(18)). It should be kept in mind that the chemical environment in the electrospray 
plume may change dramatically during the spray process (19,20). For example, the 
production of abundant protonated ions from solutions where their equilibrium 
concentration is low may be due to a lower than expected pH as a result of solvent 
oxidation, charge enrichment, uneven droplets subdivision or solvent evaporation. 
Buffers are obviously important in order to obtain and control the right pH of the LC 
eluent. Their selection should be made in the light of two practical considerations: 
• non-volatile buffers should be avoided as they deposit into the ion source 
during the vaporization/ionization process. 
• their concentration, as well as the concentration of any other ionized species 
in the LC eluent, should be kept as low as possible; in fact, an ionized species 
present at a much higher concentration than the analyte will cover the surface 
of droplets and prevent the analyte passing into the gas phase, thus reducing 
its response. 
This competition between the analyte and other ions present in the LC eluent is 
called the matrix effect –a well-known phenomenon that is particularly evident with 
ESI (21-24). This phenomenon will be described latterly. 
Finally, the percentage of organic modifier in the LC eluent should kept as high as 
possible as it improves the efficiency of solvent evaporation and, as a result, the 
yield of ions transmitted to the vacuum region. This may be a problem in the case of 
polar analytes separated under reverse-phase (RP) chromatography. Glucoronide 
conjugates, for example, require a low percentage of organic modifier to be 
sufficiently retained in an RP column. Again, post-column addition helps, provided 
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that the increase in the signal to noise (S/N) ratio due to the increase in the organic 
modifiers is not counterbalanced by an increase in flow rate (25).  
Alternatively, normal-phase chromatography with an aqueous/organic mobile phase 
enables the retention of polar species with a higher percentage of organic modifier, 
resulting in higher ionization efficiency when compared with RP separation (26). 
Figure 16 shows the range of application of LC-ESI-MS(/MS) in terms of analyte 
polarity and molecular weight compared with GC-MS analysis. 
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2.3.2. Ion separation 
The mass analyzer represents the heart of a mass spectrometer, i.e. the device able 
to measure the m/z ratios of gas-phase ions. In order to allow a free path of the ions 
through the analyzer towards the detector, the analyzer must be operated under 
vacuum. The lower the pressure (typically in the range 10-4-10-7 torr), the longer the 
mean free path of the gas-phase ions. This has an obvious positive effect on 
sensitivity and mass resolution, although these parameters ultimately also depend 
on the type of mass analyzer and on the instrumental design adopted by the 
manufacturer.  
Together with sensitivity, other parameters are important in order to decide whether 
a particular mass analyzer fulfils the requirements of a laboratory. These are mass 
range, scan speed, mass resolution and mass accuracy. 
2.3.2.1. Quadrupole 
The quadrupole is the most common mass analyzer for bench-top MS instruments. 
The most likely reason for this resides in the fact that quadrupoles offer a good 
compromise of mass range covered, reproducibility of mass spectra, mass 
resolution and precision for quantification purposes. 
A quadrupole consists of four parallel rods or poles equally spaced around a central 
axis. An electrical potential is applied to each rod so that each two adjacent poles 
have opposite polarities. By applying a precisely controlled combination of two 
electrostatic fields-one direct current (DC) and one at varying radiofrequency (RF)- a 
resonance frequency for a specific m/z ratio is obtained so that ions at that m/z ratio 
can reach the detector, whereas ions with lower and higher m/z rations are 
discarded (Figure 18). 
A quadrupole acts as a continuous mass filter, which means that most of the ions 
that are continuously transferred to the quadrupole from the ion source are lost on 
their way to the detector and only a few ions (the ions at resonant frequency) are 
translated into measurable electric signal (Figure 17). By varying the resonant 
frequency of the quadrupole, a complete set of masses can be scanned at speeds of 
up to 4000-5000 amu/s, thus obtaining a ‘full-scan’ mass spectrum. 
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In addition to the above scan mode (typically adopted for the detection and 
identification of unknown compound), a quadrupole can also be operated in 
selected-ion monitoring (SIM) mode. In this mode, the quadrupole, is set at one or a 
few resonant frequencies (depending on the number of ions to be monitored). As a 
result, both sensitivity and precision in quantification are improved. In fact, since in 
SIM mode the analyzer spends more time on a specific ion, the amount of signal 
belonging to this ion reaching the detector is larger than in scan mode. The increase 
in the S/N ratio is therefore due to a true increase in signal and should not be 
confused with the increase in the S/N ratio due to the elimination of the huge amount 
of chemical noise resulting from not monitoring the full mass range.  
A typical quadrupole covers a mass range of up to 1000-4000 amu at low resolution 
(0.7 amu FWHM) and with mass accuracy of 0.1 amu. 
Figure 17. A schematic quadrupole analyser 
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2.3.2.2. Tandem Mass Spectrometry 
Traditionally, MS/MS has been implemented in quadrupole instruments where two 
different quadrupoles, one performing mass selection of precursor (parent) ion(s) 
and the other mass selection of product (daughter) ion(s), are separated by a 
collision cell (Figure 18). Here, the precursor ion is accelerated and fragmented into 
product ions by collision with an inert gas. As the collision cell is also a quadrupole, 
although simply acting as an ion guide, the two quadrupoles mass anaysers are 
usually referred to as Q1 and Q3, Q2 being the collision cell, and the instrument is 
referred to as ‘triple quadrupole’ (QqQ). Fragmentation can be favored by increasing 
either the kinetic energy (collision energy) of the precursor or the gas pressure in the 
collision cell. 
A triple-quadrupole instrument can be operated in a number of different ways, the 
simpler one being to resemble a single-quadrupole instrument by using either Q1 or 
Q3 as a pass-all filter. One of the most typical MS/MS scanning modes is the so-
called product-ion scan, where one precursor ion is selected by Q1 and the fragment 
(product) ions obtained after collision are scanned by Q3, thus obtaining a product-
ion spectrum. This differs from an in-source CID spectrum in that all fragments 
detected necessarily originate from the precursor ion.  
Other scanning modes, which are very helpful in metabolite profiling studies, are 
precursor-ion scan and neutral-loss scan (27-29). Both these scan modes are 
unique to mass spectrometers that provide MS/MS in space. Precursor-ion scan 
allows one to screen for homologous or similar compounds having a common 
fragment ion (e.g. different metabolites of a drug): Q1 scans the mass range, 
whereas Q3 filters a unique product ion and associates it back to the precursor ion 
that it originated from. The latter is useful for screening compounds with a common 
neutral fragment loss (e.g. loss of glucoronic acid). In this operating mode, both Q1 
and Q3 are synchronously scanned with a fixed mass difference (e.g. 176), and a 
mass is assigned only to those precursor ions that have lost the predetermined 
neutral mass. 
MS/MS quantification is typically carried out in non-scanning mode by selecting one 
precursor ion in Q1 and one specific product ion in Q3. This operating mode, a 
reaction (precursor ion-product ion) instead of an ion is monitored (so-called 
selected-reaction monitoring [SRM] or, if different reactions are monitored, multiple-
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MS1 MS2 Collision Cell 
reaction monitoring [MRM] (Figure 19). In this configuration, an MS/MS instrument 
associates extreme selectivity of detection (the probability that two compounds will 
share the same precursor AND the same product ion being quite low) with the 
highest sensitivity. In fact, the addition if a further MS stage implies that a lower 
number of analyte ions will reach the ion detector. However, as the noise is largely 
reduced, the resulting S/N ratio will be enhanced. 








When different reactions are monitored consecutively, as in MRM, care should be 
taken in order to prevent unwanted contributions to a monitored signal (i.e. the 
product ion of one reaction) from other reactions monitored in the same acquisition 
cycle. This phenomenon, called cross-talk, occurs if a precursor ion enters the 
collision cell when product ions from the previous reaction monitored are still present 
(30). If the two precursor ions share common fragments, the signal pertaining to one 
precursor may be overestimated due to the contribution from the other. Different 
strategies allow one to control this problem, such as: 
-adding a pause time between two consecutive transitions (though this will obviously 
increase the acquisition cycle and will reduce the number of data points per unit time 
in the chromatogram); 
-avoiding the consecutive monitoring of two compounds sharing common product 
ion (i.e. by monitoring a third reaction in between); or, even better 
                Conventional LC-MS/MS methods 
 68
-optimising LC separation in order to avoid chromatographic overlapping between 
the cross-talking compounds (31). 
Recently designed instruments take care of this problem by speeding up the exit of 
fragments from the collision cell. Cross-talk should always be considered when 
developing an analytical method as it is obviously a source of error in quantification. 
QTOF (Quadrupole/Time Of Flight), although rather expensive, is also an interesting 
configuration for MS/MS analysis as it combines the high efficiency of selected ion 
monitoring in the first mass analyzer (Q) with the high scan rate and high resolving 
power of the second (TOF). 
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2.3.3. Ion detection 
The detector is the device where ions separated by the mass analyzer are converted 
into a measurable electric signal (current). The analogue current is the further 
converted to a digital signal (counts) stored by the data system. The most important 
characteristics for an ion-detection device are speed, dynamic range and sensitivity 
(gain). 
The most common detection device is the electron multiplier. In an electron 
multiplier, ions are converted into electrons by means of a dynode electrode-when 
an ion strikes the dynode surface, electrons are emitted and the introduced current 
is recorded.  
A less common ion-detection system is the photo-multiplier. In a photo-multiplier, 
ions are initially converted by a dynode into electrons. These electrons are then 
converted into photons by means of a phosphorous screen. A photomultiplier, 
operating in a cascading mode, provides signal amplification. The photo-multiplier is 
sealed and kept under vacuum (photons pass through the glass), and therefore may 
have a longer lifespan; this is different to the electron multiplier, which is exposed to 
the internal environment of the mass spectrometer. 
TOF mass analyzers have a very high scan speed, and require fast detectors with a 
large and plane detection are so that many different ions can be detected at the 
same time. Multi-channel plate detectors providing time responses lower than 1ns 
and high grain (more than 50 mV per single ion) are typically used for this purpose. 
Each channel works similarly to a small CEM; because of the easier saturation and 
also the rapidity of the time-to-digital conversion required, the dynamic range of this 
type of detector is typically lower than that of the electron and photo-multiplier. 
Nevertheless, saturation can be observed with any type of ion detector and should 
be taken into account when a lower than linear response is observed. Apart from 
affecting quantification, detector saturation may also influence the appearance of the 
full-scan mass spectrum, thus impairing the performance of library search-based 
information. 
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2.4. Characteristics of current LC-MS/MS applications in forensic laboratories 
Essential strengths of the LC-MS/MS technology for forensic laboratories include: 
• Specificity: the potentially very high analytical specificity of tandem mass 
spectrometry as LC detector results from using the molecular mass of the 
analyte and its specific disintegration behavior as detection principle. 
• Wide range of applicability with good practicability. In contrast to GC-MS 
as the “classical” mass spectrometry technique, the application of LC-
MS/MS is not limited to volatile molecules (usually with molecular weights 
below 50 Da). Furthermore, aside from the highly polar analytes (i.e. 
amino acids), sample preparation is usually simple and does not include 
derivatization techniques. Mass spectrometry detected LC assays are 
generally optimized to shorter runtimes. Hence, compared to GC-MS, far 
higher sample throughput can be realized. 
• Flexibility. New assays can typically be developed in house with a high 
degree of flexibility and within a short run time. 
• Information rich detection. A large number of quantitative or qualitative 
results can be obtained for a single analytical LC-MS/MS run, since due to 
the fast ion selection electronics, multi-parametric, quasi parallel analysis 
can be performed with a mass spectrometer.  
2.4.1. Handling and robustness 
Although routine handling of LC-MS/MS system is easier compared to GC-MS 
instruments, it is much more complex than operating modern day forensic chemistry 
analyzers. Incorrect use can cause substantial machine damage and training for 
several weeks is usually required for technicians to run an instrument. While 
everyday handling and basic maintenance procedures 
can doubtlessly be performed by skilled technicians, 
the main responsibility for LC-MS/MS installations is 
typically in the hands of an academic. Such an expert is 
particularly necessary for the development and 
validation of new LC-MS/MS methods which are –aside 
some exceptions- individualized (“home brewed”) assay 
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setups tailored to the equipment available. A comprehensive assay validation 
including a detailed risk assessment has to be carried out. National and international 
guidelines (e.g. as published by SOFT (32)) are usually the basis of such an 
undertaking, especially in a forensic environment where especial legal regulations 
have to be met in some countries. 
It is a key feature of LC-MS/MS using API techniques as ESI or APCI, that ideally 
only a clean beam of ions is transferred into the high vacuum area of an instrument 
while unionized molecules (LC solvents and sample matrix residuals) do not enter 
the mass spectrometer. Solid contaminants typically precipitate in the ion source 
housing around the mass spectrometer’s vacuum area entrance orifice. In most 
cases, contaminated hardware components can be cleaned without venting the 
mass spectrometer. This is in contrast to GC-MS where essentially the entire 
effluent of the chromatographic procedure enters the high vacuum area, cleaning of 
which is very difficult and laborious. Hence, state of the art LC-MS/MS instruments 
are by far more robust than GC-MS instruments and allow the continuous analysis of 
large sample batches. Daily measurements series up to 24h duration with short, 
simple maintenance interventions (e.g. exchange of the LC stationary phases) after 
several days to weeks can be achieved. Taking into account the high analyte 
specificity of tandem mass spectrometry, chromatographic analyte separation prior 
to MS/MS can be minimized, if ion suppression effects are managed. State of the art 
LC-MS/MS instruments with one- or two-dimensional chromatography setups allow 
to run up to 20 analyses per hour. Consequently, within 24 h several hundred 
quantitative analyses can be performed with one LC-MS/MS system in a continuous 
work mode. In most forensic laboratories far smaller series are run in daily routine, 
especially if switching from one assay to another requires hardware changes (e.g. of 
LC columns) causing significant down times.  
Typically LC-MS/MS instruments work for months with minimal maintenance but can 
cause unexpected substantial problems without prior warning. In general, more 
down-times are related to the LC modules with its large number of mechanical parts 
compared to the mass spectrometer. Although the chromatographic methods in 
routine Applicability are kept as simple as possible (no complex gradient, no salt-
buffered mobile phases), typically LC problems (e.g. clogging of capillaries, gas 
bubbles in the fluid system, crystallization of mobile phase additives, microbial 
growth, abrasion, erosion, and leakage problems) also occur in LC-MS/MS. Mass 
spectrometry related problems most frequently arise from the API spray capillary 
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(erosion, blockage) and problems within the ion source housing like matrix 
accumulation or salt precipitation. More severe problems result from substantial 
contamination within the vacuum area, problems in the vacuum system or electronic 
faults. Such events typically require intervention of a service engineer but may be 
prevented by regular planned maintenance visits. 
Troubleshooting, e.g. for decreasing sensitivity or insufficient precision or an 
individual method, has to include complex considerations. They have to encompass 
all aspects of the assay as the sample preparation (e.g. injected volume check, early 
blocking/leakage detection, errors in the composition of mobile phases), the MS/MS-
based analyte detection (e.g. hampered by decreasing quality of nitrogen supply 
causing high background signals, an instable ion spray, source contamination, 
electrical noise due to a failure of the detector, or decreasing vacuum quality), and 
used chemicals (e.g. contamination of mobile phases causing ion suppression 
effects, the instability of internal standards or analytes (33,34).  
It might happen that after some maintenance actions or with increased 
contaminations of some hardware components, the reoptimization of about several 
MS instruments settings is necessary. Several of these tuning operations have to be 
performed in a more the less intuitive trial and error manner. Ion spray adjustments 
(e.g. re-optimization of the capillary position) are typically done manually. 
Consequently no software read-back is offered, and the contamination of these 
settings is hardly possible.  
Since almost all LC-MS/MS systems are customized by the individual user, not two 
installations are identical. This makes professional troubleshooting vial “hotline” or 
service engineers on site additionally difficult; especially if LC and MS are purchased 
from different manufacturers. With few exceptions, there is no comprehensive 
support available from the MS industry with covers all components of an installation 
or specific applicability.  
                Conventional LC-MS/MS methods 
 73
2.4.2. Analytical limitations 
Even though the principle of tandem mass spectrometry can allow specific analyte 
detection, the quality of an individual method has to be critically and carefully 
assessed. The choice of the optimal internal standard (IS) is one of the most critical 
steps in designing a LC-MS/MS assay. Whenever a stable isotope labeled derivative 
of a target analyte is available as IS, very reliable isotope dilution mass spectrometry 
(IDMS) methods can be developed. If homologue molecules (i.e. a molecule 
structurally closely related to analyte) have to be used as IS- as in the case for most 
drugs assays –assay reproducibility and linearity may become a substantial 
problem. Only IDMS assays can assure co-elution of the targeted analyte with its IS. 
This is the only possibility to fully compensate sudden signal fluctuations caused by 
individual matrix induced reduced or increased ion yields (“ion suppression” and “ion 
enhancement”, e.g. caused by co-administered drugs) and other unpredictable 
impairments of the ionization efficacy. It should not be overlooked, that a constant 
drop in ion yields, e.g. due to instrument contamination, will even hamper the 
performance of an IDMS-based assay due to sensitivity loss .  
Additional pitfalls in the accuracy of LC-MS/MS methods can arise from ion-source 
fragmentation of conjugate derivatives of a target analyte; especially if glycosidic 
bonds are involved (35) or from isobaric mass transitions of unrelated or related 
compounds such as metabolites or isomers (36). Interference from isomers of the 
target analyte can make even IDMS methods invalid.  
Manufacturers specify the sensitivity of LC-MS/MS instruments by applying solutions 
of different reference compounds. Reserpine is widely used for this purpose. It is 
relatively stable and yields positive and negative ions in both ESI and APCI. 
However, due to different protocols used (i.e. flow rates, analyte concentration, ion 
source tuning, ion transmission conditions) direct comparison of the sensitivity of 
different instruments is hardly possible and rather appropriate; notably, sensitivity of 
instruments may differ in a compound specific manner. Therefore it is advisable to 
define analyte related specifications if an instrument is to be implemented for a 
certain assay. Moreover, it is useful to supply the vendor’s application laboratories 
with test samples (i.e. extracts from spiked samples) in order to test the feasibility of 
a specific method intended to be implemented by the costumer). Nominal sensitivity 
documented on installation of an instrument may differ significantly from the level of 
sensitivity found in long-term routine application. Long term sensitivity critically 
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depends on the robustness of a respective instrument system. Furthermore, 
substantial differences in sensitivity can be observed between identical individual 
instruments even with similar serial numbers.  
2.4.2.1. Matrix effect 
LC-MS/MS is a powerful analytical technique for quantitative bioanalysis due to its 
inherent high sensitivity and selectivity. It is susceptible, however, to matrix effects. 
The impact of matrix effects on the accuracy, precision and robustness of 
bioanalytical methods is of growing concern (37-44). Residual matrix effect 
components, endogenous phospholipids in particular, are a significant source of 
Imprecision in quantitative analyses commonly conducted by LC-MS/MS. Matrix 
effects, originally discussed by Kebarle and Tang  in the early 1990s, can be 
described as the difference between the mass spectrometric response for an analyte 
in standard solution ant the response for the same analyte in a biological matrix, 
such as plasma (45). Matrix effects result from co-eluting matrix components that 
affect the ionization of the target analyte, resulting either in ion suppression, or, in 
some cases, ion enhancement. Matrix effect can be highly variable and can be 
difficult to control or predict. They are caused by numerous factors, including, but not 
limited to endogenous phospholipids, dosing media, formulating agents and mobile 
phase modifiers (46-49). Furthermore, different sources of plasma from the same 
species can yield different validation results, such as standard curve slope and 
precision. The severity and nature of suppression or enhancement may be a 
function of the concentration of the co-eluting metabolites, impurities or degradation 
products. Furthermore, matrix effects are analyte specific. All of the above factors 
can cause significant errors in the accuracy and precision of bioanalytical methods. 
Current international chromatographic method validation guidelines now require that 
these effects be evaluated as part of quantitative LC-MS/MS method development, 
validation and routine use (50). Consequently, most current papers describing the 
quantification of drugs in biofluids discuss matrix effects in some degree. 
Several papers describing the evaluation of matrix effects have been published, 
providing the guidance and techniques necessary for researcher. There are two 
common methods to assess matrix effects: post-column infusion method (51) and 
the post-extraction spike method (52). The post-column infusion method provides a 
qualitative assessment of matrix effects, identifying chromatographic regions most 
likely to experience matrix effects. This approach is limited in that it does not provide 
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a quantitative understanding of the level of matrix effect observed by specific 
analytes, but merely identifies chromatographic regions where an analyte would be 
most susceptible to suppression or enhancement. However, this process can be 
very time consuming and require significant optimization, particularly if quantification 
of multiple analytes in a single run is desired. In contrast, the post-extraction spike 
method quantitatively assesses matrix effects by comparing the response of an 
analyte in neat solution to the response of the analyte spiked into a blank matrix 
sample that has been carried through the sample preparation process. In this 
manner, quantitative effects on ion suppression or enhancement experienced by all 
analytes in the sample can be measured each time a change is made to the 
anatycal method.  
While more researchers now include an evaluation of matrix effects as part of 
method development, only some attempt to actually reduce or eliminate matrix 
effects. Some researchers have focused on optimizing sample preparation to reduce 
matrix effects (45,53,54), while others have focused on manipulating 
chromatographic parameters (55,56). Others assess the level of matrix effects and 
compensate for the alteration of the signal through the use of an IS, often the stable 
isotope labeled analog of the drug. Still other papers describe the use of flow 
splitting to reduce matrix effects (57,58). In some cases, researchers opt to use an 
ionization source, such as APCI, that is less sensitive for their compound, simply 
because the matrix effects experienced with the more sensitive source are too great. 
APCI has shown, for certain compounds, less ion suppression and can be a better 
choice for some assays based on sensitivity and accuracy/precision, but it is not 
immune to matrix effects (52,59).  
In summary, it is evident that LC-MS/MS holds great potential as a complementary 
technology for laboratory medicine, although at present there are still important 
limitations of its routine application which have to be deal with. These are in 
particular issues related to the ease of hardware and software use, the instrument 
performance and the practicability of LC-MS/MS assays in a routine laboratory 
setup. 
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2.5. Sample preparation 
It is common knowledge that poor sample preparation, when the most modern and 
sophisticated techniques are applied, may negatively affect detection and 
quantification. LC-MS/MS for drugs makes no exception. LC-MS/MS is not a magic 
tool able to replace optimal sample preparation and separation.  
Although less laborious than GC-MS sample work-up, typical LC-MS/MS protocols 
include several purification steps. Insufficient sample preparation affects LC-MS/MS 
analysis in two mayor ways. Macromolecular and cellular sample contamination may 
lead to LC column clogging resulting in instrument down-times. Insufficient removal 
of substances co-eluting with an analyte into the mass spectrometer can lead to 
impaired analyte detection, resulting in sensitivity loss or reduced assay specificity 
and accuracy. Retaining investigated analytes in the chromatographic separation 
system is a mayor cornerstone in sample preparation. It allows to separate 
undesirable sample matrix constituents (e.g. salts, phospholipids, etc) and other 
metabolites from the analyte elution band.  
Depending on the analyte concentration range to be addressed, sample preparation 
or dilution has to be achieved in the course of sample preparation. There are many 
sample preparation technologies, all of them having certain advantages and 
disadvantages. The most widely applied simple sample preparation techniques are 
protein precipitation (PPT), liquid-liquid extraction (LLE) and solid phase extraction 
(SPE). Below there is an overview of these sample clean-up techniques. 
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2.5.1. Protein precipitation (PPT) 
The protein content of human body fluids and tissues is 
considerable. Numerous techniques have been developed to 
precipitate protein and remove it before extracting and 
concentrating drug substances. The solubility of proteins 
depends on the distribution of hydrophilic and hydrophobic amino residues on the 
proteins’ surface. Proteins that have high hydrophobic amino acid content on the 
surface have low solubility in aqueous solvent. Charged and polar surface residues 
interact with ionic groups in the solvent and increase solubility. Knowledge of amino 
acid composition of a protein will aid in determining and ideal precipitation solvent 
and method. Protein precipitation reagents include the following: organic solvents 
(acetone, acetonitrile, methanol), zinc sulfate in methanol, 5-sulfosalicylic acid, 
perchloric acid, trichloroacetic acid, sodium tungsten and ammonium sulfate. Once 
proteins have been precipitated, separation of aqueous and solid protein must occur 
by filtering or centrifugation. Some drugs are occluded (trapped) in the precipitate, 
but can be at least partially recovered by washing the precipitate with hot water or 
hot dilute hydrochloric acid. Those drugs readily hydrolyzed by heating under 
aqueous acidic or basic conditions should be either extracted without protein 
precipitation or extracted with a mild precipitation reagent such as zinc sulfate-
methanol without heating. Esters such as cocaine, benzocaine, meperidine, 
methylphenidate, and procaine need to be recovered under mild conditions. 
Alkaloids such as strychnine, nicotine, quinine, various opiates, and some narcotics 
will not be degraded by moderate heating and acid treatments to precipitate proteins 
(60-62). 
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2.5.2. Liquid Liquid Extraction (LLE) 
LLE, also known as solvent extraction and partitioning, is a 
method to separate compounds based on their relative solubility in 
two different immiscible liquids, usually water and an organic 
solvent. It is an extraction of a substance from one liquid phase 
into another liquid phase. Once a solvent is chosen, a buffer is 
usually added to convert drugs to a form that is non-ionic so it will 
partition readily in organic solvent. The key principle adjusting the 
pH for extraction is to create non-salt forms of the drugs to be partitioned into the 
organic solvent. LLE is still frequently used in analytical toxicology, especially for 
(urgent) screening purposes, when analysis of a wide range of (unknown) 
compounds rather than target analysis is the objective (63-76). Development of an 
LLE procedure is, moreover, not time-consuming, although it is difficult to automate, 
requires high-purity solvents, and can result in the formation of emulsions with 
incomplete phase separation, the last of which leads to impure extracts. Safe 
disposal of toxic solvents may also be problematic and expensive. 
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2.5.3. Solid phase extraction (SPE) 
The general definition of SPE could be as follows: 
Separation of analyte(s) from a mixture of matrix 
compounds by selective portioning of the compounds 
between a solid phase (sorbent) and a liquid phase 
(sample&solvent). SPE is a dynamic process. During extraction, the equilibrium, 
between analyte concentration in the sample and the analyte concentration on the 
sorbent, is continuously shifting. Ideally, the analyte ‘likes’ the sorbent much better 
than the sample and is completely extracted from the sample. The less sorbent 
material is required to extract the analyte from the sample, the more selective and 
thus cleaner the extract will be.  
To create a selective method, often simple sample pre-treatment steps are required 
before the actual extraction. First of all, the sample sometimes contains particulates 
that have to be filtered out. The SPE cartridge and its frit can filter out particulates, 
but this may not be sufficient or cause clogging. In this case centrifugation or 
filtration of the sample is required. Secondly, the sample is often diluted or a buffer is 
added to neutralize or charge the analyte. By changing the characteristics of the 
sample or the analyte, the conditions to retain the analyte on the sorbent can be 
improved. At the same time, to compensate for mistakes occurring from sample pre-
treatment all the way to the detection, an internal standard is added to the sample. 
Sometimes analytes also interact with matrix compounds (protein binding). For the 
analyte to retain on the cartridge, it preferably must be free in solution. Depending 
on the type of binding, a solvent can be added to the sample in order to disrupt this 
drug-protein interaction.  
Bellow is described how SPE works for a reversed phase interaction. 
• Activation: the function of this step is to wet or activate the functional 
groups of the sorbent to allow proper interaction with the analyte. If 
extraction sorbents are hydrophobic they will not be wetted by an aqueous 
solution. Therefore organic solvents are used. In case the sorbent is 
wettable, this step may be omitted. 
• Equilibration: the function of this step is to create a sorbent chemistry 
environment similar to that of the sample. If the pH is important for the 
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extraction chemistry, the sample pH should be adjusted properly in both 
the sample pre-treatment and the sample conditioning step. It is also 
important the solvent is fully miscible and compatible with the sample; 
otherwise precipitation of sample matrix components could potentially 
cause blockages. 
• Sample loading: during sample loading the free analyte will bind the 
extraction solvent. In this step, the flow rate of the loading step is directly 
related to the residence time of the analyte on the extraction solvent. A too 
high flow could result in breakthrough. Some of the matrix compounds will 
also retain on the sorbent. Usually there is enough sorbent material so this 
does not negatively impact the capacity. As long as the capacity of the 
sorbent is sufficient, the amount extracted increases proportional with the 
sample volume loaded on the cartridge. 
• Washing: with a wash step most of the retained matrix compounds are 
flushed to waste. The wash solvent usually has higher elution strength (% 
organic solvent) than the solvent used for sample loading. Matrix 
compounds with a weaker interaction with the sorbent compared to the 
analyte will go the waste while matrix compounds with stronger 
interactions will still remain on the cartridge. Use the strongest possible 
wash solvent in order to get the cleanest extract. However, during the 
wash, analyte-sorbent interactions can also be partially disrupted causing 
the analyte to move further in the SPE cartridge. Ideally, the wash is 
stopped before some of the analyte starts to elute from the cartridge 
(breakthrough). 
• Elution: after the majority of the matrix compounds have been washed to 
waste, the analyte is eluted from the sorbent. Typically, a strong elution 
solvent is used to disrupt all the interactions of the analyte with the 
sorbent. Apart from the analyte, the matrix compounds that have not been 
washed away are now also eluted with the analyte. These matrix 
compounds can still cause interferences during detection. The elution step 
can also be used to even further improve clean-up. This means the 
analyte elutes completely, but matrix compounds with stronger 
interactions are retained on the cartridge. 
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Thus, SPE is currently used as a routine sample clean up method in forensic and 
toxicology laboratories for a wide range of compounds (62,77-88). 
2.5.4. Pros and Cons 
The table below shows the advantages and disadvantages it these sample 
preparation technologies.  
Table 2. Overview of sample preparation technologies most important criteria 
 Assay Performance Method development Workflow 
 Clean-up Sensitivity Reproducibility Time Simplicity Validation Automation 
Software  
Integration 
PPT    ☺ ☺  ☺  
LLE ☺  ☺   ☺   
SPE ☺     ☺   
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2.6 LC-MS(/MS) methods for the analysis of hallucinogens, cannabinoids, and 
amphetamines in blood and urine in the literature 
A wide variety of body fluid specimens have been utilized for analysis for the 
presence of drugs of abuse. Blood is widely regarded as the specimen offering the 
best correlation between drug levels and likely dosing and likely concomitant 
pharmacological, cognitive, and psychomotor effects. Drug levels found in blood are 
often quite low (ng/mL) and often short-lived. The analysis of drugs in blood is time-
consuming, generally requiring extraction procedures before further analysis can be 
performed. There have been several publications addressing the application of urine 
immunoassays to the analysis of blood specimens, after appropriate extractions 
protocols (89,90,91). Although blood is widely used for drug testing in forensic 
toxicology settings, the invasiveness of the collection of blood specimens does not 
lend itself to routine testing in other non forensic context (e.g. workplace, testing 
environments). Furthermore, there is much greater risk of transmission of infection 
disease though handling of blood samples than with other alternative matrices not 
discussed in this thesis (e.g. oral fluid, sweat, hair).  
Urine offers the advantages of large specimen volume and relatively high drug 
concentrations. Urine is 95% water, with sodium chloride and urea in about equal 
amounts as the main dissolved substances, and with smaller amounts if a wide 
variety of other constituents. Moreover, urine is relatively easy to collect and 
analyze. There are a wide variety of immunoassays available for detection of most 
common drugs of abuse and/or their metabolites in urine. However, one of the most 
important limitations of urine is the relative difficulty in correlating urine drug/and or 
metabolite levels with likely dosing and likely impairment.  
Accordingly to the scope of this thesis, below it is described the analytical LC-
MS(/MS) methods for the determination of hallucinogens, cannabinoids and 
amphetamines in blood and urine.  
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature 
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 





















Kromasil  Water 
Acetonitrile 
Formic acid 
ESI+ QqQ Linearity 0.2-50 
ng/mL 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 
Interphase Detector Validation 















LOQ 0.2 ng/mL 
Imprecision<38% 
Matrix effect<30% 














LOQ 1.78 ng/mL 
Inaccuracy<8% 
Recovery>70% 
No matrix effect 
Stability 
Applicability 










ESI+ QqQ Linearity 0.05-5000 
ng/mL 
LOQ 0.05 ng/mL 










Hydrolysis Hypersil Gold Formic acid 
Acetonitrile 
 
ESI+ QqQ Linearity 5-500 ng/mL 
Imprecision<27% 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued)  
 
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 
Interphase Detector Validation 










































Chiral AGP Isopropanol 
Ammonium acetate  
 
ESI+ MSD Linearity 1-125 
ng/mL 











- 0.1% Formic acid 
Toluene:Acetonitrile 
 
ESI+ MSD Linearity 0-500 
ng/mL 















TIS+ QqQ Linearity 1-500 
ng/mL 
LOD 1 ng/mL 
Recovery>90% 
Applicability 




Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued)  
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 
Interphase Detector Validation 








ESI+ Ion Trap Linearity 5-1000 
ng/mL 
Imprecision<11% 
LOD 5 ng/mL 
No matrix effect 
Recovery>89% 
Applicability 








ESI+ Ion Trap Linearity 5-160 
ng/mL 
LOQ 5 ng/mL 
Imprecision<15% 
Inaccuracy<95% 
No matrix effects 





ACE 5C18 Formic acid 
Acetonitirle 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 






(MCX and C8) 
BEH C18 0.1%Formic acid 
Acetonitrile 
 
ESI+ QqQ Linearity 0.1-100 
ng/mL 
LOD> 0.03 ng/mL  

















Pak SCX UG 80 
Ammonium acetate 
Acetonitrile 



















LOQ 4 ng/mL 
Imprecision<2% 
Recovery>84% 
No matrix effects 
Applicability 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued)  
LC 
Reference Analyte Sample 
Sample 
preparation Column Mobile Phase 










Synergi Hydro RP Formate buffer 
Acetonitrile 
ESI+ Ion Trap Linearity 0-1200 
ng/mL 
LOD 0.6 ng/mL 











Atlantis dC18 Ammonium formate 
Acetonitrile 
 
ESI+ QqQ Linearity 0.2-
100ng/mL) 
LOD 0.1ng/mL 














Zorbax SB-C18 0.05% formic acid 
Acetonitrile 
 
ESI+ QqQ Linearity 0.01-200 
ng/mL 









Eclipse XDB C18 Ammonium acetate 
Acetonitrile 
 
APCI+ Ion Trap Matrix effect 
Stability 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 








Spherisorb 5 RP 
8S 
0.1% formic acid 
Acetonitrile 
 
ESI+ QqQ Linearity 0.01-4 
ng/mL 
Imprecision<7% 
LOQ 0.02 ng/mL 
Inaccuracy<12% 
Applicability 
(117) 2-Oxo-3-OH-LSD Urine 




SPE (Clean Screen) 
Eclipse XDB C18 Ammonium acetate  
Acetonitriel 
 
APCI+ Ion Trap Linearity: 1- 8ng/mL 
(r2:0.9805) 
LOQ 0.4 ng/mL 
(118) LSD Urine 
(5 mL) 
SPE  
(Bond Elut Certify) 







LOQ 0.5 ng/mL 
Imprecision<10% 












LOQ 0.05 ng/mL 
Imprecision<14% 
Recovery>93% 




Zorbax Phenyl Ammonium acetate   
Methanol 
 
APCI+ QqQ Linearity 5-
10000ng/mL 
LOD 3 ng/mL 
Imprecision<8.5% 
Recovery>99% 
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Table 3: LC-MS(/MS) methods for the analysis of hallucinogens in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 
Interphase Detector Validation 













LOQ 0.25 ng/mL 
Recovery>75% 





Hipersil Gold Ammonium acetate 
Acetonitrile 
 
ESI+ QqQ Linearity 0.5-5000 
ng/mL 
LOD>0.16 ng/mL 




No matrix effect 
Stability 
Applicability 









ESI+ QqQ Linearity 500-5000 
ng/mL 
Imprecision<10% 
LOD 0.5 ng/mL 
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 Table 4 : LC-MS(/MS) methods for the analysis of cannabinoids in blood and urine in the literature  
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 
Interphase Detector Validation 




Xterra MS C18 Ammonium 
formate (0.1%FA), 
Methanol 
APCI+ QqQ Linearity 0-500 
ng/mL 
LOD 0.2 ng/mL, 
LOQ 5.1 ng/mL, 
Imprecision 
<13.4%), 
Recovery >82%  
(126) THC Blood  
(1.2 g) 
SPMEM C18 Methanol 
Water 








LLE XTerra MS C18 Ammonium 
formate 
Methanol 
ESI+ QqQ Linearity 0.1-10 
ng/mL 
LOQ >0.1 ng/mL, 
Imprecision <6%, 
Accuracy <7% , 
Recovery >85%, No 
Matrix effect  
Stability  
Applicability  




(1 mL)  
Hydrolysis (Urine) 
SPE 





Symmetry C18 0.1% Formic acid 
Acetonitrile 







No matrix effect  
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Table 4 : LC-MS(/MS) methods for the analysis of cannabinoids in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 
Interphase Detector Validation 
(129) THC, 11-OH-THC, 
THC-COOH 
Plasma 






(Bond Elut Certify II) 









APCI+ QqQ Linearity 0.2-100 
ng/mL 
LOD 0.1 ng/mL 
LOQ >0.2 ng/mL, 
Imprecision <16% ,  
Inaccuracy <26% , 
Recovery >47%, 
Stability 
No matrix effects 
Applicability 








(Bond Elut Certify) 
 
BEH C18  0.1% Formic acid 
Acetonitrile 
ESI+ QqQ Linearity 0.05-50 
ng/mL, 
LOD>0.02ng/mL 




Matrix effect<12%  
Stability 
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Table 4 : LC-MS(/MS) methods for the analysis of cannabinoids in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 
Interphase Detector Validation 




BEH C18 0.1% Formic acid, 
Acetonitrile 
ESI+ QqQ Linearity 2-1000 
ng/mL,  
LOD 0.2 ng/mL, 
LOQ 0.7 ng/mL, 
Imprecision <5%, 
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Table 5 : LC-MS(/MS) methods for the analysis of amphetamines in blood and urine in the literature  
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 
Interphase Detector Validation 









Hypersil BDS C18 Ammonium acetate 
Acetonitrile 













Hypersil C18 Ammonium acetate 
Acetonitrile 
Methanol 
ESI+ QqQ Linearity 0.3-1000 
ng/mL 





















(135) Amphetamine Plasma 
(50 µL) 




ESI+ Ion trap No validation  
Evaluation of LPME 
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Table 5 : LC-MS(/MS) methods for the analysis of amphetamines in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 

































LOQ 2 ng/mL 
Recovery>50% 













0.05% Formic acid 
Acetonitrile 
ESI+ Ion Trap Linearity 5-500 
ng/mL 
LOD 1 ng/mL 




No matrix effect 
Applicability 
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Table 5 : LC-MS(/MS) methods for the analysis of amphetamines in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 












ESI+ Ion Trap Linearity 5-160 
ng/mL 
LOQ 5 ng/mL 
Imprecision<15% 
Inaccuracy<95% 
No matrix effects 
(114) Amphetamine, 
methamphetamine, 





Atlantis dC18 Ammonium 
formate 
Acetonitrile 
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Table 5 : LC-MS(/MS) methods for the analysis of amphetamines in blood and urine in the literature (continued) 
LC 
Reference Analyte Sample Sample preparation 
Column Mobile Phase 














ESI+ QqQ Linearity 0.1-50 
ng/mL 
LOQ 0.1 ng/mL 
Imprecision<13% 
Inaccuracy<20% 
No matriz effects 
Applicability 
(109) Methamphetamine Urine 








ESI+ Ion Trap Linearity 50-
5000ng/mL 
LOD 10 ng/mL 
Imprecision<12% 
Inaccuracy<13% 
No matrix effects 
Applicability 










Pak SCX UG 80 
Ammonium acetate 
Acetonitrile 











Dilution Luna C18 0.1%Formic acid 
Acetonitrile 





No matrix effect 
Applicability 
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3.1. Introduction 
As described in the previous chapter, samples from biological matrices are usually 
not directly compatible with LC-MS/MS analyses. Hence, sample preparation has 
traditionally been done using PPT, LLE, or SPE. Manual operations associated with 
these processes are very labor intensive and time consuming. Therefore, trends in 
sample preparation in analytical toxicology are to reduce of solvents, to simplify 
manipulations, and to reduce the time necessary for sample preparation. Increasing 
attention is being devoted to the possibility of automating analytical methods. 
Automation results in greater throughput, improved precision and accuracy, and a 
minimum of operator intervention, leading to safer sample handling and time-saving 
procedures. The current trends indicated that automated SPE is now more widely 
used than in the past. Much of this recent growth stems from increased capabilities 
of commercially available workstations (1,2). The most attractive feature of on-line 
SPE is that it almost entirely automates the sample handling process.  
In the following, the details of the new trends in on-line SPE techniques will be 
discussed. 
3.2. On-line SPE 
A drawback of off-line SPE procedures is that they can be time consuming and 
cumbersome to perform, often requiring many steps before reaching a concentrated 
extract suitable for instrumental analysis, of which only a small portion is actually 
injected onto the chromatographic column.  
The increased demand for high-throughput causes a unique situation of balancing 
cost versus analysis speed as each sample preparation technique offers unique 
advantages.  
As compared to off-line SPE, on-line SPE offers a series of advantages (see Table 
6).  When working with on-line SPE, off-line SPE elution conditions are no longer 
applied: Typically, a strong wash solvent is used to elute the analyte from the SPE 
cartridge. Moreover, the less solvent is required to elute the analyte from the 
cartridge, the less time is needed for evaporation. With on-line SPE, elution is taking 
place when the cartridge is switched inline with LC-column and the LC-method is 
started. As soon as the analyte is eluted from the SPE cartridge, by the mobile 
phase (isocratic or gradient), the cartridge is switched off-line again. Matrix 
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compounds with a stronger retention than the analyte, will remain on the cartridge 
and are not eluted to the LC-column. There is also a difference in analyzed fraction: 
the reconstitution step is also a dilution step. Usually no the entire reconstituted 
fraction is injected by the LC. With on-line SPE, all of the analyte loaded on the SPE 
cartridge, is eluted to the LC column. This means, either less sample is required or 
higher sensitivity can be reached 
Moreover, sample loading is under different conditions: Where with off-line SPE the 
sample and solvents are sucked through the cartridge using a vacuum manifold, with 
on-line SPE the sample is applied on the cartridge using a controllable flow rate. 
During sample loading, the sample is sandwiched between SPE solvents. When 
sample volumes are small, buffers or additives to break protein binding can be 
added to the SPE solvents. As long as the mixing between sample and SPE 
solvents is sufficient, it completely eliminates sample-treatment steps. 
Typically, less sample volume is required for on-line SPE, especially when ‘raw’ 
samples are injected and pre-treatment steps, which are often also a dilution, are not 
required. However, injection of ‘raw’ samples does not require the use of a suitable 
autosampler and a disposable extraction column. There is also, a difference in 
cartridge capacity: When cartridges are constructed for high-pressure (>4000 psi) 
on-line extraction, a much wider range of sorbent materials and particle size (starting 
at 8 µm) can be utilized. Chromatographically efficient SPE cartridges combine high 
extraction capacity with small elution volumes to minimize band broadening and 
consequently provide increase assay sensitivity. 
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Table 6: Comparative features on on-line and off-line SPE configurations (3) 
On-line SPE Off-line SPE 
Automatization and minimal sample 
handling  which translates in better 
precision and accuracy 
Manipulation of the sample, possibility 
of contamination, and less accuracy 
and precision 
Direct and fast elution of the sample 
after preconcentration. Minimal 
degradation 
Risk of degradation of compounds 
(longer overal analysis time) 
Minimal consumption of organic 
solvents (elution with the LC mobile 
phase) 
Consumption of organic solvents for 
elution 
No loss of analytes due to 
evaporation steps 
Possible loss of analytes during 
evaporation steps 
Reduced analysis time and high 
throughput (simultaneous extraction 
and analysis of samples in a 
sequence) 
Longer analysis time 
Matrix effects; ion suppression or 
enhancement in MS 
Less matrix effects in MS 
Reusable cartridges Disposable cartridges 
Limited portability Availability of portable SPE systems 
Expensive equipment Economical equipment 
 
Thus, the on-line technique can be fully automated. Several generic approaches 
have recently been developed for on-line sample extraction coupled to LC-MS (4-6). 
Most on-line SPE approaches use column-switching to couple with the analytical 
columns. Various column dimensions can be configured for the fast analysis of drug 
and their metabolites in biological matrix at nanogram per milliliter level or lower. 
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One commercially automated on-line SPE system is the Symbiosis system 
manufactured by Spark Holland. The system offers large flexibility in processing 
different types of sample selecting one of the three fully automated operational 
modes LC-MS(/MS) (direct LC without SPE); XLC-MS(/MS) (one-line SPE coupled 
to LC-MS(/MS)); AMD (advanced method development).  
It includes an autosampler (Reliance), two binary LC pumps, 
an on-line SPE unit with two high-pressure solvent delivery 
pumps (HPDs) and a combined valve systems to direct fluid 
for different steps of SPE (Figure 19). At the beginning of each 
run, an on-line SPE cartridge is loaded into the unit. After a 
conditioning step with high organic solvent and an equilibrium step with low organic 
aqueous solution, a sample is injected onto the cartridge and washed with aqueous 
solution. Proteins and other matrix materials from the sample are removed during 
the washing step. Analyte of interest is then eluted onto the analytical column and 
detected by mass spectrometry. During the sample elution step, a second sample is 
loaded to a new on-line SPE cartridge for the next analysis. 
In this parallel mode, the sample analysis cycle time 
approximates the LC run time without the time required for 
the SPE procedures. Since the on-line SPE cartridge is 
disposable and each sample uses a new cartridge, the 
carry-over problem from the extraction cartridge is 
eliminated.  
          New advances in LC-MS/MS methods 
 125
Figure 19. Automated SPE unit coupled to a triple quadrupole mass spectrometer 
with (A) autosampler with a sample storage compartment, (B and C) high pressure 
dispensing pumps, (D) automated cartridge exchanger and (E) triple stage 
quadrupole mass spectrometer. 
 
A generic method for the fast determination of a wide range of drugs in serum or 
plasma has been presented for the Spark Holland system (7). The method 
comprises generic solid-phase extraction with HySphere particles, on-line coupled to 
gradient LC with tandem mass spectrometry detection. The optimized generic SPE-
LC-MS/MS protocol was evaluated for 11 drugs with different physicochemical 
properties. Good quantification for 10 out of 11 of the pharmaceuticals in serum or 
plasma could be readily achieved. The quantitative assays gave recoveries better 
than 95%, lower quantification limits of 0.2-2.0 ng/mL, acceptable precision and 
accuracy and good linearity over 2-4 orders of magnitude. Carry-over was 
determined to be in the range of 0.02-0.10%, without optimization.  
An approach for on-line introduction of IS for quantitative analysis was developed on 
the Spark Holland system (8). In this approach, analyte and IS were introduced into 
the sample injection loop using a conventional autosampler (injector) needle pickup 
from a simple vial. IS was introduced into the sample injection loop on-line from a 
microresevoir containing the IS solution. As a result, both analyte and IS were 
contained in the sample loop prior to the injection into the column. The authors 
demonstrated comparable accuracy and precision to those obtained using off-line IS 
introduction (i.e. IS and analyte were pre-mixed before injection) while maintaining 
chromatographic parameters (i.e. analyte and IS elution time and peak width). This 
new technique was applied for direct analysis of model compounds in rat plasma 
using on-line SPE LC-MS/MS quantification. On-line IS introduction allows for non-
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volumetric sample (plasma) collection and direct analysis without the need of 
measuring and aliquoting a fixed sample volume prior to the on-line SPE-LC-
MS/MS. The method enables direct (plasma) analysis without any sample 
manipulation and preparation. 
 Koal et al (9) developed a method for quantification of 7 protease inhibitors in 
patient plasma samples. Only a sample dilution step was used to dilute samples and 
add internal standard before the analysis. Run time was only 3.3 min per sample 
and 6.6. min for the first sample. Alnouti et al (10) reported another study with 
Symbiosis system connected to a Luna C18 analytical column or a Chromolith C18 
monolothic column for analysis of two model compounds. Rat plasma spiked with 
the analytes was diluted with internal standard and injected direcly into the system. 
Method development including on-line SPE cartridge selection and extraction 
condition optimization was performed by the Symbiosis system automatically. The 
total cycle time of 4 min with the Luna C18 was reported. The run time was reduced 
to 2 min per sample for the monolithic column without compromising the quality and 
validation criteria of the method.  
Recently, Jagerdeo et al (11,12) developed a method for the analysis of cocaine and 
four of its metabolites in whole blood and urine, using Gemini C6-Phenyl column and 
the HySphere MM anion cartridge. Very good precision and accuracy for all of the 
compounds were obtained.  
In conclusion, the Symbiosis pharma system offers the entire process of 
conditioning, sample application, washing and elution taking place at constant flow 
rates, yielding better precision in comparison with off-line driven extraction 
procedures. Another important advantage is that no manual transfers are made and 
that the whole of the eluate is loaded onto the LC column without the need for a pre-
concentration step. Therefore, it provides a reliable and simple alternative to improve 
sensitivity and detection limits for high throughput sample preparation and analysis 
of compounds in complex matrices (13). 
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Table7: On-line SPE applications with the Symbiosis system 
SPE LC 
Reference Analytes Sample On-line 
system 












Prospekt IST Isolute 
solid-
phase CN 
Zorbax C18 RX  Acetonitrile 
Water 
TFA 
QqQ Linearity 2.5-1000 ng/mL 








Hypersil BDS C18,  Phosphate buffer 
Acetonitrile  
UV Linearity 2-140 ng/mL 
LOD 0.5ng/mL 




(16) Piroxicam Plasma 
(200 µL) 
Prospekt Bond Elut 
C8  





LOQ: 50 ng/mL 
Applicability 
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Table7: On-line SPE applications with the Symbiosis system (continued) 
SPE LC 
Reference Analytes Sample On-line 
system 








Symmetry C18  Phosphate buffer 
Acetonitrile 
Fluorescence Linearity  2.5-25000 
ng/mL 





















Hypersil ODS (C18)  Acetonitrile  
(0.1% Formic acid) 
Acetate buffer 
QqQ Linearity 2.5-40 ng/mL 
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Table7: On-line SPE applications with the Symbiosis system (continued) 
SPE LC 
Reference Analytes Sample On-line 
system 

























Luna C18  


















XDB C18  
Acetate buffer 
Methanol 
MS Linearity  10-1000 
ng/mL 
LOQ: 50 ng/mL 
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Table7: On-line SPE applications with the Symbiosis system (continued) 
SPE LC 
Reference Analytes Sample On-line 
system 






















Range: 10-1000 ng/mL 
CV%<20 
Bias%<20 
LOQ: 10 ng/mL 
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Table7: On-line SPE applications with the Symbiosis system (continued) 
SPE LC 
Reference Analytes Sample On-line 
system 
Cartridge Column Mobile Phase 
Detection Validation 


















Resin GP  
Luna C18  0.1% Formic acid Acetonitrile 
 
DAD Evaluation of trapping 
efficiency 
Influence of flow rate of 
loading solvent 
Influence of acetonitrile  
content in loading 
solvent 
Influence of analyte 
content 
Capacity of GP 
cartridges 
(21) 8 drug compounds 
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Table7: On-line SPE applications with the Symbiosis system (continued) 
 
SPE LC 
Reference Analytes Sample On-line 
system 














Gemini C6-Phenyl  0.1%Formic acid 
Acetonitrile  
QqQ Linearity: 4-500 ng/mL 
LOQ : 8-47 ng/mL 













Gemini C6-Phenyl  0.1% Formic acid  
Acetonitrile  
QqQ Linearity 7-1000 ng/mL 
Imprecision<9% 
Inaccuracy<5% 
LOD: 3-23 ng/mL 
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The aim of this work was to optimize LC-MS/MS methods in this laboratory for 
characterization and quantification of popular drugs in biological matrices, and 
additionally develop a new emerged technology: the on-line SPE-LC-MS/MS 
(Symbiosis system). Applications were chosen because of the specificity of the 
method and/or the frequent need of analysis of a large number of samples.  
At the moment of the development of a method there were several significant 
aspects to take into account a) the amount of sample required can be an analytical 
limitation, b) forensic toxicologists may be required to analyze drugs in blood to 
evaluate an impairment status, c) the analysis of urine is often demanded as the 
time window for the detection of drugs is wider than for blood and d) complete 
validation is required to guarantee the robustness of the method. 
4.1. Hallucinogens in urine (LC-MS/MS) 
Until recently in Europe, LSD was the substance that dominated the field of 
hallucinogenic drug use. The emergence of hallucinogenic plants and mushrooms 
as a potentially widespread drug trend laid relatively dormant in Europe until the late 
1990s when they began to be marketed alongside other ‘natural’ products by smart 
shops in the Netherlands. It seems that interest in natural hallucinogens appear to 
be related to a ‘return to nature’ trend and has been facilitated by the rapid 
expansion on internet sales and information. The screening of hallucinogens is quite 
complex because of the wide structural variety of compounds in these group. In the 
toxicology section of the NICC there was no method available to quantify the 
hallucinogens, while their analysis is often demanded. Due to the fact that 
concentrations of hallucinogens in blood are quite low, urine was considered as the 
best choice due to the larger sample volume, higher drug concentrations, and wider 
time window of detection of drugs. 
4.1.1. We aimed at developing an LC-MS/MS method for the analysis of a broad 
collection of hallucinogens and related compounds as chlorpheniramine, 
ketamine, ritalinic acid (including metabolites) in urine using a simple off-line SPE 
and LC-MS/MS with the highest sensitivity.  
4.1.2. This method was to be applied for the routine analysis of urine samples in 
the laboratory. 
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4.2. Cannabis and Amphetamines in blood and urine 
Since the 1990s, cannabis use has risen markedly among general and school 
populations in many EU countries. While consumption patterns remain largely 
occasional, there also signs of more intensive use which could cause health or 
social problems and in time lead to dependence. 
Globally, after cannabis, amphetamines are among the most commonly consumed 
illicit drugs. In Europe today, in terms of the absolute numbers, cocaine use may be 
higher, but the geographic concentration of cocaine in a few countries means that for 
most of the European Union, some form of synthetically produced drug remains the 
second most commonly used illicit substance.  
During 2008, the section of toxicology of the NICC was requested to analyze 1939 
blood samples, collected in a context of drugged driving, and 675 urine samples, 
collected in different forensic settings for the analysis of drugs of abuse. 
70.1% of these blood samples were positive for cannabis and 24.4 % for 
amphetamines.  
In the case of the urines, 55.9% were positive for cannabis and 6.7% for 
amphetamines.  
Therefore, the need of rapid, sensitive and robust methods using LC-MS/MS for the 
analysis of cannabis and amphetamines in blood and urine was a clear next 
objective of the Institute. 
4.2.1. Analysis of THC and metabolites in blood by LC-MS/MS:  
Up to now, in the section of toxicology of the NICC the analysis of THC and 
metabolites was carried out in 1 mL blood with GC-MS (LLE + derivatization). It was 
a very long sample preparation process and in many cases the sample volume was 
insufficient to perform the analysis (as usually the analysis of other drugs is 
demanded too). 
4.2.1.1. Our aim was to develop a simple, fast and sensitive LC-MS/MS method 
for the confirmation of THC, 11-OH-THC and THC-COOH in blood. 
4.2.1.2. The method needed to be validated requiring a small sample volume. 
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4.2.1.3. The method was to be applied to the analysis of authentic blood samples 
for routine analysis. 
4.2.2. Analysis of THC-COOH in urine by on-line SPE-LC-MS/MS:  
4.2.2.1. The aim of this study was to develop and completely validate a simple, 
rugged and high-throughput on-line SPE-LC-MS/MS method for rapid analysis of 
THC-COOH in urine.  
4.2.2.2. The method would require a minimum sample handling. 
4.2.2.3. In addition, the aim was to determine the presence or absence of THC-
COOH in urine with respect to the internationally accepted cut-off of 15 µg/L.  
4.2.3. Analysis of amphetamines in blood and urine by on-line SPE-LC-MS/MS 
4.2.3.1. The aim of this study was to develop and completely validate a simple, 
rugged on-line SPE-LC-MS/MS method for rapid and simultaneous bio-analysis 
of 7 amphetamines in blood and urine. 
4.2.3.2. The method would have enough sensitivity to reduce the sample volume 
(50-100 µL). 
4.2.3.3. Moreover, the total process from the sample preparation to the analysis 
needed to be completely automated.  
4.2.3.4. The validated method was to be applied to the routine analysis of 

























5.1. LC-MS/MS METHOD  
FOR THE SIMULTANEOUS ANALISIS OF MULTIPLE HALLUCINOGENS, 








A validated method for the simultaneous analysis of multiple
hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and
several metabolites is presented. The procedure comprises a
sample clean-up step, using mixed-mode solid-phase extraction
followed by liquid chromatography (LC)–tandem mass
spectrometry analysis. Chromatographic separation was achieved
using a Sunfire C8 column eluted with a mixture of formate buffer,
methanol, and acetonitrile. The applied LC gradient ensured the
elution of all the drugs examined within 14 min and produced
chromatographic peaks of acceptable symmetry. Selectivity of the
method was achieved by a combination of retention time and two
precursor-product ion transitions for the non-deuterated
analogues. Validation of the method was performed using 500 μL
of urine. The limits of quantification (LOQ) for LSD and 2-oxo-3-
hydroxy-LSD were 0.05 and 1 ng/mL, respectively, and ranged, for
the other hallucinogens, from 0.5 to 10 ng/mL. Linear and
quadratic regression was observed from the LOQ of each
compound to 12.5 ng/mL for LSD, 50 ng/mL for 2-oxo-3-hydroxy-
LSD and 500 ng/mL for the others (r2 > 0.99). Precision for the QC
samples, spiked at a minimum of two concentrations, was
calculated [%CV and %bias < 20% for most of the compounds,
except for bufotenine and cathinone (%bias < 24%), and ibogaine
(%bias < 30%)]. Extraction was found to be both reproducible
and efficient with recoveries > 87% for all the analytes.
Furthermore, the processed samples were demonstrated to be
stable in the autosampler for at least 24 h. Finally, the validated
method was applied to the determination of chlorpheniramine,
ketamine, LSD, and psilocin in authentic urine samples.
Introduction
Hallucinogens are mostly of vegetal origin (e.g., mush-
rooms, cacti, and other plants), and their effects were already
known by the ancestral cultures (1–7). The most powerful
among them and semisynthetic in nature, lysergic acid di-
ethylamide (LSD), was discovered about 60 years ago (8,9). Re-
cently, the illicit use of hallucinogens has re-emerged,
especially among teenagers and well-educated adults (10,11).
Typical clinical effects of hallucinogens include dizziness,
weakness, tremors, nausea, drowsiness, paraesthesia, blurred
vision, altered shapes and colors, difficulty in focusing on ob-
jects, sharpened sense of hearing, alteration in mood, tension,
distorted time sense, difficulty in expressing thoughts, deper-
sonalization, dreamlike feelings, and visual hallucinations
(12,13). In addition, one of the well-known side effects of LSD
is the occurrence of flashbacks. These are repeated hallucina-
tory and other perceptual experiences occurring after the ini-
tial LSD experience has subsided (14). Over the last few years,
human hallucinogenic drug research has regained attention.
The main areas of current interest are the pharmacology of
these drugs. However, information about how they affect the
brain is scarce (15–18). No dose-response relationship has
been reported for these compounds. Despite their high de-
gree of physiological safety and lack of dependence liability,
hallucinogens have been branded by law enforcement officials
as among the most dangerous drugs that exist (1,12,19). In-
deed, although there are no reports that confirm that LSD or
other classical hallucinogens have directly caused overdose
death, fatal accidents may occur particularly when these drugs
are used recreationally in unsupervised settings. During the
last decade, the use of prescription drugs for non-medical pur-
poses (e.g., for recreation and for psychic effects—to get high,
Liquid Chromatography–Tandem Mass Spectrometry
Method for the Simultaneous Analysis of Multiple
Hallucinogens, Chlorpheniramine, Ketamine, 
Ritalinic Acid, and Metabolites, in Urine
Reproduction (photocopying) of editorial content of this journal is prohibited without publisher’s permission.
Journal of Analytical Toxicology, Vol. 31, October 2007
* Author to whom correspondence should be addressed: Maria del Mar Ramírez Fernández,
Federal Public Service Justice, National Institute of Criminalistics and Criminology, Chaussée
de Vilvorde 100, 1120 Brussels, Belgium. E-mail: mariadelmar.ramirezfernandez@just.fgov.be.
Maria del Mar Ramirez Fernandez1,*, Marleen Laloup1, Michelle Wood2, Gert De Boeck1,
Manuel Lopez-Rivadulla3, Pierre Wallemacq4, and Nele Samyn1
1Federal Public Service Justice, National Institute of Criminalistics and Criminology, Brussels, Belgium; 2Waters Corporation, 
MS Technologies Centre, Manchester, United Kingdom; 3Forensic Toxicology Service, Institute of Legal Medicine, University 
of Santiago de Compostela, Spain; and 4Department of Clinical Chemistry, University Hospital St. Luc, Universite Catholique 
de Louvain, Brussels, Belgium
Abstract
to have fun, to get a lift, or to calm down) has increased (20).
Ketamine is catalogued as a synthetic anesthetic for human
and veterinary surgery; it induces sedation, immobility, and
amnesia. It has also gradually become popular on the Euro-
pean party scene for its hallucinogenic effects and, when used
in combination with ecstasy (“candy-flipping”), as a stimu-
lant (21,22). Methylphenidate (with ritalinic acid as its main
metabolite) is a phenethylamine derivative used in the treat-
ment of depression, narcolepsy, attention-deficit disorder, and
childhood hyperkinesis. Recently, it has become a popular
drug of abuse because of its properties similar to morphine
when combined with pentazocine (a synthetic derivative that
has properties of an analgesic) (23). Chlorpheniramine is used
to relieve or prevent the symptoms of hay fever and other al-
lergies and to prevent motion sickness, nausea, vomiting, and
dizziness. Human poisoning caused by accidental or inten-
tional ingestion has been reported (24–26).
Consequently, methods for the extraction and determination
of all of these compounds from human samples are required
for both diagnosis and effective treatment of the intoxication
and for forensic purposes. Several techniques have been used
for the toxicological analysis of hallucinogens and the licit
drugs in different biological matrices, including gas chro-
matography–mass spectrometry (GC–MS) (21,24,27–32) and
liquid chromatography–mass spectrometry (LC–MS)
(8,16,22,23,33–40). However, most of the reported methods
cover only a single substance or mixtures of a few hallucino-
gens and/or other drugs or they need time-consuming deriva-
tization or several cycles.
LC–MS–MS detection is now considered the method of
choice for the quantitative determination of thermolabiles
and polar drugs in biological matrices because of simple pre-
treatment, high sensitivity, and relatively short analysis time.
Until now, no report dealing with the simultaneous analysis of
a large series of hallucinogens in urine has been published.
In the present study, a convenient and sensitive LC–elec-
trospray ionization (ESI)-MS–MS method has been developed
and validated for the determination of multiple hallucinogens,
chlorpheniramine, ketamine, ritalinic acid, and metabolites in
urine. In addition, this method was applied to the determina-




Ammonium formate, formic acid, and sodium hydroxide
(0.1N) were purchased from Sigma-Aldrich (Steinheim, Ger-
many). Ammonia solution (32%, extra pure) and glacial acetic
acid were from Merck (Darmstadt, Germany). Acetonitrile and
methanol (LC–MS grade) were obtained from Biosolve
(Valkenswaard, the Netherlands). Solid-phase extraction (SPE)
cartridges Oasis® MCX (30 mg, 1 mL) were from Waters (Mil-
ford, MA).
Individual certified stock solutions of bufotenine, cathinone,
chlorpheniramine, ibogaine, ketamine, mescaline, and nor-
ketamine (at a concentration of 1 mg/mL in methanol);
psilocin (as a solid); LSD (at a concentration of 25 μg/mL in
methanol); 2-oxo-3-hydroxy-LSD (0.1 mg/mL in methanol);
and the deuterated analogues psilocin-d10 (as a solid), ke-
tamine-d4, LSD-d3, mescaline-d9, and norketamine-d4 (at a
concentration of 0.1 mg/mL in methanol) were from LGC Pro-
mochem (Molsheim, France). Standard reference material of
scopolamine, kavain, lobeline, and ritalinic acid (all of them as
a solid) and ritalinic acid-d5 (0.1 mg/mL in methanol) were
purchased from Sigma-Aldrich. Liquichek™ external quality
controls (QC) were purchased from Bio-Rad Laboratories
(Irvine, CA) (expressed in the text as C1 and C3). Participation
in proficiency tests [“UKNEQAS for Drugs of Abuse in urine”
(Cardiff, U.K.)] were also used in the evaluation of the accuracy
of the method.
Specimens
Urine used for the preparation of blanks, calibrators, and QC
samples was obtained from healthy drug-free volunteers. A
batch of authentic human urine was also obtained from two
subjects who admitted having used “magic mushrooms”; urine
samples were collected 1, 4, 8, and 24 h after ingestion. The
samples were analyzed anonymously. In addition, a human
sample was collected from one subject who ingested one tablet
containing 3 mg of chlorpheniramine in the morning followed
by another tablet of the same drug in the evening. A urine
sample was collected one day later. Finally, a dog urine sample
was obtained from a veterinary clinic. The dog had received a
dose of a mixture of compounds (containing ketamine) prior
to a surgical operation.
Preparation of standard solutions
An internal standard (I.S.) working solution of each of the
deuterated analytes was prepared (1 μg/mL in methanol, except
for LSD-d3 which was at 10 ng/mL).
A working solution containing all of the non-deuterated an-
alytes was prepared (10 μg/mL in methanol for all the com-
pounds except for LSD, which was 250 ng/mL, and for
2-oxo-3-hydroxy-LSD, which was 1 μg/mL).
Working solutions for the calibrators were prepared monthly
and stored at 4°C. The QCs were prepared in one single batch,
aliquoted at the beginning of the validation of the study, and
stored at –20°C until analysis.
Sample preparation and extraction
Six-hundred microliters of  0.1M sodium acetate buffer (pH
4) and 50 μL of I.S. working solution were added to 500 μL of
urine. After conditioning with 1mL of methanol, 1 mL of
water, and 1 mL of sodium acetate buffer (0.1mM, pH 4), the
diluted urine samples were applied onto the SPE columns.
Sample clean-up was optimized using a variety of washing
protocols: 1. successive 1-mL washes of sodium acetate buffer
(0.1M, pH 4) and methanol; 2. 1-mL washes of the same buffer
and a mixture of methanol and water (80:20, v/v); and 3. 1-mL
washes of buffer and a mixture of methanol and water (50:50,
v/v). After washing, cartridges were dried by applying full
vacuum for 5 min before elution with 0.5 mL of 5% ammonia
in methanol. Following the extraction, the elution solution was
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completely evaporated to dryness under a gentle stream of ni-
trogen. The dry residue was then reconstituted in 600 μL of the
aqueous mobile phase (A) used in the LC gradient. Twenty
microliters was injected into the LC–MS–MS.
LC
LC was performed using a Waters Alliance
2695 separation module. All aspects of system
operation and data acquisition were con-
trolled using MassLynx NT 4.1 software (Wa-
ters). Analytes were separated on a Sunfire®
C8 column (3.5 μm, 2.1 mm × 100 mm) (Wa-
ters) using a gradient elution with ammo-
nium formate buffer 10mM pH 3.5 (A) and
acetonitrile/methanol (2:1, v/v), at a flow rate
of 0.3 mL/min. A gradient was carried out
starting from 2% B at 3.5 min, B was then in-
creased to 20% over the next 0.5 min and
maintained over the next 4 min. From 8 min
to 11 min, B was linearly increased to 98%
and maintained for 4 min before returning to
its initial conditions within 0.5 min and equi-
librating for 6.5 min, which resulted in a total
run time of 22 min. 
MS
A Quattro Ultima tandem MS (Waters)
fitted with a Z-Spray ion interface was used
for all analyses. Ionization was achieved using
electrospray in the positive ionization mode
(ESI+). The following conditions were found
to be optimal for the analysis: capillary
voltage, 1.0 kV; source block temperature,
120°C; a desolvation gas (nitrogen) heated to
250°C and delivered at a flow of 800 L/h. The
appropriate multiple reaction monitoring
(MRM) conditions for the individual analytes
and their respective deuterated analogues
were determined by direct infusion into the
MS. The cone voltage (CV) was adjusted to
maximize the intensity of the protonated
molecular species [M + H]+ and collision-in-
duced dissociation of each protonated
molecule was performed. Collision gas
(argon) pressure was maintained at 2.7 × 10–3
mbar and the collision energy (eV) adjusted to
optimize the signal for the most abundant
product ions, which were subsequently used
for MRM analysis.
Method validation
Linearity, within-run precision, and be-
tween-run precision. Quantification was per-
formed by integrating of the area under the
specific MRM chromatograms in reference to
the integrated area of the deuterated ana-
logues. Thus, the deuterated I.S. were used to
correct for variability in the extraction proce-
dure. Where it was not possible to obtain a commercially avail-
able deuterated analogue for any compound, the deuterated
analogue of another close compound was selected. The dif-
ferent I.S. were assigned to the different analytes in the fol-
lowing combinations: LSD-d3 was used for the calculations of
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Figure 1. MRM chromatograms obtained with a single injection of a 500 μL extracted urine
sample enriched with 10 ng/mL (at 0.25 ng/mL and 1 ng/mL for LSD and 2-oxo-3-hydroxy-LSD,
respectively) of bufotenine (1) (peak at 3.2 min), cathinone (2), psilocin (3) (peak at 5.7 min),
mescaline (4), scopolamine (5), 2-oxo-3-hydroxy-LSD (6), norketamine (7), ketamine (8), rital-
inic acid (9), ibogaine (10), LSD (11), chlorpheniramine (12), lobeline (13), and kavain (14).
Table I. MRM Transitions and Conditions for All Compounds and their
Deuterated Analogues
Rt Precursor Ion Product Ions* Cone Collision 
Compound (min) (m/z) (m/z) Voltage (V) Energy (eV)
Bufotenine 3.2 205.20 160.10, 58.10 20 18, 15
Cathinone 5.4 150.10 132.20, 117.10 25 12, 20
Psilocin 5.7 205.20 160.10, 58.10 20 15, 18
Mescaline 8.0 212.20 195.20, 180.20 35 10, 20
Scopolamine 8.0 304.10 156.20, 138.00 20 15, 20
2-Oxo-3-Hydroxy-LSD 8.7 356.20 237.20, 222.20 40 25, 35
Norketamine 8.9 224.10 207.10, 125.00 30 10, 25
Ketamine 9.2 238.20 125.10, 207.10 20 30, 15
Ritalinic acid 9.2 220.20 84.20, 56.30 40 20, 45
Ibogaine 12.0 311.30 174.20, 122.10 20 35, 35
LSD 12.0 324.30 223.20, 208.20 25 25, 30
Chlorpheniramine 12.2 275.20 230.10, 167.10 20 20, 40
Lobeline 12.5 338.40 216.30, 96.10 40 20, 25
Kavain 13.4 231.10 185.10, 115.10 40 12, 12
Psilocin-d10 5.7 215.20 66.10 10 18
Mescaline-d9 8.0 221.30 204.30 20 10
Norketamine-d4 10.0 228.20 211.20 30 10
Ketamine-d4 8.2 242.20 129.10 35 30
Ritalinic acid-d5 9.2 225.10 83.90 20 20
LSD-d3 12.0 327.30 226.60 20 20
* Underlined transitions were used for quantification.
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peak-area ratios and concentrations of LSD; ketamine-d4 for
ketamine and lobeline; mescaline-d9 for bufotenine, mesca-
line, and scopolamine; norketamine-d4 for norketamine;
psilocin-d10 for cathinone and psilocin; and ritalinic acid-d5 for
chlorpheniramine, ibogaine, kavain, 2-oxo-3-hydroxy-LSD, and
ritalinic acid.
Assay linearity was investigated by constructing calibration
curves (n = 8) which ranged from 0.05 to 12.5 ng/mL (0.05,
0.25, 0.625, 1.25, 3.125, 6.25, and 12.5 ng/mL) for LSD; from
1 to 50 ng/mL (1, 2.5, 5, 12.5, 25, and 50 ng/mL) for 2-oxo-3-
hydroxy-LSD; and from 10 to 500 ng/mL (10, 25, 50, 125, 250,
and 500 ng/mL) for the other compounds. 
QCs were analyzed for every run in blank urine at least at
two concentration levels: at 4, 40, and 400 ng/mL for ketamine,
lobeline, norketamine, and ritalinic acid; 40 and 400 ng/mL for
psilocin, bufotenine, cathinone, chlorpheniramine, scopo-
lamine, mescaline, and ibogaine; 4 and 40 ng/mL for 2-oxo-3-
hydroxy-LSD; and 0.1, 1, and 10 ng/mL for LSD. Within-run
precision and between-run precision were estimated by repli-
cate (n = 2) analysis of the QC samples performed on six dif-
ferent days, according to Peters et al. (41). The precision was
expressed as the %CV (variation coefficient). A comparison of
the calculated concentrations of the QC samples to their re-
spective nominal values was used to assess the accuracy (bias)
of the method.
The limit of quantification (LOQ) was defined in this study
as the concentration of the lowest calibrator that was calcu-
lated to be within ± 20% of the nominal value and with a %CV
less than 20%. 
The limit of detection (LOD) was estimated from blanc urine
samples, spiked with decreasing concentrations of the ana-
lytes, where the response of the qualitative ion could reliably
differentiate from background noise and with signal-to-noise
ratio (S/N) of the qualifier equal to or greater than 3.
Selectivity, stability, recovery, and assessment of matrix
effects. Selectivity was evaluated by analyzing urine samples
from eight healthy volunteers who did not take any of the tar-
geted compounds for several days before urine sampling and
checked for the absence of the compounds of interest by ana-
lyzing the samples with the present technique before using as
blanks.
The stability of the processed sample, when placed in the au-
tosampler (maintained at 6 ± 2°C) was checked by repeated in-
jections of two extracted QC samples (n = 5, each) at 40 and
400 ng/mL, except for LSD (1 and 10 ng/mL) and 2-oxo-3-hy-
droxy-LSD (4 and 40 ng/mL). Five extracted samples at each
concentration were spiked with the I.S. at time zero and after
24 h, and the stabilities were estimated by comparing the peak
response ratios at each concentration. Stability was tested
against a lower percentage limit corresponding to 90% of the
mean value of control samples by one-sided t-test (P < 0.05).
Extraction recoveries were estimated by comparing the ratio
of the peak areas of the non deuterated compounds to the
peak areas of the I.S. (i.e., responses) of a 40 ng/mL QC (n = 3)
(except LSD at 1 ng/mL and 2-oxo-hydroxy-LSD at 4 ng/mL)
when the non-deuterated compounds were added before the ex-
traction step with those obtained when the non deuterated
analytes were added after sample extraction. In both cases, the
deuterated analogues were added after the extraction.
Matrix effect was investigated by adding the compounds at 40
ng/mL concentrations (except LSD at 1 ng/mL and 2-oxo-hy-
droxy-LSD at 4 ng/mL) to six different extracted blank urines
just before injection, and the peak I.S. areas were compared to
those obtained from the QCs at the same concentration and di-
luted in the same volume (aqueous mobile phase A) (n = 6).
Results and Discussion
Method validation
The applied gradient ensured the elution of all the drugs ex-
amined within 14 min and produced chromatographic peaks of
acceptable symmetry. Selectivity of the method was achieved by
500
Table II. Dynamic Range, LOD, LOQ, and Equation of a Typical Calibration Curve with the Corresponding Coefficient of
Determination (r2)
LOD LOQ Dynamic 
Compound (ng/mL) (ng/mL) Range (ng/mL) Equation r2
Bufotenine 0.0125 10 10–500 y = 0.000058159x2 + 2.2625x – 0.074542 0.999783
Cathinone 1.25 10 10–500 y = 0.689329x – 1.03924 0.996005
Psilocin 0.5 10 10–500 y = 0.000199849x2 + 2.27876x – 2.61572 0.999747
Mescaline 0.5 10 10–500 y = 1.44018x + 4.1591 0.996820
Scopolamine 0.025 10 10–500 y = –0.000304532x2 + 1.63741x + 2.60315 0.999785
2-Oxo-3-Hydroxy-LSD 0.0125 1 1–50 y = 0.855494x – 0.535242 0.992852
Norketamine 0.5 2 2–500 y = 0.000250638x2 + 1.64552x – 0.152192 0.999092
Ketamine 0.125 0.5 0.5–500 y = 0.000332073x2 + 1.13911x – 0.145666 0.999446
Ritalinic acid 2.5 2 2–500 y = 0.000319152x2 + 0.754816x + 0.141469 0.999222
Ibogaine 0.5 10 10–500 y = 0.000141267x2 + 0.612077x – 0.888373 0.999783
LSD 0.0003 0.05 0.05–12.5 y = 8.56868x – 0.118143 0.999201
Chlorpheniramine 0.0125 10 10–500 y = 0.0044298x2 + 17.04x – 6.09868 0.998370
Lobeline 0.05 2 2–500 y = 0.00144394x2 + 1.3557x – 1.11657 0.999948
Kavain 0.25 10 10–500 y = 1.26145x – 3.39317 0.996979
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a combination of retention time, precursor, and product ions
and determined acceptable in terms of absence of interference
in the blank urine samples analyzed. With the exception of 2-
oxo-3-hydroxy-LSD and ibogaine, the most prominent pre-
cursor-product transition was used for quantification and the
next most abundant used as qualifiers (Table I). For 2-oxo-3-hy-
droxy-LSD and ibogaine, an elevated background response was
noted when using the most prominent precursor product tran-
sition. Improved sensitivity (based on the signal-to-noise ratio)
was achieved when using the next most abundant for quan-
tification.
For the corresponding deuterated analogues, only one tran-
sition was monitored. Injection of single solutions did not pro-
duce interference in the other MRM channels, except for
psilocin and bufotenine. As these compounds show the same
transitions, many efforts were made to improve the chro-
matographic separation. Using the optimized chromatographic
conditions, these two compounds were separated with reten-
tion times (Rt) of 3.2 and 5.7 min for bufotenine and psilocin,
respectively. Figure 1 shows the MRM chromatograms of an ex-
tracted urine blank sample spiked at 10 ng/mL (at 0.25 ng/mL
and 1 ng/mL for LSD and 2-oxo-3-hydroxy-LSD, respectively).
The linearity of the method was verified over the concen-
tration range. After evaluating different types of regression, the
calibration curves were constructed using a 1/x weighted
quadratic regression for all of the compounds except for cathi-
none, mescaline, 2-oxo-3-hydroxy-LSD and kavain, to where
linear regression was observed to be more suitable. The study
was based on the standard error of the fit and minimization of
bias of the calibrators. In all cases a r2 > 0.99 was obtained. A
typical example of a calibration curve, dynamic range, LOD,
and LOQ for each compound is shown in Table II.
Within-run precision (%CV) was lower than 11% for all the
analytes at the QC sample concentrations. The between-run
precision (%CV) was also < 20%. A bias < 16% was observed for
all the compounds except for bufotenine, cathinone, and ibo-
gaine, which reached 23.6%, 23.8%, and 29.4%, respectively.
Although for these compounds it could be considered out of
Table V. Summary of Psilocin Urine Concentrations
Observed in Authentic Samples from Two “Magic
Mushroom” Users
Time (h)
ID 0 4 8 24
1 407.9 ng/mL 1358.7 ng/mL 757.0 ng/mL 16.6 ng/mL
2 113.7 ng/mL 624.5 ng/mL N.A.* N.A.
* Not available.
Table III. Within-Run Precision (%CV), Between-Run
Precision (%CV), and Bias (expressed as percent of
deviation) of the QC Samples
Within-Run Between-Run  
Concentration Precision Precision Bias 
(ng/mL) (%CV) (%CV) (%)
Bufotenine 400 5.1 8.9 13.0
40 5.8 18.6 23.6
Cathinone 400 5.1 17.4 18.3
40 3.2 19.0 23.8
Psilocin 400 3.7 2.6 5.5
40 2.1 11.1 10.7
Mescaline 400 3.8 9.7 7.5
40 2.6 4.3 9.8
Scopolamine 400 7.2 5.1 5.4
40 5.1 9.8 12.9
2-Oxo-3-hydroxy-LSD 40 5.4 8.3 5.4
4 7.3 9.3 4.0
Norketamine 400 1.8 4.7 1.5
40 2.1 5.1 10.8
4 5.4 5.8 13.3
Ketamine 400 4.6 4.6 1.7
40 2.3 6.7 9.1
4 2.5 5.8 13.8
Ritalinic acid 400 4.5 8.5 1.2
40 2.0 7.4 4.9
4 5.6 7.6 9.3
Ibogaine 400 7.9 13.7 15.6
40 8.3 14.5 29.4
LSD 10 8.1 7.9 9.2
1 9.2 11.8 4.0
0.1 3.4 9.6 10.0
Chlorpheniramine 400 7.1 9.4 6.3
40 6.0 9.6 9.3
Lobeline 400 4.8 7.6 2.2
40 2.5 8.8 8.4
4 4.8 4.2 15.0
Kavain 400 5.2 8.5 4.6
40 4.8 9.1 3.3
Table IV. Extraction Recovery and Matrix Suppression*
Recovery Matrix Effect
(n = 3) (n = 6) (%CV)
Bufotenine 106.9 63.8 6.8
Cathinone 99.5 69.9 9.9
Psilocin 87.6 85.0 5.6
Mescaline 103.7 78.9 9.6
Scopolamine 106.7 68.8 9.0
2-Oxo-3-Hydroxy-LSD 107.4 101.5 7.5
Ketamine 105.3 78.2 6.2
Ritalinic acid 107.9 134.0 9.5
Norketamine 106.0 87.5 8.7
LSD 107.1 75.0 12.1
Chlorpheniramine 104.7 67.5 8.8
Ibogaine 109.5 68.9 12.0
Lobeline 109.4 53.9 5.3
Kavain 108.6 92.1 9.8
* Data represent the mean of several experiments with a 40 ng/mL calibrator.
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the validation requirements, in the literature similar results
has been reported and considered ‘sufficient for screening pur-
poses’ (42). The results are summarized in Table III.
The stability in the autosampler of the spiked samples at two
concentrations was monitored at 6 ± 2°C for 24 h. No statistical
significant differences could be observed for the two concen-
trations for all compounds (P < 0.05) (data not shown).
One of the limiting factors of LC–MS(–MS) applications 
is the potential presence of matrix effects leading to suppres-
sion or enhancement of the analyte response. It may be 
eliminated or minimized by 1. changing and improving sample
preparation procedures, 2. performing the assay under more 
efficient chromatographic conditions to separate analytes 
of interest from undetected endogenous compounds that 
may effect the efficiency of ionization of analytes, and 3. by
evaluating and changing the LC–MS interface and the mech-
anism of ionization of analytes (43,44). We evaluated several
washing procedures for SPE of the hallucinogens during
method development. Looking for a compromise between
sample clean-up with a minimum loss of analyte, the best 
results were obtained by washing the cartridges with 1 mL
washes of sodium acetate (0.1M, pH 4) and a mixture of
methanol and water (50:50, v/v). Very high and reproducible 
recoveries were obtained with this SPE procedure for all ana-
lytes. On the other hand, some analytes presented a significant
matrix effect (> 20%), which could be also the cause of the 
analytical variation (higher %bias) for some of them. Never-
theless, it has been stated that the use of deuterated I.S. would
partially compensate for ion suppression effects (42). Indeed,
taking into account that this is a screening method for urine
analysis and, in this case, the sensitivity is not an issue (so false
results are unlikely), we can conclude that the matrix effect
found in some of the compounds are still 
acceptable. The results of the extraction re-
covery and matrix effect study are presented
in Table IV. 
Samples
The validated LC–MS–MS method was ap-
plied to the analysis of authentic urine sam-
ples. A dilution 1 in 10 was performed to
those samples with concentrations of drugs
out of the calibration range.  In the first case,
two young men had admitted to ingestion of
some “magic mushrooms” to have fun. Urine
samples were collected after 1, 4, 8, and 24 h.
All samples were positives for psilocin (Table
V). The highest concentrations were observed
after 4 h after ingestion, which corresponds to
an earlier report (45). One case of chlor-
pheniramine was obtained from a man who
ingested two doses of a medicament (con-
taining 3 mg of chlorpheniramine), one in
the morning and the second one at night.
The sample was collected one day after. Chlor-
pheniramine was detected at 225.6 ng/mL
(Figure 2). Finally, we received a dog urine
sample from a veterinary clinic. This sample
came from a German dog that had a dose of
ketamine prior to a surgical operation. A urine
sample was collected 1 h later. High concen-
trations of ketamine (> 500 ng/mL) and much
lower concentrations of norketamine (14.7
ng/mL) were observed in the dog urine
sample.
This method has been also successfully ap-
plied to the analysis of external quality control
samples (“ring test” organized by the
“UKNEQAS for Drugs of Abuse in Urine”) and
C1 and C3 (Bio-Rad Laboratories). Figure 3
shows the typical chromatograms obtained
following the analysis of one of the external
QC samples. The results obtained for the LSD
samples are shown in Table VI.
Figure 3. MRM chromatograms obtained following the analysis of an external QC (Cardiff, U.K.)
containing 2 ng/mL of LSD. The figure shows the response for the two LSD transitions  (quali-
fier and quantifier, middle and bottom traces respectively) and the I.S., LSD-d3 (top trace). Peak
intensity is shown on the right-hand corner of each trace.
Figure 2. Typical MRM chromatograms obtained following the analysis of an authentic urine
specimen from a chlorpheniramine user (225.6 ng/mL). The figure shows the response for the I.S.,
ritalinic acid-d5 (top trace), and for the two transitions of chlorpheniramine (quantifier and
qualifier; middle and bottom traces respectively). Peak intensity is shown in the top right-hand
corner of each trace.
Journal of Analytical Toxicology, Vol. 31, October 2007
503
Conclusions
In this report, a validated and highly sensitive LC–ESI-
MS–MS method is described for the simultaneous quantifica-
tion of multiple hallucinogens, ketamine, chlorpheniramine,
ritalinic acid, and their metabolites. The method combined
SPE with LC–MS–MS and provided thorough clean-up of the
matrix to avoid ion suppression or enhancement, in combina-
tion with high recovery, excellent precision, and bias in the
linear range investigated, using 500 μL of sample. The method
was successfully applied to authentic urine samples.
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a b s t r a c t
Cannabis is considered to be the most widely abused illicit drug in Europe. Consequently, sensitive and
specific analytical methods are needed for forensic purposes and for cannabinoid pharmacokinetic and
pharmacodynamic studies. A simple, rapid and highly sensitive and specific method for the extraction and
quantification of 9-tetrahydrocannabinol (THC), 11-hydroxy- 9-tetrahydrocannabinol (11-OH-THC)
and 11-nor-9-carboxy- 9-tetrahydrocannabinol (THC-COOH) in blood is presented. The method was
fully validated according to international guidelines and comprises simultaneous liquid–liquid extraction
(LLE) of the three analytes with hexane:ethyl acetate (90:10, v/v) into a single eluant followed by separation
and quantification using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Chromato-
graphic separation was achieved using a XBridge C18 column eluted isocratically with methanol:0.1%
formic acid (80:20, v/v). Selectivity of the method was achieved by a combination of retention time, and
two precursor–product ion transitions. The use of the LLE was demonstrated to be highly effective and
led to significant decreases in the interferences present in the matrix. Validation of the method was per-
formed using 250 L of blood. The method was linear over the range investigated (0.5–40 g/L for THC,
1–40 g/L for 11-OH-THC, and 2–160 g/L for THC-COOH) with excellent intra-assay and inter-assay pre-
cision; relative standard deviations (RSDs) were <12% for THC and 11-OH-THC and <8% for THC-COOH for
certified quality control samples. The lower limit of quantification was fixed at the lowest calibrator in the
linearity experiments. No instability was observed after repeated freezing and thawing or in processed
samples. The method was subsequently applied to 63 authentic blood samples obtained from toxicology
cases. The validation and actual sample analysis results show that this method is rugged, precise, accurate,
and well suited for routine analysis.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Cannabis is considered to be the most widely abused illicit drug
in Europe. Indeed, statistical information shows that 30% of the
under-forties age group have already consumed this drug [1,2].
9-Tetrahydrocannabinol (THC) is the main psychoactive con-
stituent. During marijuana smoking, THC is rapidly absorbed in
larger amounts than when taken orally and, due to its strong
lypophilic nature, it spreads rapidly throughout the body. It
is mainly metabolized to 11-hydroxy- 9-tetrahydrocannabinol
(11-OH-THC) by the human body. This metabolite is still
∗ Corresponding author. Tel.: +32 2 240 05 00; fax: +32 2 241 61 05.
E-mail address: mariadelmar.ramirezfernandez@just.fgov.be
(M. del Mar Ramirez Fernandez).
psychoactive and is further oxidized to 11-nor-9-carboxy- 9-
tetrahydrocannabinol (THC-COOH). In humans and animals more
than 100 metabolites could be identified but 11-OH-THC and THC-
COOH are the most predominant. Metabolism mainly occurs in the
liver by cytochrome P450 enzymes CYP2C9, CYP2C19 and CYP3A4
[3].
Urine drug concentration data do not provide adequate answers
to demanding clinical and forensic questions. These are more
readily answered with quantitative blood data which provides
more information related to the current state of impairment. How-
ever, the analysis of blood can be more challenging due to the
presence of lipophilic and proteinaceous compounds not usually
found in urine, the need for substantially lower sensitivity limits
and the lower sample volume available.
Due to the high specificity and the increased signal-to-noise
in combination with short chromatographic run times, liquid
1570-0232/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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466 M. del Mar Ramirez Fernandez et al. / J. Chromatogr. B 875 (2008) 465–470
chromatography–tandem mass spectrometry (LC–MS/MS) allows
for specific, selective and sensitive analysis of compounds with
a wide polarity range in samples of various nature. It offers the
possibility to simplify sample preparation, although this approach
should be treated with caution due to the possibility of ion sup-
pression or enhancement as a result of the matrix. Consequently,
attention must be paid to the choice of the sampling method and
the influence of the collected matrix on the LC–MS/MS analysis.
Several methods have been described for the quantification
of THC and its metabolites in blood. Immunochemical methods,
mainly ELISA, are generally used as screening tools for cannabis use
[4]. However, for workplace drug testing, driving under the influ-
ence of drugs and for forensic cases, the confirmation of positive
immunoassay test results is necessary. It is usually performed by
gas chromatography–mass spectrometry (GC–MS) methodologies
[5–7]. However, GC requires time-consuming sample preparation
and the need to use various derivatization techniques. In contrast
to GC, no decomposition of the cannabinoids occurs during liquid
chromatography and hence the cannabinoid acid forms may be ana-
lyzed directly. Several papers report the application of LC–MS(/MS)
[8–14]. Most of them require high sample volume (1 mL) to achieve
high sensitivity, they are focused on just one compound and/or the
method is not fully validated (following all criteria for chromato-
graphic assays). All of these aspects are significant at the moment of
development of a method since (a) the amount of sample required
is an analytical limitation, (b) forensic toxicologist may be required
to analyze THC and other hydroxylated metabolites in blood to eval-
uate an impairment status and (c) complete validation is required
to guarantee the robustness of the method.
Our aim was to develop and fully validate a simple, fast and
sensitive LC–MS/MS method for the confirmation of THC, 11-OH-
THC and THC-COOH in blood which required only a minimal volume
of sample and with an efficient sample clean-up procedure.
2. Experimental
2.1. Chemicals
Individual stock solutions of THC, 11-OH-THC and THC-COOH
(all certified at a concentration of 1 mg/mL in methanol), and
the internal standards (I.S.) [2H3]THC (THC-d3), [2H3]11-OH-THC
(11-OH-THC-d3) and [2H9]THC-COOH (THC-COOH-d9) (certified
concentration of 0.1 mg/mL in methanol) were obtained from LGC
Promochem (Molsheim, France).
Methanol (LC–MS grade), 0.1% formic acid in water (UPLC
grade) and water (HPLC grade) were purchased from Biosolve
(Valkenswaard, The Netherlands). N-hexane (for chromatography),
ethylacetate (for chromatography) and acetic acid (glacial) were
obtained from Merck (Darmstadt, Germany).
External quality control (QC) samples were obtained from
Medichem World (Steinenbronn, Germany).
2.2. Specimens
Pooled blank blood samples were used for development and
validation of the procedure and were obtained from a local blood
bank. Authentic samples were obtained from toxicology cases.
2.3. Preparation of standard solutions and sample extraction
Separate working solutions of the drugs, for tuning and selectiv-
ity experiments, were prepared in the laboratory at a concentration
of 4 mg/L in methanol. A mixed working solution of non-deuterated
compounds at 4 mg/L for THC and 11-OH-THC and of 16 mg/L for
THC-COOH, in methanol was used for the preparation of calibra-
tors. A mixed I.S. working solution of 1 mg/L for THC and 11-OH-THC
and of 4 mg/L for THC-COOH, was prepared in methanol. Working
solutions were stored at 4 ◦C, and were prepared monthly.
To obtain the lower concentrations needed for internal stan-
dardization and validation of each experiment, further dilutions in
methanol were prepared the same day.
The extraction procedure was carried out in 10 mL disposable
screw top vials of high quality glassware (Chromacol, Herts, UK)
using 250 L of blood. Fifty microliters of the I.S. working solution,
750 L of deionised water and 200 L of 10% acetic acid (glacial)
were added. After adding 4 mL of hexane:ethyl acetate (90:10, v/v)
mechanical shaking was carried out for 30 min. Then, the sam-
ples were centrifuged (10 min at 3000 × g), the organic phase was
transferred to a 5 mL disposable screw top vial (Chromacol) and
then evaporated to dryness with a vacuum centrifuge (Jouan, Saint
Herblain, France). The extract was reconstituted in 120 L of mobile
phase and 30 L was injected into the LC–MS/MS system.
2.4. LC–MS/MS
2.4.1. Chromatography
LC was performed using a Waters Alliance 2695 separation mod-
ule (Waters, Milford, MA, US). Analytes were separated on a XBridge
C18 column (150 mm × 2.1 mm, 3.5 m) (Waters), eluted isocrati-
cally with methanol:0.1% formic acid (80:20, v/v), delivered at a
flow rate of 0.3 mL/min. The total run time of the method was
13 min.
2.4.2. Mass spectrometry
A Quattro Ultima tandem MS (Waters) fitted with a Z-Spray ion
interface was used for all analyses. Ionization was achieved using
electrospray in the positive ionization mode (ESI+). The follow-
ing conditions were found to be optimal for the analysis: capillary
voltage, 1.0 kV; source block temperature, 120 ◦C, desolvation gas
(nitrogen) was heated to 350 ◦C and delivered at a flow rate of
800 L/h. The appropriate multiple reaction monitoring (MRM) con-
ditions for the individual analytes and their respective deuterated
analogues were determined by direct infusion into the MS/MS. The
cone voltage (CV) was adjusted to maximize the intensity of the
protonated molecular species [M+H]+ and collision-induced dis-
sociation of each protonated molecule was performed. Collision
gas (argon) pressure was maintained at 2.7 × 10−3 mbar and the
collision energy (eV) adjusted to optimize the signal for the most
abundant product ions, which were subsequently used for MRM
analysis.
All aspects of system operation and data acquisition were con-
trolled using MassLynx NT 4.2 software with automated data
processing using the TargetLynxTM software (Waters). The statisti-
cal treatment of data was carried out using Excel 2000 (Microsoft).
2.5. LC–MS/MS assay validation
The analytical validation was performed according to the
recommendations of Peters and Maurer [15,16], Shah et al. [17] and
the SOFT/AAFFS Laboratory Guidelines [18].
2.5.1. Linearity, limit of quantification (LOQ), limit of detection
(LOD), precision and accuracy
Quantification was performed by integration of the area under
the specific MRM chromatograms in reference to the integrated
area of the deuterated analogues. Freshly prepared working solu-
tions of 200, 50, 12.5 and 2.5 g/L for THC and 11-OH-THC, and of
800, 200, 50 and 10 g/L for THC-COOH in methanol were used to
prepare blood calibrators at a concentration of 40, 20, 15, 10, 5, 2, 1
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and 0.5 g/L for THC and 11-OH-THC, and of 160, 80, 60, 40, 20, 8, 4,
and 2 g/L for THC-COOH. Standard curves, freshly prepared with
each batch of QC samples and authentic samples, were generated
using a least-squares linear regression, with a 1/x-weighing factor
for all compounds.
The limit of quantification (LOQ) was estimated by replicate
analysis (n = 2) over eight different days and it was defined as the
concentration of the lowest calibrator that was calculated within
±20% of the nominal value and with a relative standard deviation
(RSD) less than 20%.
The limit of detection (LOD) was estimated from blank blood
samples, spiked with decreasing concentrations of the analytes.
It was defined as the concentration where the response of the
qualitative ion could reliably be differentiated from background
noise, i.e. signal-to-noise ratio (S/N) equal to or greater than 3:1,
and with acceptance criteria for ion ratios equal to or lower than
30% and retention time deviations lower than 3.5% relative to that
of the corresponding control or calibrator [18].
Three blood QCs for THC and 11-OH-THC and four blood QCs
for THC-COOH at three and four different concentrations, respec-
tively, were included and analyzed in every batch: (a) external QC1
(Medichem): concentration THC (2.0 g/L), 11-OH-THC (2.7 g/L),
THC-COOH (26.1 g/L), (b) external QC2 (Medichem): concentra-
tion THC (2.9 g/L), OH-THC (2.2 g/L), THC-COOH (53.1 g/L), (c)
“in house” QC ‘low’ at 3 g/L for each compound and (d) “in house”
QC ‘high’ at 120 g/L for THC-COOH. The “in house” QCs were pre-
pared by different operators from different working solutions of the
calibrators and it was stored at −20 ◦C until use.
Intra-assay and inter-assay precision was evaluated by replicate
(n = 2) analysis of the QC samples performed over eight different
days. Precision (expressed as %RSDr for intra-assay precision and
%RSDt for inter-assay precision) was determined by performing
the analysis of variance: a ‘single factor’ ANOVA test (significance
level—˛ of 0.05). Comparing the mean of calculated concentrations
of QC samples to their respective nominal values, provided data on
the accuracy of the method.
2.5.2. Selectivity and specificity
The selectivity of the method against endogenous inter-
ferences was verified by examination of the chromatograms
obtained after the extraction of eight different blank blood
samples from different origin. Moreover, specificity was also
assessed by the analysis of blood samples spiked at 200 g/L
with other drugs of abuse and their metabolites (amphetamine,
methamphetamine, MDA, MDMA, MDEA, ephedrine, PMA, ben-
zoylecgonine, cocaine, morphine, codeine, 6-MAM, hydromor-
phone, hydrocodone, dihydrocodeine, oxycodone, oxymorphone,
ethylmorphine, norcodeine, buprenorphine, methadone, EDDP,
meperidine, fentanyl, pholcodine and tramadol) usually found in
Belgium.
2.5.3. Stability
The stability of the drugs in blood samples that had been pro-
cessed and then stored in the autosampler awaiting LC–MS/MS
analysis was monitored; 250 L blank blood spiked at the initial
concentration of 34 g/L (n = 12) and extracted. The I.S. was added
to control samples (n = 6) and the concentrations were determined
immediately. Another pool of samples was kept in the autosampler
at 6 ± 2 ◦C and analyzed, previously spiked with the I.S., after 48 h
(n = 6).
For an evaluation of freeze/thaw stability, the control samples
at 34 and 2.5 g/L (n = 6, at each concentration) were spiked with
the I.S. and analyzed immediately. The stability samples, spiked at
34 and 2.5 g/L (n = 6, at each concentration), were subjected to
three freeze/thaw cycles. For each freeze/thaw cycle, the samples
were frozen at −20 ◦C for at least 24 h, thawed, and then maintained
at ambient temperature for 4 h. After the three cycles, the samples
were spiked with the I.S. and analyzed. Stability was tested against a
lower percentage limit corresponding to 90–110% of the ratio (mean
value of stability samples/mean value control samples) with a 90%
of the confidence interval of the stability samples between 80% and
120% of the mean of the control samples.
2.5.4. Assessment of matrix effects
To assess any potential suppression or enhancement of ioniza-
tion due to the sample matrix, two different analyses were carried
out. The first one involved a post-column infusion experiment. The
study was based on a continuous post-column infusion of a mixture
of the analytes and their internal standards (10 g/L at a flow rate
of 10 L/min) to produce a constant elevated response in the MRM
channels. The interference of this constant response was monitored
in the whole run following the injection of extracted blood samples
from different origin (n = 6) and compared to the response follow-
ing the injection of mobile phase only. A second type experiment
consisted of a comparison of the peak responses of the analysis of
a blank sample spiked at 37.5 and 2.5 g/L (n = 6, for each concen-
tration) with those obtained from mobile phase spiked at the same
concentration levels.
2.5.5. Recovery
Extraction recoveries were estimated by comparing the ratio
of the peak areas of the non-deuterated compounds to the peak
areas of the I.S. (i.e. responses) of blood samples spiked at 37.5 and
2.5 g/L (n = 6, for each concentration) when the non-deuterated
compounds were added before the extraction step with those
obtained when the non-deuterated analytes were added after sam-
ple extraction. In both cases, the deuterated analogues were added
after the extraction.
3. Results and discussion
The method was validated for specificity, linearity, LOQ, LOD,
precision, accuracy, recovery and matrix effect by the analysis of
spiked blood samples. In each case, a weighted (1/x) linear regres-
sion line was applied. Other weighting factors were tested before
validation of the method but they did not give significantly better
results. Correlation coefficients higher than 0.998 were achieved in
the range investigated, i.e. from 0.5 to 40 g/L for THC, from 1 to
40 g/L for 11-OH-THC and from 2 to 160 g/L for THC-COOH. Fig. 1
shows the MRM chromatograms obtained following the analysis of
the lowest calibrator (0.5 g/L for THC, 1 g/L for 11-OH-THC and
2 g/L for THC-COOH). At this concentration a S/N ratio >10:1 was
observed for the qualifier and the criteria for LOQ were satisfied.
The applied isocratic mobile phase (methanol:0.1% formic acid,
80:20, v/v) ensured the elution of all the drugs examined within
11 min and produced chromatographic peaks of acceptable symme-
try. In the early stages of method development an isocratic gradient
of 90:10 methanol: 0.1% formic acid (v/v) was tested: although
the compounds eluted earlier, giving a shorter run time, many
interferences were observed at the retention time (2.5 min) of 11-
OH-THC and THC-COOH when analysing blank blood samples.
Selectivity of the method was achieved by a combination of
retention time, precursor and two product ions. The most promi-
nent precursor–product transitions were used for quantification of
THC and THC-d3 and the next most abundant, used as qualifier.
For the other compounds, an elevated background was noted when
using the MRM transition based on the most prominent product.
Improved sensitivity (based on S/N) was achieved when the MRM
transition was based on an alternative product ion (Table 1). The
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Fig. 1. MRM chromatograms obtained following the analysis of a spiked blood sample at the LOQ for (a) THC-d3, (b) THC (quantifier), (c) THC (qualifier), (d) THC-COOH-d9, (e)
THC-COOH (quantifier), (f) THC-COOH (qualifier), (g) 11-OH-THC-d3, (h) 11-OH-THC (quantifier), and (i) 11-OH-THC (qualifier). Peak intensity is shown in the top right-hand
corner of each trace.
Table 1
MRM transitions and conditions for all compounds and their deuterated analogues.









THC 315.2 259.0 30 20
193.0 20
11-OH-THC 331.2 200.9 30 20
193.0 20
THC-COOH 345.2 192.9 30 30
119.1 30
THC-d3 318.3 196.0 30 20
11-OH-THC-d3 334.3 201.0 30 20
THC-COOH-d9 354.2 308.1 30 20
ion ratios (quantifier/qualifier) were 2.1, 0.8 and 1.5 for THC, 11-OH-
THC and THC-COOH, respectively. For the corresponding deuterated
analogues, only one transition was monitored. Injection of single
analyte solutions did not produce interference in the other MRM
channels. Fig. 2 shows the fragmentation structures of THC (a),
11-OH-THC (b), THC-COOH (c) to the quantifier ion.
Table 2
Dynamic range, LOD, LOQ, relative standard deviation (RSD, %) at the LOQ and
equation of a typical calibration curve with the corresponding coefficient of deter-
mination (r2). The limit of quantification (LOQ) was estimated by replicate analysis
(n = 2) over eight different days.
THC 11-OH-THC THC-COOH
Dynamic range (g/L) 0.5–40 1–40 2–160
LOD (g/L) 0.5 1 2
LOQ (g/L) 0.5 1 2
RSD (%) at LOQ 6.8 9.7 6.4
r2 0.999465 0.999695 0.998958
Linearity data, LOQ and LOD are shown in Table 2. No inter-
ference peaks were observed in the cannabinoids MRM channels
when blank blood samples spiked with other drugs were analysed.
The LOD and the LOQ were identical for all compounds, since lower
concentrations did not meet the acceptance criteria for ion ratios. In
Belgium, the concentration of THC in a blood sample from a driver
Fig. 2. Fragmentation of THC (a), 11-OH-THC (b), THC-COOH (c) to the quantifier
ion.
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Table 3
Intra-assay (expressed as RSDr, %) and inter-assay precision (expressed as RSDt, %) and accuracy of the QC samples. Intra-assay and inter-assay precision was evaluated by
replicate (n = 2) analysis of the QC samples performed over eight different days and it was determined by performing the analysis of variance: a ‘single factor’ ANOVA test
(significance level—˛ of 0.05).
THC 11-OH-THC THC-COOH
RSDr (%) RSDt (%) Accuracy (%) RSDr (%) RSDt (%) Accuracy (%) RSDr (%) RSDt (%) Accuracy (%)
External control 1 3.7 11.5 91.3 4.0 5.2 94.7 3.8 7.8 95.4
External control 2 2.3 7.2 99.4 2.8 5.7 0.0 2.3 4.4 100.8
‘In house’ QC ‘low’ 1.4 7.1 96.0 3.9 4.9 105.8 6.4 6.2 99.8
‘In house’ QC ‘high’ – – – – – – 3.3 4.6 97.9
Table 4
Matrix effect, matrix effect RSD (%) and extraction recovery (%) evaluated at two different concentrations (n = 6, for each concentration).
THC 11-OH-THC THC-COOH
37.5g/L 2.5 g/L 37.5 g/L 2.5 g/L 37.5 g/L 2.5 g/L
Mean matrix effect (%) −8.5 0.4 23.6 26.5 −6.6 0.8
Matrix effect RSD (%) 8.1 8.5 2.6 8.4 6.7 5.4
Recovery (%) 109.4 108.1 110.8 111.5 105.0 104.8
that constitutes an offence is 2 g/L. For other European counties
like France and Germany (for plasma samples) it is fixed at 1 g/L
[19].
The intra- and inter-assay precisions were satisfactory, with all
RSDs lower than 12% (Table 3). Results indicated that the accuracy
of the assay was >90%.
The stability of processed samples (spiked at 34 g/L and then
stored in the autosampler at 6 ± 2 ◦C) was monitored after 48 h. No
statistical significant difference could be observed for any of the
compounds. Furthermore, all compounds, when spiked in blood at
two concentrations, i.e. 34 and 2.5 g/L, were demonstrated to be
stable after three freeze/thaw cycles.
The matrix effect, defined as the effect of co-eluting residual
matrix components on the ionization of the target analyte, typically
results in either signal suppression or enhancement. Moreover,
interfering matrix components can affect the reproducibility and
accuracy of the developed procedure, leading to compromising
or erroneous results. Consequently, in the development of any
LC–MS(/MS) method, an efficient sample clean-up and use of
appropriate internal standardization is necessary and the potential
for any such ion suppression and enhancement should be assessed.
Post-column infusion experiments (based on the method described
by Bonfiglio et al. [20]) were performed to provide information of
the effect of the matrix throughout the course of the elution time for
the analytes. Fig. 3(a)–(c) shows the responses obtained following
an injection of an extracted blank blood sample and a mobile phase
only control (top and bottom chromatograms for each compound,
respectively). A second experiment was carried out and we com-
pared peak responses obtained when the cannabinoids were spiked
to a blank blood sample with the response obtained when the
Fig. 3. Evaluation of the effect of the matrix on (a) THC, (b) THC-COOH and (c) 11-OH-THC by post-column infusion following an injection of extracted blank blood (top trace
for each compound) and mobile phase only control (bottom trace). The dotted areas indicate the elution-position of each drug. MRM transition and peak intensity are shown
on the right-hand corner of each trace.
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cannabinoids were added to a mobile phase only at the same con-
centration. For 11-OH-THC some ion enhancement was observed,
nevertheless it has been stated that the use of deuterated I.S. would
partially compensante for matrix effects [21,22]. The results of the
matrix effects at the two different concentrations are presented in
Table 4.
The results of the extraction recovery study are also presented
in Table 4. Very high and reproducible recoveries were obtained
with this LLE procedure for all analytes. It must be pointed out the
importance of adding the solution of 10% acetic acid to achieve a
pH lower than 4.5 due to the pKa of THC-COOH.
The validated LC–MS/MS method was applied to the analysis
of 63 authentic samples from toxicology cases. Concentrations of
THC-COOH were quite variable and generally high. The correspond-
ing 11-OH-THC concentrations remained quite low. Samples with a
concentration above the linear range of the calibration curve were
diluted 1:2 with blank blood and re-analyzed. The median and
minimum–maximum range (in g/L), respectively, were as follows:
THC (7.45 [1.3–34.1]), 11-OH-THC (2.7 [1.0–13.4]) and THC-COOH
(44.8 [7.9–224.3]).
4. Conclusions
Reliable analytical data are a prerequisite for correct interpreta-
tion of toxicological findings in the evaluation of scientific studies,
as well as in daily routine work. Unreliable analytical data might not
only be contested in court, but could also lead to unjustified legal
consequences for a defendant. Therefore, new analytical methods
to be used in forensic and/or clinical toxicology require careful
method development and thorough validation of the final method.
In this report, a fully validated and highly sensitive LC–MS/MS
method is described for the simultaneous analysis of THC, 11-OH-
THC and THC-COOH in blood. The method combined LLE with
LC–MS/MS and provided a thorough clean-up of the matrix to
minimize ion suppression and enhancement, in combination with
high recovery, excellent precision and accuracy in the linear range
investigated, using 250 L of sample. The method was successfully
applied to authentic samples.
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a b s t r a c t
A simple, rapid and highly sensitive method for the analysis of THC-COOH in urine, using automated
on-line solid-phase extraction (SPE) combined with liquid chromatography (LC)–mass spectrometry
(MS/MS), is developed and fully validated according to international guidelines. Chromatographic sep-
aration was achieved on an Atlantis dC18 column with an isocratical gradient, ensuring the elution of
THC-COOH within 4.1 min. The total process time was 6 min and 500 L of sample was required. SPE
using C8 cartridges was highly effective, reproducible and led to significant decreases in the interfer-
ences present in the matrix. The method showed an excellent intra- and inter-assay precision (relative
standard deviation (RSD) <7% and bias <13%) for four external quality control (QC) samples and three
‘in house’ QCs. Responses were linear over the investigated range (r2 > 0.99, 5–200 g/L). Limits of
quantification (LOQ) and detection (LOD) were determined to be 5 g/L and 0.25 g/L, respectively.
Furthermore, the analyte and the processed samples were demonstrated to be stable. Moreover, no car-
ryover was observed after the analysis of high concentrated urine samples (5000 g/L THC-COOH)). The
method was subsequently applied to authentic samples previously screened by a routine immunoassay
method.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
High-throughput analysis is becoming increasingly important
in all areas of science; the forensic sciences being no exception.
Moreover, due to the development of more potent drugs, drug
concentrations in biological samples are often present at much
lower levels than before. Therefore, fast analytical techniques with
higher sensitivity and selectivity are needed. One of the bottle-
necks in bio analysis is sample preparation, especially if the method
requires manual extraction techniques. An elegant system for the
rapid analysis of complex samples can be obtained by on-line cou-
pling of SPE to LC–MS detection. With this procedure, the sample
is injected directly into the SPE-MS system and the rate-limiting
off-line extraction step is eliminated. As a result, automation leads
to higher sample throughput and increased sensitivity as the whole
∗ Corresponding author. Tel.: +32 2 240 05 00; fax: +32 2 241 61 05.
E-mail address: mariadelmar.ramirezfernandez@just.fgov.be
(M.d.M.R. Fernández).
sample extract is analyzed and not a fraction. Other advantages are
safer sample handling and improved precision as operator inter-
vention is minimized [1].
Cannabis is one of the most widely used illicit drug in the
world, being the most frequently detected drugs in cases of driv-
ing under the influence of drugs (DUID) in several countries [2].
Cannabis use is detected by identifying the presence of the major
psychoactive constituent of marijuana, 9-tetrahydrocannabinol
(THC) or its metabolites in biological fluids. The major metabo-
lite found in urine is 11-nor-9-tetrahydrocannabinol-9-carboxylic
acid (THC-COOH), which exists in both the free and glu-
curonide form [3–5]. Analytical procedures are well-documented
for determining the presence of THC-COOH in urine using gas
chromatography–mass spectrometry (GC–MS(/MS)) [6–10], liquid
chromatography–mass spectrometry (LC–MS(/MS)) [1,6,11–13] and
immunoassays [14–17]. However, to date, no report has been pub-
lished dealing with the analysis of THC-COOH in urine by any type
of on-line SPE-LC–MS/MS.
Therefore, the aim of this study was to develop and vali-
date a simple, rugged and high-throughput on-line SPE-LC–MS/MS
method for quantification of THC-COOH in urine.
1570-0232/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
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2. Materials and methods
2.1. Reagents
Individual stock solutions of THC-COOH (1 mg/mL in methanol),
and the internal standard (IS) [9H3] THC-COOH (THC-COOH-d9)
(0.1 mg/mL in methanol) were from LGC Promochem (Molsheim,
France).
Water (HPLC grade), methanol (LC–MS grade), 0.1% formic
acid in water (UPLC/MS grade) and acetonitrile (LC–MS grade)
were purchased from Biosolve (Valskenswaard, The Netherlands).
Potassium hydroxide (powder), triethylamine, (puriss.p.a.) and tri-
fluoroacetic acid (puriss.p.a.) were purchased from Sigma–Aldrich
(Steinheim, Germany). HySphere C8 cartridges were from Cofraz
(Elsene, Belgium). Glacial acetic acid was from VWR (Leuven,
Belgium).
External quality control (QC) urine samples (Medidrug U-screen
cut-off −25% and +25%) were obtained from Medichem World
(Steinenbronn, Germany). Liquicheck external quality controls C1
and C3 for urine were purchased from Bio-Rad Laboratories (Irvine,
CA).
2.2. Specimens
Blank urine samples were obtained from drug-free volunteers.
Authentic urine samples were obtained from forensic toxicology
cases.
2.3. Preparation of standard solutions for calibrators and QC
samples
Two different working solutions of the non-deuterated com-
pound at 10 mg/L in methanol were prepared. The first was used for
preparation of the calibrators and the second for the ‘in house’ QC
samples. The internal standard (IS) working solution of 1 mg/L was
prepared in methanol. Working solutions were prepared monthly
and stored at 4 ◦C. The ‘in house’ QCs were stored at −20 ◦C until
use.
The external QCs were prepared following the indications of
the manufacturer. Each vial of the Medidrug U-screen controls was
reconstituted exactly with 5.0 mL of bidistilled water, swirled gen-
tly and allowed to equilibrate for 20 min at room temperature (RT).
Before sampling, the vial was gently homogenized for 5 min using a
rotation mixer. After reconstitution, the QCs were stable for 7 days
(at 2–8 ◦C in the dark). The Liquicheck controls were equilibrated
to RT and swirled gently to ensure homogeneity before sampling.
Once the control was opened, it was stable for 30 days when stored
tightly capped at 2–8 ◦C.
2.4. SPE-LC–MS/MS
2.4.1. Sample preparation: hydrolysis
Fifty microliters of potassium hydroxide 10 M and 50 L of the IS
working solution (0.25 mg/L) were added to 500 L of urine and the
samples were incubated at 60 ◦C for 15 min. Similar hydrolysis pro-
cedures have been described by other authors [1,18]. Samples were
cooled to RT before the addition of 300 L distilled water. Before
injection onto the on-line SPE system, the samples were acidified
by adding 600 L of glacial acetic acid.
2.4.2. XLC (on-line SPE)
Sample extraction was performed using the on-line SPE
SymbiosisTM Pharma System (Spark HollandTM, Emmen, The
Netherlands). The entire system was operated by SparkLink for
MasslynxTM software (version 4.1, Waters).
The following XLC program was used: after conditioning with
2 mL of methanol and 1 mL of water, 200 L of the diluted and acid-
ified urine sample was applied to the SPE cartridge using 2 mL of
water as transport solvent. Clean-up was accomplished through
successive 2 mL washes of 0.1% formic acid, and methanol:0.1%
formic acid (50:50, v/v) in order to remove salts and endogenous
interferences present in the biological samples. Elution of the ana-
lytes from the cartridge was achieved by application of the LC
mobile phases (0.1% formic acid (A) and acetonitrile (B)) (standard
(gradient pump) elution mode) during the chromatographic run.
Whilst the elution step was being performed, a new cartridge was
conditioned, loaded and washed in the left clamp. Following the
elution step, several automated clamp and valve washes with water,
0.2% triethylamine and 0.1% trifluoroacetic acid were performed to
avoid carryover between samples.
2.4.3. Chromatographic conditions
Analytes were separated using an Atlantis dC18 column, 3 m,
3 mm × 100 mm (Waters). Separation was carried out in isocratic
mode (0.1% formic acid:acetonitrile, 20:80, v/v). The complete run
time was 6 min.
2.4.4. Tandem mass spectrometry
A Quattro Premier tandem mass spectrometer (Waters) was
used. Ionization was achieved using electrospray in positive ion-
ization mode (ESI+). Nitrogen was applied as nebulisation and
desolvation gas at a flow rate of 600 L/h and heated to 350 ◦C. Cap-
illary voltage and source block temperature were 3 kV and 120 ◦C,
respectively.
In order to establish the appropriate multiple reaction monitor-
ing (MRM) conditions for the individual compounds, solutions of
standards (200 g/L, in 0.1% formic acid–acetonitrile (20:80, v/v))
were infused into the mass spectrometer and the cone voltage (CV)
was optimised to maximise the intensity of the protonated molec-
ular species [M+H]+. Collision-induced dissociation (CID) of each
protonated molecule was performed. The collision gas (argon) pres-
sure was maintained at 0.35 Pa (3.5 × 10−3 mbar) and the collision
energy (eV) adjusted to optimise the signal for the most abun-
dant product ions, which were subsequently used for MRM analysis
(Table 1).
2.5. On-line SPE-LC–MS/MS assay validation
Validation was performed based on the FDA guidelines and
recent publications concerning validation of bio analytical methods
[19,20].
Table 1
MRM transitions and conditions for THC-COOH and its deuterated analogue. Underlined transition was used for quantification.





THC-COOH-d9 354.2 308.4 30 20
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2.5.1. Linearity, limit of quantification (LOQ), limit of detection
(LOD), precision and bias
It is known that the concentration of drugs in urine can vary
considerably (e.g. from some g/L to few thousands of g/L of
THC-COOH) depending on the individual and the time of collec-
tion, In routine urine toxicological analysis, it is necessary to fix
the quantification range depending on the cut-off established in
the laboratory. The aim in our toxicological laboratory is to deter-
mine the presence of THC-COOH in urine with respect to the Belgian
legal cut-off of 15 g/L. Thus, the established quantification range
has been determined to guarantee a good quantification around this
concentration.
Quantification was performed by integration of the area under
the specific MRM chromatograms in reference to the integrated
area of the deuterated analogue. Freshly prepared working solu-
tions of 1000 g/L and 100 g/L in water were used to prepare urine
calibrators at a concentration of 200, 100, 50, 20, 10 and 5 g/L
using HPLC-grade water. Standard curves, freshly prepared with
each batch of QC samples and authentic samples, were generated
using a least-squares linear regression, with a 1/x-weighting factor.
The limit of quantification (LOQ) was estimated by replicate
analysis (n = 2) over 8 different days and was defined as the con-
centration of the lowest calibrator that was calculated within ±20%
of the nominal value and with a relative standard deviation (RSD)
less than 20%.
The limit of detection (LOD) was estimated from blank urine
samples, spiked with decreasing concentrations of the analyte. It
was defined as the concentration for which the response of the
qualitative ion could reliably be differentiated from background
noise, i.e. signal-to-noise ratio (S/N) equal to or greater than 3:1.
The acceptance criteria for ion ratios equal to or lower than 20%
and retention time deviations lower than 3.5% relative to that of
the corresponding control or calibrator.
Seven QCs were analyzed, four external QCs (two each from
Medichem and Bio-Rad Laboratories) and three ‘in house’ QCs.
Intra- and inter-assay imprecision was evaluated by replicate
(n = 2) analysis of the QC samples performed over eight different
days. Imprecision (expressed as %RSDr for intra-assay impreci-
sion and %RSDt for inter-assay imprecision) was determined by
performing the analysis of variance: a ‘single factor’ ANOVA test
(significance level (˛) of 0.05). Bias of the method was determined
by comparison of the mean of calculated concentrations of QC sam-
ples to their respective nominal values.
2.5.2. Selectivity and specificity
The selectivity and specificity of the method against endogenous
interferences was verified by examination of the chromatograms
obtained after the extraction of eight different blank urine sam-
ples from healthy volunteers, and after the analysis of authentic
urine samples from cocaine and amphetamine users. Moreover,
blank urine samples (n = 3) spiked with amphetamine, metham-
phetamine, MDA, MDMA, ephedrine, PMA, mCPP, morphine,
codeine, benzoylecgonine, codeine, 6-MAM, fentanyl, pholco-
dine, hydromorphone, hydrocodone, norcodeine, dihydrocodeine,
oxycodone, oxymorphone, cocaine, methadone, EDDP, 27 benzodi-
azepines, zolpidem, zopiclone, zaleplon, THC and 11-OH-THC were
also analyzed to check for interferences.
2.5.3. Stability
The autosampler stability of processed samples at concentra-
tions of 160 g/L and 15 g/L (n = 6 at each concentration) was
monitored as follows; one pool of samples were determined imme-
diately, while another pool of samples was analyzed after remaining
in the autosampler at 6 ± 2 ◦C for 24 h and at RT for 72 h (a weekend).
All samples were spiked with the IS just before analysis.
Stability of THC-COOH in the matrix was determined through
spiked blank urine samples with concentrations of 160 g/L and
15 g/L (n = 6 at each concentration). Stability was checked after
storage at 2–6 ◦C for 72 h (weekend) and after three freeze/thaw
cycles.
All the stability experiments were tested against a lower per-
centage limit corresponding to 90–110% of the ratio (mean value
of stability samples/mean value control samples) with a 90% of the
confidence interval of the stability samples between 80 and 120%
of the mean of the control samples.
2.5.4. Assessment of matrix effects
To assess any potential suppression or enhancement of ioniza-
tion due to the sample matrix, two different experiments were
carried out.
The first one involved a post-column infusion experiment [21].
This experiment was based on a continuous post-column infusion
of THC-COOH and its internal standard (10 g/L at a flow rate of
10 L/min) to produce a constant response in the MRM channels.
This constant response was monitored throughout the whole run
following the injection of urine samples from different origin (n = 6)
and compared to the response following the injection of mobile
phase only.
The second experiment consisted of a comparison between the
peak responses of THC-COOH spiked to a blank urine sample at con-
centrations of 160 g/L and 15 g/L (n = 6, for each concentration)
with those obtained after being spiked in the mobile phase at the
same concentration levels [22].
2.5.5. Recovery
Extraction recoveries were estimated by performing the fol-
lowing experiments: blank urine samples spiked at 160 g/L and
15 g/L (n = 6, for each concentration) were loaded and washed in a
first SPE cartridge while a second cartridge was placed in series to
determine the breakthrough of the first one. Both cartridges were
subsequently eluted independently. Recovery was considered to be
the ratio between the response obtained after elution of the first
cartridge and the total response (sum of both, the first and the
second SPE cartridge).
2.5.6. Carryover
Carryover was evaluated by the analysis of blank urine sam-
ples spiked with the IS after the analysis of the upper calibrator
(200 g/L, n = 8), after the analysis of authentic urine samples from
cannabis users (n = 8) and after the analysis of a highly concentrated
sample (5000 g/L).
2.5.7. Dilution integrity
Spiked blank urine samples at 3200 g/L and 600 g/L were
rediluted 1:20 (v/v) with blank urine (n = 6) and analyzed to evalu-
ate the dilution integrity.
3. Results and discussion
The method was validated for selectivity, linearity, LOQ, LOD,
imprecision, bias, analyte and processed sample stability, matrix
effect, recovery, carryover and dilution integrity.
The applied chromatographic method ensured the elution
of THC-COOH within 4.1 min and produced peaks of accept-
able symmetry. Selectivity of the method was achieved by
a combination of retention time, precursor and two prod-
uct ions. The most prominent precursor-product transition was
used for quantification and the next most abundant as qual-
ifier (Table 1). For the corresponding deuterated analogue,
only one transition was monitored. Fig. 1 shows the MRM
chromatograms obtained following the analysis of the urine
2156 M.d.M.R. Fernández et al. / J. Chromatogr. B 877 (2009) 2153–2157
Fig. 1. MRM chromatograms obtained following the analysis of a spiked urine sample with 5 g/L (LOQ) and a blank urine injected after the highest calibrator: (A) IS, (B1)
quantifier of THC at LOQ, (B2) quantifier of THC in the blank urine, (C1) qualifier of the LOQ and (C2) qualifier of the blank urine. Peak intensity is shown in the top right-hand
corner of each trace. Blank urine samples are displayed at the same peak intensity of the LOQ.
lowest calibrator (5 g/L) and a blank injected after a high
concentrated sample. No interferences were observed after
the analysis of blank urine samples spiked with over—the
counter-drugs and cannabinoids, ensuring the selectivity of the
method.
During pre-validation experiments, the linearity was tested up
to 5000 g/L (r > 0.99). However, due to the legal cut-off in Belgium
for THC-COOH, which is 15 g/L, the quantification range applied
in the laboratory was 5–200 g/L. Correlation coefficients of the
weighed (1/x) linear regressions for this range were higher than
r2 = 0.99.
The LOQ was determined at 5 g/L as a S/N > 10:1 was observed
for the qualifier and the criteria for LOQ were satisfied. LOD was
0.25 g/L.
The intra- and inter-assay imprecision were satisfactory, with all
RSDs lower than 7% (Table 2). The results indicated that the bias of
the assay was <13%.
Stability of the processed samples in the autosampler was moni-
tored after 24 (at 2–6 ◦C) and 72 h (RT). No instability was observed
during this period of time. Moreover, THC-COOH spiked to blank
urine samples was also stable after the three freeze/thaw cycles
and after 72 h in the fridge.
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Table 2
Intra-assay (expressed as RSDr (%)) and inter-assay precision (expressed as RSDt (%)) and bias of the LOQ and QC urine samples. Intra-assay, inter-assay precision and bias
were evaluated by replicate (n = 2) analysis of the QC samples performed over eight different days.
Nominal value (g/L) Average (g/L) (n = 16) RSDr (%) (n = 16) RSDt (%) (n = 16) Bias (%) (n = 16)
C1 6.0 6.4 2.9 4.1 7.2
C3 18.5 20.1 1.9 2.8 8.8
Medichem cutoff −25% 37.5 34.3 5.2 5.8 −8.5
Medichem cutoff +25% 62.5 55.1 1.9 5.1 −11.8
‘In house’ QC low 15.0 13.1 6.2 6.8 −12.3
‘In house’ QC medium 80.0 79.8 2.0 4.4 −0.3
‘In house’ QC high 160.0 156.8 2.9 5.4 −2.0
Post-column infusion experiments were performed to provide
information of the matrix effect throughout the course of the elu-
tion time for the analyte and its IS. No significant changes in
response were observed. The second experiment performed to
assess matrix effects compared the peak area responses, obtained
when the compound was spiked into blank urine samples, with
the responses obtained when the compound was added to mobile
phase at the same concentration. No significant matrix effect (mean
3.6%) was observed with this on-line SPE procedure.
Moreover, for the recovery studies, no breakthrough was
observed in the second cartridges placed in series, so recovery was
100%.
No carryover was observed in the analysis of a blank urine sam-
ple injected after the analysis of the upper calibrator (200 g/L),
neither after the analysis of authentic urine samples or after a highly
concentrated sample (5000 g/L).
The dilution integrity test demonstrated a bias <2% and an
RSD (%) of 13.4% and 11.6% for the diluted blank urine samples at
3200 g/L and 600 g/L, respectively.
4. Samples
Thirty-four urine samples from cannabis users were analyzed in
one run with the present method. Concentrations varied consider-
ably. Those samples with concentrations above the upper calibrator
were diluted 1/20 with blank urine and reanalyzed. The median was
652 g/L with minimum–maximum range of 12.1–3681.
5. Conclusions
In this report a fully validated and highly sensitive automated
LC–MS/MS method is described for the analysis of THC-COOH in
urine. The method combined on-line SPE with LC–MS/MS and pro-
vided a thorough clean-up of the matrix in combination with high
recovery, excellent precision and bias within the investigated linear
range. The method was successfully applied to authentic samples
from cannabis users.
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5.4. HIGH THROUGHPUT ANALYSIS OF AMPHETAMINES 
 IN BLOOD AND URINE  




An automated online solid-phase extraction-liquid
chromatography–tandem mass spectrometry (SPE-LC–MS–MS)
method for the analysis of amphetamines in blood and urine was
developed and validated. Chromatographic separation was
achieved on a Nucleodur® Sphinx RP column with an LC gradient
(a mixture of 10 mM ammonium formate buffer and acetonitrile),
ensuring the elution of amphetamine, methamphetamine, MDMA,
MDA, MDEA, PMA, and ephedrine within 11 min. The method was
fully validated, according to international guidelines, using only
100 and 50 μL of blood and urine, respectively. The method
showed an excellent intra- and interassay precision [relative
standard deviation (RSD) < 11.2% and bias < 13%] for two
external quality control samples (QC) for both matrices and three
and two ‘in house’ QCs for blood and urine, respectively.
Responses were linear over the investigated range (r2 > 0.99, 2.5–
400 μg/L for blood and 25–1000 μg/L for urine). Limits of
quantification were determined to be 2.5 and 25 μg/L for blood
and urine, respectively. Limits of detection ranged from 0.05 to 0.5
μg/L for blood and 0.25 to 2.5 μg/L for urine, depending on the
compound. Furthermore, the analytes and the processed samples
were demonstrated to be stable (in the autosampler for at least 72
h and after three freeze/thaw cycles), and no disturbing matrix
effects were observed for all compounds. Moreover, no carryover
was observed after the analysis of high concentration samples
(15,000 μg/L). The method was subsequently applied to authentic
blood and urine samples obtained from forensic cases, which
covered a broad range of concentrations. The validation results and
actual sample analyses demonstrated that this method is rugged,
precise, accurate, and well-suited for routine analysis as more than
72 samples are analyzed non-stop in 24 h with minimum sample
handling. The combination of the high-throughput online SPE and
the well-known sensitivity and selectivity assured by MS–MS
resulted in the elimination of the bottleneck associated with the
sample preparation requirements and provided increased
sensitivity, accuracy, and precision.
Introduction
Amphetamine is a psychostimulant drug known to produce
wakefulness and increase focus and appetite. The main effects
reported after use of amphetamines are euphoria, increased en-
ergy, muscle tremor, hypertension, increased blood tempera-
ture, and dry mouth (1). Designer amphetamines chemically
related to amphetamine include methamphetamine,
methylenedioxyamphetamine (MDA), methylendioxymetham-
phetamine (MDMA), methylenedioxyethylamphetamine
(MDEA), and 4-methoxyamphetamine (PMA). They also present
similarities to some naturally occurring weak stimulants such
as ephedrine.
Globally, after cannabis, amphetamines are among the most
commonly consumed illicit drugs. According to the annual
report of the European Monitoring Center for Drugs and Drug
Addiction (EMCDDA), surveys conducted in the European
countries in recent years showed an increase in amphetamine
and ecstasy consumption (2). Methamphetamine use was not
observed in Belgium but was reported in other countries (e.g.,
U.S., Lithuania, Slovenia, Russia, and Poland).
Several techniques have been used for the toxicological anal-
ysis of amphetamines in blood and/or urine including gas
chromatography with mass spectrometry (GC–MS) (3,4) and
liquid chromatography with tandem mass spectrometry
(LC–MS–MS) (5–10). With the advent of increased selectivity
when using LC–MS–MS, the possibility of omitting the sample
preparation step arose (11–13) because sample preparation is
considered the main bottleneck as it is often time consuming.
Therefore, several clinical and forensic laboratories simply use
direct injection of the biological sample. However, sample
preparation is often required to reduce matrix effects. The
increased demand for high-throughput causes a unique situa-
tion of balancing cost versus analysis speed. An elegant system
for the rapid analysis of complex samples can be obtained by
online coupling of solid-phase extraction (SPE) to LC–MS de-
tection. With this procedure, the sample is injected directly
into the SPE-MS system, and the rate-limiting off-line extrac-
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tion step is eliminated. As a result, automation leads to higher
sample throughput, and increased sensitivity as the whole
sample extract is analyzed and not a fraction. Other advantages
are safer sample handling and improved precision as operator
intervention is minimized (14,15). Several generic approaches
have recently been developed for online sample extraction cou-
pled to LC–MS (15–21).
Wu et al. (22) developed a method for the direct analysis of
amphetamines for urine by column-switching connecting a
SPE column before the analytical column. However, the
method was not completely validated because no studies of
matrix effects and carryover were carried out. According to the
literature, when extractions are performed using automated
liquid handlers, the potential of carryover and cross-contami-
nation increases (23). Thus, it must be included in method
validation.
The aim of this study was to develop and completely validate
a new simple, rugged, and high-throughput online SPE-LC–
MS–MS method for rapid and simultaneous analysis of am-
phetamine, methamphetamine, MDMA, MDA, MDEA, PMA,
and ephedrine in blood and urine. This online SPE-LC–MS
method offers the entire process of conditioning, sample ap-
plication, washing, and elution taking place at constant flow
rates. Another important advantage is that no manual transfers
are made and that the whole extracted sample is loaded onto
the LC column without the need for a preconcentration step.
Disposable cartridges were applied for each injection mini-
mizing the carryover. The method was fully validated with re-
spect to precision, accuracy, quantification and detection limit,
stability, sample throughput, and carryover.
Materials and methods
Reagents
Individual stock solutions of amphetamine, metham-
phetamine, MDA, MDMA, and PMA (all certified at a concen-
tration of 1 mg/mL in methanol), and the internal standards
(IS) [3H11] amphetamine (amphetamine-d11), [3H5] metham-
phetamine (methamphetamine-d5), [3H5] MDA (MDA-d5), [3H5]
MDMA (MDMA-d5), [3H6] MDEA (MDEA-d6), and [3H3]
ephedrine (ephedrine-d3) (certified concentration at 0.1 mg/mL
in methanol) were from LGC Promochem (Molsheim, France).
HPLC-grade water, LC–MS-grade methanol, UPLC–MS-grade
0.1% formic acid in water, and LC–MS-grade acetonitrile were
purchased from Biosolve (Valskenswaard, The Netherlands).
Ammonia solution (32%, extra pure) was from Merck (Darm-
stadt, Germany). Ammonium formate (99.995+% powder) and
triethylamine (puriss.p.a.) were purchased from Sigma Aldrich
(Steinheim, Germany). Oasis HLB Prospekt cartridges were
fromWaters (Milford, MA). External quality control (QC) blood
samples were obtained from Medichem World (Steinenbronn,
Germany). Liquichek external quality controls C1 and C3 for
urine were purchased from Bio-Rad Laboratories (Irvine, CA).
The concentrations of the amphetamines in these external
QCs are displayed in Table I (for blood) and Table II (for urine)
as ‘nominal value’.
Specimens
Pooled blank blood samples were used for development and
validation of the procedure and were obtained from a local
blood bank whereas drug-free volunteers provided blank urine.
Authentic blood and urine samples were obtained from
forensic cases or from 28 volunteers who received either
placebo or a dose of MDMA (75 mg). Blood samples were
freshly collected 1 h and 15 min after ingestion, and the veno-
tubes (without anticoagulant) were directly centrifuged for 10
min at 3000 rpm. The serum obtained was stored at –20°C
prior to analysis. The study protocol was approved by the ethics
committee of the University Hospital of Maastricht in the
Netherlands.
Preparation of standard solutions
Two different working solutions of the non-deuterated
compounds at 4 mg/L in methanol were prepared. The first
was used for preparation of the calibrators and the second for
the ‘in house’ QC samples. The internal standard (IS) working
solution of 1 mg/L was prepared in methanol. Working solu-
tions were prepared monthly and stored at 4°C. The ‘in house’
QCs were stored at –20°C until use. The external QCs were
prepared following the indications of the manufacturer.
To obtain the lower concentrations needed for internal stan-
dardization and validation of each experiment, further dilutions
in water were prepared the same day.
SPE-LC–MS–MS
Sample preparation: XLC (online SPE)
Sample extraction was performed using the online SPE Sym-
biosisTM Pharma System (Spark HollandTM, Emmen, the
Netherlands). It comprises two integrated units: the RelianceTM
autosampler with two integrated binary LC pumps and the
online SPE unit Prospekt-2 system, which includes the auto-
mated cartridge exchange (ACE) unit and two high-pressure
dispensers. The entire system was operated by SparkLink for
Masslynx™ software version 4.1 (Waters, Milford, MA). The
extraction procedure was carried out in glass screw-neck vials
of high-quality Waters glassware.
Initially, 10 SPE cartridges were evaluated to determine the
optimal SPE sorbent for the extraction of all analytes. The
evaluated cartridges were HySphere CN, C2, C8, C8EC, C18,
Resin SH, and Resin GP (SparkHolland) and Oasis HLB, MCX,
MAX cartridges (Waters). The solvents used for the SPE pro-
cedure were thoroughly investigated to determine the optimal
combination to maximize recovery of the analytes of interest
while eliminating carryover and elution of any endogenous
components causing matrix effects.
Nine hundred and fifty microliters of ammonium formate
buffer (10 mM) and 50 μL of the IS working solution (0.1
mg/L) were added to 100 μL of blood and 50 μL of urine,
respectively. The following XLC program was subsequently
used: after conditioning with 2 mL of methanol, 1 mL of water
and 1 mL of water (5% NH4OH), 150 μL of the diluted blood or
urine sample was applied onto the SPE cartridge using 1.5
mL of water (5% NH4OH) as transport solvent. Clean-up was
accomplished with 1 mL washes of 5% NH4OH and water in
order to remove salts and endogenous interferences present in
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the biological samples. The cartridge was then physically
moved with a robotic arm to the elution (right) clamp in line
with the LC pumps, thus leaving the extraction (left) clamp
ready to start with a new sample. While the elution step was
being performed, a new cartridge was conditioned, loaded, and
washed in the left clamp. The elution was performed with the
LC gradient of the mobile phase [ammonium formate buffer 10
mM (A) and acetonitrile (B)] [standard (gradient pump) elution
mode] during the whole chromatographic run. Following the
elution step, several automated clamp and valve washes with
water, acetonitrile, and 0.2% triethylamine were carried out to
avoid contamination between samples.
Chromatographic conditions. Several C18 analytical
columns (XBridge, Waters), SunFire (Waters), Gemini (Phe-
nomenex, Torrance, CA), Chromolith (Merck, Whitehouse
Station, NJ) and Nucleodur Sphinx (Macherey-Nagel,
Dueren, Germany) were initially evaluated in terms of chro-
matographic retention, peak shape, and carryover. The Nu-
cleodur Sphinx RP column (3 μm, 120 × 2 mm) (FilterSer-
vice, Eupen, Belgium) was finally chosen. A gradient was
performed starting from 30% B and a flow rate of 0.25
mL/min for 3 min. From 3 to 8 min, B was subsequently in-
creased to 35%. Then, from 8 to 9 min, B was linearly
increased to 95% and kept for 1.5 min before returning to
the initial conditions. Before the next injection, the column
was equilibrated for 9.5 min to assure the appropriate initial
conditions of the gradient for the next injection.
TandemMS. A Quattro Premier tandemMS (Waters) was ap-
plied. Ionization was achieved using electrospray in positive
ionization mode (ESI+). Nitrogen was used as nebulization
and desolvation gas at a flow rate of 600 L/h and heated to
350°C. Capillary voltage and source block temperature were 1
kV and 120°C, respectively.
In order to establish the appropriate multiple reaction
monitoring (MRM) conditions for the individual com-
pounds, solutions of standards [200 μg/L, in 10 mM ammo-
nium formate/acetonitrile (50:50, v/v)] were infused into
the MS, and the cone voltage (CV) was optimized to maxi-
mize the intensity of the protonated molecular species [M +
H]+. Collision-induced dissociation (CID) of each proto-
Table I. Intraassay*, Interassay Precision†, and Bias of the LOQ and QC Blood Samples
Amphetamine Methamphetamine MDA MDMA MDEA PMA Ephedrine
LOQ Nominal value (μg/L) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Average (μg/L) 2.2 2.5 2.4 2.6 2.4 2.7 2.5
RSDr (%) 2.2 1.5 4.5 11.1 2.5 3.5 5.5
RSDt (%) 9.2 7.2 7.2 10.4 3.0 4.3 7.0
Bias –12.7 –0.2 –3.5 2.5 –3.3 8.1 –1.3
External QC 1 Nominal value (μg/L) 94.4 85.3 58 102.8 69.8 N/A N/A
Average (μg/L) 97.6 83.9 59 101.9 67.5 N/A N/A
RSDr (%) 4.4 3.7 4.3 3.9 4.7 N/A N/A
RSDt (%) 5.7 4.1 3.8 3.9 4.4 N/A N/A
Bias 3.4 –1.7 1.8 –0.9 –3.2 N/A N/A
External QC 2 Nominal value (μg/L) 51.1 128.8 99.3 76.9 57.6 N/A N/A
Average (μg/L) 52.8 126.7 106.2 75 56.4 N/A N/A
RSDr (%) 2.7 3.8 2.6 3.3 2.8 N/A N/A
RSDt (%) 6.1 4.4 3.2 4.9 4.8 N/A N/A
Bias 3.4 –1.7 6.9 –2.4 –2.1 N/A N/A
In house QC Low Nominal value (μg/L) 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Average (μg/L) 3.2 3.6 3.5 3.4 3.5 3.7 3.5
RSDr (%) 4 2.2 3.9 8.7 3.5 2.5 2.5
RSDt (%) 6.2 4.9 4.5 9.2 4.3 3.5 3.4
Bias 7.3 2.7 –0.7 –1.7 –0.3 5.9 –0.8
In house QC Medium Nominal value (μg/L) 50 50 50 50 50 50 50
Average (μg/L) 53.1 51.3 52.7 51.2 50.7 N/A 51.5
RSDr (%) 3.5 1.8 1.6 2.5 1.9 N/A 2.7
RSDt (%) 3.8 4.3 2.7 2.6 3.1 N/A 2.7
Bias 6.1 2.5 5.5 2.4 1.3 N/A 3
In house QC High Nominal value (μg/L) 160 160 160 160 160 160 160
Average (μg/L) 163.1 159.3 160.8 160.2 159.7 158.2 161.7
RSDr (%) 2.5 3.2 1.4 2 1.3 1.7 2.9
RSDt (%) 2 4.5 2.7 2.2 2.7 2.5 2.9
Bias 1.9 –0.4 0.5 0.1 –0.2 –1.2 1.1
* Expressed as RSDr (%).
† Expressed as RSDt (%).
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nated molecule was performed. The collision gas (argon)
pressure was maintained at 0.35 Pa (3.5 × 10–3 mBar) and
the collision energy (eV) adjusted to optimize the signal
for the most abundant product ions, which were subse-
quently used for MRM analysis.
Online SPE-LC–MS–MS assay validation
Validation was performed based on the FDA guidelines and
recent publications concerning validation of bioanalytical
methods (24,25).
Linearity, limit of quantification (LOQ), limit of detection
(LOD), precision, and accuracy (bias)
Quantification was performed by integration of the area
under the specific MRM chromatograms in reference to the in-
tegrated area of the deuterated analogues. Freshly prepared
working solutions at 4000 μg/L were used to prepare blood cal-
ibrators at concentrations of 400, 200, 100, 50, 25, 12.5, 5, and
2.5 μg/L for blood and at 1000, 800, 500, 250, 200, 125, 100, 50,
and 25 μg/L for urine. Standard curves, freshly prepared with
each batch of QC samples and authentic samples, were gener-
ated using a least-squares linear regression with a 1/x-weighing
factor for all compounds.
The LOQ was estimated by replicate analysis (n = 2) over
eight different days and was defined as the concentration of the
lowest calibrator that was calculated within ±20% of the nom-
inal value and with a relative standard deviation (RSD) of less
than 20%. The LOQ was calculated performing the analysis of
variance: a ‘single factor’ ANOVA test [significance level (α) of
0.05].
The LOD was estimated from blank blood and urine samples,
spiked with decreasing concentrations of the analytes. It was
defined as the concentration where the response of the quali-
tative ion could reliably be differentiated from background
noise [i.e., signal-to-noise ratio (S/N) equal to or greater than
3:1]. The acceptance criteria for ion ratios should be equal to
or lower than 20% and retention time deviations lower than
3.5% relative to that of the corresponding control or cali-
brator.
Five QCs were analyzed for blood: two external QCs
(Medichem) and three in house QCs. For urine, four QCs were
monitored: two external from Bio-rad and two in house. The in
house QCs were prepared by different operators from different
working solutions different of those for the calibrators and
stored at –20°C until use.
Table II. Intraassay*, Interassay Precision†, and Bias of the LOQ and QC Urine Samples
Amphetamine Methamphetamine MDA MDMA MDEA PMA Ephedrine
LOQ Nominal value (μg/L) 25.0 25.0 25.0 25.0 25.0 25.0 25.0
Average (μg/L) 22.1 24.8 25.0 23.8 24.2 27.2 24.7
RSDr (%) 7.8 5.3 4.2 6.4 5.9 3.5 5.6
RSDt (%) 7.0 5.9 4.5 6.1 5.3 3.5 5.8
Bias –11.6 –0.8 0.1 –4.9 –3.4 8.9 –1.2
External C 1 Nominal value (μg/L) 100.0 100.0 100.0 100.0 100.0 N/A‡ N/A
Average (μg/L) 105.3 101.8 96.5 99.6 99.5 N/A N/A
RSDr (%) 5.0 4.0 5.0 4.5 4.7 N/A N/A
RSDt (%) 4.5 9.3 4.5 5.2 4.8 N/A N/A
Bias 5.3 1.8 –3.5 –0.4 –0.5 N/A N/A
External C 3 Nominal value (μg/L) 625.0 625.0 312.0 312.0 312.0 N/A N/A
Average (μg/L) 635.2 620.5 305.9 299.5 317.5 N/A N/A
RSDr (%) 2.2 3.4 3.0 3.2 2.3 N/A N/A
RSDt (%) 3.2 6.5 3.4 4.4 3.1 N/A N/A
Bias 1.6 –0.7 –1.9 –4.0 1.8 N/A N/A
In house QC Low Nominal value (μg/L) 80.0 80.0 80.0 80.0 80.0 80.0 80.0
Average (μg/L) 80.8 80.0 81.5 81.0 81.0 80.1 79.6
RSDr (%) 4.9 3.6 3.4 2.6 2.3 4.2 3.2
RSDt (%) 4.4 2.9 4.1 2.6 2.3 3.9 3.3
Bias 1.0 0.0 1.9 1.3 1.2 0.1 –0.5
In house QC High Nominal value (μg/L) 400.0 400.0 400.0 400.0 400.0 400.0 400.0
Average (μg/L) 419.9 405.0 407.5 406.8 399.9 407.9 402.9
RSDr (%) 3.4 3.3 4.3 1.9 3.6 3.1 2.6
RSDt (%) 3.3 3.1 3.9 3.0 3.4 3.1 2.6
Bias 5.0 1.3 1.9 1.7 0.0 2.0 0.7
* Expressed as RSDr (%).
† Expressed as RSDt (%).
‡ N/A (not available).
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Intraassay and interassay precision was evaluated by replicate
(n = 2) analysis of the QC samples performed over eight dif-
ferent days. Precision (expressed as %RSDr for intraassay pre-
cision and %RSDt for interassay precision) was determined by
performing the analysis of variance: a single factor ANOVA
test [significance level (α) of 0.05]. Comparing the mean of cal-
culated concentrations of QC samples to their respective nom-
inal values, provided data on the accuracy of the method.
Selectivity
The selectivity of the method was verified by examination of
the chromatograms obtained after the extraction of eight dif-
ferent blank blood and urine samples from different origins.
Moreover, a blank urine and blood sample spiked with mor-
phine, codeine, benzoylecgonine, codeine, 6-MAM, fentanyl,
pholcodine, hydromorphone, hydrocodone, norcodeine, dihy-
drocodeine, oxycodone, oxymorphone, cocaine, methadone,
EDDP, 27 benzodiazepines, zolpidem, zopiclone, zaleplon,
THC, 11-OH-THC, and THC-COOH were also analyzed to check
for interferences.
Stability in the autosampler and after three freeze/thaw
cycles
The autosampler stability of diluted samples at concentra-
tions of 160 and 3.5 μg/L for blood and
400 or 80 μg/L in urine (n = 6 at each
concentration) were monitored as follows:
one pool of samples were determined im-
mediately and another pool of samples
were analyzed after remaining in the au-
tosampler at 6 ± 2°C for 24 and 72 h (a
weekend). All samples were spiked with
the IS just before analysis.
Stability studies of amphetamines after
three freeze/thaw cycles in both matrices
were determined through spiked blank
urine and blood samples with concentra-
tions of 160 and 3.5 μg/L for blood and
400 or 80 μg/L in urine (n = 6 at each
concentration).
All the stability experiments were tested
against a lower percentage limit corre-
sponding to 90–110% of the ratio (mean
value of stability samples/mean value con-
trol samples) with a 90% confidence in-
terval of the stability samples between 80
and 120% of the mean of the control sam-
ples.
Assessment of matrix effects
To assess any potential suppression or
enhancement of ionization due to the
sample matrix, two different analyses were
carried out. The first one involved a post-
column infusion experiment (26). This ex-
periment is based on a continuous post-
column infusion of a mixture of the
analytes and their internal standards (10
μg/L at a flow rate of 10 μL/min) to produce a constant elevated
response in the MRM channels. This constant response was
monitored throughout the whole run following the injection of
urine and blood samples from different origin (n = 6) and
compared to the response following the injection of mobile
phase only.
The second experiment consisted of a comparison between
the peak responses of the analytes of interest spiked into blank
blood (160 and 3.5 μg/L) or urine (400 and 800 μL) (n = 3 for
each concentration) and those obtained after being spiked in the
mobile phase at the same concentration levels (27).
Recovery
Extraction recoveries were estimated by performing the fol-
lowing experiments: a blank sample spiked at 160 and 3.5 μg/L
(and the IS to each concentration) for blood and 400 and 80
μg/L (and the IS to each concentration) for urine (n = 3 for
each concentration) were loaded and washed in a first SPE
cartridge while a second cartridge was placed in series to de-
termine the breakthrough of the first one (breakthrough is the
maximum volume from which 100% recovery can be
achieved). Both cartridges where subsequently eluted inde-
pendently. Recovery was considered to be the ratio between the
response obtained after elution of the first cartridge and the
Table III. MRM Transitions and Conditions For All Compounds and Their
Deuterated Analogues
Precusor Ion Product Ions* Cone Voltage Collision Energy
(m/z) (m/z) (V) (eV)
Amphetamine 136.1 91.1 15 15
118.9 10
Methamphetamine 150.0 91.1 20 15
119.1 10
MDA 180.1 105.0 15 20
134.9 15
MDMA 194.2 105.0 20 25
163.1 15
MDEA 208.2 105.0 20 15
163.1 15
PMA 166.1 121.1 15 18
149.0 10
Ephedrine 166.1 133.0 15 20
148.3 10
Amphetamine-d11 147.1 98.0 15 15
Methamphetamine-d5 155.0 91.9 20 20
MDA-d5 185.0 167.9 18 10
MDMA-d5 199.2 165.1 15 15
MDEA-d6 214.2 165.9 20 12
Ephedrine-d3 169.1 151.1 20 15
* Underlined transitions were used for quantification.
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Figure 1.MRM chromatograms obtained following the analysis of a spiked blood sample with 2.5 μg/L. Chromatogram identification: 1, ephedrine (qualifier);
2, ephedrine (quantifier); 3, ephedrine-d3; 4, amphetamine (qualifier); 5, amphetamine (quantifier); 6, amphetamine-d11; 7, MDA (qualifier); 8, MDA (quanti-
fier); 9, MDA-d5; 10, PMA (qualifier); 11, PMA (quantifier); 12, methamphetamine (qualifier); 13, methamphetamine (quantifier); 14, methamphetamine-d5; 15,
MDMA (qualifier); 16, MDMA (quantifier); 17, MDMA-d5; 18, MDEA (qualifier); 19, MDEA (quantifier); and 20, MDEA-d6. Peak intensity is shown in the top
right-hand corner of each trace.
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total response (sum of both the first and second SPE car-
tridge).
Carryover
Carryover was evaluated by the analysis of blank blood and
urine samples spiked with the IS after the analysis of the
upper calibrator (n = 8) for both matrices and after the anal-
ysis of a very concentrated urine sample
(n = 3) (15,000 μg/L).
Results and Discussion
During optimization of the SPE, the
Oasis MCX, C18, and HLB cartridges
demonstrated excellent recovery for all
analytes of interest. HLB cartridges were
the best choice because of optimal analyte
elution from the MCX, an extremely high
pH was required, which was not compat-
ible with the chosen analytical column.
The HLB cartridge is a macroporous
polimer made of a balanced ratio of two
monomers, the lipophilic divinylbenzene
and the hydrophilic N-vinylpyrrolidone.
The applied gradient ensured the elu-
tion of all the drugs examined within 11
min and produced chromatographic
peaks of acceptable symmetry.
The method was validated for selec-
tivity, linearity, LOQ, LOD, precision, ac-
curacy, matrix effect, recovery, stability,
and carryover by the analysis of spiked
blood and urine samples.
Selectivity of the method was achieved
by a combination of retention time, pre-
cursor, and two product ions. The most
prominent precursor-product transitions
were used for quantification and the next
most abundant used as qualifier (Table
III). For the corresponding deuterated
analogues, only one transition was mon-
itored. Injection of single analyte solu-
tions did not produce interference in the
other MRM channels. No interferences
were observed after the analysis of blank
urine samples spiked with several over-
the-counter drugs, ensuring the selec-
tivity of the method. The ion ratios quan-
tifier versus qualifier were as follows:
amphetamine 2.5, methamphetamine 2.9,
MDA 2.2, MDMA 1.4, MDEA 1.5, PMA 1.0,
and ephedrine 5.6.
The quantification range applied was
2.5–400 μg/L for blood and 25–1000 μg/L
for urine. Correlation coefficients of the
weighed (1/x) linear regressions for this
range were higher than r2 = 0.99.
Figure 1 shows the MRM chromatograms obtained following
the analysis of the blood lowest calibrator (2.5 μg/L). At this
concentration a S/N >10:1 was observed for the qualifier, and
the criteria for LOQ were satisfied. LOD ranged from 0.05 μg/L
to 0.5 μg/L for blood and 0.25 μg/L to 2.5 μg/L for urine, de-
pending on the compound. The intra- and interassay precision
Figure 2.MRM chromatograms obtained following the analysis of blank urine analyzed after a high con-
centrated sample (15,000 μg/L). Chromatogram identification: 1, ephedrine (qualifier); 2, ephedrine (quan-
tifier); 3, amphetamine (qualifier); 4, amphetamine (quantifier); 5, MDA (qualifier); 6, MDA (quantifier);
7, PMA (qualifier); 8, PMA (quantifier); 9, methamphetamine (qualifier); 10, methamphetamine (quan-
tifier); 11, MDMA (qualifier); 12, MDMA (quantifier); 13, MDEA (qualifier); and 14, MDEA (quantifier).
Dotted area represents the retention time of each amphetamine. Peak intensity is shown in the top right-
hand corner of each trace.
Table IV. Extraction Recovery and Matrix Effects for Blood and Urine*
Urine Blood
Recovery Matrix effect Recovery Matrix effect
(%) (%) (%) (%)
Amphetamine 99.8 –17.8 99.9 –3.6
Methamphetamine 99.1 –3.7 100 –14.3
MDA 100.0 –12.0 99.8 –11.0
MDMA 100.0 –4.7 100 –13.9
MDEA 99.6 7.7 99.9 –31.3
PMA 100.0 –9.8 100 –12.0
Ephedrine 99.7 –14.3 97.6 –6.4
* Data represent the mean of six experiments at two concentration levels (n = 3) for both matrices;
blood (n = 3) at 160 and 3.5 μg/L; urine (n = 3) at 400 and 80 μg/L.
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were satisfactory with all RSDs lower than 12% (Table I and II
for blood and urine, respectively). Results indicated that the
bias of the assay was < 13%. Post-column infusion experi-
ments were performed to provide information of the matrix ef-
fect throughout the course of the elution time for the analytes.
A second experiment was carried out where peak responses ob-
tained when the compounds were spiked to a blank blood and
urine samples were compared with the response obtained when
the compounds were added to a mobile phase only at the same
concentration. In both experiments, no matrix effects were
observed except for MDEA. For MDEA some ion suppression
was observed for blood (–31.3%); nevertheless, the use of
deuterated IS partially compensates for the observed matrix ef-
fect, and thus, it did not compromise the quantification as
demonstrated with the results obtained for the intra- and in-
terassay precision (28). The results of the matrix effects and re-
covery at the two different concentrations are presented in
Table IV. Very high and reproducible recoveries were obtained
with this online SPE procedure for all analytes. The stability of
samples in the autosampler after 24 h and 72 h and after three
freeze/thaw cycles were monitored. No compound presented
instability during this period of time.
After optimization of the method, no carryover was observed
in the analysis of a blank sample injected after the analysis of
the upper calibrator (neither with blood nor urine). No signif-
icant carryover was observed after the analysis of a blank urine
sample analyzed after the injection a very high concentrated
authentic urine sample (15,000 μg/L) (Figure 2). In addition,
during analyses of authentic urine samples (n = 50) from
forensic and toxicology cases, a blank was injected after each
sample to check for carryover.
Samples
Blood samples were collected from 28
healthy volunteers 1 h and 15min after the
ingestion of a single dose of MDMA (75
mg) or a placebo. The blood samples were
centrifuged for 10 min at 3000 rpm, and
the serum obtained was stored at –20°C
prior to analysis. The results are presented
in Table V. Concentrations of MDMA were
generally low. Themedian andminimum-
maximum range (in μg/L) for MDMAwere
48.3 (919.7–77.00). The concentrations of
the authentic urine samples varied con-
siderably. Those urine samples with con-
centrations higher than the upper cali-
brator (1000 μg/L) were diluted 1:10 and
reanalyzed. Figure 3 shows the MRM
chromatogram of the analysis of a urine
sample from an amphetamine user.
Conclusions
LC–MS–MS offers high specificity,
good precision and accuracy, a wide dy-
Table V. Results Obtained From the MDMA Study*
ID MDMA MDA
P2101A 45.8 < LOQ
P2101B – –
P2102A 50.0 < LOQ
P2102B – –
P2103A – –
P2103B 46.0 < LOQ
P2104A 50.6 < LOQ
P2104B – –
P2105A – –






P2108B 24.3 < LOQ
P2109A – –
P2109B 19.7 < LOQ
P2110A 77.0 < LOQ
P2110B – –
P2111A – –
P2111B 66.0 < LOQ
P2112A 64.9 < LOQ
P2112B – –
P2113A 46.5 < LOQ
P2113B – –
P2114A 40.4 < LOQ
P2114B – –
* Concentrations are given in μg/L.
Figure 3. Typical MRM chromatograms obtained following the analysis of an authentic urine sample with
a concentration of 103 μg/L for amphetamine. The figure shows the response for the two transitions (quan-
tifier and qualifier). Peak intensity is shown in the top right-hand corner of each trace.
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namic range, and high sensitivity. Due to its mass selectivity,
it was expected that method development time and sample
turnover time would be reduced significantly. However, ion-
suppresion requires that the majority of biological matrix con-
stituents are removed prior to LC–MS–MS analysis making
sample preparation a time consuming element in the devel-
opment of LC–MS–MS bioassays. During the process of method
development the demands on sensitivity, precision and accu-
racy become more stringent, which resulted in increasing
assay development time (ranging from day 1 for ‘quick and
dirty’ work up to several weeks for a fully validated assay ap-
plicable for pre-clinical study samples). Especially, for clinical
studies, high demands on specificity, accuracy, and precision
must be complied. Apart from full automation, state-of-the-art
online SPE provides high precision and sensitivity and a higher
sample throughput as compared to liquid liquid extraction
(LLE) or off-line SPE (21).
In this article, a fully validated and highly sensitive LC–MS–
MS method is described for the simultaneous analysis of the
main amphetamines in blood and urine. The method com-
bined online SPE with LC–MS–MS and provided a thorough
clean-up of the matrix in combination with high recovery, ex-
cellent precision, and accuracy in the linear range investi-
gated using just 100 μL and 50 μL of blood and urine samples.
The method was successfully applied to authentic samples
from drug users and sensitive enough to detect a single use of
MDMA in healthy volunteers. This method is certainly of
interest on the field of forensic toxicology.
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Conclusions 
This thesis intended to demonstrate the usefulness of present day LC-MS/MS 
applications used in forensic routine laboratories, and instrument improvement, 
supporting the successful spreading of LC-MS/MS. 
6.1. Analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid 
and metabolites: 
-A validated method for the simultaneous analysis of multiple 
hallucinogens, chlorpheniramine, ketamine, ritalinic acid and several 
metabolites with LC-MS/MS was developed and validated.  
-Sample preparation consisted of a SPE using mixed mode cation 
exchange cartridges because most of the selected hallucinogens have a 
pKa higher than 7. After evaporation of the elution SPE solvent, samples 
were reconstituted in mobile phase for their analysis by LC-MS/MS. The 
method required 500 µL of urine achieving a LOQ for LSD and 2-Oxo-3-
Hydroxy-LSD of 0.05 and 1 ng/mL, respectively and ranged, for the other 
hallucinogens, from 0.5 to 10 ng/mL. Linear and quadratic regression was 
observed from the LOQ of each compound to 12.5 ng/mL for LSD, 50 
ng/mL for 2-oxo-3-OH-LSD, and 500 ng/mL for the others. The precision 
and bias were < 20% for most of the compounds, except for bufotenine 
and cathinone (%bias <24%), and ibogaine (%bias <30%)). External QCs 
containing LSD were analysed within each batch. Excellent recoveries for 
all the analytes were obtained (>87%). No instability was observed when 
the processed samples were kept in the autosampler for at least 24h. 
-The method was applied to the analysis of urine samples from two young 
men who declare to have ingested magic mushrooms. Urine samples 
were collected after 1, 4, 8 and 24 h. Maximum concentrations of psilocin 
were found at 4 hours after ingestion, and it was still present after 24 
hours. Authentic samples containing ketamine and chlorpheniramine were 
also analysed with the present method. 
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6.2. Analysis of cannabis in blood: 
-An LC-MS/MS method was developed for the analysis of THC, and its 
main metabolites, 11-OH-THC and THC-COOH, in 250 µL of blood. 
Sample clean-up consisted of a LLE with hexane: ethyl acetate (90:10, 
v/v). No significant matrix effect was observed and excellent recoveries 
were obtained. The linearity range was 0.5-40 µg/L for THC, 1-40 µg/L for 
11-OH-THC, and 2-160 µg/L for THC-COOH, and excellent intra-assay 
and inter-assay precision; RSDs were < 12% for THC and 11-OH-THC 
and < 8% for THC-COOH for certified QC samples were obtained. The 
compounds demonstrated to be stable in the processed samples and after 
three freeze/thaw cycles.  
-Finally, 63 authentic blood samples from cannabis users were analyzed 
which demonstrated the usefulness of the method. The median and 
minimum maximum range (in ng/mL), respectively, were as follows: THC 
(7.45, [1.3-34.1]), 11-OH-THC (2.7, [1.0-13.4]) and THC-COOH (44.8, 
[7.9-224.3]). 
6.3. Analysis of cannabis in urine: 
-On-line SPE-LC-MS/MS was applied to the analysis of THC-COOH in 
urine (500 µL). Samples were hydrolyzed at strongly basic conditions 
(KOH) and then acidified before injection. C8 cartridges demonstrated to 
be highly effective to reduce matrix interferences and give a high recovery. 
The total run time was 6 min working at isocratic conditions. The method 
showed an excellent intra- and inter-assay precision (RSD <7% and bias 
<13%) for four external QC samples and three in house’ QCs. The 
dynamic range was from 5 to 200 µg/L (r2>0.99). LOQ and LOD were 
determined to be 5 µg/L and 0.25 µg/L, respectively. Furthermore, the 
analyte and the processed samples did not present instability and no 
carryover was observed after the analysis of high concentrated urine 
samples.  
-Then, the method was consequently applied to 34 authentic samples 
analysed in one batch. The median was 652 ug/L with a minimum-
maximum range of [12.1-3681] 
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6.4. Amphetamines in blood and urine: 
-An on-line SPE-LC-MS/MS method was developed for the analysis of 
amphetamine, methamphetamine, MDMA, MDA, MDEA, PMA and 
ephedrine in blood and urine. The method was fully validated, following 
international guidelines, using only 100 µL and 50 µL of blood and urine, 
respectively. Very good intra- and inter-assay precision were obtained for 
all the compounds (RSD <11.2% and bias <13%) for two external QC for 
both matrices, and three and two ‘in house’ QCs for blood and urine, 
respectively. Linearity was demonstrated in the range of 2.5 ng/mL to 400 
µg/L for blood and from 25 to 1000 µg/L for urine. LOQ was 2.5 µg/L and 
25 µg/L for blood and urine, respectively. The analytes as well as the 
processed samples were stable (in the autosampler at least during 72 h 
and after three freeze/thaw cycles) and no matrix effects and carryover 
were observed. 
-Finally, the method was applied to 28 volunteers who ingested consumed 
either a placebo or a dose of MDMA. The median and minimum-maximum 
range (in ng/mL) for MDMA were 48.3, [19.7-77.0], respectively. The 
method was also applied to authentic blood and urine from forensic cases.  
General conclusion 
Toxicology in all its application areas is heavily dependent on analytical methods. In 
the wake of analytical developments in other scientific fields, we have witnessed the 
introduction of a variety of new instrumental analytical approaches, especially in the 
field of forensic toxicology. The essence of the discipline entails that one is 
continuously confronted with new and unexpected cases in which very often one is 
asked to find the well-known needle in a haystack, actually often without knowing 
that the needle looks like! In scientific terms, toxicologist most of the time has very 
little foreknowledge and is forced by these circumstances to make use of all his 
intellectual creativity and analytical skills. As a result, new trends are continuously 
appearing in the analytical tool chest of the toxicologist. Some of these are short 
lived, but others grow to become new standard tools. 
LC-MS/MS offers high specificity, good precision and accuracy, a wide dynamic 
range and high sensitivity. Due to its mass selectivity, it was expected that method 
development time and sample turnover time would be reduced significantly. 
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However, ion-suppression requires that the majority of biological matrix constituents 
are removed prior to LC-MS/MS analysis making sample preparation a time 
consuming element in the development of LC-MS/MS bioassays. During the process 
of method development the demands on sensitivity, precision and accuracy become 
more stringent, resulting in increasing assay development time (ranging from 1 day 
for ‘quick and dirty’ work up to several weeks for a fully validated assay applicable 
for (pre)-clinical study samples). Especially, for forensic studies, high demands on 
specificity, accuracy and precision must be complied. Apart from full automation, on-
line SPE provides high precision and sensitivity and a higher sample throughput as 
compared to LLE or off-line SPE.  
The LC-MS/MS methods (using off-line and on-line sample clean up) were applied to 
authentic blood and urine samples obtained from forensic cases which covered a 
broad range of concentrations. A reduction of sample volume was obtained compare 
to current GC-MS analysis used in the laboratory, and currently, these methods are 
working for routine forensic cases in the NICC for a number of years. They have 
demonstrated to be robust, accurate, while using external QCs within each batch.  
In this thesis on-line SPE-LC-MS/MS has been evaluated in terms of practical gain 
in speed and efficiency that can be achieved compared to current LC-MS/MS 
systems. 
The combination of the high throughput on-line SPE with the well-known sensitivity 
and selectivity assured by MS/MS resulted in the elimination of the bottleneck 
associated with the sample preparation requirements and provided increased 
sensitivity, accuracy and precision. Table 8 summarizes the approximate time 
employed in each step for the applications presented in this work (considering a 
batch of 15 samples). 
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blood 3 15 - 30 20 5 13 
Cannabis in urine 1 15 15 - - - 6 
Amphetamines in 






urine 7 15 - - - - 20 
*Shaded area corresponds to the sample preparation time. 
As it can be observed from this table, the use of on-line SPE-LC-MS/MS technique 
has made possible the development of faster methods by reducing the sample 
preparation time and increasing the sample throughput. Conditioning, washing and 
elution steps can be performed automatically and to extract one sample while 
another is being analyzed by LC-MS/MS. Other important advantages of the on-line 
coupling are decreased risk of contamination of the sample, elimination of analyte 
losses by evaporation or by degradation during sample preconcentration, and 
improved precision and accuracy. Higher sensitivity is also achieved due to the 
transfer and analysis of the totality of the extracted species to the analytical system, 
in contrast to off-line clean-up procedures where only an aliquot of the extract is 
injected into the column. In addition, the on-line SPE has low solvent consumption 
requirements thereby decreasing the costs of organic solvents waste disposal. 
Moreover, the on-line system avoids mistakes due to elimination of sample 
preparation steps. As everything is automated, a higher number of samples may be 
analysed in a raw, giving the possibility of including more QC samples within each 
batch, being of significant importance in terms of laboratory accreditation. 
However, there are several limitations when working with on-line SPE-LC-MS/MS. In 
our experience, when automating a SPE method one must keep in mind that a 
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manual procedure cannot be transferred without minor modifications. Pressures, 
flow-rates, and injection solvent composition which must be suitable to the type of 
SPE (stability!), must be optimized again. Thus, the compounds of interest when 
developing a method must present similar physic-chemical properties (less flexibility 
than the off-line SPE procedures). Carryover is also an important parameter to 
evaluate when working with the Symbiosis system. Although disposable cartridges 
are used within each injection, precipitation and/or adsorption of the analytes to the 
tubing may occur. Carryover is a matter of proper combination of hardware and 
chemistry. In addition, the compatibility of the SPE elution solvent with the pH range 
of the analytical column is another consideration to take into account (e.g. when 
working with cation exchange cartridges the elution solvent is at highly organic pH, 
while common analytical columns usually can work up to a pH of 8). Strong changes 
in pH should be avoided. 
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Conclusions 
Cette thèse a eu pour objet de démontrer l’utilité des applications actuelles avec LC-
MS/MS employées dans les laboratoires médico-légaux et du développent 
instrumental, grâce au grand développement de la technique LC-MS/MS. 
 6.1. Analyse de multiples hallucinogènes, chloropheniramine, ketamine, acide 
 ritalinique et plusieurs métabolites 
- Une méthode utilisant le LC-MS/MS a été développée et validé pour 
l’analyse simultanée de multiples hallucinogènes, chloropheniramine, 
ketamine, acide ritalinique et plusieurs métabolites dans l’urine. 
-La préparation de l’échantillon a été réalisée par SPE avec des 
cartouches d’échange cationique étant donné que la plupart des 
hallucinogènes sélectionnés avaient un pKa supérieur à 7. Après 
l’évaporation du solvant SPE, les échantillons ont été reconstitués dans la 
phase mobile et analysés avec LC-MS/MS. La méthode a demandé 500 
µL d’urine et a permis d’obtenir un LOQ de 0.05 ng/mL pour LSD, 1 ng/mL 
pour le 2-oxo-3-OH-LSD et de 0.5 ng/mL à 10 ng/mL pour les autres 
hallucinogènes. Il a été observé une régression linéaire et quadratique du 
LOQ pour chaque composé à 12.5 ng/mL pour LSD, 50 ng/mL pour le 2-
oxo-3-OH-LSD et à 500 ng/mL pour les autres. La précision et le bias 
étaient <20% pour la plupart des hallucinogènes, sauf pour la bufotenine 
et la cathinone (bias(%)<24) et l’ibogaine (bias(%)<30). Les QCs externes 
qui contenaient le LSD ont été étudiés avec chaque série d’analyse. Nous 
avons obtenu d’excellentes récupérations (>87%) et il n’y a pas eu de 
problématique d’instabilité des échantillons extraits qui ont été conservés 
dans l’injecteur automatique pendant 24 h. 
-La méthode a été appliquée à l’analyse des échantillons d’urine de deux 
jeunes qui avaient déclaré avoir pris des champignons hallucinogènes. 
Les échantillons d’urine ont été prélevés à 1, 4, 8 et 24 h. Les 
concentrations de psilocine plus élevées ont été retrouvées après 4 h et 
elle était présente dans l’urine pendant au moins 24 h. Nous avons 
également analysé des échantillons d’urine réels qui contaient la ketamine 
et la chlorpheniramine avec cette méthode. 
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 6.2. Analyse de cannabis dans le sang 
- Une méthode LC-MS/MS a été développée pour l’analyse du THC et de 
ses principaux métabolites, 11-OH-THC et THC-COOH, dans 250 µL de 
sang. Le nettoyage de l’échantillon a été réalisé avec une LLE avec 
hexane : éthyle acétate (90 :10,v/v). Il n’y a pas été constaté d’effet 
matrice et on a obtenu d’excellentes récupérations. L’intervalle de linéarité 
a été de 0.5-40 µg/L pour le THC, 1-40 µg/L pour le 11-OH-THC et de 2-
160 µg/L pour le THC-COOH, avec une excellente précision intra et inter-
jour, avec un RSD (%) <12 pour le LSD et le 11-OH-THC et <8% pour le 
THC-COOH pour les QCs externes certifiés. Les composés étaient 
stables dans les échantillons extraits et après 3 cycles de 
congélation/décongélation. 
-Finalement, l’utilité de la méthode a été démontrée avec l’analyse de 63 
échantillons réels de sang de consommateurs de cannabis. 
 6.3. Analyse de cannabis dans l’urine 
-La technique SPE-LC-MS/MS on -line a été appliquée à l’analyse de 
THC-COOH dans l’urine (500 µL). Les échantillons ont été hydrolysés 
dans des conditions fortement basiques (KOH) et puis acidifiés avant leur 
injection. Les cartouches C8 ont prouvé leur efficacité pour réduire les 
interférences de la matrice et ils ont démontré une grande récupération. 
Le temps de l’analyse total était de 6 min sous conditions isocratiques. La 
méthode a démontrée une excellente précision intra et inter-jour 
(RSD(%)<7 et bias(%)<13) des 4 QCs externes et des 3 QCs internes. 
L’intervalle dynamique a été de 5 à 200 µg/L (r2>0.99). Le LOQ et LOD 
ont été fixés à 5 µg/L et 0.25 µg/L, respectivement. En plus, les composés 
et les échantillons extraits n’ont pas présenté instabilité et on n’a pas 
trouvé de problèmes de contamination après l’analyse des urines 
fortement concentrées.  
-Par la suite, la méthode a été appliquée à l’analyse de 34 échantillons 
authentiques dans une seule série. La médiane a été de 652 µg/L avec un 
intervalle minimum-maximum de [12.1-3681].  
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 6.4. Analyse d’amphétamines dans le sang et l’urine 
-Une méthode SPE-LC-MS/MS on-line a été développée pour l’analyse 
d’amphétamine, methamphétamine, MDMA, MDA, MDEA et éphédrine 
dans le sang et l’urine. La méthode a été complètement validée selon les 
normes internationales, en utilisant respectivement seulement 100 et 50 
µL de sang et urine. On a obtenu des précisions intra et inter-jour très 
bonnes (RSD(%)<11.2 et bias(%)<13) pour les 2 QCs externes des deux 
matrices et pour les 3 QCs internes du sang et deux de l’urine. Le LOQ a 
été respectivement de 2.5 µg/L et 25 µg/L pour le sang et l’urine. La 
linéarité a été dans un intervalle de 2.5 à 400 µg/L pour le sang et de 25 à 
1000 µg/L pour l’urine. Les composés et les extraits ont été stables (dans 
l’injecteur automatique pendant 72 h et après trois cycles de 
congélation/décongélation). On n’a pas constaté d’effet matrice, non plus.  
-Finalement, la méthode a été appliquée à des échantillons de sang de 28 
volontaires qui avaient consommé tant placebo comme une dose de 
MDMA. La médiane et l’intervalle minimum-maximum (en µg/L) pour le 
MDMA étaient respectivement de 48.3, [19.7-77.0],. La méthode a 
également été appliquée à l’analyse de sang et urine provenant des cas 
médico-légaux réels.  
Conclusion générale 
La toxicologie dans tous ses domaines d’application est largement dépendente des 
méthodes analytiques. Dans la nouvelle vague des développements analytiques, 
nous avons été témoins de l’introduction d’une variété de nouveaux avancements 
instrumentaux, particulièrement dans le domaine de la toxicologie médico-légale. 
L’essence de la discipline implique que l’on soit constamment confronté à de 
nouveaux cas inattendus pour lesquels il s’agit souvent de chercher une aiguille 
dans une botte de foin sans même savoir à quoi l’aiguille ressemble ! En termes 
scientifiques, le toxicologue n’a fréquemment aucune idée d’où chercher et se 
trouve dans des circonstances dans lesquelles il faut employer sa créativité et son 
expérience analytique. Le résultat est que de nouvelles tendances apparaissent 
comme les outils analytiques pour le toxicologue. Quelques unes ne restent pas 
beaucoup de temps dans le marché, d’autres devient les nouvelles techniques de 
référence. 
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Le LC-MS/MS offre une grande spécificité, une bonne précision et exactitude, un 
large intervalle dynamique et une haute sensibilité. Grâce à sa sélectivité de 
masses, on s’attend que le temps de développement d’une méthode et le flux 
d’analyse d’échantillons soit significativement réduit. Pourtant, l’effet matrice, exige 
que la plupart des constituants de la matrice biologique soient éliminés avant 
l’analyse avec le LC-MS/MS, faisant que la préparation de l’échantillon semble une 
perte de temps dans le développement d’un essai. Pendant le développement d’une 
méthode, la demande de sensibilité, précision et exactitude deviennent de plus en 
plus élevées, résultant en une augmentation du temps de développent de l’essai 
(passant d’un jour de façon rapide à plusieurs semaines pour valider complètement 
une méthode pour l’analyse des échantillons cliniques). C’est en particulier le cas 
des études médico-légales qui doivent répondre à des critères élevés de spécificité, 
exactitude et précision.  
Dans cette thèse, les méthodes LC-MS/MS (qui utilisent le nettoyage de l’échantillon 
‘off-line et ‘on-line’) ont été appliqués à des échantillons réels de sang et urine 
provenant des cas médico-légaux qui couvraient un intervalle large de 
concentrations. On a obtenu une réduction du volume de l’échantillon par rapport 
aux analyses GC-MS actuellement utilisées dans le laboratoire De plus, ces 
méthodes LC-MS/MS sont déjà utilisés depuis plusieurs années dans le laboratoire. 
Elles se sont montrées robustes et exactes quand on utilise des QCs externes dans 
chaque série d’analyses.  
Le SPE-LC-MS/MS on-line a été évalué du point de vue pratique, rapidité et 
efficacité par rapport aux systèmes LC-MS/MS classiques actuels. 
La combinaison de la productivité du SPE on-line avec la sensibilité et sélectivité 
renommées assurées par le MS/MS a résulté en l’élimination du goulet 
d’étranglement associé aux exigences de la préparation de l’échantillon et il a fourni 
une haute sensibilité, exactitude et précision. Le Tableau 8 résume le temps 
approximatif employé à chaque étape pour les applications présentées dans cette 
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le sang 3 15 - 30 20 5 13 
Cannabis dans 
l’urine 1 15 15 - - - 6 
Amphètamines 






dans l’urine 7 15 - - - - 20 
*La surface grisée correspond au temps employé pour la préparation de l’échantillon 
Comme on peut constater dans ce tableau, l’utilisation de la technique SPE-LC-
MS/MS on-line a permis le développement de méthodes plus rapides en réduisant le 
temps de la préparation de l’échantillon et en augmentant la productivité. Le 
conditionnement, le lavage et l’élution ont été réalisés automatiquement et pendant 
qu’un échantillon était en train de d’être extrait, un autre était en train d’être analysé 
avec le LC-MS/MS. D’autres avantages importants de la SPE on-line sont le 
moindre risque de contamination de l’échantillon, l’élimination de la perte de 
composés du à l’évaporation ou la dégradation pendant la préparation de 
l’échantillon et l’augmentation de la précision et de l’exactitude. Ainsi, on a obtenu 
une plus grande sensibilité grâce au fait que la totalité de l’échantillon extrait est 
analysé par le système analytique, contrairement aux procédures off-line où 
seulement une aliquote de l’extrait est injecté dans la colonne. De plus, le système 
SPE on-line engendre une faible consommation de solvant et permet de diminuer 
les coûts de solvants.  
Par ailleurs, le système on-line évite les erreurs de manipulation grâce à l’élimination 
de la préparation de l’échantillon. Comme tout est automatisé, on peut analyser 
successivement un grand nombre d’échantillons en donnant la possibilité d’inclure 
plus de QCs entre chaque série, ce qui est crucial pour les laboratoires accrédités.  
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Néanmoins, il y existe des limitations lorsque l’on travaille avec le système SPE-LC-
MS/MS on-line. D’après notre expérience, quand on automatise une méthode SPE 
on doit garder à l’esprit qu’une méthode off-line ne peut pas être transférée sur le 
système on-line sans faire l’objet de quelques modifications. La pression et la 
composition du solvant d’injection doivent être optimalisés selon le type de SPE 
(attention à la stabilité !) . De plus, les composés doivent avoir des propriétés 
physico-chimiques similaires quand on développe une méthode on-line (moins de 
flexibilité qu’avec les procédures off-line). La contamination est aussi un paramètre à 
prendre en compte quand on travaille avec le système Symbiosis. Même si on utilise 
des cartouches jetables à chaque injection, des précipitations et/ou adsorptions du 
composé peuvent se produire dans les tuyaux et valves de l’appareil. La 
contamination est une question de bonne combinaison du hardware et de la chimie. 
De plus, la compatibilité du solvant d’élution du SPE avec l’intervalle de pH de la 
colonne est un autre paramètre à prendre en compte (par ex. si on travaille avec des 
cartouches d’échange cationique, on doit utiliser des solvants organiques à haut pH 
quand les colonnes génériques qui ne peuvent que travailler jusqu’un pH de 8). Il 
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Conclusiones  
Esta tesis ha pretendido demostrar la utilidad de las aplicaciones actuales con LC-
MS/MS empleadas en los laboratorios forenses y el desarrollo instrumental, gracias 
a la gran evolución de la técnica LC-MS/MS. 
 6.1. Análisis de múltiples alucinógenos, clorofeniramina, ketamina, ácido  
 ritalínico y varios metabolitos: 
- Se ha desarrollado y validado un método con LC-MS/MS para el análisis 
simultáneo de múltiples alucinógenos, clorofeniramina, ketamina, ácido 
ritalínico y varios metabolitos en orina. 
-La preparación de la muestra consistió en una SPE utilizando cartuchos 
de intercambio catiónico debido ya que la mayoría de los alucinógenos 
seleccionados tenían un pKa mayor de 7. Tras la evaporación del 
disolvente SPE, las muestras fueron reconstituidas en la fase móvil para 
su análisis con LC-MS/MS. El método ha requerido 500 µL de orina 
logrando un LOQ de 0.05 ng/mL para el LSD, 1 ng/mL para el 2-oxo-OH-
LSD y de 0.5 ng/mL a 10 ng/mL para el resto de los alucinógenos. Se 
observó una regresión lineal y cuadrática del LOQ de cada compuesto 
hasta 12.5 ng/mL para el LSD, 50 ng/mL para el 2-oxo-3-OH-LSD y 500 
ng/mL para los otros. La precisión y el bias fueron <20% para la mayoría 
de los alucinógenos, excepto para bufotenina y la catinona (bias(%)<24) e 
ibogaína (bias(%)<30). Con cada grupo de análisis se analizaron  QCs 
externos que contenían LSD. Se obtuvieron excelentes recuperaciones 
(>87%) y no hubo inestabilidad de las muestras procesadas que se 
mantuvieron en el autocargador de muestras durante 24 h. 
-El método fue aplicado al análisis de muestras de orina de dos jóvenes 
que habían declarado haber consumido setas alucinógenas. Las 
muestras de orina fueron recogidas tras 1, 4, 8 y 24h. Las 
concentraciones más altas de psilocina se obtuvieron a las 4 h tras la 
ingestión y estuvo presente en la orina al menos hasta durante 24 h. Con 
este método también se analizaron muestras de orina auténticas que 
contenían ketamina y clorofeniramina.  
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 6.2. Análisis de canabis en sangre 
-Se ha desarrollado un método LC-MS/MS para el analisis de THC y de 
sus principales metabolitos, 11-OH-THC y THC-COOH, en 250 µL de 
sangre. La limpieza consistió en una LLE con hexano:acetato de etilo 
(90:10,v/v). No se observó efecto matriz y se obtuvieron excelentes 
recuperaciones. El rango de linealidad fue de 0.5-40 µg/L para el THC, 1-
40 µg/L para el 11-OH-THC y de 2-160 µg/L para el THC-COOH, con 
excelente precisión intra e inter-día, obteniendo un RSD (%) <12 para el 
LSD y el 11-OH-THC, y <8% para el THC-COOH para los QCs externos 
certificados. Los compuestos fueron estables en las muestras procesadas 
y tras 3 ciclos de congelado/descongelado. 
-Finalmente, la utilidad del método fue demostrada con el análisis de 63 
muestras de sangre auténticas de consumidores de canabis.  
 6.3. Análisis de canabis en orina 
-La técnica SPE-LC-MS/MS fue aplicada al análisis de THC-COOH en 
orina (500 µL). Las muestras fueron hidrolizadas en condiciones 
fuertemente básicas (KOH) y acidificadas antes de su inyección. Los 
cartuchos C8 demostraron ser muy eficaces para reducir las 
interferencias de la matriz y dieron una gran recuperación. El tiempo de 
análisis total fue de 6 min trabajando en condiciones isocráticas. El 
método mostró una excelente precisión intra e inter-día (RSD(%)<7 y 
bias(%)<13) en los 4 QC externos y los 3 QC internos. El rango dinámico 
fue de 5 a 200 ng/mL (r2>0.99). El LOQ y LOD fueron determinados a 5 
µg/L y 0.25 µg/L, respectivamente. Además, el analito y las muestras 
procesadas no presentaron inestabilidad y no se observó contaminación 
(prueba de arrastre) tras el análisis de orinas altamente concentradas.  
-Posteriormente, el método fue aplicado al análisis de 34 muestras 
auténticas en una serie de análisis. La mediana fue 652 µg/L con un 
rango mínimo-máximo de [12.1-3681]. 
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 6.4. Análisis de anfetaminas en sangre y orina 
-Se ha desarrollado un método on-line SPE-LC-MS/MS para el análisis de 
anfetamina, metanfetamina, MDMA, MDA, MDEA, PMA y efedrina en 
sangre y orina. El método ha sido completamente validado según las 
normas internacionales, empleando solo 100 µL y 50 µL de sangre y 
orina, respectivamente. Se obtuvieron precisiones intra e inter-día muy 
buenas (RSD(%)<11.2 y bias(%) <13) para los 2 QCs externos para 
ambas matrices y para los 3 y 2 QCs internos para sangre y orina, 
respectivamente. La linealidad fue en el rango de 2.5 a 400 µg/L para la 
sangre y de 25 a 1000 µg/L para la orina. El LOQ fue de 2.5 µg/L y 25 
µg/L para la sangre y orina, respectivamente. Los analitos así como las 
muestras procesadas fueron estables (en el autocargador de muestras 
durante 72 h y tras tres ciclos de congelado/descongelado). Tampoco se 
observó efecto matriz. 
-Finalmente, el método fue aplicado a 28 voluntarios que habían 
consumido tanto placebo como una dosis de MDMA. La mediana y el 
rango mínimo-máximo (en µg/L) para el MDMA fueron 48.3, [19.7-77.0], 
respectivamente. El método también fue aplicado al análisis de sangre y 
orina autentica procedente de casos forenses. 
Conclusión general 
La toxicología en todas sus áreas de aplicación depende fuertemente de los 
métodos analíticos. En la ola de las nuevas tecnologías analíticas hemos sido 
testigos de la introducción de una variedad de nuevos avances instrumentales, 
especialmente en el campo de la toxicología forense. La esencia de la disciplina 
suscita que uno se enfrente continuamente a casos nuevos e inesperados en los 
cuales a menudo a uno se le pregunta buscar una aguja en un pajar, ¡incluso aun 
sin saber a que se parece esa aguja!. En términos científicos, el toxicólogo a 
menudo no tiene mucha idea de donde buscar y se encuentra en circunstancias en 
las que tiene que emplear la creatividad y sus habilidades analíticas. Como 
resultado, están apareciendo nuevas tendencias como herramientas analíticas para 
el toxicólogo. Algunas de ellas duran poco tiempo en el mercado, otras, se 
convierten en las nuevas técnicas de referencia.  
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LC-MS/MS ofrece gran especificad, buena precisión y exactitud, un amplio rango 
dinámico y alta sensibilidad. Debido a su selectividad de masas, se espera que el 
tiempo de desarrollo de un método y el flujo de análisis de muestra se reduzca 
significativamente. Sin embargo, la supresión iónica requiere que la mayoría de los 
constituyentes de la matriz biológica sean eliminados antes del análisis con el LC-
MS/MS haciendo que la preparación de la muestra parezca más bien una perdida 
de tiempo en el desarrollo de un experimento. Durante el proceso del desarrollo de 
un método la demanda de sensibilidad, precisión y exactitud se vuelven cada vez 
más estrictos, resultando en un aumento del tiempo del desarrollo del método 
(desde un día ‘de forma rápida y mal’ hasta varias semanas para validar 
completamente un método para el análisis de muestras clínicas). Sobretodo en el 
caso de los casos forenses se debe cumplir con la gran demanda de especificidad, 
exactitud y precisión. 
En esta tesis, los métodos LC-MS/MS (empleando limpieza de la muestra ‘off-line’ y 
‘on-line’) han sido aplicados a muestras auténticas de sangre y orina obtenidas de 
casos forenses que cubrieron un amplio rango de concentraciones. Se ha obtenido 
una reducción del volumen de muestra, comparado con los análisis con GC-MS 
actuales que se emplean en nuestro laboratorio y además estos métodos LC-
MS/MS se están utilizando actualmente en el trabajo de rutina de los casos forenses 
que llegan al INCC ya durante varios años. Han demostrado ser robustos y exactos 
al utilizar QCs externos encada serie de análisis.  
El on-line SPE-LC-MS/MS ha sido evaluado desde el punto de vista práctico, 
rapidez y eficacia que se pueden logran comparado con los sistemas LC-MS/MS 
actuales. 
La combinación de la productividad del SPE on-line con la conocida sensibilidad y 
selectividad asegurada con el MS/MS ha resultado en la eliminación del obstáculo 
asociado a los requerimientos de la preparación de la muestra y ha proporcionado 
una alta sensibilidad, exactitud y precisión. La Tabla 8 resume el tiempo aproximado 
empleado en cada etapa para las aplicaciones presentadas en este trabajo 
(considerando una serie de 15 muestras). 
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en orina 7 15 - - - - 20 
*El área sombreada corresponde al tiempo empleado en la preparación de la 
muestra. 
Como se puede observar en esta tabla, el uso de la técnica SPE-LC-MS/MS on-line 
ha hecho posible el desarrollo de métodos más rápidos reduciendo el tiempo de la 
preparación de la muestra y aumentado la productividad. El condicionamiento, 
lavado y la elución han sido realizados automáticamente y de manera que mientras 
una muestra era extraída la otra era analizada por el LC-MS/MS. Otras ventajas 
importantes de la SPE on-line son el menor riesgo de contaminación de la muestra, 
eliminación de la perdida de analito debido a la evaporación o degradación durante 
la preparación de la muestra y el aumento de la precisión y la exactitud. También se 
logra una mayor sensibilidad gracias a que el total de la muestra extraída es 
analizada por el sistema analítico, al contrario de los procedimientos off-line donde 
solo una alícuota del extracto es inyectado en la columna. Además, el sistema SPE 
on-line tiene un bajo consumo de disolvente por lo tanto disminuye el gasto total del 
análisis.  
Al mismo tiempo, el sistema on-line evita errores de manipulación debido a la 
eliminación de la preparación de la preparación de la muestra. Como todo está 
automatizado, se pueden analizar seguidas un gran número de muestras, dando la 
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posibilidad de incluir más QCs en cada serie, siendo de gran importancia en los 
laboratorios acreditados. 
Sin embargo, existen varias limitaciones cuando se trabaja con el sistema SPE-
MS/MS on-line. Según nuestra experiencia, cuando se automatiza un método SPE 
uno debe mantener en mente que un procedimiento manual no se puede transferir 
sin hacer varias modificaciones. Se deben optimizar la presión y la composición del 
disolvente de inyección, debiendo ser adecuados según el tipo de SPE (!cuidado 
con la estabilidad!). Asimismo, los compuestos deben poseer propiedades físico-
químicas parecidas cuando se desarrolla un método (menos flexibilidad que en on 
procesos SPE off-line). La contaminación también es un parámetro a tener en 
cuenta cuando se trabaja con el sistema Symbiosis. Aunque se utilizan cartuchos 
desechables en cada inyección, pueden producirse precipitaciones y/o adsorciones 
del analito en los conductos y válvulas del instrumento. La contaminación es  
cuestión de una combinación adecuada de hardware y química. Además, la 
compatibilidad del disolvente de elución del SPE con el rango de pH de la columna 
es otro parámetro a tener en cuenta (por ejemplo, cuando se trabaja con cartuchos 
de intercambio catiónico se suelen utilizar disolventes orgánicos a pH muy básico 
cuando las columnas genéricas llegan solo hasta un pH 8). En la manera de lo 






























7.1. A new trend in Liquid Chromatography: Ultra Performance Liquid 
Chromatography (UPLC) 
Analysis of benzodiazepines in biological matrices by UPLC-MS/MS: 
As efficiency and speed of analysis has become of a 
great importance in many applications of liquid 
chromatography, especially in the field of toxicological 
analysis where it is important to increase throughput and 
reduce analysis costs, UPLC could play a significant role 
in the future of liquid chromatography. The recent 
commercialization of porous hybrid organic-inorganic silicon-based particles with a 
narrow size distribution in the range of 1.7 µm has enabled a new level of 
performance, but only through the use of newly developed technology that permits 
pumping and injection of liquids at pressures in excess of 10,000 psi. In addition, the 
use of porous, sub-2µm particles allowed a wide ‘sweet pot’ in the van Deemter 
curve for the increased flow rates without the loss of chromatographic resolution, 
and smaller particles increase the efficiency of separation because efficiency (N) is 
inversely proportional to particle size (dp). The linear velocity of the mobile phase 
(flow rate for a fixed column ID) at which the maximum efficiency occurs increases 
as dp reduces. Furthermore, with sub-2µm particles, the flow rate region at which 
the optimal efficiency is obtained is much wider. The overall result is higher 
efficiency at high flow rates, resulting in faster analytes and better sensitivity (1). 
Therefore, to keep up with the pace of data acquisition the mass spectrometer must 
acquire data quickly enough to match the chromatographic output. Mass 
spectrometers without enough scan speed could not keep up with this type of 
analytical strategy because they need a longer scan time to acquire high-resolution 
data, typically 1 sec to achieve a resolution of 60000 FWHM. As a result, few data 
points will be collected, which might result in the loss of information.  
For some analyses, however, speed is of secondary importance, and peak capacity 
and resolution are priority, for example for the analysis of methods including more 
than 30 compounds, including isomers, that must be separated.  
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The next step in the section of toxicology of the NICC will be to completely validate 
an UPLC-MS/MS method for the analysis of 30 benzodiazepines and related 
compounds in biological matrices. During the past years, a conventional LC-MS/MS 
method for the analysis of 30 benzodiazepines in blood, urine and hair was used. 
The method comprises a LLE with 1-butylchlororide. Two injections onto the LC-
MS/MS of 35 min were necessary due to the number of compounds. Recently, a 
new UPLC-MS/MS method is under development for the analysis of these 
compounds. The sample preparation has been modified in such a way that LLE is 
now carried out with n-butyl acetate. N-butyl acetate is a medium polarity solvent. 
The emulsion formation, which is generally considered to be the major shortcoming 
of LLE, was completely avoided. Furthermore, n-butyl acetate is also comparatively 
safe for health, especially compared to other alternatives, and has a strong and 
typical odor, which makes the presence of the solvent clearly recognizable and 
suitable for routine use. Only the relatively high boiling point of n-butyl acetate 
(126°C) is its minor shortcoming, but it is not a problem in the case of 
benzodiazepines and other hypnotics, which evaporate at significantly higher 
temperature. 
The first results show that the chromatographic method has been shortened to one 
single injection of just 13 min for the analysis of the 30 compounds (prazepam is the 
last compound to elute at 10 min). Next step will be the complete validation of the 
method and the application to forensic blood, urine and hair samples. 
7.2. Analysis of alternative matrices for driving under the influence of drugs (DUID): 
oral fluid 
Analysis of drugs in oral fluid by on-line SPE-LC-MS/MS:  
In Belgium, the law concerning DUID has changed very recently, 
i.e. blood and urine analysis will be replaced by oral fluid 
screening and analysis. Advantages of this matrix include the 
ease and non-invasiveness of specimen collection and reduced 
opportunity for specimen substitution and adulteration. Salivary 
glands have a high blood flow. It has been suggested that the concentrations of 
many drugs in oral fluid correlate well with their concentrations in blood, which 
suggests that the analysis of the former matrix may show value in the determination 
of the current degree of exposure to a particular drug at a time of sampling. Drug 
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concentrations in oral fluid reflect the free, unbound parent drug and lipophilic 
metabolites. Since these are the forms of the drug which cross the blood-brain 
barrier and affect performance and behavior, oral fluid is a good specimen for 
detecting drug involvement in driving behavior. However, the oral fluid sample 
volume is usually low (1 mL or less).  
The section of toxicology of the NICC has already some experience in the analysis 
of drugs of abuse in oral fluid using off-line sample preparation procedures with LC-
MS/MS (2-5). Our Institute has also participated in an external quality assessment 
scheme for drugs of abuse testing in oral fluid, ORALVEQ (6). During the 2007 and 
2008 round of this program, the off-line SPE method and the under development on-
line SPE procedure were carried out in parallel. Very comparable results were 
obtained assessing that on-SPE-LC-MS/MS is a good alternative tool for the 
analysis of drugs in oral fluid. Just a slight difference was observed for the results 
obtained for cocaine. One explanation could be that cocaine is a relatively instable 
compound (7). In terms of stability during the SPE procedure, one of the advantages 
of the on-line SPE is that the whole eluate is loaded directly onto the analytical 
column, thus there is a lesser risk of degradation of the compounds during the clean-
up procedure.  
Therefore, the next step will be the development and validation of an on-line SPE-
LC-MS/MS method for the analysis of drugs in oral fluid, including MDMA, MDA, 
amphetamine and methamphetamine, morphine, codeine, 6-MAM, cocaine, 
benzoylegonine and THC, requiring just  250 µL of sample. As in on-line SPE 
everything is automated, all these compounds will be extracted and analyzed in the 
same run, with the highest sensitivity and lowest sample preparation (just dilution of 
the oral fluid directly in the LC vials). 
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Perspectives futures 
7.1. La nouvelle tendance en Chromatographie Liquide : Ultra Chromatographie 
Liquide de Haute Performance  
Analyse de benzodiazépines dans les matrices biologiques avec UPLC-MS/MS 
Puisque l’efficacité et la vitesse d’analyse sont devenues 
cruciales pour diverses applications de la 
chromatographie liquide, surtout dans le domaine des 
analyses toxicologiques où il est important d’augmenter la 
productivité et réduire le coût d’analyse, l’UPLC pourrait 
jouer un rôle prédominant dans le futur de la 
chromatographie liquide. La commercialisation récente de particules poreuses 
composées d’un hybride organique – inorganique de silice avec une distribution de 
taille étroite dans l’intervalle de 1.7 µm a amélioré le rendement, mais uniquement 
avec l’utilisation de la nouvelle technologie UPLC qui permet de pomper et injecter 
des liquides à des hautes pressions qui dépassent les 10000 psi. Par ailleurs, 
l’usage de particules inférieures à 2 µm entraîne une d’amélioration de la courbe de 
Van Deemter avec l’augmentation de la vitesse de flux sans la perte de résolution 
chromatographique. Aussi, l’emploi de particules si petites augmente l’efficacité de 
la séparation grâce au fait de que l’efficacité (N) est inversement proportionnelle à la 
taille de particule (dp). La vitesse linéaire de la phase mobile (vitesse de flux pour 
une colonne avec un ID fixé) à laquelle nous avons la plus grande efficacité 
augmente à mesure que le dp diminue. De plus, avec des particules inférieures à 2 
µm, la région de flux à laquelle on obtient l’efficacité optimale est plus large. Le 
résultat général est une plus grande efficacité à des flux plus élevés et permet des 
analyses plus rapides avec la plus grande sensibilité (1). D’autre part, pour maintenir 
le flux d’acquisition des données, le spectromètre de masses doit acquérir les 
donnés suffisamment rapides en fonction de la productivité chromatographique. Les 
spectromètres de masses qui n’ont pas la vitesse de scan nécessaire, typiquement 
d’un sec pour obtenir une résolution de 60000 FWHM, ne pourront pas bénéficier de 
ce type de technique analytique, du fait qu’ils n’enregistreraient que quelques points 
de chaque chromatogramme, générant une grande perte d’information. 
Néanmoins, pour quelques analyses, la vitesse est d’importance secondaire, et la 
capacité de pic et résolution sont prioritaires, par exemple dans les méthodes 
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analytiques qui comprennent plus de 30 composés, avec des isomères, qui doivent 
être séparés.  
La prochaine étape dans la section de toxicologie de l’INCC consistera à développer 
et valider entièrement une méthode UPLC-MS/MS pour l’analyse de 30 
benzodiazépines et composés similaires dans les matrices biologiques. Au cours 
des dernières années, on a utilisé une méthode avec LC-MS/MS classique pour 
l’analyse des 30 benzodiazépines dans le sang, urine et cheveux. La méthode 
utilisait une LLE avec 1-chlorobutane. Du fait d’avoir tellement de composés, il était 
nécessaire d’injecter deux fois pendant une analyse de 35 min. Récemment, nous 
sommes en train de développer une méthode UPLC-MS/MS pour l’analyse de ces 
composés. La préparation de l’échantillon a été modifiée de sorte que la LLE est 
faite avec butyle acétate. Le butyle acétate est un solvant de polarité moyenne. On a 
éliminé la formation d’émulsion, qui est le plus grand inconvénient de la LLE. De 
plus, le butyle acétate est moins nocif pour la santé par rapport à d’autres 
alternatives et il a une odeur caractéristique qui permet de détecter sa présence, ce 
qui fait qu’il est plus conseillé pour le travail de routine. Le seul inconvénient est son 
haut point d’ébullition (126 °C), mais ce n’est pas un problème dans le cas des 
benzodiazépines et d’autres hypnotiques, puisqu’elles se’ évaporent à une 
température relativement élevée.  
Les premiers résultats montrent que la méthode chromatographique est plus rapide 
en effectuent une seule injection de 13 min pour l’analyse des 30 composés 
(prazepam est le dernier à sortir après 10 min). La prochaine étape sera la validation 
complète de la méthode et son application sur des échantillons médico-légaux dans 
le sang, urine et cheveux.  
7.2. Analyse des matrices alternatives dans les cas de conduite sous l’influence des 
drogues (DUID). 
Analyse des drogues dans le fluide oral avec SPE-LC-MS/MS on-
line 
En Belgique, la loi relative à la DUID a récemment changée de 
sorte que les analyses de sang et urine sont remplacées par le 
screening et l’analyse du fluide oral. Les avantages de cette 
matrice sont que le prélèvement de l’échantillon est simple, non invasif et la chance 
d’adultérer ou de remplacer l’échantillon est plus faible. Il est suggéré que la 
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concentration des différentes drogues dans le fluide oral est proportionnelle à la 
concentration dans le sang, c’est qui suggère que l’analyse de cette matrice 
permettrait une estimation du degré d’altération du comportement et l’effet de la 
drogue sur la personne au moment du prélèvement. Les concentrations de drogues 
dans le fluide oral représentent la drogue libre et les métabolites lipophiliques. Etant 
donné qu’il existe des formes de la drogue qui traversent la barrière du sang au 
cerveau et affectent le comportement de la personne, le fluide oral permet détecter 
l’effet de la drogue sur la conduite. Cependant, le volume de fluide oral est souvent 
bas (1 mL ou moins). 
La section de toxicologie de l’INCC avait déjà un peu d’expérience dans le domaine 
de l’analyse des drogues dans le fluide oral en utilisant des procédures de 
préparation des échantillons off-line (2-5). Notre Institut a participé au concours 
externe de contrôle de qualité pour l’analyse des drogues dans le fluide oral 
ORALVEQ (6). Au cours des années 2007 et 2008 du concours, la méthode off-line 
employée habituellement dans notre laboratoire et la méthode on-line en cours de 
développement ont été appliquées en parallèle. On a obtenu des résultats très 
comparables ce qui démontre que la méthode on-line SPE-LC-MS/MS est une 
excellente alternative pour l’analyse des drogues dans le fluide oral. Cependant, on 
a trouvé une légère différence entre les concentrations obtenues pour la cocaïne. 
Une explication possible est que  la cocaïne est relativement instable (7). En ce qui 
concerne la stabilité pendant la procédure du SPE, un des avantages de l’extraction 
on-line est que l’élution du SPE va directement à la colonne analytique. Il y a donc 
moins de risque de dégradation des composés pendant la préparation de 
l’échantillon. 
C’est pourquoi la prochaine étape sera le développement et validation d’une 
méthode SPE-LC-MS/MS on-line pour l’analyse de drogues dans le fluide oral, en 
incluant le MDMA, MDA, amphétamine, méthamphétamine, cocaïne, 
benzoylecgonine et THC, en utilisant seulement 250 µL de fluide oral. Puisque tout 
est automatisé dans le système SPE on-line , ces composés pourraient être extraits 
et analysés dans la même analyse, en obtenant la plus grande sensibilité avec la 
une moindre préparation de l’échantillon (seulement la dilution du fluide oral 
directement dans les fioles LC). 
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Perspectivas futuras 
7.1. La nueva tendencia en Cromatografía Líquida: Ultra Cromatografía Líquida de 
Alto Rendimiento (UPLC) 
Análisis de benzodiazepinas en matrices biológicas mediante UPLC-LC-MS/MS 
Como la eficacia y la rapidez de análisis se han vuelto de 
gran importancia en varias aplicaciones de la 
cromatografía líquida, sobretodo en el área de los análisis 
toxicológicos donde es importante aumentar la 
productividad y reducir el coste de análisis, UPLC podría 
jugar un rol substancial en el futuro de la cromatografía líquida. La reciente 
comercialización de partículas porosas hechas de un híbrido orgánico-inorgánico de 
sílice con una distribución de tamaño estrecha en el rango de 1.7 µm ha permitido 
un nuevo nivel de rendimiento, pero solo con el uso de la nueva tecnología UPLC 
que permite bombear e inyectar líquidos a presiones que sobrepasan los 10000 psi. 
Además, el uso de partículas de menos de 2 µm permite dar un toque de mejora a 
la curva de van Deemter con el aumento de la velocidad de flujo sin la pérdida de 
resolución cromatográfica. Igualmente, el uso de partículas tan pequeñas aumenta 
la eficacia de la separación ya que la eficacia (N) es inversamente proporcional al 
tamaño de partícula (dp). La velocidad lineal de la fase móvil (velocidad de flujo 
para una columna con un ID determinado) a la cual tenemos la mayor eficacia 
aumenta a medida que el dp reduce. Lo que es más, con partículas menores de 2 
µm, la región de flujo a la que se obtiene la eficacia óptima es más amplio. El 
resultado general es una mayor eficacia a flujos más elevados, resultando en 
análisis más rápidos con la mayor sensibilidad (1). Sin embargo, hay que tener en 
cuenta que para mantener el flujo de adquisición de datos el espectrómetro de 
masas debe adquirir los datos lo suficientemente rápido de acuerdo a la producción 
cromatográfica. Los espectrómetros de masas que no tengan la velocidad de 
escaneo necesaria, generalmente 1 sec para obtener una resolución de 60000 
FWHM, no podrán aprovechar este tipo de técnica analítica, ya que solo registrarían 
unos pocos puntos de cada cromatograma, resultando una pérdida importante de 
información. 
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Sin embargo, para algunos análisis, la velocidad es secundaria, y la capacidad de 
pico y resolución son prioridades, por ejemplo en los métodos de análisis que 
incluyen mas de 30 compuestos, incluyendo isómeros, que deben ser separados. 
La próxima etapa en la sección de toxicología del INCC será desarrollar y validar 
completamente un método UPLC-MS/MS para el análisis de 30 benzodiazepinas y 
compuestos relacionados en matrices biológicas. Durantes estos años, se ha 
utilizado un método con LC-MS/MS clásico para el análisis de las 30 
benzodiazepinas en sangre, orina y pelo. El método empleaba una LLE con 1-
cloruro de butilo. Debido al gran número de compuestos eran necesarias dos 
inyecciones de 35 minutos. Recientemente,  se esta desarrollando un método con el 
UPLC-MS/MS para el análisis de estos compuestos. La preparación de la muestra 
ha sido modificada de tal modo que la LLE se lleva a cabo ahora con acetato de 
butilo. El acetato de butilo es un disolvente de polaridad media. Se ha eliminado la 
formación de emulsión, que es el mayor inconveniente de las LLE. Además, el 
acetato de butilo es más seguro para la salud, comparado con otras alternativas, y 
tiene un olor característico que permite detectar su presencia y que lo hace 
adecuado para su uso en la rutina. El único inconveniente es su alto punto de 
ebullición (126°C), pero no es un problema en el caso de las benzodiazepinas y 
otros hipnóticos, ya que se evaporan a una temperatura relativamente alta. 
Los primeros resultados muestran que el método cromatográfico es más corto 
realizando una sola inyección de solo 13 min para el análisis de los 30 compuestos 
(prazepam es el ultimo compuesto en salir a los 10 min). El próximo paso será la 
validación completa del método y su aplicación a muestras forenses de sangre, 
orina y pelo. 
7.2. Análisis de matrices alternativas en casos de conducción bajo la influencia de 
las drogas (DUID) 
Análisis de drogas en fluido oral con on-line SPE-LC-MS/MS 
En Bélgica, la ley que trata el DUID ha cambiado recientemente, 
de modo que el análisis de sangre y orina serán remplazados 
por el screening (barrido) y análisis de fluido oral. Las ventajas 
de esta matriz es que la toma de la muestra es fácil, no invasiva 
y hay una menor posibilidad de adulterar o sustituir la muestra. 
Las glándulas salivales tienen un alto flujo de sangre. Se ha sugerido que la 
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concentración de varias drogas en el fluido oral se correlaciona bien con sus 
concentraciones en sangre, lo que indica que el análisis de esta matriz permitiría 
una estimación del grado de deterioro y efecto de la droga sobre en consumidor en 
el momento de la toma de la muestra. Las concentraciones de droga en fluido oral 
reflejan la droga madre libre y los metabolitos lipofílicos. Debido a que hay formas 
de la droga que cruzan la barrera de la sangre-cerero y que afectan al rendimiento y 
el comportamiento de la persona, el fluido oral es un espécimen para detectar el 
efecto de la droga cuando se conduce. Sin embargo, el volumen de fluido oral es 
normalmente bajo (1 mL o incluso menos). 
La sección de toxicología del INCC ya tenía algo de experiencia en el campo del 
análisis de drogas en fluido oral empleando procedimientos de preparación de la 
muestra off-line (2-5). Nuestro Instituto ha participado al concurso externo de control 
de calidad para el análisis de drogas en fluido oral, ORALVEQ (6). Durante la ronda 
del 2007 y 2008 de este programa, el método off-line empleado habitualmente en 
nuestro laboratorio y el método en desarrollo on-line fueron aplicados ambos a las 
muestras. Se obtuvieron resultados bastante comparables con ambos métodos 
demostrando que el SPE-LC-MS/MS on-line es una buena alternativa para el 
análisis de drogas de abuso en fluido oral. Solamente se encontró una ligera 
diferencia en las concentraciones obtenidas para la cocaína. Una explicación 
posible es que la cocaína es relativamente inestable (7). Respecto a la estabilidad 
durante el proceso SPE, una de las ventajas de la extracción on-line es que la 
elución del SPE va directamente a la columna analítica, por lo que hay menor riesgo 
de degradación de los compuestos durante la preparación de la muestra.  
Por lo tanto, la próxima etapa será el desarrollo y validación de un método on-line 
SPE-LC-MS/MS para el análisis de drogas de abuso en fluido oral, incluyendo 
MDMA, MDA, anfetamina, metanfetamina, cocaína, benzoyleconina y THC, 
empleando solo 250 µL de muestra. Como en el sistema SPE on-line todo está 
automatizado estos compuestos podrán ser extraídos y analizados en el mismo 
análisis, obteniendo la mayor sensibilidad con la mínima preparación de la muestra 
(solamente la dilución del fluido oral directamente el los viales LC).  
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Abstract Sedative agents are used to facilitate sexual
assault due to their ability to render the victim passive,
submissive and unable to resist. The primary pharmacolog-
ical effect of the benzodiazepine tetrazepam is muscle
relaxation, whereas the benzodiazepine diazepam acts on
the central nervous system (CNS) exerting mainly sedation
effects. Therefore, contrary to tetrazepam, diazepam is an
often-abused drug, which can potentially be used as a date-
rape drug. In this study, we describe the detection of low
amounts of diazepam in Myolastan® (Sanofi–Synthelabo
S.A., Brussels, Belgium) and Epsipam® (Will-Pharma,
Wavre, Belgium) 50mg tablet preparations by LC-MS-
MS, GC-FID and HPLC-DAD. Considering the important
forensic implication of this finding, a study was conducted
with volunteers receiving a single or repeated dosage of
Myolastan®. Urine, hair and preserved oral fluid samples
were analysed using a previously described sensitive and
specific LC-MS-MS detection method allowing for the
simultaneous quantification of tetrazepam, diazepam, nor-
diazepam, oxazepam and temazepam. This study demon-
strates that diazepam can be observed in urine samples even
after a single dose of Myolastan®. In addition, maintaining
therapy for 1 week results in the detection of both diazepam
and nordiazepam in urine samples and of diazepam in the
first hair segment. Importantly, comparing urine and hair
samples after a single intake of diazepam versus the single
and 1 week administration of Myolastan® shows that the
possible metabolic conversion of tetrazepam to diazepam is
a more plausible explanation for the detection of diazepam
in biological samples after the intake of Myolastan®. As
such, these results reveal that the presence of diazepam and/
or nordiazepam in biological samples from alleged drug-
facilitated assault cases should be interpreted with care.
Keywords LC-MS-MS . Tetrazepam . Diazepam . Urine .
Hair . Oral fluid
Introduction
In the past few years, an increase in the number of scientific
publications on so-called date-rape drugs, drug-facilitated
sexual assault (DFSA) and drug-facilitated crimes (DFC) has
been observed [1–8]. The most renowned drug associated
with sexual assault is Rohypnol® (flunitrazepam) [9].
However, many other drugs have been implicated in these
crimes, including other benzodiazepines, GHB (+-hydroxy-
butyric acid) and ketamine. These drugs are all characterized
by having depressant effects on their users, resulting in
confusion, drowsiness, impaired memory and reduced
inhibition. In addition, they induce amnesia, presumably the
principal reason for their selection as date-rape drugs. During
a 3-year surveillance in the UK, the toxicology results from
Anal Bioanal Chem
DOI 10.1007/s00216-007-1297-9
M. Laloup (*) :M. d. M. Ramirez Fernandez :G. De Boeck :
Y. Vanbeckevoort :N. Samyn
Federal Public Service Justice,






Waters Corporation, MS Technologies Centre,
Manchester M22 5PP, UK
V. Maes
Department of Clinical Chemistry-Toxicology,
Academic Hospital, Free University of Brussels,
1090 Brussels, Belgium
1,014 cases of claimed DFSA showed a relatively high
number of cases which contained benzodiazepines (9%), with
diazepam being the most prevalent benzodiazepine [10].
However, several difficulties in the diagnosis of DFC are
apparent. These crimes are often difficult to prove due to
factors such as the low concentrations of drugs used or their
rapid clearance from the body. In addition, many victims of
DFC do not report an incident until several days later, often
due to the amnesia caused by the drug. Hence, conventional
specimens from alleged victims such as blood or urine may
have limited value. Recently, hair samples have been
successfully used to document cases of DFC [4, 8, 11–
14]. Kintz and co-workers concluded that due to the
extremely low concentrations of drugs typically encoun-
tered in hair analysis (in the lower ranges of picograms per
milligram) the “sensitivity of LC-MS-MS appears to be a
pre-requisite to document any case involving drug-facili-
tated sexual assault” [4]. However, they also added the
caveat that hair analysis should not simply be considered as
an alternative to blood and urine testing but as a
complementary technique where possible.
Furthermore, the use of preserved oral fluid samples to
document DFC has recently been reported [15–17]. Indeed,
preserved oral fluid offers a series of advantages over
traditional specimens since it is non-invasive, with an easy
collection protocol and can be considered as an additional
source of information. It has been suggested that the
concentrations of many drugs in oral fluid correlate well
with their concentrations in blood, which suggests that the
analysis of the former matrix may show value in the
determination of the current degree of exposure to a
particular drug at the time of sampling [18].
Recently, we presented a validated and highly sensitive
LC-ESI-MS-MS method for the quantification of 26
commonly encountered benzodiazepines and their metabo-
lites, zolpidem and zopiclone in three different biological
matrices, i.e. blood, urine and hair [13]. During the routine
application of this method on a hair sample from a regular
Myolastan® user, diazepam and traces of nordiazepam were
also detected in several segments (concentrations ranging
from 1.0 to 8.2 pg mg−1 for diazepam). Myolastan® is a
pharmaceutical specialty available on the Belgian market
(Sanofi–Synthelabo, Brussels) which contains the benzodi-
azepine tetrazepam. Whereas tetrazepam is only used for its
muscle-relaxant properties, diazepam (and its metabolite
nordiazepam) also exerts strong hypnotic and sedative
activities. As such, diazepam also appears on the list of
alleged date-rape drugs [9]. In view of the possible erratic
conclusions regarding DFC in victims taking therapeutic
doses of Myolastan®, we evaluated the diazepam and
tetrazepam concentrations in urine, hair and preserved oral
fluid after the intake of a single or sustained therapeutic
dose of Myolastan® and compared these results with




Six healthy subjects (4 females and 2 males, aged
27–38 years, with a body weight varying between 64
and 93 kg) received either 50 mg tetrazepam in the form
of one tablet of Myolastan® (Sanofi–Synthelabo S.A.,
Brussels, Belgium) or 10 mg diazepam in the form of one
tablet of Valium® (Roche, Brussels, Belgium) along with
100 mL of water. In addition, one healthy female (aged
27 years, 64 kg) received a single dose of 25 mg
tetrazepam in the form of half a tablet of Myolastan®
each day, during a 1-week therapy. Subjects participated
in the experimental part of the study through written
informed consent. Urine was collected over 280 h in
plastic tubes, without any preservative, and frozen at
−20 °C until analysis (performed within 15 days).
Preserved oral fluid was collected at regular time intervals
during 600 min following administration, using the
Intercept® device (OraSure Technologies, Bethlehem,
PA) according to the manufacturer’s instructions. The
device collects an average of 0.38±0.19 mL of oral fluid
and a dilution factor of 1 in 3 is arbitrarily accepted [19].
All devices were weighed before and after collection. An
average weight of 0.86±0.14 g of oral fluid was collected.
The tubes were centrifuged and the preserved oral fluid
was stored at −20 °C prior to analysis (within 15 days).
Blank preserved oral fluid, used for the preparation of
negative controls, calibrators and quality control (QC)
samples, was obtained from healthy volunteers (also
collected with the Intercept®). The data are expressed as
nanograms per milliliter of diluted specimen.
A lock of hair the size of the diameter of a pencil (about
100 mg) was collected from the posterior vertex of the head
3 weeks after the last dose of Myolastan®/Valium®. Hair
was clipped as close to the scalp as possible and stored at
room temperature. Hair strands were aligned to keep root
ends together.
Chemicals
Individual ampoules of 7-aminoclonazepam, 7-amino-
flunitrazepam, bromazepam, clonazepam, flunitrazepam,
clobazam, desmethylflunitrazepam, estazolam, nitrazepam,
alprazolam, temazepam, desalkylflurazepam, oxazepam,
nordiazepam, triazolam, lormetazepam, lorazepam, praze-
pam, tetrazepam, diazepam and flurazepam (at a concentration




oxazepam-d5, nordiazepam-d5, triazolam-d4, loraze-
pam-d4, prazepam-d5 and diazepam-d5 (0.1 mg mL−1
in methanol) were purchased from LGC Promochem
(Molsheim, France). Brotizolam, clotiazepam, chlornor-
diazepam, loprazolam, cloxazolam, zolpidem and zopi-
clone were a gift from Dr. V. Maes (VUB, Brussels) (pure
standards obtained from respective manufacturers).
Methanol (Biosolve, Valkenswaard, The Netherlands),
water (Biosolve), dicholoromethane (Merck, Darmstadt,
Germany) and 1-chlorobutane (Merck) were HPLC grade.
Acetic acid (glacial) 100% anhydrous (Merck) and NaOH
(Fluka, Buchs, Germany) were used for the preparation of
the acetate buffer 3 M, pH 4.6. For the saturated
ammonium chloride buffer pH 9.2, ammonium chloride
from Fluka and ammonia solution 32% from Merck were
used. β-Glucuronidase, Type HP-2 from Helix pomatia
(111,480 units mL−1) was obtained from Sigma (Stein-
heim, Germany). For the mobile phase of the HPLC-DAD
method, phosphoric acid, 85% wt % solution in water
(Aldrich, Steinheim, Germany) and potassium dihydrogen
phosphate (Merck) were used.
Preparation of standard solutions
An internal standard (IS) working solution of the deuterated
analytes was prepared (0.4 μg mL−1 in methanol), which
was further diluted with methanol to yield appropriate
concentrations to add to samples, calibrators and QC
samples.
A benzodiazepine working solution of all analytes was
prepared (4 μg mL−1 in methanol) and further diluted with
methanol to yield working solutions at appropriate concen-
trations to add to calibrators and QC samples. Separate
stock solutions of tetrazepam, diazepam, nordiazepam,
oxazepam and temazepam were prepared (4 μg mL−1 in
methanol) and further diluted with methanol for the stability
and ion suppression experiments.
Working solutions were prepared monthly and stored at
4 °C.
Sample preparation and extraction for LC-MS-MS analysis
Sample preparation
Urine and hair samples were analysed by LC-MS-MS for 26
benzodiazepines and metabolites, zolpidem and zopiclone
according to a published validated procedure [13]. Briefly,
urine samples (250 μL) mixed with 50 μL of the IS stock
solution were buffered to pH 4.6 with 200 μL acetate buffer
(3 M) and then incubated for 1 h at 56 °C with 25 μL of
β-glucuronidase.
Hair samples were decontaminated, dried and cut in
segments of 1–3 cm each. Approximately 20 mg was
powdered in a ball mill which allowed simultaneous
pulverization of 48 segments (Precellys 48, Bertin Tech-
nologies, Montigny-Le-Bretonneux, France) and then
50 μL of a 1:20 dilution of the IS stock solution was
added. After incubation of the pulverized samples with
1 mL of methanol at 45 °C for 2 h with orbital shaking,
samples were centrifuged. The supernatants were subse-
quently transferred to 10-mL disposable screw top vials and
concentrated under nitrogen to 100–200 μL.
Preserved oral fluid samples (500 μL) were mixed with
50 μL of a 1:20 dilution of the IS stock solution.
Extraction
Following sample preparation, samples were extracted
with 4 mL of 1-chlorobutane after the addition of a
saturated ammonium chloride buffer (pH 9.2); 500 μL
was used for urine and preserved oral fluid samples and
1 mL was used for the pulverized hair samples. After
mechanical shaking (10 min) and centrifugation (10 min
at 3,000 g), the organic phase was transferred to a 5-mL
disposable screw top vial and then evaporated to dryness
at 40 °C in a vacuum centrifuge. For the extracted urine
samples, the residue was reconstituted in 100 μL of 0.1%
formic acid in water/methanol (70:30, v/v) and 10 μL was
injected into the LC-MS-MS system. The residue of
the preserved oral fluid and hair samples was reconsti-
tuted in 80 μL of 0.1% formic acid in water/methanol
(70:30, v/v) and 20 μL was injected into the LC-MS/MS
system. The limit of quantification (LOQ) in urine was
25 ng mL−1 for tetrazepam and 10 ng mL−1 for diazepam,
nordiazepam, oxazepam and temazepam. For hair sam-
ples, the LOQ was established at 10 pg mg−1 for




LC was performed using a Waters Alliance 2690 separation
module (Waters, Milford, MA, USA). Analytes were
separated on a Gemini C18 column (150×2.0 mm,
3.5 μm) (Phenomenex, Torrance, CA), using a gradient
elution with 0.1% formic acid (A) and methanol (B), at a
flow rate of 0.2 mL min−1. A gradient was applied starting
from 10% B, and increased to 50% over the first 5 min.
From 5 min to 20 min, B was linearly increased to 70%
before returning to the initial conditions within 0.1 min and




A Quattro Premier tandem mass spectrometer (Waters) was
used for all analyses. Ionization was achieved using
electrospray in positive mode (ESI+). The optimum con-
ditions were capillary voltage, 1.0 kV; source block
temperature, 120 °C; desolvation gas (nitrogen) heated to
270 °C and delivered at a flow rate of 700 L h−1.
The collision gas (argon) pressure was maintained at
0.35 Pa (3.5×10−3 mbar) and the collision energy (eV)
adjusted to optimize the signal for the most abundant
product ions, which were subsequently used for MRM
analysis. Quantification and a confirmation transition were
selected for each compound, except for the deuterated
analogs, for which only one transition was chosen. The
optimized MRM transitions for diazepam, nordiazepam,
oxazepam, temazepam, tetrazepam and the internal stan-
dards, diazepam-d5, nordiazepam-d5, oxazepam-d5 and
temazepam-d5, are presented in Table 1. All aspects of
data acquisition were controlled using MassLynx NT 4.1
software with automated data processing using the Target-
Lynx program (Waters).
LC-MS-MS assay validation for preserved oral fluid
samples
Linearity, LOQ, precision, accuracy and recovery
The method was validated for the detection of diazepam,
nordiazepam, oxazepam, temazepam and tetrazepam in
preserved oral fluid samples. Selectivity was evaluated by
analysing preserved oral fluid samples from eight healthy
volunteers who did not take any of the targeted compounds
for several days before preserved oral fluid sampling and
checked for the absence of the compounds of interest by
analysing the samples with the present technique before
using them as blanks. Assay linearity was investigated by
constructing calibration curves (n=5) using blank preserved
oral fluid spiked with the analytes at concentrations of 0.05,
0.1, 0.25, 0.5, 1, 2, 5, 10, 20 and 40 ng mL−1. Quantification
was achieved by integration of the area under the specific
MRM chromatograms in reference to the integrated area of
the deuterated analogues. Standard response curves were
generated daily using a weighted (1/x) least-squares linear
regression model.
The LOQ was defined as the concentration of the lowest
calibrator which was calculated to be within ±20% of the
nominal value and with a RSD (relative standard deviation)
less than 20% [20, 21].
QCs were prepared for every run in blank matrix at a
concentration of 0.75 ng mL−1 (low), 4 ng mL−1 (medium)
and 15 ng mL−1 (high). Intra-assay precision was evaluated
by analysis of five replicates of each QC in one run. Inter-
assay precision was evaluated by replicate analysis of one
set of QC samples in several experiments performed on five
different days. The precision was expressed as the %RSD.
A comparison of the calculated concentrations of the QC
samples to their respective nominal values was used to
assess the accuracy (bias) of the method.
Relative recoveries were estimated by comparing the
ratio of the peak area of the low, medium and high QC
samples when the non-deuterated compounds were added
before extraction (n=3) divided by the peak area of the
internal standards with the ratio of the peak area obtained
when the non-deuterated analytes were added after the
extraction (n=3) divided by the peak area of the IS. The
deuterated standards were added before the extraction in all
experiments.
Table 1 MRM transitions and conditions for tested benzodiazepines and the deuterated analogues
Compound Precursor ion (m/z) Product ion (m/z) Cone voltage (V) Collision energy (eV)
Temazepam 300.90 255.00a 28 20
283.00 28 15
Oxazepam 287.00 241.00a 27 22
269.00 27 15
Nordiazepam 271.00 139.80a 43 28
164.80 43 28
Tetrazepam 289.00 225.10a 45 28
253.10 45 25
Diazepam 285.00 153.80a 40 28
193.00 40 30
Temazepam-d5 305.90 260.10 25 23
Oxazepam-d5 292.00 246.10 40 23
Nordiazepam-d5 276.00 139.80 45 28
Diazepam-d5 290.00 153.80 40 28
a Transitions used for quantification
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Stability of unprepared and prepared samples
Stability of tetrazepam, diazepam, nordiazepam, oxazepam
and temazepam was monitored in non-extracted preserved
oral fluid samples spiked at the initial concentrations of
0.75 and 15 ng mL−1. Concentrations of the drugs in the
samples were either determined (each in triplicate) imme-
diately (control samples) or following incubation at room
temperature for 24 h or at 4 °C for a period of 24 h, 48 h
and 72 h after preparation. In addition, the stability of the
same preserved oral fluid samples was evaluated after
2 weeks of incubation at −20 °C. Stability at each time
point was tested against a lower acceptance limit
corresponding to 90% of the mean of control samples by
a one-sided t-test (P<0.05).
The stability of tetrazepam, diazepam, nordiazepam,
oxazepam and temazepam in the extracted sample (pre-
served oral fluid initially spiked at 0.75 ng mL−1 and 15 ng
mL−1) was investigated by repeated injections of a mixture
of six extracted samples (maintained in the autosampler at
4 °C) over a period of 24 h. Absolute peak areas were
plotted as a function of injection time and the stability of
the processed samples tested by regression analysis.
Instability of the processed samples would be indicated by
a slope that was significantly different from zero (P<0.05).
Assessment of matrix effects
To assess any potential suppression or enhancement of
ionization from components present in the extracted
biological matrix, a continuous post-column infusion was
performed using a separate solution of tetrazepam, diaze-
pam, nordiazepam, oxazepam and temazepam (10 ng mL−1
at a flow rate of 10 μL min−1) to produce a constant
elevated response in both MRM channels. The interference
of this constant response was monitored following the
injection of extracted samples and compared to the
response following the injection of mobile phase only.
Quantification of creatinine
The concentration of creatinine in urine was determined
using a Vitros 5,1 FS Chemistry System (Ortho-Clinical
Diagnostics, Beerse, Belgium) and corresponding reagents
according to the manufacturer’s recommendations.
GC-FID
One tablet of Myolastan® was pulverized, weighed and
dissolved in 10 mL of methanol. Tribenzylamine was added
as internal standard at a concentration of 0.5 mg mL−1.
Samples were sonicated for 15 min and filtered using a
Puradisc™ 25 NYL filter (0.45-μm pore size) (Whatman,
Clifton, NJ), after which a 1-μL aliquot was injected into
the chromatographic system for analysis. A Hewlett–
Packard 6890 Series GC System was used furnished with
a HP5-MS column (25 m, 0.32-mm i.d, 0.52-μm film
thickness) (J&W Scientific, Folsom, CA) and a flame
ionization detector at 300 °C. The injector was operated at
250 °C in the split mode, using a split ratio of 25:1. Helium
was used as the carrier gas. The oven temperature programme
was as follows: 150 °C (hold 1 min), 15 °C min−1 ramp to
300 °C (hold 3 min). The total running time was 14 min. For
quantification, calibration curves with eight calibrators of
diazepam and tetrazepam were prepared for each batch
ranging from 2.88 μg mL−1 to 1.36 mg mL−1. Internal QC
samples were analysed with each batch of samples.
HPLC-DAD
One tablet of Myolastan® was dissolved in 10 mL of
methanol. After addition of the internal standard (clobazam)
and 500 μL of a saturated ammonium chloride buffer (pH
9.2), a 500-μL aliquot of this solution was extracted with
4 mL of 1-chlorobutane. Analyses were performed using a
Hewlett–Packard HP 1100 Series HPLC (Agilent Technol-
ogies). Analytes were separated on a Lichrospher RP8ec
column (250×4.0 mm, 5 μm) (Merck, Darmstadt, Ger-
many), eluted isocratically with 100 mM phosphate buffer
pH 2.3/acetonitrile (63:37, v/v), delivered at a flow rate of
1 mL min−1 with a run time of 30 min. Systematic
toxicological analysis was performed using a UV spectra
library [22]. Wavelength calibration and accuracy checks of
the DAD were performed regularly.
Results
Validation of the analytical method for preserved oral fluid
samples
The selectivity of the method was acceptable in terms of
absence of interferences in the blank preserved oral fluid
samples analyzed. The combination of retention time and
two transitions (and their relative abundances) provided
high specificity for all of the compounds [13]. The
deuterated IS selected for each compound is shown in
Table 2. No cross-talk interference with the deuterated IS
was observed.
Calibration curves for all compounds tested were
prepared in blank preserved oral fluid for each batch and
ranged from the LOQ to 40 ng mL−1. Linearity, LOQ, intra-
assay and inter-assay precision and bias are summarized in
Tables 2 and 3. The observed LOQ, ranging from 0.05 to
0.2 ng mL−1, is consistent with previous reports [23, 24]. %
RSD at the low (0.75 ng mL−1), medium (4 ng mL−1) and
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high (15 ng mL−1) QC level were consistently below 15%.
The extraction recovery of the analytes is presented in
Table 4.
The stability of non-extracted spiked samples (0.75 and
15 ng mL−1) was monitored at room temperature for 24 h or
at 4 °C for a period of 24 h, 48 h and 72 h. No statistically
significant differences could be observed for the two
different concentrations under both conditions. Also no
statistical differences could be noted for the stability of non-
extracted spiked samples (0.75 and 15 ng mL−1) during
2 weeks at −20 °C.
The potential for instability of the processed samples
was also tested. To this end, the stability of the compounds
was monitored by means of repeated injections of extracted
samples (0.75 ng mL−1 and 15 ng mL−1) over a period of
24 h, and by plotting the absolute peak areas as a function
of time. The results indicated no significant instability over
the course of the experiment.
Post-column infusion experiments (based on the method
described by Bonfiglio et al. [25]) indicated no significant ion
suppression or enhancement during the chromatographic
run.
Analysis of the pharmaceutical specialty Myolastan®
To assess the origin of the diazepam and nordiazepam
present in hair samples from a regular Myolastan® user, it
was decided to initially analyse one tablet of the pharma-
ceutical specialty Myolastan® (50 mg tetrazepam). The
presence of diazepam in this tablet was confirmed in two
different lots by various techniques (LC-MS-MS, HPLC-
DAD and GC-FID). Quantification with GC-FID showed a
relative concentration of around 0.068% and 0.061% of the
active ingredient for two different lots of Myolastan®.
Since tetrazepam is available as Myolastan® or Epsipam®
50 mg (Will–Pharma, Wavre, Belgium) tablets, an analysis
of the latter was also performed. Diazepam was also present
in this preparation at a relative concentration of 0.37% of the
active ingredient.
Analysis of urine samples after the controlled
administration of Myolastan® and Valium®
Urine samples were analyzed according to a previously
published procedure [13]. In this report, a reduced stability
for tetrazepam was observed during the enzymatic hydro-
lysis of the urine samples. Indeed, an experiment with spiked
urine samples (n=3) showed a reduction of 94.3±0.3% and
96.8±0.2% for QCs at 150 ng mL−1 and 600 ng mL−1
respectively, when incubated at 56 °C for 1 h. However, no
statistically significant difference was noted for diazepam,
nordiazepam, oxazepam and temazepam under these con-
ditions. Therefore, we decided to analyze all urine samples
twice: once without enzymatic hydrolysis in order to have the
optimal conditions for tetrazepam detection, and once using
the described protocol for the quantification of diazepam,
nordiazepam, oxazepam and temazepam. A limited validation
including linearity, LOQ, precision and accuracy was
performed (n=5). The obtained r2 was in all cases >0.998
with an LOQ of 10 ng mL−1. The %RSD and bias were
Table 3 Intra-assay and inter-assay precision (expressed as %RSD) and bias (%) of the QC samples spiked at a concentration of 0.75 ng mL−1
(low), 4.0 ng mL−1 (medium) and 15.0 ng mL−1 (high) in preserved oral fluid
Compound Intra-assay precision (n=5) Inter-assay precision (n=5) Bias
Low Medium High Low Medium High Low Medium High
Temazepam 8.3 3.4 1.4 7.7 8.3 3.1 −12.9 −10.0 −1.7
Oxazepam 8.6 3.3 2.4 5.1 7.6 5.5 −9.3 −7.8 −2.6
Nordiazepam 5.7 2.7 5.1 12.2 7.6 6.3 13.9 9.6 −1.8
Tetrazepam 8.3 3.4 3.8 5.6 4.6 6.1 10.1 7.2 −5.1
Diazepam 7.9 2.3 2.3 7.7 7.0 4.6 −12.9 −7.3 −3.0
Table 2 Equation of a typical calibration curve with coefficient of determination (r2), and the estimated limits of quantification (LOQ) of the
method for preserved oral fluid
Compound IS Equation r2 LOQ (ng mL−1)
Temazepam Temazepam-d5 y ¼ 1:1626x 0:0682 0.9990 0.20
Oxazepam Oxazepam-d5 y ¼ 1:5647x 0:0317 0.9988 0.05
Nordiazepam Nordiazepam-d5 y ¼ 1:1832xþ 0:0221 0.9981 0.05
Tetrazepam Diazepam-d5 y ¼ 0:8676x 0:1062 0.9989 0.20
Diazepam Diazepam-d5 y ¼ 1:2846x 0:0366 0.9992 0.05
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evaluated at 40, 150 and 600 ng mL−1 and were consistently
<15%.
After oral administration of a single tablet of Myolastan®
(50 mg tetrazepam) to three subjects, 17 consecutive speci-
mens of urine were collected over 280 h (Fig. 1a).
Benzodiazepine concentrations of all urine samples were
interpreted with respect to the creatinine content to
compensate for the diuretical state. Tetrazepam was present
in all urine samples, with the highest concentration on
average after 12 h. After 280 h, urine samples were still
positive for tetrazepam at a LOQ of 10 ng mL−1. In
addition, diazepam could be detected in the first sample of
two persons and was observed up to 36 h after intake.
However, no metabolites of diazepam were noted in these
samples. In order to rule out a possible formation of
diazepam during the extraction process, blank urine
samples, spiked with 600 ng mL−1 tetrazepam were
analyzed following the described method. No diazepam
was detected in these samples.
A typical therapy with tetrazepam includes a daily
administration of 25–150 mg for 1 week. Therefore, half
a tablet of Myolastan® (25 mg tetrazepam) was adminis-
tered to one subject during 1 week. Urine specimens were
collected for 280 h after the first intake and quantified with
respect to creatinine concentrations in these samples
(Fig. 1b). Diazepam was detected in these samples up to
210 h and a peak concentration was seen after 114 h.
Furthermore, nordiazepam was additionally detected be-
tween 66 and 138 h. Further metabolites of diazepam could
not be detected.
The concentrations detected in urine samples after single
and repeated administration of Myolastan® were compared
with those obtained after a single dose of Valium® (10 mg
diazepam) to three persons (Fig. 1c). Traces of diazepam
could only be detected in the first urine sample (8 h after
intake) from one person. In the following samples from this
person and all of the samples of the two other persons, only
the metabolites of diazepam, i.e. nordiazepam, oxazepam
and temazepam, were detected. Mean urine concentrations
showed a large variation throughout the whole collection
period. Whereas temazepam and oxazepam were alternately
detected as the most abundant metabolite, nordiazepam was
the minor metabolite in all urine samples analyzed.
Analysis of preserved oral fluid samples after the controlled
administration of Myolastan® and Valium®
After administration of one tablet of Myolastan® (50 mg
tetrazepam) to three volunteers, 20 specimens of oral fluid
were collected from each subject with the Intercept®
collection device (Fig. 2a). Tetrazepam was detectable
15 min after intake in all volunteers. Peak concentrations
of tetrazepam were obtained after 105 min. Samples were
still positive after 600 min. However, no diazepam or
metabolites were detected in these samples.
The same study was conducted including three persons
receiving one tablet of Valium® (10 mg diazepam) (Fig. 2b).
Peak concentrations were noted in all subjects after 15 min,
rapidly decreasing at the second time point (30 min),
indicating a possible contamination of the oral cavity. A
second peak was observed after 120 min. Oral fluid samples
tested positive for diazepam over 600 min. The metabolites
of diazepam could not be detected in these samples.
Analysis of hair samples after the controlled administration
of Myolastan® and Valium®
The corresponding hair samples after the administration of
a single dose or 1-week therapy with Myolastan® and a
single dose of Valium® were collected 3 weeks after the last
intake. After segmentation, the first three proximal seg-
ments were analyzed. Following a single dose ofMyolastan®,
the first segments of the three volunteers were positive for
tetrazepam (17.3–59.7 pg mg−1). No diazepam or metabolites
could be detected in any of the segments tested. After 1 week
of therapy with the same drug, tetrazepam was detected in the
first (454.0 pg mg−1) and second (13.0 pg mg−1) segment
(Fig. 3). In addition, the first segment of this person was also
positive for diazepam (10.7 pg mg−1). No nordiazepam was
observed in any of the segments. After a single dose of
Table 4 Extraction recovery (%) of tested benzodiazepines for the QC samples spiked at a concentration of 0.75 ng mL−1 (low), 4.0 ng mL−1
(medium) and 15.0 ng mL−1 (high) in preserved oral fluid
Compound Relative recovery (mean±1 SD)
Low Medium High Averagea
Temazepam 86.4±4.7 87.1±12.0 86.2±15.0 86.6±10.2
Oxazepam 72.6±9.3 92.8±15.1 88.3±6.0 84.6±9.3
Nordiazepam 88.3±8.8 95.1±8.5 94.0±1.3 92.5±6.6
Tetrazepam 80.8±7.8 78.9±6.5 79.8±12.3 79.8±8.4
Diazepam 81.0±8.1 87.2±9.3 87.7±13.1 85.3±9.9
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Valium®, the first and second segments were positive for
diazepam (2.3–6.0 pg mg−1) and nordiazepam (traces–
5.4 pg mg−1). The third segment of all volunteers was
negative for all drugs tested.
Discussion
Whereas tetrazepam is a medication with primarily muscle-
relaxant effects and is commonly prescribed for the
treatment of muscle spasms, diazepam acts on the CNS
with mainly sedation effects. Therefore, diazepam belongs
to the class of abused drugs and shows a potential to be
used as a date-rape drug [10]. The detection of the latter in
all hair segments from a regular Myolastan® user, who
denied the consumption of diazepam at any time in her life,
led us to analyze the presence of diazepam in the
pharmaceutical specialty Myolastan®. Confirmation of the
presence of low quantities of diazepam in different lots of
this preparation was obtained through GC-FID, LC-MS-MS
and HPLC-DAD. Owing to the important forensic implica-
tion of this finding, a small-scale study with single and/or
repeated administration of Myolastan® and Valium® was
designed. Urine and hair samples were analyzed according
to a previously published method [13]. In the present paper,
the same liquid–liquid extraction protocol and LC-MS-MS
method have been applied for the detection of diazepam,
nordiazepam, oxazepam and tetrazepam in oral fluid
samples, collected with the Intercept® device. The method
Fig. 1 Mean excretion pattern in urine a after a single Myolastan®
dose (50 mg tetrazepam, 3 subjects); b during and after a 1-week
therapy with Myolastan® (25 mg tetrazepam, 1 subject); and c after a
single Valium® dose (10 mg diazepam, 3 subjects). Error bars
represent 1 SD

Fig. 2 Mean excretion pattern
in preserved oral fluid a after a
single Myolastan® dose (50 mg
tetrazepam, 3 subjects); and
b following a single Valium®
dose (10 mg diazepam, 3 sub-
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was fully validated and the high sensitivity of the method
permits the detection of very low concentrations of drugs in
these samples.
Due to the instability of tetrazepam in urine samples
during the enzymatic hydrolyzation process, we decided to
analyze the urine specimens with and without a hydrolysis
step. Indeed, whereas diazepam is extensively metabolized
to oxazepam glucuronide, conjugated nordiazepam and
conjugated temazepam, it appears that tetrazepam is not
excreted in the glucuronidated form [26]. Thus, a hydrolysis
step would not yield a higher concentration for tetrazepam.
After the administration of a single dose of one tablet of
Myolastan® (3 subjects), the presence of diazepam in urine
was observed for up to 36 h after the intake. Following a 1-
week therapy with half a tablet of this preparation, both
diazepam and nordiazepam were present at 8–210 h and
66–138 h, respectively, after the ingestion of the first dose.
These results were compared with those obtained after a
single dose of Valium®. However, in this case, only the
metabolites of the parent drug, i.e. nordiazepam, oxazepam
and temazepam, could be detected in these urine samples,
indicating a complete metabolization of diazepam.
In contrast to an earlier report [27], diazepam could be
detected in oral fluid samples throughout the whole
collection period after the administration of a single dose
of Valium®. However, the analysis of the preserved oral
fluid samples showed the presence of only the parent
benzodiazepines after a single dose of Myolastan® or
Valium®. Similar concentrations of tetrazepam in oral fluid
were observed in a previous study [15], taking into account a
1:3 dilution due to the use of the Intercept® collector. Peak
concentrations were obtained after 105 min and 120 min for
tetrazepam and diazepam, respectively, which is approxi-
mately the time of peak plasma concentration [26]. The
absence of nordiazepam in the preserved oral fluid samples
after the intake of Valium® can be explained by the fact that
average peak concentrations of nordiazepam in blood are
only reached 24 h following a single oral dose of 10 mg
diazepam. In addition, approximately 97% of the nordiaze-
pam in plasma is bound to proteins [26], consequently the
concentrations in the preserved oral fluid samples are
probably below the LOQ during the collection period. This
is also likely to be the cause of the absence of diazepam in
these samples after the administration of Myolastan®.
Fig. 3 MRM chromatogram obtained after the analysis of the first
hair segment following a 1-week therapy with Myolastan® (25 mg
tetrazepam). The figure shows the response (quantifier and qualifier)
for diazepam (a, b) and tetrazepam (c, d). Diazepam-d5 (e) was used
as internal standard. Peak intensity is shown in the top right-hand
corner of each trace
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Finally, hair samples were also collected and analyzed.
These results indicated that after a single dose of Myolastan®,
no diazepam could be observed; however, the 1-week therapy
resulted in a positive first segment for this compound. In
addition, the observed concentration was higher than that
observed following a single dose of Valium®. Under the latter
condition, nordiazepam could also be detected. However, it is
not clear why diazepam and nordiazepam could also be
detected in the second segment of all persons after the intake
of a single dose of Valium®. Hair strands were collected after
3 weeks of delay, in order for the region of drug incorporation
to emerge above the scalp. Therefore, with an average growth
of 1 cm month−1, the administered drug should be present in
the proximal segment, and not in the following segments. One
possible interpretation is the variability in the incorporation of
this drug into the hair shaft and axial migration after
incorporation, leading to a further distribution, an observation
already reported for bromazepam [7] and cocaine [28].
However, a decreased concentration would be expected in
the second segment. Therefore, more research has to be done
to study the incorporation of diazepam and nordiazepam in
hair after controlled administration.
Another question remains as to whether or not the
diazepam observed in the urine and hair samples after
administration of Myolastan® is the result of the diazepam
present in the pharmaceutical preparation. If this were true,
diazepam should also experience complete metabolic
conversion to nordiazepam, oxazepam and temazepam, as
was observed after a single dose of Valium®. The presence
of nordiazepam was however only noted after a repeated
administration of Myolastan® with diazepam remaining the
primary drug detected and the absence of other metabolites.
In addition, after repeated administration of Myolastan®,
only diazepam was detected in the first hair segment of this
person, whereas after a single dose of Valium®, nordiaze-
pam was also observed although lower concentrations of
diazepam were present in comparison with the latter.
Therefore, the results of this study may indicate that there
is a metabolic conversion of tetrazepam to diazepam in the
human body. In 1987, Maurer and Pfleger described the
presence of the hydrolysis product of diazepam in urine
samples collected after the ingestion of tetrazepam follow-
ing acid hydrolysis [29]. Only one other recent report
mentions the possibility of this metabolic conversion
process [30]. In this report, plasma and urine were collected
for 11 h and 72 h, respectively, after administration of
50 mg of tetrazepam. Nordiazepam was not detected in any
of the plasma samples and diazepam could be found in only
one sample. In all cases, diazepam was also detected in the
first sample. In contrast to our observations, these authors
also detected nordiazepam between 4 and 26 h after a single
tetrazepam intake. However, no other matrices were
analyzed and no correlation has been made after a single
diazepam intake. Benzodiazepines are metabolized in the
liver by enzymes of the cytochrome P-450 family of oxido-
reductases. Therefore, the metabolic conversion of tetraze-
pam could be explained by a double hydroxylation of the
unsaturated tetrazepam ring followed by subsequent elim-
ination of two water molecules and the formation of the
stable aromatic ring, and hence diazepam. However, further
research is needed to elucidate the complete conversion
process of tetrazepam.
In conclusion, detection of the presence of diazepam and
nordiazepam in biological samples from suspected DFSA
cases could lead to erratic conclusions. However, this study
showed that, following the intake of diazepam, only
diazepam metabolites were observed in urine, whereas the
single or repeated administration of Myolastan® led mainly
to diazepam in these samples.
Conclusions
Sedative agents are used to facilitate sexual assault due to
their ability to render the victim passive, submissive and
unable to resist. Most of these substances possess anter-
ograde amnesic properties and can rapidly impair an
individual. Benzodiazepines and related hypnotics are
frequently observed in these cases. Diazepam is regarded
as having a significant potential as a date-rape drug,
whereas tetrazepam has only a low sedative effect and is
commonly prescribed as a muscle relaxant. Tetrazepam is
available as Myolastan® and Epsipam® 50 mg tablets in
Belgium. However, the presence of low doses of diazepam
in these preparations, as confirmed by LC-MS-MS, GC-
FID and HPLC-DAD, could be the reason for the presence
of diazepam and nordiazepam in the hair sample from a
regular Myolastan® user. In the present paper, a sensitive,
specific and reproducible method for the detection and
quantification of tetrazepam, diazepam, nordiazepam, oxaz-
epam and temazepam in preserved oral fluid samples is
described and applied to a study involving the administra-
tion of Myolastan® and Valium®.
Our study shows that diazepam can be observed in urine
samples even after a single dose. In addition, a 1-week
therapy resulted in the detection of both diazepam and
nordiazepam in urine samples and of diazepam in the first
hair segment. However, a comparison with urine and hair
samples after a single diazepam dose showed that the
possible metabolic conversion of tetrazepam to diazepam is
a more plausible explanation for the detection of diazepam
in biological samples after the intake of Myolastan®. Due
to the high protein binding property of diazepam, however,
this compound was not observed in preserved oral fluid
samples. These results have an important forensic implica-
tion and, therefore, the presence of diazepam and/or
Anal Bioanal Chem
nordiazepam in biological samples from alleged DFSA
cases should be interpreted with care.
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a Forensic Toxicology Service, Institute of Legal Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
b Federal Public Service Justice, National Institute of Criminalistics and Criminology, Brussels, Belgium
c Waters Corporation, MS Technologies Centre, Manchester, UK
d Department of Clinical Chemistry-Toxicology, Academic Hospital, Free University of Brussels, Brussels, Belgium
Available online 8 February 2007
Abstract
A rapid, sensitive and fully automated on-line solid-phase extraction–liquid chromatography–tandem mass spectrometry (SPE–LC–MS/MS)
method was developed and validated for the direct analysis of 14 antidepressants and their metabolites in plasma. Integration of the sample extraction
and LC separation into a single system permitted direct injection of the plasma without prior sample pre-treatment. The applied gradient ensured the
elution of all the examined drugs within 14 min and produced chromatographic peaks of acceptable symmetry. The total process time was 20 min
and only 50 L of plasma was required. Selectivity of the method was achieved by a combination of retention time and two precursor-product
ion transitions for the non-deuterated compounds. The use of SPE was demonstrated to be highly effective and led to significant decreases in
the interferences present in the matrix. Extraction was found to be both reproducible and efficient with recoveries >99% for all the analytes. The
method showed excellent intra-assay and inter-assay precision (relative standard deviation (RSD) and bias <20%) for quality control (QC) samples
spiked at a concentration of 40, 200 and 800 g/L and the r2 > 0.99 over the range investigated (10–1000 g/L). Limits of quantification (LOQs)
were estimated to be 10 g/L. Furthermore, the processed samples were demonstrated to be stable for at least 48 h, except for clomipramine and
norclomipramine, where a slight negative trend was observed, but did not compromise the quantification. The method was subsequently applied
to authentic samples previously screened by a routine HPLC method with diode array detection (DAD).
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Major depressive disorder (MDD) is a condition
characterized by a prolonged depression of mood or by a
marked loss of interest or pleasure. Depression has received
increased attention owing to the growing recognition of its
prevalence. For many years, the prevailing hypothesis has been
that the condition is caused by (or associated with) a deficiency
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of Criminalistics and Criminology, Chaussée de Vilvorde 100, 1120 Brussels,
Belgium. Tel.: +32 2 240 05 00; fax: +32 2 241 61 05.
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of the monoamines, notably noradrenaline and serotonin;
current theories also acknowledge that other factors may be
involved in the pathogenesis of depression.
Pharmacological treatment for depression has advanced
greatly since the development of the first therapies in the 1950s,
with the introduction of monoamine oxidase inhibitors (MAOIs)
and tricyclic antidepressants (TCAs) [1]. Since the late 1980s,
a whole new generation of chemically and neuropharmacologi-
cally unrelated agents have been introduced which appear to
be safer and better tolerated [2]. These include: selective sero-
tonin reuptake inhibitors (SSRIs), serotonin and noradrenaline
reuptake inhibitors (SNaRIs), noradrenergic and specific sero-
tonergic antidepressants (NaSSAs) and noradrenaline reuptake
inhibitors (NaRIs) [3].
0021-9673/$ – see front matter © 2007 Elsevier B.V. All rights reserved.
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A shared characteristic to the majority of the antidepressant
drugs is the high interindividual variability in the plasmatic
concentrations. It can be explained partly due to the exis-
tence of polymorphism in the genes that encode some of the
CYP450 isoenzymes implicated in their metabolization [4,5].
These genetic differences have been well characterized mainly
in the case of CYP2D6 and CYP2C19, and some studies about
the recommendations on individual dose adjustment regard-
ing it have been carried out [6]. These clinical consequences
are more dramatic in the case of TCA since they are charac-
terized by having a narrow therapeutic window with risk of
cardiac and CNS toxicity [7,8]. Thus, therapeutic drug moni-
toring (TDM) for this class of antidepressant agents has become
widely used because of its efficacy, safety and cost-effectiveness,
the novel antidepressants show a less predictable concentration-
efficacy relationship [9–12], in combination with a relatively
low toxicity. Therefore, several authors also support the ben-
efit of TDM for these drugs in special situations, such as to
monitor compliance in the case of those patients who do not
respond to an apparently adequate dose to identify those individ-
uals who have particularly slow or rapid drug clearance, during
pharmacokinetic studies and when administered to special popu-
lations (i.e., elderly or people with organic diseases) [10,13–15].
Although, there are some discrepancies about the therapeutic
range for antidepressants, mainly the new generations, pro-
posed therapeutic concentrations have been determined. They
can be found in the list published by Winek et al., as well as
the one elaborated by some recognised organizations such as
TIAFT (The International Association of Forensic Toxicologist)
[16,17].
Several methods have been published for the determination
of one or more antidepressants in different biological matri-
ces such as plasma or urine for monitoring or toxicological
purposes [18–32]. In these reports, the use of gas chromato-
graphy (GC) coupled to nitrogen–phosphorus (NPD) [18,19],
flame ionization (FID) [20], electron-capture (ECD) [21] and
mass spectrometry (MS) [21–23] detection have been described.
Liquid–liquid or solid-phase extraction (SPE) have been used
for sample clean-up followed, in some cases, by a derivatiza-
tion step [21–24]. However, in most of these reports, HPLC
has been used in conjunction with UV [25–27] or fluores-
cence (FL) detection [27,28], thus necessitating an appropriate
derivatization step to increase the fluorescence capacities of the
compounds of interest. More recently, LC–MS or LC–MS/MS
have been applied [29–32]. These techniques provide a high
selectivity and sensitivity in combination with a good precision
and accuracy over a wide dynamic range, allowing the develop-
ment of very rapid and efficient analytical methods. Therefore,
in many cases it is now the sample pre-treatment process that
has become the bottleneck in method development and sample
analysis [33,34].
High-throughput analysis is becoming increasingly impor-
tant in all areas of science, the forensic sciences being no
exception. Many efforts have been made to develop on-line
extraction techniques, allowing automation and a high through-
put of samples [35–37]. These procedures have been applied for
the detection of only a few antidepressants.
The aim of this study was to develop a simple, rugged and
high-throughput on-line SPE–LC–MS/MS method for rapid
and simultaneous bio-analysis of the main antidepressants
prescribed in Belgium and their metabolites in plasma. The
method involves a fully automated SPE system (Spark Sym-
biosis Pharma), which allows the simultaneous extraction of
the second sample in one clamp and the elution of the first
sample in a second clamp, as such, achieving an optimal use
of the extraction time. This system offers the entire process
of conditioning, sample application, washing and elution
taking place at constant flow rates, yielding better precision in
comparison with off-line driven extraction procedures. Another
important advantage is that no manual transfers are made and
that the whole of the eluate is loaded onto the LC column
without the need for a pre-concentration step.
2. Materials and methods
2.1. Reagents
Individual stock solutions of amitriptyline, nortriptyline,
imipramine, desipramine, trazodone, fluoxetine, norfluoxetine,
paroxetine, fluvoxamine, sertraline (all certified at a concen-
tration of 1 mg/mL in methanol), and the internal stan-
dards (I.S.) [2H3]imipramine (imipramine-d3), [2H3]desipra-
mine (desipramine-d3), [2H3]clomipramine (clomipramine-
d3), [2H6]fluoxetine (fluoxetine-d6) and [2H6]paroxetine
(paroxetine-d6) (certified concentration of 0.1 mg/mL in
methanol) were obtained from Cerilliant (Round Rock, TX,
USA). Venlafaxine as a solid was obtained from Lederle
Labs. (New York, USA). Norclomipramine and citalopram in
solid form were supplied by Sigma–Aldrich (St. Louis, MO,
USA) and clomipramine as a solid was a gift from Novartis
Farmacéutica (Barcelona, Spain).
Ammonium hydrogencarbonate (99% purity) and formic acid
(mass spectroscopy grade) was purchased from Sigma–Aldrich
(Steinheim, Germany). Acetonitrile and methanol (both LC–MS
grade) and water were purchased from Biosolve (Valkenswaard,
The Nederlands). Isopropyl alcohol and ammonia solution
(32%, extra pure) were from Merck (Darmstadt, Germany).
Oasis MCX (mixed-mode cation-exchange) Prospekt car-
tridges (30 mg, 1 mL) were from Waters (Milford, MA, USA).
2.2. Specimens
Pooled blank plasma samples were used for development and
validation of the procedure and were obtained from a local blood
bank. Authentic plasma samples were obtained from hospital
cases.
2.3. Preparation of standard solutions
Separate working solutions of the drugs, for tuning and
selectivity experiments, were prepared in the laboratory at a
concentration of 1 mg/L in methanol. A mixed working solution
of non-deuterated compounds at 10 mg/L in methanol was used
for the preparation of calibrators and QC samples. A mixed I.S.
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working solution of 1 mg/L was prepared in methanol. Working
solutions were stored at −20 ◦C, and were prepared monthly.
To obtain the lower concentrations needed for internal stan-
dardization and validation of each experiment, further dilutions
in water were prepared the same day.
2.4. SPE–LC–MS/MS
2.4.1. Sample preparation: XLC (on-line SPE)
Sample extraction was performed using the on-line SPE
Symbiosis Pharma System (Spark Holland, Emmen, The
Netherlands). It comprises two integrated units: the Reliance
autosampler with two binary LC pumps integrated and the on-
line SPE unit Prospekt-2 system [consisting of the automated
cartridge exchange (ACE) unit and two high-pressure dispensers
(HPD)]. The entire system was operated by SparkLink soft-
ware (version 3.10, Spark Holland). The extraction procedure
was carried out in total recovery screw top vials of high qual-
ity glassware (Waters). A 950 L volume of 0.1% formic acid
and 50 L of the I.S. working solution (0.1 mg/L) were added to
50 L of plasma. The following XLC program was subsequently
used (Fig. 1): After conditioning with 1 mL of methanol, 1 mL
of water and 1 mL of 0.1% formic acid (Fig. 1A), 100 L of
the diluted plasma sample was applied onto the SPE MCX car-
tridge (cation-exchange mode) using 1 mL of 0.1% of formic
acid as transport solvent. Clean-up was accomplished with suc-
cessive 1 mL washes of 0.1% of formic acid and methanol in
order to wash out salts and endogenous interferences present
in the biological sample (Fig. 1B). The cartridge was then
physically moved with a robotic arm to the elution (right)
clamp in line with the LC pumps, leaving the extraction (left)
clamp ready to start with a new sample. Whilst the elution
step was being performed, a new cartridge was conditioned,
loaded and washed in the left clamp. The elution was performed
with 300 L of 5% ammonia in methanol (at 100 L/min). Fo-
llowing the elution step, several automated clamp and valve
washes were carried out to avoid contamination between
samples.
2.4.2. Chromatographic conditions
Focusing of the eluate was simultaneously performed as the
compounds were eluted from the SPE cartridge by the use of a
focusing column, Gemini C18 guard column (4 mm × 2.0 mm,
5 m) (Phenomenex, Torrance, CA, USA), and a gradient elu-
tion with 10 mM ammonium hydrogencarbonate (pH 10) (A)
and acetonitrile (B) (Fig. 1C). A gradient was carried out start-
ing from 0% B and a flow rate of 1 mL/min for 3 min, as the
eluate was diverted to the waste using the MS/MS Rheodyne
switching valve. At 3.01 min, a switch of the valve delivered the
eluent to the analytical Gemini C18 column (150 mm × 2 mm,
5 m) (Phenomenex) (Fig. 1D) to start with the separation of
the compounds at a flow rate of 0.3 mL/min and 50% B over the
next minute. From 4 to 5 min, B was subsequently increased to
70%, and then kept for 6.5 min. At 11.5 min, B was increased
to 95% in 1.5 min before returning to 50% within 0.5 min and
equilibrating for 4.5 min. At 18 min a switch of the MS/MS
valve diverted the eluent again to the waste, returning to the
initial conditions to be ready for the analysis of the following
sample.
2.4.3. Tandem mass spectrometry
A Quattro Premier tandem mass spectrometer (Waters) was
used for all analyses. Ionization was achieved using electrospray
in positive ionization mode (ESI+). Nitrogen was used as nebu-
lisation and desolvation gas at a flow rate of 800 L/h and heated
to 350 ◦C. Capillary voltage and source block temperature were
1 kV and 120 ◦C, respectively.
In order to establish the appropriate multiple reaction
monitoring (MRM) conditions for the individual compounds,
solutions of standards [200 g/L, in 10 mM ammonium hydro-
gencarbonate (pH 10)–acetonitrile (50:50, v/v)] were infused
into the mass spectrometer and the cone voltage (CV) opti-
mised to maximise the intensity of the protonated molecular
species [M + H]+. Collision-induced dissociation (CID) of each
protonated molecule was performed. The collision gas (argon)
pressure was maintained at 0.35 Pa (3.5 × 10−3 mBar) and the
collision energy (eV) adjusted to optimise the signal for the most
abundant product ions, which were subsequently used for MRM
analysis.
All aspects of data acquisition were controlled using
MassLynx NT 4.0 software with automated data processing
using the TargetLynx software (Waters).
2.5. On-line SPE–LC–MS/MS assay validation
The analytical validation was performed according to the
recommendations of Peters and Maurer [38] and Shah et al. [39].
2.5.1. Linearity, limit of quantification (LOQ), limit of
detection (LOD), precision and accuracy
Quantification was performed by integration of the area under
the specific MRM chromatograms in reference to the integrated
area of the deuterated analogues. Freshly prepared working solu-
tions of 0.01, 0.05, 0.25, and 1 mg/L in water were used to
prepare plasma calibrators at a concentration of 10, 25, 50, 125,
250, 500 and 1000 g/L. Standard curves, freshly prepared with
each batch of QC and authentic samples, were generated using
a least-squares linear regression, with a 1/x-weighting factor for
most of the compounds, except for trazodone, nortrityline and
norclomipramine, for which a quadratic response was found to
be more suitable.
The limit of quantification (LOQ) was defined as the concen-
tration of the lowest calibrator that was calculated within ±20%
of the nominal value and with a relative standard deviation (RSD)
less than 20%.
The limit of detection (LOD) was estimated from blanc
plasma samples, spiked with decreasing concentrations of the
analytes, where the response of the qualitative ion could relia-
bly differentiate from background noise and with signal to noise
ratio (S/N) of the qualifier equal to or greater than three.
QCs were prepared for every run in blank plasma at a con-
centration of 40, 200 and 800 g/L. Intra-assay precision was
evaluated by replicate (n = 5) analysis of the three QC sam-
ples in one run. Inter-assay precision was evaluated by replicate
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Fig. 1. Scheme of on-line SPE system-LC (Symbiosis Pharma) coupled to the MS/MS. (A) The sample is loaded into the sample loop while the first SPE cartridge is
conditioned in the left clamp. (B) The sample is loaded onto the cartridge followed by a washing step. (C) The cartridge is moved to the right clamp, where the sample
is eluted; the analytes are subsequently retained on the focussing column. Simultaneously, a second sample is subjected to the initial procedure of extraction in the
left clamp. (D) After the elution step the MS valve is switched and the analytes are now directed to the analytical column in connection to the MS/MS. Following
the analysis of the first sample, the second SPE cartridge is transferred to the right clamp in order to be eluted and analysed.
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analysis of the QC samples in several experiments performed
on six different days. Comparing the calculated concentra-
tions of all calibrators and QC samples to their respective
nominal values, provided data on the bias (accuracy) of the
method.
2.5.2. Selectivity and specificity
The selectivity of the method against endogenous inter-
ferences was verified by examination of the chromatograms
obtained after the extraction of six different blank plasma sam-
ples conserved in two different anticoagulants (sodium citrate
(n = 3) and sodium fluoride (n = 3).
The combination of benzodiazepines with antidepressants
potentiates the treatment of depression, thus, benzodiazepines
are frequently encountered in these samples. For this rea-
son, the specificity of the method was also assessed by the
analysis of plasma samples spiked at 2 mg/L of a solution con-
taining 27 benzodiazepines used for routine analysis in our
laboratory.
2.5.3. Stability of samples
The stability of the drugs in plasma was monitored in diluted
plasma samples as follows; 50 L of blank plasma spiked at the
initial concentrations of 40, 200 and 800 (n = 9, at each concen-
tration) were diluted with 950 L of 0.1% formic acid. The I.S.
was added to the control samples (n = 3) and the concentrations
were determined immediately. Another pool of samples was kept
in the autosampler at 6 ± 2 ◦C and analyzed prior to the addition
of the I.S., after 24 h (n = 3) and 48 h (n = 3). For an evaluation of
freeze/thaw stability, the control samples at the concentrations
of 40 and 200 g/L (n = 3) were spiked with the I.S. and analysed
immediately. The stability samples, spiked at the same concen-
trations (n = 3), were subjected to three freeze/thaw cycles. For
each freeze/thaw cycle, the samples were frozen at −20 ◦C for
Fig. 2. MRM chromatograms obtained following the analysis of a spiked plasma sample with 10 g/L of (1) clomipramine, (2) amitriptyline, (3) sertraline, (4)
imipramine, (5) norclomipramine, (6) nortriptyliline, (7) desipramine, (8) fluoxetine, (9) venlafaxine, (10) citalopram, (11) paroxetine, (12) norfluoxetine, (13)
fluvoxamine and (14) trazodone. Peak intensity is shown on the right-hand corner of each trace.
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Table 1
MRM transitions and conditions for all the compounds and their deuterated analogues
Compound Precursor ion (m/z) Product ion (m/z) Cone voltage (V) Collision energy (eV)
Trazodone 372.1 147.9 40 35
176.0 25
Fluvoxamine 319.1 70.8 25 15
86.8 15
Norfluoxetine 296.1 30.0 15 8
133.9 6
Paroxetine 330.1 69.8 40 28
192.1 20
Citalopram 325.1 108.8 30 25
115.8 25
Venlafaxine 278.1 57.8 20 18
260.1 12
Fluoxetine 310.1 43.9 20 12
147.9 8
Desipramine 267.2 44.0 25 30
71.8 15
Nortriptyline 264.1 90.8 25 20
233.2 15
Norclomipramine 301.1 43.9 25 35
71.8 20
Imipramine 281.2 57.7 25 35
85.7 10
Sertraline 306.1 158.8 15 30
275.0 12
Amitriptyline 278.1 90.8 30 25
104.8 20
Clomipramine 315.1 57.9 30 30
85.8 18
Paroxetine-d6 336.1 75.8 35 32
Fluoxetine-d6 316.1 43.9 20 12
Desipramine-d3 270.2 74.8 25 15
Imipramine-d3 284.2 88.8 25 18
Clomipramine-d3 318.1 88.8 30 20
Underlined transitions were used for quantification.
24 h, thawed, and then maintained at ambient temperature for
1 h. After the three cycles, the samples were spiked with the
I.S. and analyzed. Stability was tested against a lower percent-
age limit corresponding to 90% of the mean value of control
samples by on-sided t-test (P < 0.05).
2.5.4. Assessment of matrix effects
To assess any potential suppression or enhancement of ion-
ization due to the sample matrix, two different analyses were
carried out. The first one involved a post-column infusion experi-
ment. The study was based on a continuous post-column infusion
of a mixture of the drugs and their internal standards (10 g/L
at a flow rate of 10 L/min) to produce a constant elevated
response in the MRM channels. The interference of this constant
response was monitored following the injection of plasma sam-
ples (in two different anticoagulants: sodium citrate (n = 3) and
sodium fluoride (n = 3) and compared to the response following
Table 2








Trazodone 500–2500 0.99995 10 0.5
Fluvoxamine 50–250 0.99848 10 1
Norfluoxetine 100–500 0.99890 10 1
Paroxetine 10–75 0.99939 10 0.5
Citalopram 20–200 0.99793 10 0.5
Venlafaxine 250–750 0.99727 10 0.5
Fluoxetine 150–500 0.99720 10 1
Desipramine 75–250 0.99945 10 1
Nortriptyline 50–250 0.99922 10 1
Norclomipramine 150–550 0.99702 10 1
Imipramine 45–150 0.99951 10 0.5
Sertraline 50–250 0.99900 10 1
Amitriptyline 50–300 0.99845 10 0.5
Clomipramine 20–250 0.99947 10 0.5
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the injection of mobile phase only. A second type of experiment
consisted of a comparison of the peak responses of the analysis
of a blank plasma sample spiked at 1000 g/L calibrator (n = 3)
with those obtained from water spiked at the same concentration
level.
2.5.5. Recovery
Recoveries were estimated by performing two experiments.
In order to optimize the elution conditions i.e. elution volume
and flow rate, a 1000 g/L calibrator (n = 3) was injected in
the absence of both the analytical and focusing column. As
such the compounds achieve directly the MS/MS as they elute
from the SPE cartridge. In a second experiment, performed to
calculate de total recovery, a 1000 g/L calibrator (n = 3) was
loaded and washed in a first SPE cartridge while a second car-
tridge was placed in series to determine the breakthrough of
the first one. Both cartridges where subsequently eluted inde-
pendently. Recovery was considered to be the ratio between
Table 3
Intra-assay and inter-assay precision and bias of the QC samples prepared in plasma at a concentration of 40, 200 and 800 g/L
Compound Concentration
of QC (g/L)
Intra-assay precision (n = 5) Inter-assay precision (n = 6)
Mean concentration
found (g/L)
RSD (%) Bias (%) Mean concentration
found (g/L)
RSD (%) Bias (%)
Trazadone 40 43.6 6.1 9.0 41.0 11.5 2.5
200 233.2 1.5 16.6 199.6 7.0 −0.2
800 692.6 4.7 −13.4 673.4 13.2 −15.8
Fluvoxamine 40 41.9 7.2 4.8 36.5 10.9 −8.8
200 216.5 3.3 8.3 189.4 7.6 −5.3
800 843.8 3.8 5.5 807.0 8.7 0.9
Norfluoxetine 40 45.6 7.5 14.0 41.1 14.3 2.8
200 236.1 3.8 18.1 193.2 15.0 −3.4
800 880.9 7.5 10.1 801.5 8.6 0.2
Paroxetine 40 40.8 6.4 2.0 38.5 6.5 −3.8
200 212.8 2.2 6.4 193.6 7.2 −3.2
800 807.3 4.3 0.9 805.9 8.8 0.7
Citalopram 40 44.1 4.4 10.3 43.1 7.8 7.8
200 222.0 2.0 11.0 201.3 7.8 0.7
800 796.7 2.8 −0.4 780.7 10.1 −2.4
Venlafaxine 40 44.0 5.6 10.0 43.1 12.5 7.8
200 227.4 1.7 13.7 198.3 10.4 −0.8
800 780.8 5.5 −2.4 785.4 13.0 −1.8
Fluoxetine 40 43.8 7.3 9.5 40.0 10.7 0.0
200 220.0 3.0 10.0 196.3 9.8 −1.8
800 817.0 8.3 2.1 814.3 9.9 1.8
Desipramine 40 43.3 5.4 8.2 40.5 5.4 1.3
200 213.7 3.1 6.9 194.4 6.2 −2.8
800 830.6 3.2 3.8 791.0 11.1 −1.1
Nortriptyline 40 41.7 6.4 4.3 38.1 8.4 −4.8
200 211.0 3.6 5.5 192.1 8.3 −4.0
800 813.4 5.1 1.7 800.0 13.6 0.0
Norclomipramine 40 40.0 6.5 0.0 36.6 15.4 −8.5
200 226.9 15.5 13.5 197.0 7.0 −1.5
800 798.6 3.4 −0.2 808.9 5.5 1.1
Imipramine 40 43.4 2.3 8.5 40.1 6.4 0.3
200 226.1 1.3 13.1 198.1 7.4 −1.0
800 827.1 3.8 3.4 806.5 11.4 0.8
Sertraline 40 42.2 5.2 5.5 37.2 14.1 −7.0
200 221.9 3.5 11.0 193.9 9.2 −3.1
800 850.2 5.5 6.3 824.6 7.6 3.1
Amitriptyline 40 38.3 5.9 −4.3 35.2 10.1 −12.0
200 203.1 3.1 1.6 181.8 9.2 −9.1
800 805.6 4.2 0.7 780.1 9.7 −2.5
Clomipramine 40 43.9 6.5 9.8 41.5 9.9 3.8
200 219.1 1.7 9.6 207.1 7.5 3.6
800 764.4 5.1 -4.5 808.2 10.3 1.0
10 A. de Castro et al. / J. Chromatogr. A 1160 (2007) 3–12
the response obtained after elution of the first cartridge and
the total response (sum of both, the first and the second SPE
cartridge).
3. Results and discussion
The method was validated for linearity, LOQ, precision and
accuracy by the analysis of spiked plasma samples. In each
case, a weighted (1/x) linear regression line was applied, except
for trazodone, nortriptyline and norclomipramine, for which a
quadratic response was found to be more suitable to obtain the
best fit across the calibration range [38]. Correlation coefficient
of r2 > 0.99 was achieved in the range investigated: from 10 up
to 1000 g/L. The range investigated was considered according
the therapeutic range elaborated by TIAFT [16] (Table 2) Fig. 2
shows the MRM chromatograms obtained following the ana-
lysis of the lowest calibrator (10 g/L). At this concentration a
signal-to-noise ratio (S/N) > 10:1 was observed for the qualifier
and the criteria for LOQ were satisfied.
The applied gradient ensured the elution of all the drugs
examined within 14 min and produced chromatographic peaks
of acceptable symmetry. Since a focusing step is a crucial factor
to obtain good peaks and sensitivity, many efforts were made to
determine the optimal conditions.
Selectivity of the method was achieved by a combination of
retention time, precursor and product ions.
The most prominent precursor-product transitions were used
for quantification of the non-deuterated compounds and the next
most abundant, used as qualifiers.
For the corresponding deuterated analogues, only one tran-
sition was monitored. Table 1 summarises the MRM transitions
and conditions of all quantifiers and qualifiers for all analytes
and I.S.
Injection of single analyte solutions did not produce interfe-
rence in the other MRM channels. Linearity data, LOQ and LOD
are shown in Table 2. No interference peaks were observed in
the antidepressants MRM channels when blank plasma samples
spiked with 27 benzodiazepines were analysed.
The intra-assay precision (repeatability) and inter-assay pre-
cision were satisfactory, with all relative standard deviations less
than 20% (Table 3). Results indicated that the accuracy of the
assay was >81%.
The stability of spiked samples (40, 200, 800 g/L) was
monitored at 24 and 48 h while kept in the autosampler at
6 ± 2 ◦C. No statistical significant difference could be observed
for the three different concentrations, except for clomipramine
and norclomipramine where a slightly negative trend was
observed (P > 0.05), but it did not compromise de quantifica-
tion. All compounds were stable (P < 0.05) after the three freeze
thaw/cycles.
Insufficient sample clean-up can result in matrix effects,
leading to either suppression or enhancement of the analyte
Fig. 3. Post-column infusion experiments: matrix effect. (1) trazodone, (2) paroxetine, (3) nortriptyline and (4) amitriptyline, of an injection of a mobile phase control
(A) and a blank sample following the extraction of plasma (B). The shaded area indicates the elution position of the respective antidepressants.
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response. This can lead to variable sensitivities and decreased
precision and accuracy. Consequently, in the development of any
LC–MS(/MS) method, the potential for any such ion suppres-
sion or enhancement should be assessed. Post-column infusion
experiments (based on the method described by Bonfiglio et
al. [40]) were performed to provide information of the effect
of the matrix throughout the course of the elution time for the
analytes. An example of the effect on drug response, obtained
following the injection of a mobile phase control, is shown in
Fig. 3A. As expected, no changes in response were observed.
Another example of the effects obtained following the injec-
tion of a sample subjected to XLC are given in Fig. 3B. The
results confirm the utility/benefits of the extraction as a sam-
ple clean-up before chromatography to obtain reproducible and
reliable quantitative results for all the compounds without major
interferences of matrix compounds. A second experiment was
carried out and we compared peak responses obtained when
the antidepressants were spiked to a blank plasma sample with
the responses obtained when the antidepressants were added
to a sample where the plasma was substituted with water. No
statistically significant differences in peak areas were observed.
The Oasis MCX Prospekt cartidges (30 mg, 1 mL) utilise
mixed-mode (cation-exchange) sorbents, which provide effec-
tive sample clean-up for basic drugs. The results of the extraction
recovery study are presented in Table 4. Very high and repro-
ducible recoveries were obtained with this SPE procedure for
all analytes and all compounds were totally eluted from the SPE
cartridge at the elution step conditions.
The validated SPE–LC–MS–MS method was applied to the
analysis of 11 authentic samples from clinical cases and pre-
viously analysed by liquid chromatography with diode array
detection (DAD) using a routine screening method. The results
Table 4
Extraction recovery and matrix effect
Recovery (%) Estimated matrix
effect after SPE (%)















Data represent the mean of three experiments with a 1000 g/L calibrator.
of both methods were compared qualitatively (Table 5). Fig. 4
shows the chromatogram obtained after the analysis of one of
these samples, positive for trazodone and venlafaxine. The mea-
sured concentrations varied in a wide range and several samples
had to be re-analysed after 1:10 dilution with blank plasma.
Several analytical methods for the determination of antide-
pressants have been published using LC or LC–MS/MS.
However, most of them only allow the determination of one or
few compounds with longer off-line SPE procedures [30,41–43].
Sauvage et al. [44] have also developed an innovative method
for the determination of 13 antidepressants and some metabo-
lites using turbulent-flow liquid chromatography (TFC). The
Fig. 4. Typical MRM chromatograms obtained following the analysis of one authentic plasma sample. Concentrations were 127 g/L for venlafaxine (A) 1036 g/L
for trazodone (B). The figure shows the response for the two transitions of both compounds (quantifier and qualifier). Peak intensity is shown in the top right-hand
corner of each trace.
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Table 5
Comparative results when analysing the real samples with the on-line
SPE–LC–MS/MS method and LC–DAD
Sample ID Concentration (g/L) SPE-LC-MS/MS LC-DAD
1 Citalopram (14) −
Fluoxetine (114) +
Norfluoxetine (47) +
2 Trazodone (1036) +
Venlafaxine (127) +
3 Fluoxetine (214) +
Norfluoxetine (170) +
4 Trazodone (1963) +
5 Fluoxetine (381) +
Norfluoxetine (95) +
6 Amitriptyline (132) +
Nortriptyline (90) +
7 Trazodone (1284) +
8 Fluoxetine (92) +
Norfluoxetine (47) +
9 Amitriptyline (1542) +
10 Fluoxetine (114) +
Norfluoxetine (160) +
11 Fluoxetine (108) +
Norfluoxetine (183) +
antidepressants were divided into two groups depending on their
chromatographic properties, thus two injections were necessary
to screen all the compounds. On the other hand, it shows lower
sensitivity and longer duration of entire total process (sample
preparation and analysis) when comparing to the present paper.
4. Conclusions
To our knowledge, this is so far the first on-line SPE method
with single use cartridges, coupled to LC–MS/MS applied for
the direct analysis of 14 antidepressants and metabolites in
plasma. The combination of on-line SPE with MS/MS allowed
the development of a high-throughput, fast and sensitive method
with a 20 min total analysis time without compromising the
method validation criteria. The method was successfully applied
to 11 authentic plasma samples, proven to be appropriate for
the quantification of low both dose as high dose of these
compounds in plasma collected from forensic toxicology cases.
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Abstract
Oral fluid (collected with the Intercept1 device) and plasma samples were obtained from 139 individuals suspected of driving under the
influence of drugs and analyzed for D9-tetrahydrocannabinol (THC), the major psychoactive constituent of cannabis, using a validated quantitative
LC–MS–MS method.
The first aim of the study was to investigate the correlation between the analytical data obtained in the plasma and oral fluid samples, to evaluate
the use of oral fluid as a ‘predictor’ of actual cannabis influence. The results of the study indicated a good accuracy when comparing THC detection
in oral fluid and plasma (84.9–95.7% depending on the cut-off used for plasma analysis). ROC curve analysis was subsequently used to determine
the optimal cut-off value for THC in oral fluid with plasma as reference sample, in order to ‘predict’ a positive plasma result for THC. When using
the LOQ of the method for plasma (0.5 ng/mL), the optimal cut-off was 1.2 ng/mLTHC in oral fluid (sensitivity, 94.7%; specificity, 92.0%). When
using the legal cut-off in Belgium for driving under the influence in plasma (2 ng/mL), an optimal cut-off value of 5.2 ng/mL THC in oral fluid
(sensitivity, 91.6%; specificity, 88.6%) was observed.
In the second part of the study, the performance of the on-site Dräger DrugTest1 for the screening of THC in oral fluid during roadside controls
was assessed by comparison with the corresponding LC–MS–MS results in plasma and oral fluid. Since the accuracy was always less than 66%, we
do not recommend this Dräger DrugTest1 system for the on-site screening of THC in oral fluid.
# 2006 Elsevier Ireland Ltd. All rights reserved.
Keywords: Oral fluid; Plasma; THC; Driving under the influence; Roadside drug test
1. Introduction
In Belgium, cannabis is the most frequently detected drug in
cases of driving under the influence of drugs (DUID) and
surveys show an increase in current and lifetime consumption
[1]. As with many other CNS active drugs, experimental studies
using instrumented cars have shown that the use of cannabis
(100–200 mg/kg) significantly affects the standard deviation of
lateral position (SDLP), which is somewhat higher than the
impairment produced by 0.5 g/L ethanol [2]. Drummer et al.
obtained epidemiological data for D9-tetrahydrocannabinol
(THC), the major psychoactive constituent of cannabis, in
blood during an Australian responsibility study on 3398 fatally
injured drivers [3]. Results confirmed that the probability of
being responsible for a crash is significantly higher in drivers
with THC in their blood than in the group of the drug-free
drivers. An odds ratio of 2.7 was calculated for the group of
THC-positive drivers. The risk of being culpable for a fatal
crash increased to nearly seven-fold when THC blood
concentrations exceeded 5 ng/mL.
For several years now, fast urine tests have been used to
detect illegal drugs in different settings, e.g. workplace drug
www.elsevier.com/locate/forsciint
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testing, treatment programs and roadside screenings. However,
the detection of cannabinoids in oral fluid is a better indication
of recent use than the detection in urine [4,5]. Despite the lack
of contribution from blood THC to oral fluid concentrations,
Niedbala et al. [4] and Huestis and Cone [6] showed that, after
dissipation of the initial contamination of oral fluid during
smoking (generally within 30 min), THC levels in oral fluid
followed a similar time course as plasma THC following
cannabis smoking under controlled dosing conditions.
The first on-site tests for drugs in oral fluid appeared in the
late 1990s, allowing an immediate testing of the oral fluid
specimen during roadside controls. At the initiative of the
European Commission, the Rosita (acronym for ROadSIde
Testing Assessment) study was started to evaluate the value of
on-site roadside tests for oral fluid and sweat. This study
showed that the on-site oral fluid screenings, particularly for
testing of THC, required significant improvement [7]. These
results are in concordance with other reports [8,9]. In 2003, the
Rosita-2 study was started, involving six European countries
and five US states, in order to evaluate new on-site oral fluid
devices.
Recently, we have developed a rapid and sensitive LC–
MS–MS method for the detection of THC in oral fluid
collected with the Intercept1 device [10]. The Intercept1 is
a Food and Drug Administration (FDA) approved sampling
device that is used on a large scale in the U.S. for workplace
drug testing [5]. It is also one of the devices currently being
used to collect oral fluid samples for confirmation analyses in
the Rosita-2 study [7]. The collection system contains a
buffer with stabilizing salts, non-ionic surfactants for surface
wetting and antibacterial agents, and guarantees a good
stability for most illicit drugs and their metabolites during
storage at 4 8C. However, these ingredients can also cause
interferences, e.g. ion suppression or enhancement during
LC–MS–MS analysis in the absence of a suitable clean-up
method. The value for recovery from the Intercept1 device
reported by Kintz et al. was 80.1  4.6% [11]. As stated by
these authors, one of the drawbacks of this collection device,
is that it is not possible to evaluate the amount of collected
oral fluid, even by weighing the test tube before and after the
centrifugation, as the volume of the blue buffer varies from
device to device. However, it was reported that the device
collects an average of 0.38  0.19 mL (range 0.05–0.8 mL)
of oral fluid [4] and a dilution factor of 1 in 3 is arbitrarily
accepted [4,5,11]. The problems associated with the
collection aspect of this device have been thoroughly
discussed in previous reports [4,5].
In the present study, the validated LC–MS–MS method was
used to determine concentrations of THC in oral fluid
(Intercept1 device) and plasma of impaired drivers, collected
at the roadside. Correlations between THC levels in both
biological matrices were established and the optimal cut-off for
oral fluid was calculated using ROC curve analysis (using
plasma as reference sample). In addition, the reliability of the
Dräger DrugTest1 for the detection of THC in oral fluid was
assessed by comparing its on-site results with the confirmatory
LC–MS–MS results in plasma and oral fluid.
2. Materials and methods
2.1. Biological samples
During the course of police controls, conducted over the
period from February 2004 until April 2005, 139 subjects
agreed to provide oral fluid samples on a voluntary basis
(written informed consent) in addition to plasma and urine. In
127 cases, the collection of the blood sample was preceded by
on-site analysis of oral fluid with the Dräger DrugTest1 system.
Blood samples were collected in 7 mL glass Vacutainer
tubes using sodium fluoride and potassium oxalate as anti-
coagulant. The tubes were cooled immediately to +4 8C (cool
box) and centrifuged the next day. The corresponding plasma
was frozen at 20 8C until analysis. Pooled blank plasma
samples were used for development and validation of the
procedure and were obtained from a local blood bank.
Oral fluid was collected with the Intercept1 device (OraSure
Technologies, Bethlehem, PA, USA) according to the
manufacturer’s instructions. The tubes were centrifuged and
the oral fluid was stored at 20 8C prior to analysis. Blank oral
fluid used for the preparation of negative controls, calibrators
and quality control (QC) samples was obtained from healthy
volunteers (also collected with the Intercept1). The data are
expressed as nanograms per millilitre of diluted specimen. The
exact volume of specimen collected by the individual devices
was not determined.
2.2. Analysis of oral fluid and plasma samples
Oral fluid samples were analyzed by LC–MS–MS for THC
according to a published validated procedure [10]. The limit of
quantification (LOQ) for THC was 0.5 ng/mL using 100 mL of
oral fluid.
The same procedure was applied to plasma samples.
Initially, the internal standard (THC-d3) at a concentration
of 5 ng/mL was added to 250 mL of specimen, calibrator or
control sample. Each sample was subsequently extracted with
4 mL of hexane. After mechanical shaking (30 min) and
centrifugation (10 min at 3000  g), the organic phase was
removed and evaporated to dryness at 40 8C under nitrogen.
The extract was reconstituted in 100 mL of mobile phase and
20 mL was injected into the LC–MS–MS system.
Quantitative analyses were performed using a Waters
Alliance 2690 separation module (Waters, Milford, MA,
USA), interfaced with a Quattro Premier tandem mass
spectrometer (Waters). Analytes were separated on a XTerra
MS C18 column (150 mm  2.1 mm, 3.5 mm) (Waters), eluted
isocratically with 1 mM ammonium formate–methanol (10:90,
v/v), delivered at a flow rate of 0.2 mL/min. Ionization was
achieved using electrospray in positive ionization mode (ESI+).
The optimum conditions were: capillary voltage, 2.0 kV; source
block temperature, 120 8C; desolvation gas (nitrogen) heated to
280 8C and delivered at a flow rate of 700 L/h. Collision-
induced dissociation (CID) of each protonated molecule was
performed. The collision gas (argon) pressure was maintained
at 0.35 Pa (3.5  103 mbar) and the collision energy (eV)
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adjusted to optimise the signal for the most abundant product
ions, which were subsequently used for multiple reaction
monitoring (MRM) analysis. The transitions were m/z
315.2 ! 193.1 and m/z 315.2 ! 259.3 for THC. The former
(and most prominent precursor-product transition) was used for
quantification and the latter transition used as a qualifier. The
transition for THC-d3 was m/z 318.2 ! 196.1.
2.3. Data analysis
The experimental data were processed to obtain the
following parameters: the true positives (TP, positive oral fluid
samples matching a positive plasma sample; positive drug tests
matching a positive oral fluid/plasma sample), true negatives
(TN, negative oral fluid samples matching a negative plasma
sample; negative drug tests matching a negative oral fluid/
plasma sample), false positives (FP, positive oral fluid samples
that were not confirmed in plasma; positive drug tests that were
not confirmed in oral fluid/plasma) and false negatives (FN, oral
fluid samples that were negative but corresponding to a positive
plasma result; drug tests that were negative but corresponding
to a positive oral fluid/plasma result). Based on these results, the
sensitivity, specificity and accuracy were calculated.
In addition, the LC–MS–MS results for oral fluid and plasma
were used to establish receiver operating characteristic (ROC)
curves: the sensitivity was plotted versus 100-specificity for
each cut-off concentration using MedCalc1 (version 7.3)
statistical software. The optimal cut-off for oral fluid to
‘predict’ a positive plasma result is the value corresponding
with the highest accuracy (minimal FN and FP results).
For the analysis of the results, the applied cut-off for oral fluid
was always the LOQ of the LC–MS–MS method for oral fluid
(0.5 ng/mL). For plasma, two different cut-off values were used:
the LOQof the LC–MS–MSmethod for plasma (0.5 ng/mL) and
the legal limit in Belgium for DUID (2 ng/mL for THC).
2.4. The on-site Dräger DrugTest1 system for oral fluid
Aspart of theBelgian participation in theRosita-2 project, the
Dräger DrugTest1 for the on-site detection of THC in oral fluid
was tested. This system combines the test strip method of
immunological drug detection with an innovative signal
technology known as UPT (Up-Converting Phosphor Technol-
ogy). It consists of twomain components: the Dräger DrugTest1
Kit for Oral Fluids (comprising the collection device and the test
cassettewith insertedbuffer cartridge) and theDrägerDrugTest1
Analyzer (a portable analyzer for reading the test cassette and for
data management). Different panel cassettes are available for
detecting up to six substance classes in a single cassette. The test
subject collects an oral fluid sample by gently moving the
collection device in the mouth for about a minute. The sampling
sponge swells in size as it soaks up the oral fluid, signaling to the
tester that the sampling process is complete. The collection
device is first inserted into the test cassette and pushed down to
release someof the oral fluid into the buffer cartridge. The handle
of the collection device is removed and the buffer cartridge is
sealed. After a 4 min reaction time, the buffer cartridge is turned
and lowered, triggering the immunological detection reaction
within the test cassette. After 8 min, the test cassette can be
inserted into theDräger DrugTest1Analyzer, which displays the
results of the analysis, distinct for each class of drugs, in the form
of a qualitative reading (positive or negative). According to the
manufacturer, the cut-off value for THC is 20 ng/mL.
3. Results and discussion
3.1. Validation of the analytical method for plasma
samples
Selectivity of the method was achieved by a combination of
retention time, precursor and product ions. Quantification was
based on the most prominent product ion (i.e. quantifier);
confirmation of THC was evaluated through the presence of the
second product (i.e. qualifier). At the LOQ the qualifier had a
signal to noise ratio (S:N) >10:1. The acceptance range for the
peak area ratio quantifier/qualifier was 2.34  0.28 for all
analyses.
Calibration curves for THC were prepared in blank plasma
for each batch and ranged from 0.5 to 100 ng/mL. Negative
controls and low and high QC samples containing 2.5 and
25 ng/mL THC respectively, were included in each batch. In
each case, a weighted (1/x) linear regression line was applied.
Linearity with correlation coefficients r2 > 0.999 were
achieved within the range investigated. The back-calculated
concentrations of all calibrators were compared with their
respective nominal values and were within 100  15% of the
nominal value. The LOQ, defined as the concentration of lowest
calibrator which was calculated to be within 20% of the
nominal value and with a % relative standard deviation (R.S.D.)
less than 20%, was 0.5 ng/mL. The intra-assay precision
(repeatability) and inter-assay precision (reproducibility) are
shown in Table 1. Intra-assay variation was evaluated by
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Table 1
Precision and accuracy data for the LC–MS–MS analysis of THC in plasma
Concentration
of QC (ng/mL)
Intra-assay precision (n = 5) Inter-assay precision (n = 10)
Mean concentration found (ng/mL) R.S.D. (%) Bias (%) Mean concentration found (ng/mL) R.S.D. (%) Bias (%)
2.5 2.5 3.4 1.1 2.6 11.9 2.0
25.0 24.9 1.1 0.5 25.3 11.1 1.1
Samples were prepared by the liquid–liquid extraction method as described in the text. QCs were prepared for every run in blank plasma. Intra-assay variation was
evaluated by replicate (n = 5) analysis of both QC samples in a single run. Inter-assay variation was evaluated by replicate analysis of the QC samples in several
experiments performed on 10 different days and by two operators. A comparison of the calculated concentrations of the QC samples to their respective nominal
values, was used to assess the bias of the method.
replicate (n = 5) analysis of both QC samples in a single run.
Inter-assay variation was evaluated by replicate analysis of
these QC samples in several experiments performed on ten
different days and by two operators. A comparison of the
calculated concentrations of the QC samples to their respective
nominal values, was used to assess the bias of the method.
Results indicated that the bias of the assay was 2.0% with all
R.S.D.s <12%. The recovery of the method was estimated by
comparing the response of a 5 ng/mL calibrator when the non-
deuterated compound was added before the extraction step
(n = 3) with the response obtained when the non-deuterated
analyte was added after sample preparation (n = 3). THC-d3
was added before the extraction step in both conditions. The
recovery was 79.2  0.9%. Matrix effects were evaluated by
post-column infusion as described by Bonfiglio et al. [12]. No
ion suppression or enhancement could be detected at the elution
time of THC (n = 3).
3.2. Comparison of analytical data in oral fluid and
plasma
The detection of the inactive metabolite 11-nor-9-carboxy-
THC in plasma, which is considered not to be present in oral
fluid [13], was not included in the method since only the
indication of recent cannabis use (through the presence of
THC) was of interest. In total, 139 combined oral fluid–plasma
samples were obtained. These plasma samples included 114
positive samples (82.0%) for THC using the LOQ of the LC–
MS–MS method at a cut-off value of 0.5 ng/mL. Using the
legal limit for plasma as a cut-off value (2 ng/mL), 95 cases
(68.3%) were positive for THC. The median concentration in
plasma (8.8 ng/mL) clearly exceeded the legal cut-off level;
concentrations ranged from 0.6 to 51.3 ng/mL. The analysis of
the oral fluid samples from the same subjects showed a median
THC concentration of 23.0 ng/mLwith concentrations ranging
from 0.5 to 1462 ng/mL. Table 2 presents the sensitivity,
specificity and accuracy when comparing the analytical data
obtained for oral fluid with those for plasma (i.e. the reference
sample), using both cut-off values for the detection of THC in
plasma. When using the LOQ of the LC–MS–MS method as
cut-off value for plasma samples, the sensitivity and accuracy
were >95%. A somewhat lower specificity of 84% was noted.
These results indicate a good correlation of oral fluid and
plasma samples and are in concordance with previous
published reports, although other collection protocols and
cut-off values were used [14–17]. However, when applying the
legal cut-off value for plasma samples, the specificity
decreased dramatically (51.2%) due to a high number of FP
results. In this case, a high sensitivity was calculated since
there were no FN results. An accuracy of 84.9% was noted.
These results indicate a high probability of detecting recent
cannabis use, however, a certain number of positive oral fluid
samples may not be confirmed in plasma.
The usefulness of oral fluid testing for THC is dependent on
its ability to serve as a diagnostic indicator of recent cannabis
use. In this study, we determined what would be the optimal
cut-off for THC in oral fluid, in order to ‘predict’ that the
plasma sample would be positive for THC. This optimal cut-off
was calculated using ROC curve analysis, with different cut-off
values for plasma as reference sample: (A) the LOQ of the
analytical method and (B) the legal limit in Belgium. Using the
LOQ of the method, the analysis showed an optimal cut-off
value at 1.2 ng/mL oral fluid, corresponding to a sensitivity of
94.7% and a specificity of 92%. This cut-off value was
somewhat lower in comparison with the SAMHSA proposed
confirmation cut-offs in oral fluid, i.e. 2 ng/mL THC [18].
When applying the legal cut-off for plasma samples, a higher
optimal cut-off value of 5.2 ng/mL was calculated with a
sensitivity of 91.6% and a specificity of 88.6%.
3.3. Evaluation of the on-site Dräger DrugTest1 system
for the detection of THC in oral fluid
The sensitivity, specificity and accuracy for on-site oral
fluid analyses with the Dräger DrugTest1 for THC are shown
in Table 3, with either oral fluid or plasma (using the LOQ of
the method or the legal cut-off value) as reference sample. In
all cases, a low sensitivity and accuracy were noted (< 66%),
due to a high number of FN results. However, there is no
indication that the FN results correspond to the oral fluid
samples with the lowest concentrations of THC. The
application of higher confirmation cut-off values will
therefore not alter the results significantly. On the other
hand, the high number of FN results could be due to a state of
dryness in the oral cavity, leading to insufficient sample
volume in the sampling sponge. Based on previous reports,
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Table 2
Prediction of the presence of THC in plasma by LC–MS–MS analysis of the
corresponding oral fluid samples (collected with the Intercept1 device)




The sensitivity, specificity and accuracy were calculated based on the number of
true positives, true negatives, false positives and false negatives, using plasma as
the reference sample. The applied cut-off values were the LOQ of the method
for oral fluid (0.5 ng/mL) and either the LOQ of the LC–MS–MS method for
plasma (0.5 ng/mL) or the legal limit in Belgium for DUID for THC in plasma
(2.0 ng/mL).
Table 3
Sensitivity, specificity and accuracy of the on-site Dräger DrugTest1 system
during roadside controls, calculated based on the number of true positives, true







Sensitivity 49.5 50.9 57.8
Specificity 100 92.9 87.5
Accuracy 55.0 55.7 65.6
Either oral fluid or plasma were used as reference sample; the applied cut-off
values were the LOQ of the method for oral fluid (0.5 ng/mL) and either the
LOQ of the LC–MS–MS method for plasma (0.5 ng/mL) or the legal limit in
Belgium for DUID for THC in plasma (2.0 ng/mL).
the detection of cannabis use in oral fluid appears to be a
general problem for most on-site drug tests, due to low
sensitivities [8–10,14].
4. Conclusions
The aim of the study was to evaluate (A) oral fluid as a
predictor of positive plasma samples and (B) the use of the on-
site Dräger DrugTest1 system for the detection of THC in oral
fluid at roadside controls. Oral fluid (collected with the
Intercept1 device) and plasma samples were analyzed with a
validated LC–MS–MS method. The overall results of the study
indicated a good accuracy (84.9–95.7% depending on the cut-
off used for plasma analysis) when correlating THC detection
in oral fluid and plasma, suggesting that oral fluid is a good
predictor of actual cannabis influence. However, the Dräger
DrugTest1 system cannot be recommended for on-site oral
fluid tests for THC due to the low accuracy (<66%). The search
for an on-site screening method that can provide acceptable
accuracies for the detection of THC in oral fluid remains a
major hurdle.
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Abstract
Recent years have seen the development of powerful technologies that have provided forensic scientists with new analytical capabilities,
unimaginable only a few years ago. With liquid chromatography–mass spectrometry (LC–MS) in particular, there has been an explosion in the
range of new products available for solving many analytical problems, especially for those applications in which non-volatile, labile and/or high
molecular weight compounds are being analysed. The aim of this article is to present an overview of some of the most recent applications of
LC–MS (/MS) to forensic analysis. To this end, our survey encompasses the period from 2002 to 2005 and focuses on trace analysis (including
chemical warfare agents, explosives and dyes), the use of alternative specimens for monitoring drugs of abuse, systematic toxicological analysis
and high-throughput analysis. It is not the intention to provide an exhaustive review of the literature but rather to provide the reader with a ‘flavour’
of the versatility and utility of the technique within the forensic sciences.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
The term “forensic science” covers those professions which
are involved in the application of the social and physical sciences
to the criminal justice system. Forensic experts are required to
explain the smallest details of the methods used, to substantiate
the choice of the applied technique and to give their unbiased
conclusions—all under the critical and often mistrustful gaze of
the servants of the justice, as well as the general public and the
media. The final result of the work of the forensic scientist exerts
a direct influence on the fate of a given individual. This burden
is a most important stimulus, and one which determines the way
of thinking and acting in forensic sciences. Consequently, the
methods applied in forensic laboratories should assure a very
high level of reliability and must be subjected to extensive quality
assurance and rigid quality control programs. The legal system
is based on the belief that the legal process results in justice. This
has come under some question in recent years. Of course, the
forensic scientist cannot change scepticism and mistrust single-
handedly. He or she can, however, contribute to restoring faith
in the judicial processes by using science and technology in the
search for facts in civil, criminal and regulatory matters.
Recent years have seen the development of powerful tech-
nologies that have provided forensic scientists with new analyt-
ical capabilities which were unimaginable only a few years ago.
The ability of mass spectrometry (MS) to extract chemical fin-
gerprints from microscopic levels of analyte is invaluable in this
quest, enabling the legally defensible identification and quan-
tification of a wide range of compounds. Gas chromatography
(GC)–MS, liquid chromatography (LC)–MS, isotope ratio (IR)-
MS and inductively coupled plasma (ICP)-MS have become
routine tools to enable detection and characterization of minute
quantities in what can often be very complex matrices.
In the case of LC–MS, the last two decades have seen some
significant developments and improvements in instrumentation
design. Particularly noteworthy has been the introduction of
robust, user-friendly interfaces such as those based on atmo-
spheric pressure ionisation techniques, e.g. electrospray (ESI)
and atmospheric pressure chemical ionisation (APCI). Conse-
quently, many analysts and laboratories are finally at the point
where they are considering the acquisition of LC–MS capabili-
ties. According to Willoughby et al. [1] LC–MS has progressed
from the “innovators” stage through the “early adaptors”, to the
“early majority” stage and is now open to specialists from a
variety of disciplines, especially for those applications where
involatile, labile and/or high molecular weight compounds are
being analyzed.
The purpose of this article is to review some of the most recent
applications of LC–MS (/MS) to forensic analysis with special
focus on the following; trace analysis, the use of alternative spec-
imens for monitoring drugs of abuse, systematic toxicological
analysis and high-throughput analysis.
2. Trace chemicals
2.1. Chemical warfare agents
Determining the use of chemical warfare agents (CWAs) in
times of war or in acts of terrorism requires rapid and reliable
methods. The sarin gas attacks by a Japanese cult in Matsumoto
city (1994) and the Tokyo subway system (1995) represented the
first cases in which a CWA was indiscriminately released against
a civilian population [2]. The latter incident resulted in the deaths
of 12 people and led over 5000 to seek medical attention. Nerve
agents are extremely potent organophosphorus compounds that
cause biological effects by irreversibly inhibiting the enzyme
acetylcholinesterase (AChE). To confirm exposure, biological
samples, e.g. urine, can be analysed for the agents themselves,
their metabolites or their degradation products. Nerve agents are
rather volatile compounds, thus analysis by GC–MS might be
considered the obvious choice. However, in an aqueous environ-
ment, these agents readily hydrolyse to produce alkyl alkylphos-
phonates (RMPAs), these in turn can be further hydrolysed to
methyl phosphonate (MPA) (Fig. 1). LC–MS is increasingly
being used for these low molecular weight, highly polar com-
pounds whilst exploiting the benefits over GC–MS, of reduced
sample handling and no requirement for derivatisation [3–5].
Hayes et al. [6] recently developed LC–tandem MS
(LC–MS/MS) methods for the analysis of the short-lived
metabolites of several CWAs including; sulfur mustard, sarin,
soman, cyclohexyl methylphosphonofluridate (GF) and O-ethyl
S-2-diisopropylamino ethyl methylphosphonothioate (VX) in
urine. These methods were also used to determine the feasibil-
ity of using saliva as a complementary or alternative matrix to
urine; this could be a particularly valuable approach to assess the
exposure of young children, where collection of a urine sample
on demand is often difficult.
VX comprises a mixture of two enantiomers which demon-
strate significant differences in the rate of AChE inhibition and
overall toxicity. Thus, the ability to distinguish between them is
desirable for toxicological studies and for the development of
antidotes. Smith [7] has used normal-phase LC in conjunction
with MS detection for this purpose.
LC–MS has also been used to investigate the longer-lived
metabolites. Several groups have used LC–MS to determine the
metabolites of sulfur mustard, i.e. the -lyase metabolites in
urine samples from human casualties after sulphur mustard poi-
soning [8,9].
In the case of large-scale attacks, analysis of the environ-
ment and other materials may also be required. Hancock and
D’Agostino have developed a LC–ESI-MS (/MS) procedure
which allows the identification of a munitions grade sample of
tabun, sarin, soman, GF and the nerve agent stimulant triethyl
phosphate (TEP) on manmade fibres [10]. Although this tech-
nique uses only minimal sample preparation the same group
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Fig. 1. Hydrolysis pathway of nerve gases and the alkyl alkylphosphonates (RMPAs) namely, isopropyl (IMPA), pinacolyl (PMPA) and ethyl (EMPA) methyl
phosphonates. In turn, these can be hydrolysed to methyl phosphonate (MPA).
have more recently experimented to omit sample preparation
completely and to allow the direct analysis of TEP collected on
solid-phase microextraction (SPME) fibres [11].
The biotoxin ricin originates from the seeds (castor beans)
of the Ricinus communis plant and is extremely toxic (human
LD50 estimated at 3–30 g/kg by inhalation or ingestion, respec-
tively) [12]. It has the unique position of being the only protein
listed under the Chemical Weapons Convention and is of foren-
sic interest due to its potential for terrorist use or as a homicide
agent [13]. Due to the high molecular weight of this compound
(66 kDa) absolute structural elucidation of the intact protein
is not possible using nominal mass analysis. However, several
groups have used a preliminary enzymatic digestion to convert
the protein into intermediate molecular weight peptides followed
by LC–MS (/MS) using a hybrid quadrupole time-of-flight (Q-
TOF) instrument [12,14]. The methods were used to characterise
purified ricin from several different varieties of R. communis and
also from crude castor bean extracts.
2.2. Explosives
The analysis of trace levels of explosives is critical in crime
scene forensic investigations, homeland security and environ-
mental analysis. LC–MS is a well-established technique for
explosives in associated complex matrices such as post-blast
residues and in environmental samples such as soil and plant
material extracts [15,16]. Although these compounds have a low
vapour pressure they tend to be heat labile and can degrade at the
high temperatures typically used in GC injectors. Thus, LC–MS
is particularly well-suited to the analysis of these relatively polar
molecules, heat labile compounds. Many of the methods rely on
the formation of cluster or adduct ions for identification. Gapeev
et al. [17] studied the formation of cluster ions of 1,3,5-trinitro-
1,3,5-triazacyclohexane (RDX), one of the most commonly used
military explosives in both ESI and APCI. Results showed that
in ESI, self-decomposition of RDX did not play a role in adduct
formation; the adducts were produced from impurities present
in the mobile phase at ppm levels. In contrast, with APCI, part
of the RDX molecule decomposes yielding a NO2− species; this
in turn clusters with other RDX molecules.
More recently, Mathis and McCord presented a compre-
hensive method to allow the screening of a panel of high
explosives including; RDX, 2,4,6,-trinitrotoluene (TNT), pen-
taerythritol tetranitrate (PETN), 1,3,5,7-tetramethylene-2,4,6,8-
tetranitramine (HMX), nitrogycerine (NG) and ethylene glycol
dinitrate (EGDN). This method was based on the competitive
formation of adducts following infusion of the high explosives
with a mixture of four anions; chloride, formate, acetate and
nitrate. Information relating to the relative extent of adduct for-
mation (based on intensity ratios) in addition to adduct stability,
was used to provide a multiplexed detection scheme (Fig. 2) [18].
Anti-personnel (AP) mines are currently in place in over sev-
enty countries and are designed to maim or kill humans. In
addition to the lives that are lost, the mere suspicion that they
may be present, can prevent the use of large areas which could
otherwise be utilised for agriculture or social infrastructure.
Removal of landmines from such areas is known as humanitarian
de-mining and relies on the accurate detection of the explo-
sive. A potentially useful approach and one which is currently
under investigation, is the detection of the chemical vapours
which arise from the explosives and are transported into the
surrounding atmosphere. High sensitivity is required since the
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Fig. 2. (a) Mass spectrum of a mixture of high explosives containing EGDN,
NG, TNT, PETN, RDX and HMX in 50% MeOH/50% aqueous mixture with
0.3 mM ammonium chloride, ammonium formate and ammonium nitrate. (b)
Relative stability of high explosive adducts of chloride, formate, acetate and
nitrate using negative ion ESI-MS. From Ref. [18] with permission.
concentration of molecules expected to reach the gas phase is
low. Sanchez et al. [19] have developed a method for the sam-
pling and identification of nitroaromatic explosives. Air was
sampled at flow rates of up to 15 L/min using a holder fitted
with a C18 solid-phase extraction (SPE) membrane. After sam-
pling, trapped analytes were desorbed on-line and analysed by
LC–MS/MS using an APCI interface. Storage stability studies
indicated that the captured analytes were stable for 1 week or 3
weeks, when membranes were stored at room temperature or at
−4 ◦C, respectively. The method allowed the identification and
separation of most of the isomers of TNT and 2,4-dinitrotoluene
(DNT); limits of detection were in the range of femtogram/L.
The method is suitable for the chemical profiling of military-
grade explosives and is valuable for both forensic identification
and for de-mining purposes.
2.3. Dyes
Textile fibres found at a crime scene can be used as chemi-
cal evidence in a wide range of crimes; dye identification and
comparison can be of particular importance. Recently, Huang
et al. [20] have used LC–MS to enable unambiguous differ-
entiation between structurally related textile dyes which were
previously indistinguishable by UV–vis absorption profile or
by microspectrophotometry. They concluded that where single-
stage LC–MS fails to differentiate, analysis should be extended
to include LC–MS/MS of the extracted dye mixture.
The group of colour additives known as the Sudan dyes are
synthetically produced azo-dyes. Their degradation products are
considered to be carcinogens and teratogens. Due to this fact
their use as food additives is banned in the USA and the Euro-
pean Union (EU). However, in some countries they are still used
to enhance the colour of bell pepper and chilli powders. The dis-
covery of a batch of chilli powder contaminated with Sudan I
in February 2005 resulted in the largest product recall in British
history [21]. The widespread use of this batch of chilli powder
led to the withdrawal of hundreds of food products includ-
ing Worcester sauce, pizza and seafood sauces. Calbiani et al.
[22] reported a LC–MS/MS (nominal mass/low resolution triple
quadrupole) method for the simultaneous analysis of four Sudan
dyes in foodstuffs (Fig. 3). More recently, this group have used
capillary LC in conjunction with high-resolution MS instrumen-
tation to further distinguish between isobaric ions and to further
increase confidence by providing elemental composition [23].
Using exact mass in both MS and MS/MS experiments, they
were able to provide unambiguous confirmation of Sudan I in
authentic food samples.
Pepper sprays are readily available to law-enforcement per-
sonnel and to the general public for a variety of uses including
riot control and self-defence. In these cases, the presence of
pepper sprays, on clothing for example, may help to determine
the facts of an incident. A common active ingredient of these
sprays is capsaicin, an oily resin extracted from capsicum fruits.
Some of the pepper sprays also contain a coloured dye or a
UV-activated fluorescent marker to permit the localisation of
the product. However, there are now a number of products on
the market that do not contain such visible aids to analysis.
Cavett et al. [24] have developed a method to initially visualise
colourless pepper sprays on fabric and to subsequently confirm
the presence of naturally occurring and synthetic capsaicinoid
molecules. Visualisation was achieved by chemical derivatisa-
tion of the capsaicinoids using a diazonium salt. Identification
of the capsaicinoids and their derivatives was then accomplished
following methanolic extraction from the garment. Extracts were
analysed within 6.5 min, using a YMC Basic column in conjunc-
tion with LC–APCI-MS detection. Work is on-going to confirm
the spectra and proposed fragment ions of the derivatives via
MS/MS and exact mass determination.
3. Drugs of abuse in alternative matrices
For the detection of illicit drugs, plasma and urine are cur-
rently the most common matrices investigated. However, over
the past few years there has been an increased interest in the use
of more convenient, less invasive specimens, e.g. hair, oral fluid
and sweat, to document drug use and exposure [25,26]. Indeed
in April 2004, the US Department of Health and Human Ser-
vices proposed new guidelines for the use of these alternative
specimens as an adjunct to urine, for the testing of employees
in a number of situations including; pre-employment, random,
reasonable cause and post-accident testing [27]. For these sam-
ples, collection is relatively easy to perform and requires no
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Fig. 3. LC–ESI–MS/MS MRM traces obtained from 125 g/L standard solution of (a) Sudan I; (b) Sudan II; (c) Sudan III; (d) Sudan IV; (e) Disperse Orange 13
internal standard (100 g/L; left column) and from a blank chilli tomato and cheese sauce sample spiked with 125 g/L each (1685 g/kg sample) of (f) Sudan I; (g)
Sudan II; (h) Sudan III; (i) Sudan IV; (j) Disperse Orange 13 internal standard (100 g/L; right column). From Ref. [22] with permission.
special equipment or facilities. Furthermore, collection can be
supervised, thus reducing the opportunity for sample adulter-
ation. One of the main disadvantages however, of using these
alternatives is that the volume or amount of sample is usually
limited, consequently highly sensitive confirmatory techniques
such as LC–MS/MS become a necessity.
3.1. Hair
In addition to the convenience of sample collection, any drugs
and metabolites incorporated into hair, tend to persist much
longer than in conventional specimens. Recently, hair has been
used to document drug exposure in a variety of scenarios such
as forensic and workplace testing [28–30], to monitor compli-
ance to drug therapy [31,32] and particularly for investigating
cases of drug-facilitated crimes (DFC) [33–43]. The availability
of standard reference materials for drugs of abuse in hair is vital
and enables those laboratories performing hair analysis to check
the accuracy of their methods [44].
Over the last few years DFC, e.g. sexual assault and robbery,
have been increasing; these crimes are often difficult to prove
due to factors such as the low concentrations of drugs used, or
their rapid clearance from the body. In addition, many victims
of DFC do not report an incident until several days later, often
due to the amnesia caused by the drug. Hence, conventional
specimens such as blood or urine may have limited value. Hair
samples have been successfully used to document cases of
DFC involving a variety of drugs including; benzodiazepines
and the hypnotics (zolpidem and zopiclone), methadone and
buprenorphine [33–43]. Kintz and co-workers concluded that
due to the extremely low concentrations of drugs typically
encountered in hair analysis (low pg/mg) the “sensitivity of
LC–MS/MS appears to be a pre-requisite to document any
case involving drug-facilitated sexual assault”. However, they
also added the caveat that hair analysis should not simply be
considered as an alternative to blood and urine testing but as
a complementary technique where possible. The importance
of this was revealed in a controlled study to investigate the
window of detection for lorazepam in urine, oral fluid and hair
[39]. Following a single (2.5 mg) dose, the drug could be still
be detected in urine and oral fluid for 144 and 8 h, respectively,
after dosing. However, they were unable to detect lorazepam in
hair samples collected 4 weeks after administration.
Cheze et al. [42] used LC–MS/MS to conduct a survey into
the drugs most commonly used to commit DFC in Paris over
the period from June 2003 to May 2004. Out of the total of
128 cases investigated, 18% were proven DFC cases and they
found a high prevalence of zolpidem and clonazepam, followed
by bromazepam, nordazepam and midazolam (Fig. 4).
Laloup et al. [43] recently reported a LC–MS/MS method for
the simultaneous analysis of 26 benzodiazepines and metabo-
lites, zolpidem and zopiclone in blood, urine and hair. The
Fig. 4. Distribution of benzodiazepines and benzodiazepine-like hypnotics in
23 cases of proved DFC. From Ref. [42] with permission.
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method was applied to authentic samples from both clinical and
forensic cases, including the analysis of hair from a woman who
claimed to have been drugged and sexually abused over a period
of several years. Thirty-three centimetre lengths of hair were
submitted for analysis and cut into 1–3 cm sections; all segments
were found to be positive for more than one benzodiazepine,
indicating multiple drug exposure, with higher concentrations
closer to the root. These results demonstrated the utility of hair
to provide a long-term drug history.
3.2. Oral fluid
The use of oral fluid as an alternative specimen is also increas-
ing in popularity especially for monitoring recent drug use
within the workplace, at the roadside, in prisons and to check
compliance to medication.
Concheiro et al. [45] developed a method for the quan-
tification of the active constituent of cannabis, i.e. 9-
tetrahydrocannabinol (9-THC) in oral fluid. Samples were
collected by spitting into polypropylene tubes. Two hundred
microlitres of sample was processed using liquid/liquid extrac-
tion (LLE) with hexane followed by analysis using LC–MS.
Limits of detection of 2 g/L were achieved. Wood et al. [46]
reported a validated method for the simultaneous analysis of six
amphetamines in oral fluid (also collected by expectoration).
The procedure required only 50 L of sample to achieve limits
of detection of 2 g/L or better and comprised rapid and sim-
ple sample preparation, i.e. protein precipitation (PPT) using
methanol followed by LC–MS/MS. Dams et al. [47] described
a method for methadone and multiple illicit drugs in addition
to their metabolites in oral fluid. Their method also involved
PPT using acetonitrile followed by LC–MS/MS analysis. The
method proved useful for determining methadone concentra-
tions in pregnant opiate and/or cocaine addicts.
Although the methods referenced above utilized oral fluid
that has been collected by expectoration, it should be noted
that the increased interest in oral fluid has also been accompa-
nied by an increase in the availability of specialized collection
devices; these promise a simplified, more controllable collection
and sample stability. The final choice of oral fluid collection sys-
tem, however, has been shown to have serious implications on
drug analysis [48–50]. The Intercept is a US Food and Drugs
Administration (FDA) approved sampling device that is used
on a large scale in the USA for workplace drug testing and
is one of the devices currently under investigation in a joint
roadside study between the EU and the USA to detect driving
under the influence of drugs [51]. The collection system con-
tains additives which can cause problems, e.g. ion suppression
during LC–MS/MS analysis in the absence of a suitable clean-
up method. Several groups have employed LLE (with hexane)
to prepare the so-called ‘preserved oral fluid’ specimen prior
to analysis; drugs of interest have included 9-THC, benzodi-
azepines and hypnotics [52,53]. A SPE method has also been
developed, which is combined with LC–MS/MS to allow the
simultaneous determination of a panel of common basic illicit
drugs [50]. Work is underway to extend the current panel of
analytes to include 9-THC [54].
Other groups have used different devices to collect samples
for the purpose of drug monitoring. Wylie et al. [55] developed
a method for the analysis of 49 licit and illicit drugs in oral fluid
collected using the Omni-Sal device. Samples were extracted
using SPE and then analysed by LC–MS/MS and GC–MS.
Recently, Teixeira et al. [49] used the Salivette device to
collect samples and to quantify 9-THC in oral fluid samples
following SPE and LC–MS.
A method was developed for the separation of the enan-
tiomers of methadone and its metabolite EDDP in saliva [56].
Methadone is administered therapeutically as a racemic mix,
i.e. a 50:50 mix of the enantiomers. There are significant
differences between the enantiomers in terms of receptor
affinity, analgesic potency and pharmacokinetic profiles. Thus,
therapeutic monitoring of this agent and its metabolite requires
an enantioselective technique. Samples were collected using
the Salivette device. Following centrifugation, analytes were
separated using an immobilized 1-acid glycoprotein chiral
stationary phase (AGP-CSP) in conjunction with MS detection.
The optimized and validated method was applied to the analysis
of samples collected from patients following a methadone
maintenance program.
3.3. Meconium
Drug abuse during pregnancy is a major problem and has
been associated with prenatal complications and high morbidity
and mortality rates of newborns. Some birth defects are thought
to be related to fetal exposure to drugs. Detection of in utero drug
exposure has traditionally been accomplished by urine drug test-
ing. However, this only reflects maternal drug use over the last
3–4 days and abstinence of the mother for several days prior
to delivery, may produce a negative result. Monitoring expo-
sure through testing of alternative matrices, such as neonatal
meconium and hair, offers advantages including non-invasive
collection and detection earlier in gestation [57–59].
Meconium is the first fecal matter produced by the neonate
typically within the first 5 days after birth. Since the formation
of meconium starts between the 12th and 16th week of gestation
and accumulates in the fetal bowel until birth, use of this speci-
men can extend the window of drug detection considerably, i.e.
to approximately the last 20 weeks of pregnancy.
Pichini et al. have described methods for the analysis of opi-
ates and cocaine and respective metabolites [60] and for the
analysis of amphetamine derivatives in this specimen [61]. In
both cases samples were prepared by SPE and analysis was
achieved using LC–MS (three qualifying ions per compound).
Sensitivity was sufficient to allow the detection of all drugs
in the low nanograms per gram meconium. Another report
describes the application of LC–MS/MS for the simultane-
ous quantification of methadone and its metabolites in meco-
nium after methanolic extraction followed by SPE [62]. This
method represents an improvement over previous methods in
terms of sensitivity and specificity and was successfully applied
for the quantification of these compounds in meconium from
infants whose mothers were maintained on methadone during
pregnancy.
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3.4. Post-mortem alternative specimens
Clearly, alternative specimens can prove invaluable for the
documentation of drug use in the living person. This can also
be true for post-mortem investigations. Toxicological analysis
of the usual post-mortem specimens can often pose special dif-
ficulties. This may because of the decomposed nature of the
specimens themselves and/or the presence of putrefactive com-
pounds. In the absence of any suitable tissues or fluids, insects
have been proposed as reliable alternate specimens and indeed
have been used to identify the presence of various drugs within
the cadaver [63,64]. Although the involvement and contribution
of the identified drugs to the actual death may be questionable,
the insect tissues have, nevertheless, proved a useful sample.
Wood et al. [65] presented a method for the simultaneous
analysis of 10 benzodiazepines in larvae and puparia of the
Calliphora vicina (Diptera, Calliphoridae). Benzodiazepines are
the most widely prescribed psychoactive active drugs in the
world. However, they are frequently misused and are conse-
quently often encountered in post-mortem analysis. Larvae were
prepared by homogenization followed by precipitation using
acetonitrile. Puparia were pulverized in a ball mill and then
extracted by ultrasonification in methanol. All extracts were sub-
sequently analysed using LC–MS/MS. The utility of this method
was confirmed through its application to the analysis of larvae
and puparia that had been reared on media spiked with a range of
concentrations of nordiazepam. The concentrations were equiv-
alent to those expected in skeletal muscle following fatal human
overdoses. Both the parent drug and its metabolite oxazepam
could be detected in single larvae or puparia.
Pien et al. [66] extended these preliminary studies to inves-
tigate the effects of different concentrations of nordiazepam on
larval development and growth. Larval development can be used
in the estimation of post-mortem interval. In some cases, the
presence of drugs has been shown to affect development of the
insect, consequently these disturbances can have serious impli-
cations on the accuracy of post-mortem interval calculations.
4. Systematic toxicological analysis using liquid
chromatography–mass spectrometry
The ability to screen for a large number of unknown ana-
lytes in human samples is of interest to many areas of society
including hospital emergency departments, forensic patholo-
gists, police/prison officials and employers. Currently, the ‘gold
standard’ for screening is GC–MS, owing in part, to the speci-
ficity and sensitivity of the technique, but also as a result of
the availability of large libraries of standardized electron ioni-
sation (EI) mass spectra. However, since GC–MS is limited to
the analysis of volatile and thermally stable compounds, and
because the technique usually requires a specific derivatisation
for polar analytes, alternative methods have been investigated.
One of the most important questions at present is: To what extent
can LC–MS be applied to the search for unknown substances?
Although its use as a confirmatory tool is becoming more widely
accepted, its use for screening purposes is still not fully estab-
lished. This is reflected in the many different LC–MS strategies
currently being investigated for systematic toxicological anaysis
(STA).
4.1. Targeted screening using liquid
chromatography–tandem mass spectrometry
One approach for screening is to use LC-multiple (or
selected) reaction monitoring (MRM or SRM) analysis. The
clear advantage of MRM analysis is in its specificity (sensi-
tivity); a precursor ion from the targeted molecule is selected by
the first quadrupole or mass filter, fragmented in the collision
cell and then a structurally significant or specific product ion (or
ions) selected by the second quadrupole filter. For confidence
in identification, several MRM channels should be included per
compound and their ratios calculated (and compared to stan-
dards). The main drawback in terms of screening, is that the
technique relies on the selection of a pre-defined precursor ion
in the first quadrupole. Clearly, this is not applicable to the
analysis of complete unknowns but rather is a method targeted
against a panel of known/expected compounds. Nevertheless,
this approach has been used successfully for single or multiple
drug classes in a variety of biological matrices. However, due to
the relatively low number of analytes often included, its utility
for screening of real toxicological samples may be limited. In an
attempt to circumvent this, investigators have attempted to cre-
ate targeted methods for much larger panels of drugs. In 2003,
Gergov et al. [67] reported a qualitative screening method for
238 drugs in blood. Following a two-step LLE procedure, com-
pounds were separated on a C18 column. For each compound,
identification was based on a single MRM channel and reten-
tion time (tR). For 80% of the drugs investigated, the analytical
sensitivity was sufficient to detect at therapeutic concentrations
in blood. Although clearly a useful method, the high number
of analytes meant that dwell times had to be low (25 ms), typi-
cally resulting in ∼4 data points across a chromatographic peak;
whilst suitable for qualitative purposes, this is insufficient for
accurate quantification which really requires 10–15 data points.
Furthermore, such limitations on dwell times also meant that
any attempts to try to increase the panel of drugs further, would
be problematic without providing better chromatographic sep-
aration between compounds or by using instrumentation with
faster scan capabilities.
Müeller et al. [68] recently presented a novel targeted method
for the analysis of 301 compounds. In this procedure an initial
‘survey’ scan was performed which involved monitoring 301
MRM channels. An intensity threshold was set and if any MRM
exceeded this pre-set threshold, the instrument was instantly
switched into ‘enhanced parent ion’ (EPI) scan mode. Product
ions were generated by acquisition at three different collision
energies, i.e. 20, 35 and 50 eV and the resultant spectra sub-
sequently searched against a database. The developed method
was successfully applied to blood and urine from forensic cases.
This procedure also met with the same limitations as the previ-
ous method, i.e. utilisation of the short dwell times means that
this technique is currently limited to ∼300 analytes; better chro-
matographic separation will be required if this is to be increased
in the future.
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4.2. Liquid chromatography–mass spectrometry with
reference libraries
An alternative to the use of MS/MS is single-stage MS. With
this technique, collision-induced dissociation (CID) can be per-
formed within the ion source region of the instrument and, by
employing different voltage settings on the cone or orifice, can be
used to generate reference libraries containing structural infor-
mation.
In some cases, a targeted panel approach is still used. Maurer
and co-workers have developed several LC–MS methods for the
screening of separate panels of drugs in plasma including; benzo-
diazepines and benzodiazepine-receptor agonists, beta-blockers
and neuroleptics [69–71]. Following sample clean-up and LC
separation, analytes were detected using full MS scan in positive
ionisation mode. Spectra were acquired throughout the chro-
matographic analysis at two fragmenter voltages, i.e. 100 and
200 V and compared then to the library spectra. Relative reten-
tion time (RRT) to the internal standard was used in cases of
doubt.
A more general, less targeted approach has been used by
some groups by employing larger spectral databases. In the cre-
ation of these databases two concepts have been used, i.e. the
use of single or multiple spectral entries per compound. Mar-
quet and co-workers have created libraries which are based on
single composite spectra. Data were acquired throughout the
chromatographic run in both positive and negative ionisation
modes, and at both a low and a high cone voltage setting, i.e. 20
and 80 eV. Thus, for each ionization mode a single reconstructed
spectrum was produced by summing the low and high spec-
tra [72,73]. The method was evaluated by comparison to their
other routinely used reference techniques including GC–MS
(underivatised) and HPLC-diode array detection (DAD) and
was shown to perform well in the identification of unknowns
in 51 serum samples. Seventy-five percent of compounds were
detected using the LC–MS method, compared to 66 and 71%,
for GC–MS and HPLC-DAD, respectively. The authors con-
cluded that the LC–MS technique performed at least as well as
their other standard reference techniques and that in future all
three analytical techniques would be employed simultaneously
in their routine work.
Humbert et al. [74] created a LC–MS CID library for more
than 500 toxicologically relevant compounds based on multi-
ple spectral entries/analyte. Data were acquired using up to six
different cone voltages in positive ionisation mode and six in
negative ionisation mode during a 30 min chromatographic sep-
aration. Each analyte could be therefore be characterized by a
maximum of 12 spectra in combination with tR. The technique
was assessed by the analysis of authentic serum and urine sam-
ples and performed well in comparison to their existing screen-
ing methods, i.e. LC-DAD and immunoassay. More recently,
Humbert and co-workers have been investigating the feasibility
of a generic sample preparation method. Currently they are eval-
uating the utility of LLE (both acid and basic) and an optimized
SPE procedure using MCX cartridges. Future investigations are
likely to include the possibility of an on-line version of the SPE
protocol [75].
To date, the major obstacle for the wide-spread adoption of
LC–MS in combination with reference libraries is considered to
be the variability of spectra between instruments; not only those
produced as a result of in-source CID but also those produced in
the collision cell when performing classical MS/MS on a tandem
MS instrument. Several groups have studied this phenomenon.
Jansen et al. [76] showed relatively poor MS/MS spectral repro-
ducibility both inter- and intra-instrument, despite an attempt
to standardise the fragmentation using a reference compound.
Spectra were studied on one instrument operated in EPI mode
with the same instrument operated in standard product ion scan
(PIS) mode. In addition, they studied PIS spectra obtained using
instruments from two other manufacturers. Since the main dif-
ferences appeared to be in relative ion intensities rather than
the actual ions present, they concluded that in library search-
ing algorithms it might be prudent to assign a heavier weight
to the m/z ratio rather than the relative intensity in the mass
spectra. These findings were in contrast to Gergov et al. [77]
who compared MS/MS spectra from a total of four instruments.
Two of the instruments were identical but installed in separate
toxicology laboratories; the other two instruments were from
two other manufacturers. All instruments were operated in PIS
mode using three different collision energies. Identical instru-
ments showed good agreement for MS/MS spectra. Following
standardization of instrument parameters, very good agreement
was also observed between the other brand instruments. Conse-
quently, they concluded MS/MS spectral libraries were indeed
suitable for inter-laboratory use after tuning.
4.3. Liquid chromatography–(tandem) mass spectrometry
with exact mass
The undeniable appeal of using TOF-MS for drug analysis
is related to its determination of the exact mass of the analytes,
i.e. mass assignment accurate to four decimal places. The abil-
ity to determine the m/z of an ion to within 5 parts per million
(ppm) allows the determination of a unique ionic formula based
on the mass sufficiency of the constituent atoms. The ability to
closely match the expected/theoretical mass with the observed
mass greatly increases the confidence of identification; effec-
tively removing matrix effects, reducing background signal from
interferences and by reducing the number of other possibili-
ties for identification. In other words, the better the accuracy
and precision of the mass measurement, the fewer the number
of compounds theoretically possible. Nowadays most LC-TOF
instrumentation is capable of routinely offering mass accura-
cies of 5 ppm or better. Furthermore, when operated in full scan
mode, these instruments can provide significantly better sensi-
tivity compared to a quadrupole instrument. The last few years
have seen some notable developments in both hardware and
software which have led to an overall increased robustness of
LC-TOF, e.g. the facility to allow the simultaneous introduction
of a reference or ‘lock-mass’ which serves to ensure accurate
mass assignment throughout the analytical run. In the past, one
of the disadvantages of TOF-MS was its lack of dynamic range;
modern instrumentation is now capable of offering linearity of
response over 3–4 orders of magnitude.
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One of the main limitations in building libraries based on
nominal mass is that it requires the analysis of primary refer-
ence compounds. Such material is not always easy to obtain,
particularly when dealing with metabolites, or the products of
the ever-changing designer drugs scene. Owing to the advan-
tage of the exact mass approach, any library can be created or
updated without requiring such reference material. Information
can be entered simply by provision of the molecular formula and
a calculation of the theoretical accurate mass of the target com-
pound. The utility of this was recently demonstrated by Laks
et al. [78] who used full scan LC-TOF to analyse street drugs
in seized material without reference standards being available.
It should be noted, however, that exact mass alone still cannot
always provide unequivocal identification of compounds, par-
ticularly in real forensic samples. This fact was illustrated in
earlier work by the same group who developed a novel screen-
ing method based on LC-TOF analysis followed by reference
to an exact mass database of 637 drugs, metabolites and pes-
ticides [79]. Since a significant number of these compounds,
i.e. 245 drugs, were metabolites, reference material (and con-
sequently tR information) was unavailable. Fifty autopsy urine
samples were analysed and the results compared to the refer-
ence GC–MS screening method. Parent drugs were classed as
positive by LC-TOF according to the following criteria; masses
were accurate within 30 ppm and tR values within 0.2 min. Due
to the fact that tR information for most of the metabolites was
unavailable, positive metabolite findings were determined by a
combination of theoretical accurate mass and the presence of a
specific parent compound (matching the aforementioned crite-
ria). Overall, the number of compounds identified by LC-TOF
was higher than GC–MS but, due to some false positives, the
authors concluded that a combination of accurate mass, tR and
metabolite profiles was really necessary for unambiguous iden-
tification of toxicological compounds.
Within the author’s own laboratory, work is underway to cre-
ate a rapid screening method for samples collected in suspected
DFC cases [80]. The method is based on ultra performance liq-
uid chromatography (UPLC) in conjunction with TOF analysis.
Identification of analytes is based on a combination of exact
mass, CID fragmentation patterns and tR.
4.4. Data (or information)-dependent acquisition
Another attractive possibility for screening is the use of data
(or information)-dependent acquisition (DDA or IDA) using LC-
TOF instrumentation. This technique is capable of finding true
unknowns since the method does not require any pre-selection
of masses but rather operates ‘on the fly’. Decaestecker et al.
[81] investigated the use of a Q-TOF instrument for STA. Dur-
ing the chromatographic run the instrument is initially set to
operate in MS mode, i.e. the quadrupole is operated in radio
frequency (RF)-only mode and transmits all masses until an
ion or ions exceed a certain threshold. Thereupon the instru-
ment instantly switches into MS/MS mode with the quadrupole
now selectively transmitting these ions of interest. Subsequent
fragmentation within the collision cell leads to the generation of
product ions. By limiting the TOF spectral accumulation time in
MS/MS mode (to a statistically acceptable minimum) the instru-
ment rapidly switches back into MS mode. Consequently, in a
single acquisition, the exact mass of the initial precursor ions and
any product ions are generated (Fig. 5). This method was used
to provide a comprehensive profile of 17 common drugs. The
limitations to this technique were the high and variable back-
ground signal seen with authentic samples which ultimately led
to low overall sensitivity and a lack of linear dynamic range.
More recently, Marquet et al. [82] explored the use of a DDA-
based method on a nominal mass instrument for STA. In this
procedure the instrument is initially set to operate in full scan
(‘survey’) mode until an ion exceeds a preset threshold at which
point the instrument switches into EPI mode. Product ions were
generated by acquisition two collision energies, i.e. 20 and 50 eV
in positive mode or −15 and −40 eV in negative mode. Resultant
spectra were subsequently searched against a database of com-
posite spectra. The performance of the method was assessed by
analysis of serum extracts spiked with eight test compounds and
compared to the results obtained with their reference method.
The method was successful in identifying all eight test com-
pounds. The authors stated that the main difficulties with the
technique were related to the settings of the threshold in survey
mode; at that time it was only possible to use one threshold set-
ting for all m/z ratios, thus too low a threshold meant that the
method was not selective enough, too high a threshold meant
that informative peaks could be lost.
4.5. Sample preparation: considerations for systematic
toxicological analysis
Currently there is no established or generic protocol for the
preparation of samples for STA; most investigators tend to use
some form of LLE or SPE. When analysing samples by LC–MS
techniques in particular, adequate sample clean-up has been
demonstrated to be critical and close attention must be paid to the
possibility of matrix effects, e.g. ion suppression or enhancement
[83]. These effects may, or may not, be obvious, especially when
taking into account the mode of data collection. For example,
the use of exact mass instrumentation can truly reduce matrix
effects by narrowing down the mass to such an extent that con-
taminating ions are ‘removed’ from the signal unless they fall
within a defined ppm range. On the other hand, the use of MRM
can essentially ‘blind’ us to, or mask, any contaminant which
may be (and most likely is) present in the sample, quite simply
because we are choosing to exclude them from our data in the
first place.
In an attempt to find a suitable generic sample prepara-
tion procedure, Müller et al. [84] assessed the ion suppression
effects associated with their own STA methodology (ESI in-
source CID/library searching). In these experiments they used
a post-column infusion of two test compounds, i.e. codeine and
glafenine to determine matrix effects (in positive and negative
mode, respectively), after several sample preparation protocols
including; LLE, mixed-mode SPE, PPT-only and PPT in com-
bination with polymer-based mixed-mode SPE. The results for
these two compounds indicated that their two-step LLE protocol
resulted in less ion suppression than the other methods investi-
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Fig. 5. (a) TIC in the MS mode, (b) MS extracted ion chromatogram of cocaine, (c) MS, (d) MS–MS spectra of cocaine and (e and f) TICs of the first two channels
in the MS–MS mode. From Ref. [81] with permission.
gated and that the most critical period for suppression, regardless
of the sample clean-up used, was just after the elution of the polar
LC front (∼2.9 min). After this, no significant suppression was
observed with any sample preparation method.
5. High-throughput liquid chromatographic–(tandem)
mass spectrometric analysis
High-throughput analysis is becoming increasingly impor-
tant in all areas of science; the forensic sciences being no excep-
tion. Moreover, due to the development of more potent drugs,
drug concentrations in biological samples are often present at
much lower levels than before. Therefore, fast analytical tech-
niques with much higher sensitivity and selectivity are needed.
One of the main bottlenecks in bioanalysis is often asso-
ciated with the sample preparation requirements, especially if
the method requires manual extraction techniques. However,
automation of off-line SPE is possible and the utility of “96-well
SPE” was introduced some years ago. Nowadays an even more
attractive approach is on-line SPE; the entire process of con-
ditioning, sample application, washing and elution takes place
at constant flow rates yielding better precision of quantitative
methods in comparison with off-line vacuum driven extrac-
tion procedures. Another important advantage is that no manual
M. Wood et al. / J. Chromatogr. A 1130 (2006) 3–15 13
transfers are made and that the whole of the eluate is loaded onto
the LC column without the need for a pre-concentration step.
A very elegant system for rapid analysis of complex samples
can be obtained by the on-line coupling of SPE or short-column
LC to MS detection. In this way, the sample is directly injected
into the SPE-MS system and a rate-limiting step is eliminated.
However, some restrictions should be considered, such as the
presence of endogenous matrix components, which can interfere
in the different stages of the procedure. This is certainly true if no
analytical column is present. Bruins et al. [85] developed a SPE-
MS/MS procedure for the detection of clenbuterol in urine. They
showed that the choice of sorbent was critical for the elimination
of matrix effects. In addition, it was noted that, with single stage
MS, the obtained sensitivity and selectivity were insufficient.
The detection of various opioids using on-line SPE-LC–MS
(/MS) has also been described; results were similar (or better)
in comparison to their corresponding off-line methods [86,87].
Using the Prospekt-2 system (Spark, Emmen, The Netherlands),
Kuhlenbeck et al. [88] developed an on-line SPE-LC–MS/MS
method for the determination of dextromethorphan, dextrorphan
and guaifenesin, the active ingredients of some cough medica-
tions, in human plasma. This system allows the simultaneous
extraction of the second sample in one clamp and the elution of
the first sample in the second clamp, thus leading to an optimal
use of the extraction time.
Another rate-limiting step in bioanalytical analysis is the
chromatography, especially when multiple drugs and metabo-
lites are monitored simultaneously. Efforts to increase the
throughput of chromatography are hindered by the inherent
chromatographic efficiency of traditional columns packed with
spherical silica particle phases and the pressure limit on con-
ventional HPLC systems. One approach to resolve these restric-
tions was the introduction of monolithic columns, which have
a bimodal pore structure, characterized by internal macrop-
ores and mesopores, providing extended surface area and high
permeability for mobile phase solvents. As such, the mass trans-
fer limitations inside the column are reduced, allowing higher
mobile phase flows and lower backpressures on the LC system.
Several approaches combining this monolithic chromatography
with the advantages of on-line SPE have been presented [89–91].
The advent of UPLC technology promises significantly faster
chromatography in addition to increased chromatographic res-
olution and sensitivity. The technology has resulted from a
culmination of developments in several areas including LC
columns based on smaller particle sizes (1.7 m) and the neces-
sary hardware to be able to cope with the associated increases
in system pressure. Yu et al. [92] described a comparison of
UPLC–MS/MS with the standard LC chromatography (also cou-
pled with MS/MS), for the separation of five drugs (ibuprofen,
alprazolam, naproxen, prednisolone, diphenhydramine) in rat
plasma and noted that UPLC demonstrated improved sensitiv-
ity, sharper peaks and faster separation. UPLC–MS was also
used for the analysis of seven -blockers and results com-
pared to those obtained using LC–MS. They concluded that
UPLC gave superior separation performance and that the qual-
ity of the mass spectra, were at least as good as those obtained
with their standard LC conditions [93]. A study conducted by
Apollonio et al. [94], demonstrated the benefits of this tech-
nique for the determination of the commonly occurring “club”
drugs and of the more novel analogues p-methoxyamphetamine
(PMA), 4-methylthioamphetamine (4-MTA) and N-methyl-
1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB). Others
have reported improved chromatographic resolution and a reduc-
tion in ion suppression with their UPLC based methods, ulti-
mately this has led to increased sensitivity and lower limits of
detection [95,96].
6. Conclusion
The combination of LC and MS has been used for many
years. However, since the introduction of more user-friendly
LC-interfaces, e.g. ESI and APCI, there has been a tremendous
increase in the popularity of the technique amongst scientists
from a wide variety of disciplines. LC–MS has evolved into a
robust and reliable tool that also offers versatility, specificity
and sensitivity.
For those involved in the forensic sciences in particular, the
use of LC–MS has changed considerably. Where it was once
a technique that was only used very infrequently, i.e. as an
alternative to GC–MS for the more ‘troublesome’ analytes, it is
now used extensively and has proved itself invaluable especially
for the analysis of highly polar, involatile and thermolabile
compounds.
The analytical environment is a dynamic one. Most tech-
nological advances are driven by analytical demands; e.g. the
need for faster, more accurate/robust analysis. New and exciting
technologies are constantly emerging. One of the most recent is
UPLC, its advent promises significantly faster chromatography
in addition to improved chromatographic resolution and sensi-
tivity. It seems likely that over the next few years, we will see
a significant increase in the use of this technology within the
forensic sciences. The increased analytical capabilities afforded
by UPLC, in turn drives the need for improved detection systems;
in the case of MS detection, this means faster scan capabilities.
Thankfully, continual developments in hardware and software
lead to more robust, easier-to-use and more accurate instrumen-
tation, all of which, help to establish what might initially be
considered to be a ‘novel’ technique, and one which was only
available to ‘innovators’, into one which is usable in a more
routine setting and available to a wider group of analysts.
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A liquid chromatography–tandem mass spectrometry method
was developed for the simultaneous quantification of
26 benzodiazepines and metabolites, zolpidem and zopiclone, in
blood, urine, and hair. Drugs were extracted from all matrices by
liquid–liquid extraction with 1-chlorobutane. Chromatography was
achieved using a XTerra MS C18 column eluted with a mixture of
methanol and formate buffer. Data were acquired using positive
electrospray ionization and multiple reaction monitoring using one
precursor ion/product ion transition per compound.
Quantification was performed using 13 deuterated analogues.
Further confirmation of the identity of the compounds was
achieved through a second injection of positive samples,
monitoring two transitions per compound. The limits of
quantification for all benzodiazepines ranged from 1 to 2 ng/mL in
blood, 10 to 25 ng/mL in urine, and 0.5 to 10 pg/mg in hair.
Linearity was observed from the limit of quantification of each
compound to 200 ng/mL, 1000 ng/mL, and 1000 pg/mg for blood,
urine, and hair, respectively (r2 > 0.99). Precision for quality
control samples, spiked at three concentrations, was calculated
(CV < 20% in most cases). Extraction recoveries for the three
matrices ranged from 25.1 to 103.8%, except for one compound
(cloxazolam in urine). Ion suppression was studied for all matrices.
The validated assay was applied to authentic blood, urine, and hair
samples from forensic cases.
Introduction
Benzodiazepines are a large class of prescribed psychoactive
drugs used widely for different medical conditions such as the
symptomatic treatment of anxiety and sleep disorders, the
treatment of anxiety-related conditions, and as anti-convul-
sants (1). Benzodiazepines bind with high affinity to the - s u b-
unit of the GABAA receptor in the central nervous system.
Zolpidem and zopiclone are structurally different from the
benzodiazepines, but also bind to the GABAA receptor. They
provoke the same (side-) effects as the benzodiazepines, in-
cluding sedation and hypnosis. Chronic use can generate tol-
erance to the effects.
Because of their wide therapeutic index, benzodiazepines
have a low risk of serious adverse reactions and toxicity. Un-
f o r t u n a t e l y, misuse of these compounds is often reported (1–4),
and they are often implicated in connection with various types
of crime, such as murder and drug-facilitated assault (5), in
suicide attempts (6), and, due to their interference with cog-
nitive and psychomotor functions, in road traffic accidents
(7,8). Consequently, benzodiazepines are frequently encoun-
tered in clinical and forensic toxicology cases.
Blood and urine are the conventional specimens to docu-
ment drug exposure. Hair analysis has proven to be a reliable
indicator of past drug abuse, as a complement to blood or
urine analysis, for proving or excluding chronic drug use, or,
at least, exposure to drugs; therefore it becomes highly useful
in monitoring long-term histories of drug abuse (9). As a bio-
logical matrix, hair offers particular advantages: it can be easily
obtained without violating individual privacy and, due to its
stability, it can be stored and transported without requiring
specific precautions. However, the extraction and detection of
benzodiazepines from hair samples is relatively difficult due to
the low levels of drugs that are incorporated into the hair.
Therefore, highly sensitive analytical techniques are required
for trace-level quantification of benzodiazepines.
A number of studies have been reported on the qualitative
and quantitative analysis of benzodiazepines and their metabo-
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lites in different biological matrices. Sev-
eral techniques have been used for the
toxicological analysis of benzodiazepines
in blood, urine, or hair, including im-
munoassays (10–14), gas chromatography
(GC) (11,14–19), and high performance-
liquid chromatography (HPLC)
(11,15,20–27). However, most methods
covered only a single substance or mix-
tures of a few benzodiazepines in only one
biological matrix. 
Until now, only three reports dealing
with the simultaneous analysis of a large
series of benzodiazepines have been pub-
lished. Pirnay et al. were the first to pub-
lish a GC–mass spectrometry (MS)–MS
ion trap method covering 22 benzodi-
azepines in urine and blood extracts after
trimethylsilylation of the drugs (28).
H o w e v e r, due to partial or full thermal
degradation of some benzodiazepines
during the injection step [a phenomenon
already reported by Japp et al. and We-
ston et al. (29,30)], decomposition prod-
ucts had to be taken into account in the
method. Detection thresholds for this
method were in the range of 10–500
ng/mL, except for the triazolo-benzodi-
azepines (alprazolam, estazolam, and tri-
azolam), for which the detection
threshold was 1000 ng/mL, due to poor
chromatographic resolution. 
The ability of HPLC to separate a large
range of underivatized substances, cou-
pled with the milder working conditions
of the technique, makes it particularly
valuable for the analysis of some of the
more thermolabile benzodiazepines.
Kratzsch et al. reported on a validated
LC–atmospheric pressure chemical ion-
ization-MS method for the screening of
23 benzodiazepines (their antagonist
flumazenil and zaleplon), zolpidem, and
zopiclone in plasma using liquid–liquid
extraction (31). After screening and iden-
tification in the scan mode using an
LC–MS library, the analytes were quanti-
fied in the selected-ion monitoring mode.
The limit of quantification (LOQ) ranged
from 0.5 to 200 ng/mL. Smink et al. de-
scribed an LC–MS(–MS) ion trap method
after solid-phase extraction for the deter-
mination of 33 benzodiazepines, metabo-
lites, and benzodiazepine-like substances
in whole blood (32). The LOQ for this
method ranged from 0.4 to 41.9 ng/mL.
In this report, a validated and highly
sensitive LC–electrospray ionization
Table I. MRM Transitions and Conditions for all Compounds and
Their Deuterated Analogues*
Precursor Product Cone Collision
Compound ion (m/z) ion (m/z) voltage (V) energy (eV)
7-Aminoclonazepam 286.00 120.80 40 28
250.10 40 20
7-Aminoflunitrazepam 284.00 134.80 40 28
227.00 40 25
Bromazepam 315.90 181.90 40 30
209.00 40 25
Clonazepam 315.90 214.00 38 35
270.00 38 25
Flunitrazepam 314.00 239.10 43 35
268.10 43 25
Clobazam 301.00 224.00 35 33
259.00 35 20
Desmethylflunitrazepam 300.00 198.00 40 38
254.10 40 25
Estazolam 295.00 205.00 35 40
267.10 35 23
Nitrazepam 282.00 180.00 38 35
236.10 38 25
Alprazolam 309.00 205.00 45 43
281.10 45 43
Chlornordiazepam 304.90 139.80 45 30
206.00 45 35
Temazepam 300.90 255.00 28 20
283.00 28 15
Desalkylflurazepam 289.00 139.80 43 28
226.00 43 28
Oxazepam 287.00 241.00 27 22
269.00 27 15
Nordiazepam 271.00 139.80 43 28
164.80 43 28
Brotizolam 394.90 279.10 40 28
314.00 40 23
Triazolam 342.90 308.10 45 25
315.00 45 30
Lormetazepam 334.90 176.90 25 40
289.00 25 22
Lorazepam 320.90 229.00 30 30
275.00 30 22
Prazepam 325.00 139.80 40 38
271.10 40 22
Clotiazepam 319.00 153.80 40 28
291.10 40 23
Tetrazepam 289.00 225.10 45 28
253.10 45 25
Diazepam 285.00 153.80 40 28
193.00 40 30
Loprazolam 465.00 84.70 48 23
110.80 48 25
Flurazepam 388.00 288.10 35 25
315.10 35 23
Cloxazolam 349.00 139.80 40 38
164.80 40 35
Zolpidem 308.10 91.70 45 50
235.10 45 35
continued
* Underlined transitions were used for quantification.
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(ESI)-MS–MS method is described for the
quantification of 26 commonly encoun-
tered benzodiazepines and their metabo-
lites, zolpidem and zopiclone, in three
different biological matrices (i.e., blood,
urine, and hair). This method covers
more than 85% of all benzodiazepines
and benzodiazepine-like substances reg-
istered for the Belgian market and was
applied to authentic blood, urine, and









Zopiclone 277.00 111.80 35 43
217.00 35 25
7-Aminoclonazepam-d4 290.00 120.80 40 30
7-Aminoflunitrazepam-d7 291.10 137.90 40 28
Clonazepam-d4 320.00 274.10 40 25
Flunitrazepam-d7 321.10 275.20 40 25
Alprazolam-d5 314.00 286.10 45 25
Temazepam-d5 305.90 260.10 25 23
Desalkylflurazepam-d4 293.00 139.80 45 30
Oxazepam-d5 292.00 246.10 40 23
Nordiazepam-d5 276.00 139.80 45 28
Triazolam-d4 349.00 314.10 40 28
Lorazepam-d4 326.90 281.00 30 20
Prazepam-d5 330.00 276.10 40 22
Diazepam-d5 290.00 153.80 40 28
* Underlined transitions were used for quantification.
Table I (continued). MRM Transitions and Conditions for all Compounds and
Their Deuterated Analogues*
Precursor Product Cone Collision
Compound Ion (m/z) Ion (m/z) Voltage (V) Energy (eV)
Figure 1. MRM chromatograms obtained following the analysis of a spiked hair sample with 10 pg/mg of flurazepam (1), cloxazolam (2), zolpidem (3), 7-amin-
oclonazepam (4), 7-aminoflunitrazepam (5), zopiclone (6), loprazolam (7), clonazepam (8), bromazepam (9), flunitrazepam (10), clobazam (11), desmethylflu-
nitrazepam (12), estazolam (13), nitrazepam (14), lorazepam (15), alprazolam (16), chlornordiazepam (17), temazepam (18), desalkylflurazepam (19), oxazepam
(20), nordiazepam (21), lormetazepam (22), triazolam (23), brotizolam (24), diazepam (25), tetrazepam (26), clotiazepam (27), and prazepam (28).
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temazepam, desalkylflurazepam, ox-
azepam, nordiazepam, triazolam, lor-
metazepam, lorazepam, prazepam,
tetrazepam, diazepam, and flurazepam (at
a concentration of 1 mg/mL in methanol)
and 7-aminoclonazepam-d4, 7-aminoflu-
n i t r a z e p a m - d7, clonazepam-d4, fluni-
t r a z e p a m - d7, alprazolam-d5, temazepam-
d5, desalkylflurazepam-d4, oxazepam-d5,
n o r d i a z e p a m - d5, triazolam-d4, lorazepam-
d4, prazepam-d5, and diazepam-d5 ( 0 . 1
mg/mL in methanol) were purchased
from LGC Promochem (Molsheim,
France). Brotizolam, clotiazepam,
chlornordiazepam, loprazolam, cloxa-
zolam, zolpidem, and zopiclone were a
gift from Dr. V. Maes (pure standards ob-
tained from respective manufacturers).
All solvents were HPLC grade.
Specimens
Pooled blank blood samples were used
for development and validation of the pro-
cedure for blood and were obtained from
a local blood bank. Blank urine and hair
samples for the development and valida-
tion of the procedure were obtained from
drug-free volunteers. Authentic blood,
urine, and hair samples were collected
during roadside controls for drugged
driving, from drug-facilitated sexual as-
sault (DFSA) cases (submitted as a part of
the sexual assault kit), suicide cases, and
(attempted) murder cases.
Preparation of standard solutions
An internal standard (IS) stock solu-
tion of each of the deuterated analytes
was prepared (0.4 μg/mL in methanol),
which was further diluted with methanol
to yield appropriate concentrations to add
to samples, calibrators, and quality con-
trol (QC) samples. 
A benzodiazepine stock solution of all an-
alytes was prepared (4 μg/mL in methanol)
and further diluted with methanol to yield
working solutions at appropriate con-
centrations to add to calibrators and QC
s a m p l e s .
Working solutions were prepared
monthly and stored at 4°C.
Sample preparation and extraction
Preparation of blood samples. B l o o d
samples (250 μL) were mixed with 50 μL
of a 1:4 dilution of the IS stock solution.
Preparation of urine samples. U r i n e
samples (250 μL) mixed with 50 μL of
Table II. Intra-assay and Interassay Precision and Bias of the QC Samples,
Prepared in Blood, Spiked at a Concentration of 4.0, 12, and 100 ng/mL
Concentration of 
Intra-assay Precision Interassay Precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
7-Aminoclonazepam 4 2.3 –2.8 3.1 –1.9
12 1.0 1.3 2.0 0.0
100 1.6 2.3 3.1 0.5
7-Aminoflunitrazepam 4 2.6 0.0 2.6 2.7
12 0.4 6.5 1.2 9.3
100 1.1 2.2 2.5 4.0
Bromazepam 4 5.9 –5.4 10.4 –1.7
12 2.8 –8.4 4.7 –4.0
100 5.3 –7.6 4.9 –1.1
Clonazepam 4 1.0 –4.7 2.2 –0.2
12 2.3 2.3 2.8 2.6
100 1.6 4.4 2.5 3.7
Flunitrazepam 4 2.4 –0.9 5.1 –2.0
12 2.4 0.9 2.9 –0.2
100 2.1 1.7 2.1 0.6
Clobazam 4 4.0 –1.9 5.1 1.2
12 2.6 6.3 4.7 5.6
100 3.1 4.5 4.4 3.7
Desmethylflunitrazepam 4 2.8 –18.0 10.6 –11.0
12 2.5 –12.9 10.6 –8.1
100 3.4 –13.7 9.6 –7.6
Estazolam 4 4.0 –3.6 4.2 –1.4
12 3.9 3.0 5.1 2.2
100 2.2 2.8 3.0 3.0
Nitrazepam 4 1.7 –8.8 7.7 –4.0
12 1.6 –6.2 5.8 –1.9
100 5.0 –11.6 6.9 –4.9
Alprazolam 4 6.3 6.0 6.5 14.5
12 3.8 –4.6 4.4 –1.9
100 3.2 0.8 3.0 0.2
Chloornordiazepam 4 3.2 –0.3 5.1 –1.3
12 4.9 4.2 6.0 0.5
100 2.1 7.6 4.3 3.1
Temazepam 4 3.1 0.6 5.1 –1.0
12 3.0 1.8 3.7 –0.3
100 2.1 2.1 2.0 0.7
Desmethylflurazepam 4 1.1 –1.6 4.6 –1.5
12 3.2 –0.6 3.5 –0.9
100 1.3 1.4 2.2 0.9
Oxazepam 4 3.4 –2.8 5.3 1.0
12 3.0 1.4 5.6 0.8
100 1.7 0.9 2.7 1.4
Nordiazepam 4 5.4 –17.2 4.3 –2.8
12 4.3 –2.6 5.2 –0.2
100 3.7 1.8 4.1 1.4
Brotizolam 4 3.6 –1.8 7.1 0.3
12 3.1 –0.1 9.4 –1.3
100 1.3 1.0 6.2 1.6
Triazolam 4 3.4 0.8 6.3 –2.2
12 6.1 2.1 5.4 0.5
100 4.2 2.3 4.4 0.4
Lormetazepam 4 3.8 4.2 10.3 3.4
12 3.6 3.5 9.5 3.0
100 2.6 8.9 9.7 6.8
continued
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the IS stock solution were buffered to pH 4.6 with 200 μL
acetate buffer (3M) and then incubated for 1 h at 56°C with
25 μL of -glucuronidase (Helix pomatia, 127,300 U/mL)
(Sigma, St. Louis, MO).
Preparation of hair samples. After decontamination (twice
with dichloromethane, once with water, and once with
methanol, 15 min. each, under ultrasonication), hair sam-
ples were dried and cut in segments of 1–3 cm each. Approx-
imately 20 mg was powdered in a ball mill, which allowed
simultaneous pulverization of 48 segments (Precellys 48,
Bertin Technologies, Montigny-Le-Bretonneux, France), and
then 50 μL of a 1:20 dilution of the IS stock solution was
added. After incubation of the pulverized samples with 1 mL
of methanol at 45°C for 2 h with orbital shaking, samples
were centrifuged. The supernatants were subsequently trans-
ferred to 10-mL disposable screw-top vials and concentrated
under nitrogen to 100–200 μL.
Extraction. After sample preparation, samples were extracted
with 4 mL of 1-chlorobutane after the addition of a saturated
ammonium chloride buffer (pH 9.2); 500 μL was used for blood
and hydrolyzed urine samples and 1 mL was used for the pul-
verized hair samples. After mechanical shaking (10 min) and
centrifugation (10 min at 3000  g), the organic phase was
transferred to a 5-mL disposable screw-top vial and then evap-
orated to dryness at 40°C in a vacuum centrifuge. For the ex-
tracted urine and blood samples, the residue was reconsti-
tuted in 100 μL of 0.1% formic acid in water/methanol (70:30,
v/v), and 10 μL was injected into the LC–MS–MS system. The
residue of the hair samples was reconstituted in 80 μL of 0.1%
formic acid in water/methanol (70:30, v/v), and 20 μL was in-
jected into the LC–MS–MS system.
LC–MS–MS
C h r o m a t o g r a p h y. LC was performed using a Waters Alliance
2690 separation module (Waters, Milford, MA). Analytes were
separated on a XTerra MS C18 column (150-  2.1-mm, 3.5
μm) (Waters), using a gradient elution with 0.1% formic acid
(A) and methanol (B), at a flow rate of 0.2 mL/min. A gradient
was applied starting from 10% B, and increased to 50% over
the first 5 min. From 5 min to 20 min, B was linearly in-
creased to 70% before returning to the initial conditions within
0.1 min and equilibrating for 14.9 min, which resulted in a
total run time of 35 min.
M S . A Quattro Premier tandem MS (Waters) was used for all
analyses. Ionization was achieved using
electrospray in positive mode (ESI+). The
optimum conditions were capillary
voltage, 1.0 kV; source block temperature,
120°C; desolvation gas (nitrogen) heated
to 270°C, and delivered at a flow rate of
700 L/h.
In order to establish the appropriate
multiple reaction monitoring (MRM) con-
ditions for the individual compounds, so-
lutions of standards [200 ng/mL, in 0.1%
formic acid in water/methanol (70:30,
v/v)] were infused into the MS and the
cone voltage (CV) optimized to maximize
the intensity of the protonated molecular
species [M+H]+. Collision-induced disso-
ciation of each protonated molecule was
performed. The collision gas (argon) pres-
sure was maintained at 0.35 Pa (3.5  1 0– 3
mbar) and the collision energy adjusted to
optimize the signal for the most abun-
dant product ions, which were subse-
quently used for MRM analysis. 
All aspects of data acquisition were con-
trolled using MassLynx NT 4.0 software
with automated data processing using the
QuanLynx program (Waters).
LC–MS–MS assay validation
L i n e a r i t y, LOQ, precision, accuracy,
and recovery. Quantification was per-
formed by integration of the area under
the specific MRM chromatograms in
reference to the integrated area of the
deuterated analogues. The different IS
were assigned to the different analytes in
Lorazepam 4 2.4 –2.0 4.2 –3.7
12 4.5 1.4 5.4 –0.3
100 1.5 2.2 2.8 1.9
Prazepam 4 1.6 –8.9 2.3 –6.7
12 2.7 –2.3 5.4 –4.2
100 2.3 3.9 4.8 1.3
Clotiazepam 4 1.5 –2.4 4.9 –2.7
12 2.9 –1.4 6.4 –3.3
100 3.1 3.5 5.2 2.3
Tetrazepam 4 2.1 –5.5 4.2 –3.3
12 3.1 –3.0 4.4 –4.6
100 3.9 0.9 5.1 –0.3
Diazepam 4 2.7 –11.8 3.5 –3.0
12 2.0 –0.5 4.0 3.3
100 3.6 2.7 5.0 4.1
Loprazolam 4 2.0 –5.0 15.4 –9.7
12 8.2 –15.6 19.4 –16.0
100 9.6 –4.3 19.9 –3.2
Flurazepam 4 9.7 –3.2 12.1 –0.8
12 7.3 –4.5 10.8 –5.5
100 9.3 –11.8 9.4 –4.3
Cloxazolam 4 11.7 –11.3 11.5 –6.9
12 13.4 –9.9 12.0 –9.1
100 2.5 –6.6 16.6 –9.2
Zolpidem 4 1.3 –5.2 16.9 0.2
12 3.4 –9.8 16.8 –5.3
100 3.7 –4.5 13.1 1.7
Zopiclone 4 14.2 –12.5 17.3 –20.0
12 12.6 –16.7 13.2 –15.0
100 8.1 –15.0 9.7 –16.3
Table II (continued). Intra-assay and Interassay Precision and Bias of the QC
Samples, Prepared in Blood, Spiked at a Concentration of 4.0, 12, and 100 ng/mL
Concentration of 
Intra-assay Precision Interassay Precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
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the following combinations: 7-aminoflu-
nitrazepam-d7 was used for the calcula-
tions of peak-area ratios and concen-
trations of 7-aminoflunitrazepam,
loprazolam, flurazepam, cloxazolam,
zolpidem, and zopiclone; 7-aminoclon-
a z e p a m - d4 for 7-aminoclonazepam;
f l u n i t r a z e p a m - d7 for bromazepam and
flunitrazepam; clonazepam-d4 for clon-
azepam, clobazam, desmethylfluni-
trazepam, estazolam and nitrazepam;
t e m a z e p a m - d5 for temazepam; de-
s a l k y l f l u r a z e p a m - d4 for desalkylflu-
razepam and lormetazepam; nor-
d i a z e p a m - d5 for chlornordiazepam,
nordiazepam and brotizolam; triazolam-
d4 for triazolam; lorazepam-d4 for loraze-
pam; alprazolam-d5 for alprazolam;
prazepam-d5 for prazepam; diazepam-d5
for clotiazepam, tetrazepam, and di-
azepam; oxazepam-d5 for oxazepam.
Calibration curves ranged from 1 to 200
ng/mL (1, 2, 5, 10, 20, 40, 80, 160, and
200 ng/mL) for blood samples, from 10 to
1000 ng/mL (10, 25, 50, 100, 250, 500,
750, and 1000 ng/mL) for urine, and from
0.5 to 1000 pg/mg (0.5, 1, 2, 5, 10, 50,
100, 200, 500, and 1000 pg/mg) for hair
samples. Standard response curves were
generated daily using a weighted (1/x)
least-squares linear regression model. 
The LOQ was defined as the concentra-
tion of the lowest calibrator, which was
calculated to be within ± 20% of the nom-
inal value and with a relative standard de-
viation (RSD) less than 20% (33,34). QCs
were prepared for every run in blank ma-
trix at a concentration of 4, 12, and 100
ng/mL for blood samples, at a concentra-
tion of 40, 150, and 600 ng/mL for urine
and at a concentration of 7.5, 75, and 750
pg/mg for hair samples. Intra-assay preci-
sion was evaluated by analysis of 5 sets of
the QC samples in one run for each of the
three biological matrices. Interassay pre-
cision was evaluated by replicate analysis
of one set of QC samples in several exper-
iments performed on five different days.
The precision was expressed as the RSD. A
comparison of the calculated concentra-
tions of the QC samples to their respective
nominal values was used to assess the ac-
curacy (bias) of the method.
For the three matrices, relative recov-
eries were estimated by comparing the
ratio of the peak area of the medium QC
sample when the non-deuterated com-
pounds were added before any pretreat-
Table III. Intra-assay and Interassay Precision and Bias of the QC Samples,
Prepared in Urine, Spiked at a Concentration of 40, 150, and 600 ng/mL
Concentration of 
Intra-assay Precision Interassay Precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
7-Aminoclonazepam 40 1.5 0.3 3.8 5.6
150 2.5 –4.6 3.0 –3.3
600 3.8 –4.5 4.6 –5.9
7-Aminoflunitrazepam 40 2.3 8.4 2.8 14.1
150 2.3 3.2 4.0 11.7
600 1.6 –1.9 3.2 5.0
Bromazepam 40 5.8 3.5 5.3 7.7
150 9.4 4.8 10.0 –7.5
600 8.1 5.0 7.6 –1.1
Clonazepam 40 2.0 5.4 1.9 4.8
150 0.9 –0.6 1.2 1.8
600 1.4 –1.3 3.0 –5.2
Flunitrazepam 40 2.7 3.9 2.6 3.7
150 2.9 –1.5 3.0 –1.7
600 0.9 –0.8 3.5 –0.5
Clobazam 40 1.8 8.5 1.6 6.8
150 3.5 4.3 3.2 1.1
600 2.8 –0.3 2.8 –4.1
Desmethylflunitrazepam 40 4.9 –1.1 6.5 10.0
150 4.3 –0.1 4.2 6.2
600 7.9 –5.0 7.7 –1.9
Estazolam 40 1.8 4.0 2.6 9.0
150 2.3 –2.8 1.9 –2.6
600 0.8 0.4 3.2 –7.6
Nitrazepam 40 2.8 1.9 2.3 3.3
150 1.2 –3.3 1.0 –2.9
600 1.6 –2.7 3.2 –9.8
Alprazolam 40 5.0 1.9 4.1 1.0
150 3.9 –4.9 3.4 –5.7
600 2.3 3.4 3.4 –2.2
Chloornordiazepam 40 2.9 5.2 3.6 10.7
150 2.2 0.1 2.3 1.8
600 3.4 –1.9 4.0 1.6
Temazepam 40 2.2 1.2 2.5 5.4
150 2.4 –4.5 2.2 –5.3
600 2.1 –3.9 3.9 1.4
Desalkylflurazepam 40 1.9 2.2 2.6 3.2
150 1.7 –2.6 1.7 –1.1
600 3.3 2.4 3.2 –1.8
Oxazepam 40 3.5 –0.1 4.1 0.3
150 3.1 –6.5 3.6 –8.6
600 3.1 –2.0 2.8 0.5
Nordiazepam 40 0.9 3.7 2.3 6.6
150 3.5 –1.1 3.0 –0.4
600 1.6 1.0 2.0 –0.2
Brotizolam 40 3.1 3.8 4.1 8.2
150 3.1 –1.8 3.0 –1.5
600 3.2 3.8 4.1 4.7
Triazolam 40 2.1 3.5 3.2 –1.1
150 1.3 –4.3 1.5 –6.3
600 2.7 –1.2 3.0 –5.4
Lormetazepam 40 2.1 1.6 2.9 –0.2
150 2.7 –4.0 3.6 –10.8
600 3.6 5.0 3.7 –1.3
continued
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ment or extraction (n = 3) divided by the peak area of the in-
ternal standards with the ratio of the peak area obtained when
the nondeuterated analytes were added after the extraction
(n = 3) divided by the peak area of the internal standards. The
deuterated standards were added before the extraction in all
experiments.
Assessment of matrix effects. To assess any potential sup-
pression or enhancement of ionization from components present
in the extracted biological matrix, a continuous post-column in-
fusion was performed using a mixture of all benzodiazepines and
deuterated analogues (10 ng/mL at a flow rate of 10 μL/min) to
produce a constant elevated response in both MRM channels.
The interference of this constant response was monitored fol-
lowing the injection of extracted samples and compared to the
response following the injection of mobile phase only.
Results and Discussion
The applied gradient ensured the elution of all the drugs ex-
amined within 20 min and produced chromatographic peaks of
acceptable symmetry. Selectivity of the method was achieved by
a combination of retention time, precursor, and transitions.
During the first injection of an extracted sample, the most
prominent precursor-product transitions (except for alpra-
zolam, for which an elevated background was noticed in this
transition) were used for quantification. Further confirmation
of the identity of the compounds was achieved through a
second injection of positive samples and by monitoring two
transitions (i.e., a quantifier and a qualifier) per compound. For
the deuterated internal standards, a single MRM transition
was used. Table I summarizes the MRM transitions and condi-
tions of all quantifiers and qualifiers for all analytes and IS. For
all compounds investigated, peak-area ratios quantifier/quali-
fier were found to be very reproducible with variation (as RSD)
less than 10%.
The method was validated for linearity, LOQ, precision, ac-
c u r a c y, and analytical recovery by the analyses of spiked
blood, urine, and hair samples. In each case, a weighted
( 1 /x) linear regression line was applied. Linearity with cor-
relation coefficients r2 > 0.99 were achieved in the range in-
vestigated (i.e., from the LOQ to 200 ng/mL for blood sam-
ples, from the LOQ to 1000 ng/mL for urine samples, and
from LOQ to 1000 pg/mg for hair samples). The back-calcu-
lated concentrations of all calibrators were compared with
their respective nominal values and
were within 100 ± 20% of the nominal
value.
The obtained LOQ in blood was 1.0
ng/mL for all analytes, except for lo-
razepam, loprazolam, zolpidem, and zopi-
clone, where an LOQ of 2.0 ng/mL was
observed. For urine samples, the LOQ was
established at 10 ng/mL for all analytes,
except for brotizolam and tetrazepam
with an LOQ of 25 ng/mL. Finally, for hair
samples, LOQs ranging from 0.5 pg/mg
(prazepam) to 10 pg/mg (tetrazepam, lo-
prazolam, and zopiclone) were observed.
Figure 1 shows the MRM chromatograms
obtained following the analysis of a hair
sample spiked with 10 pg/mg of each of
the compounds. At the LOQ, the quali-
fier had a signal-to-noise ratio > 10:1. The
intra-assay precision (repeatability), in-
terassay precision (reproducibility), and
bias were < 20% in most cases for all ma-
trices tested (Tables II–IV).
The obtained LOQ was comparable
with previous reports dealing with a large
series of benzodiazepines (28,31,32). The
reported sensitivities for hair samples
were comparable with the values for other
LC–MS–MS methods dealing with only
one or a limited number of benzodi-
azepines (35–39). The LOQs were slightly
higher than the values obtained with pre-
vious negative-ion chemical ionization-
GC–MS methods detecting one or a few
benzodiazepines in hair (40,41).
Lorazepam 40 2.5 2.8 3.0 0.5
150 3.5 –3.9 3.1 –0.9
600 2.8 –1.7 2.7 –5.4
Prazepam 40 2.2 5.2 2.4 6.4
150 1.1 –2.2 1.0 –1.3
600 1.0 0.4 1.7 –1.4
Clotiazepam 40 3.0 5.9 2.5 5.3
150 1.0 –2.1 1.7 –4.5
600 1.5 4.3 5.1 –8.9
Tetrazepam 40 7.3 9.8 17.8 12.7
150 4.9 5.8 18.0 –20.6
600 6.5 –0.2 20.6 –6.5
Diazepam 40 2.7 3.7 2.9 7.1
150 2.1 –1.7 1.8 –1.7
600 1.2 –0.1 2.0 –0.6
Loprazolam 40 10.2 19.0 12.0 13.0
150 8.3 18.6 9.1 –12.5
600 8.6 10.1 13.0 –6.8
Flurazepam 40 9.7 19.4 10.9 –10.1
150 4.5 6.7 9.7 –19.3
600 3.4 5.0 5.7 –7.9
Cloxazolam 40 4.5 11.2 16.5 –3.8
150 2.3 –0.4 20.8 –5.9
600 4.9 –3.1 19.5 –9.7
Zolpidem 40 9.6 13.5 10.4 –18.1
150 1.3 6.3 6.3 –2.7
600 2.4 4.5 2.3 3.7
Zopiclone 40 9.1 18.0 12.6 –7.8
150 2.5 7.1 10.7 7.9
600 4.1 1.2 10.3 11.2
Table III (continued). Intra-assay and Interassay Precision and Bias of the QC
Samples, Prepared in Urine, Spiked at a Concentration of 40, 150, and 600 ng/mL
Concentration of 
Intra-assay Precision Interassay Precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
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After sample preparation, the same ex-
traction procedure was applied for the
three biological matrices. Reproducible
recoveries were obtained, ranging from
49.2 to 103.7% in blood, from 25.1 to
98% for urine (except for cloxazolam,
with an extraction recovery of 3.8%), and
from 53.0 to 103.8% for hair. The ex-
traction recoveries are similar for the
three matrices, except for tetrazepam
and cloxazolam, where significantly
lower recoveries were noted for the ex-
traction of spiked urine samples. To
demonstrate that these compounds show
a reduced stability when incubating at
higher temperatures in aqueous solu-
tions (during the hydrolysis of urine
samples), an additional experiment was
performed, adding the nondeuterated
compounds after sample preparation,
but before extraction with 1-chlorobu-
tane. In this experiment, these extrac-
tion recoveries for tetrazepam and clox-
azolam were similar as those obtained
for blood, indicating a decomposition
during the preparation of urine samples.
The extraction recoveries obtained are
comparable with previous reports
( 1 5 , 2 2 , 2 6 – 2 8 , 3 1 , 3 2 ) .
Insufficient sample clean up can result
in matrix effects, leading to either sup-
pression or enhancement of the analyte
response (42–44). This can lead to vari-
able sensitivities and decreased precision
and accuracy. Consequently, in the de-
velopment of any LC–MS(–MS) method,
the potential for any such ion suppres-
sion or enhancement should be assessed.
To test this, post-column infusion exper-
iments [based on the method described
by Bonfiglio et al. (42)] were performed
for the three biological matrices to pro-
vide information of the effect of matrix
throughout the course of the detection
w i n d o w. A decrease in response ranging
from 20 to 90% was observed starting
from 1.7 min to maximal 6.0 min for the
three matrices tested (data not shown).
H o w e v e r, this suppression had dimin-
ished and normal baseline responses
were restored before the elution time of
the compounds. In the rest of the chro-
matographic run, no significant changes
in responses were observed. The results
confirm the usefulness of the liquid–
liquid extraction procedure as a sample
clean up before chromatography to ob-
tain reproducible and reliable quantita-
Table IV. Intra-assay and Interassay Precision and Bias of the QC Samples,
Prepared in Hair, Spiked at a Concentration of 7.5, 75, and 750 pg/mg
Concentration of 
Intra-assay precision Interassay precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
7-Aminoclonazepam 7.5 5.5 9.4 6.1 5.0
75 2.5 0.8 2.2 2.5
750 4.4 –2.7 4.2 –2.3
7-Aminoflunitrazepam 7.5 4.4 7.9 4.4 6.3
75 1.6 0.1 2.7 2.2
750 0.4 2.3 2.5 2.2
Bromazepam 7.5 16.8 –7.8 13.6 8.6
75 8.1 12.7 7.4 9.8
750 13.1 12.7 10.6 3.8
Clonazepam 7.5 3.5 12.7 4.3 9.7
75 2.2 10.3 1.9 10.0
750 2.0 4.9 4.5 2.8
Flunitrazepam 7.5 3.3 5.4 3.4 5.2
75 1.1 2.2 5.3 5.6
750 1.3 3.7 3.9 6.8
Clobazam 7.5 2.9 3.6 4.9 –1.3
75 2.8 9.5 13.9 1.2
750 5.6 5.2 14.5 –3.8
Desmethylflunitrazepam 7.5 9.1 10.3 9.0 15.1
75 9.9 13.1 11.1 8.5
750 9.0 4.9 9.0 10.0
Estazolam 7.5 5.0 10.4 9.9 15.2
75 4.7 3.0 16.6 14.2
750 2.9 0.4 12.6 10.2
Nitrazepam 7.5 5.6 8.8 4.9 11.8
75 3.6 8.3 8.3 15.9
750 2.6 2.2 3.4 8.1
Alprazolam 7.5 17.8 19.4 16.6 17.9
75 3.8 –0.5 3.6 –0.3
750 7.3 6.9 1.2 4.5
Chlornordiazepam 7.5 6.4 3.5 6.2 2.7
75 2.7 6.5 4.5 5.8
750 5.8 3.2 6.7 1.9
Temazepam 7.5 8.2 4.0 7.9 2.6
75 0.8 3.7 2.1 5.0
750 4.5 4.7 5.4 4.0
Desalkylflurazepam 7.5 7.4 8.9 6.7 9.1
75 1.1 5.2 2.3 7.3
750 2.7 6.5 2.3 8.0
Oxazepam 7.5 7.2 8.6 9.3 10.8
75 3.5 2.7 16.5 9.1
750 2.7 0.5 5.0 2.5
Nordiazepam 7.5 7.0 4.3 6.6 3.6
75 3.4 4.1 4.0 7.2
750 5.7 6.4 4.9 7.0
Brotizolam 7.5 7.0 5.8 8.2 6.3
75 7.0 4.8 6.2 4.2
750 8.6 4.2 7.6 3.0
Triazolam 7.5 12.3 2.4 11.0 4.7
75 1.9 –1.6 3.9 2.0
750 4.3 3.0 3.8 4.8
Lormetazepam 7.5 7.1 10.2 8.1 2.4
75 8.0 8.9 7.5 1.6
750 4.2 9.4 4.3 4.1
continued
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tive results for all compounds without major interference of
matrix compounds.
The validated LC–MS–MS method has been successfully ap-
plied to the analysis of external quality control samples in
serum (organized by the Gesellschaft für Toxikologische und
Forensische Chemie). A certificate was obtained for all com-
pounds tested (diazepam, nordiazepam, bromazepam, clon-
azepam, flunitrazepam, desmethylflunitrazepam, 7-aminoflu-
nitrazepam, and oxazepam).
In addition, the method was used for the analysis of au-
thentic blood, urine, and hair samples. Blood and urine sam-
ples were collected during roadside controls for drugged
driving, from DFSA cases, suicide cases, and (attempted)
murder cases. Samples with a concentration above the linear
range of the calibration curve were appropriately diluted in
water (before extraction), and reanalyzed. To check the va-
lidity of the quantification for this modified sample prepara-
tion, five different added concentrations above the calibration
range for blood and urine (n = 3 for each concentration) were
analyzed with different dilutions. The bias was always < 20%.
Hair analysis was applied to two authentic cases. In the first
case, a young woman claimed to have been sexually abused
over a period of several years while being drugged. Because of
the increased detection window, toxicological analysis of hair
yields long-term information about drug consumption and al-
lows the personal history of drug use to be established. As
such, the laboratory was requested to analyze the victim’s hair
(33 cm). Starting from the root, 16 segments of 1–3 cm were
analyzed. All segments were positive for more than one ben-
zodiazepine, with generally higher concentrations in segments
closer to the root. Benzodiazepines detected above the LOQ
were 7-aminoclonazepam (in 5 segments, ranging from 2.2 to
11.7 pg/mg), bromazepam (in all segments, ranging from 19.1
to 1405 pg/mg), clonazepam (in 2 segments, ranging from
16.0 to 32.6 pg/mg), clobazam (in 1 segment, 11.8 pg/mg),
oxazepam (1 segment, 8.5 pg/mg), nordiazepam (in 5 seg-
ments, ranging from 2.3 to 6.9 pg/mg), lormetazepam (in 5
segments, ranging from 5.0 to 28.1), lorazepam (in 4 seg-
ments, ranging from 7.6 to 13.9 pg/mg), tetrazepam (in 2 seg-
ments, 55.6 and 123.6 pg/mg), loprazolam (in 1 segment, 24.7
pg/mg), and zolpidem (in all segments, ranging from 8.5 to
177.5 pg/mg). These results indicate long-term multiple drug
exposure.
In the second case, a middle-aged
woman ingested one tablet of Lexotan
(containing 3 mg of bromazepam) on two
consecutive days, followed by one tablet
on three consecutive days a month later.
Hair (7 cm) was cut 6 weeks later and 5
segments of 1–1.5 cm were analyzed.
Figure 2 shows the chromatogram ob-
tained after the analysis of the first two
proximal segments, positive for bro-
mazepam at 24.2 pg/mg (segment 1, 1.5
cm) and 11.7 pg/mg (segment 2, 1.5 cm).
In the third segment (1 cm) traces of bro-
mazepam were detected, probably because
of the variability in the incorporation of
this drug into the hair shaft and axial mi-
gration after incorporation, leading to a
distribution over a small region (35). This
result is consistent with the doses taken
and is in accordance with concentrations
of bromazepam found in hair in earlier
reports (35,37).
Conclusions
In this report, a validated and highly
sensitive LC–ESI-MS–MS method is
described for the simultaneous quantifi-
cation of 26 commonly encountered ben-
zodiazepines and their metabolites,
zolpidem and zopiclone, in three different
biological matrices (i.e., blood, urine, and
hair). Because of the low LOQs, the
method was demonstrated appropriate for
Lorazepam 7.5 7.4 –0.8 15.0 –5.3
75 4.0 3.3 16.0 –1.7
750 6.4 4.8 18.0 –1.1
Prazepam 7.5 3.2 7.7 4.2 6.3
75 1.3 3.8 2.4 7.1
750 4.2 6.2 5.8 6.5
Clotiazepam 7.5 12.4 2.1 15.7 0.2
75 3.1 –5.8 13.6 –4.8
750 7.1 7.4 17.6 5.7
Tetrazepam 7.5 NA* NA NA NA
75 6.8 –5.5 19.4 –10.4
750 7.1 6.4 16.3 0.2
Diazepam 7.5 4.7 5.2 4.8 5.2
75 2.0 3.1 4.0 6.1
750 7.5 1.2 7.1 2.6
Loprazolam 7.5 NA NA NA NA
75 8.9 15.1 19.7 –1.1
750 7.9 14.1 6.3 9.8
Flurazepam 7.5 25.0 –6.1 20.0 18.1
75 8.9 –15.2 14.3 11.2
750 15.7 –4.3 17.3 15.2
Cloxazolam 7.5 12.6 4.3 11.9 11.5
75 6.3 9.5 5.0 –3.9
750 10.4 18.2 8.6 –0.4
Zolpidem 7.5 17.2 8.6 15.7 –3.1
75 7.6 0.0 17.9 –3.4
750 12.9 –6.2 14.2 10.8
Zopiclone 7.5 NA NA NA NA
75 11.9 –3.2 13.1 15.9
750 11.2 14.0 10.2 15.0
*NA = not analyzed < LOQ.
Table IV (continued). Intra-assay and Interassay Precision and Bias of the QC
Samples, Prepared in Hair, Spiked at a Concentration of 7.5, 75, and 750 pg/mg
Concentration of 
Intra-assay Precision Interassay Precision
Compound QC (ng/mL) RSD Bias (%) RSD Bias (%)
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the quantification of low doses of these compounds in au-
thentic blood, urine, and hair samples collected from forensic
toxicology cases.
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Abstract
A rapid and sensitive method for the analysis of 9-tetrahydrocannabinol (THC) in preserved oral fluid was developed and fully validated.
Oral fluid was collected with the Intercept, a Food and Drug Administration (FDA) approved sampling device that is used on a large
scale in the U.S. for workplace drug testing. The method comprised a simple liquid–liquid extraction with hexane, followed by liquid
chromatography–tandem mass spectrometry (LC–MS-MS) analysis. Chromatographic separation was achieved using a XTerra MS C18
column, eluted isocratically with 1 mM ammonium formate–methanol (10:90, v/v). Selectivity of the method was achieved by a combination
of retention time, and two precursor-product ion transitions. The use of the liquid–liquid extraction was demonstrated to be highly effective
and led to significant decreases in the interferences present in the matrix. Validation of the method was performed using both 100 and 500 L
of oral fluid. The method was linear over the range investigated (0.5–100 ng/mL and 0.1–10 ng/mL when 100 and 500 L, respectively, of oral
fluid were used) with an excellent intra-assay and inter-assay precision (relative standard deviations, RSD <6%) for quality control samples
spiked at a concentration of 2.5 and 25 ng/mL and 0.5 and 2.5 ng/mL, respectively. Limits of quantification were 0.5 and 0.1 ng/mL when
using 100 and 500 L, respectively. In contrast to existing GC–MS methods, no extensive sample clean-up and time-consuming derivatisation
steps were needed. The method was subsequently applied to Intercept samples collected at the roadside and collected during a controlled
study with cannabis.
© 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Currently, there is a strong interest in monitoring drug use
through oral fluid testing in the context of driving under the in-
fluence, drug treatment, criminal justice, and workplace drug-
testing [1–5]. Advantages of this matrix include the ease and
non-invasiveness of specimen collection and reduced oppor-
tunity for specimen substitution and adulteration. However,
two main limitations of oral fluid are apparent: the specimen
volume is often small and the analyte concentration is lower
∗ Corresponding author. Tel.: +32 2 240 05 00; fax: +32 2 242 47 61.
E-mail address: marleen.laloup@just.fgov.be (M. Laloup).
than in urine. As such, oral fluid testing is a greater analytical
challenge and highly sensitive techniques are required.
Due to the high specificity and the increased signal-to-
noise in combination with short chromatographic run times,
liquid chromatography–tandem mass spectrometry (LC–MS-
MS) allows for specific, selective and sensitive analysis of
compounds with a wide polarity range in samples of various
nature. It offers the possibility to simplify sample prepara-
tion, although this approach should be treated with caution
due to the possibility of ion suppression or enhancement as a
result of the matrix. Consequently, attention must be paid to
the choice of the sampling method and the influence of the
collected matrix on the LC–MS-MS analysis. Several meth-
0021-9673/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
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ods of oral fluid collection have been used. The Intercept is
a Food and Drug Administration (FDA) approved sampling
device that is used on a large scale in the U.S. for workplace
drug testing [6]. It is also used to collect oral fluid samples for
confirmation analyses in the joint roadside study between the
European Union and the U.S. to detect driving under the influ-
ence of drugs [5]. The collection system contains stabilising
salts, non-ionic surfactants for surface wetting and antibac-
terial agents, and guarantees a good stability for most illicit
drugs and their metabolites during storage at 4 ◦C. However,
these ingredients can also cause interferences, e.g. ion sup-
pression or enhancement, during LC–MS-MS analysis in the
absence of a suitable clean-up method.
Drugs may appear in oral fluid via multiple pathways. 9-
tetrahydrocannabinol (THC), the major psychoactive con-
stituent of cannabis, is deposited in the oral cavity during
cannabis smoking. This “depot” represents the primary or
sole source of THC detected when oral fluid is collected and
analysed [7]. Despite the lack of contribution from blood
THC to oral fluid concentrations, Huestis and Cone [7] and
Niedbala et al. [8] showed that, after dissipation of the ini-
tial contamination of oral fluid during smoking (generally
within 30 min), THC levels in oral fluid followed a similar
time course as plasma THC following smoked cannabis ad-
ministration under controlled dosing conditions. Within 12 h,
both oral fluid and plasma THC concentrations generally de-
clined below 1 ng/mL.
With the exception of a report by Schramm et al. [9], no
other studies have revealed evidence of 11-hydroxy-THC or
carboxy-THC in oral fluid after smoking of cannabis. How-
ever, it appears that in addition to THC, cannabidiol (CBD)
and cannabinol (CBN) may be detected in oral fluid after
smoking of hashish or marijuana cigarettes [10].
Most laboratories analyse THC in blood and oral
fluid by GC–MS(-MS) after extraction and derivatisation
[7,8,11–13]. Recently, LC–MS(-MS) has been successfully
used to analyse cannabinoids in urine and blood [14–17].
However, only one paper reported on the application of
LC–MS to detect THC in oral fluid [18]. These authors
reported on the determination of THC in 200 L of oral
fluid, which was obtained by spitting. The limit of detection
achieved was 2 ng/mL.
Our aim was to develop a fast and sensitive LC–MS-MS
method for the confirmation of THC in preserved oral fluid
samples collected with the Intercept. Validation of the method
was performed using both 100 and 500 L of preserved oral
fluid. The method was subsequently applied to Intercept sam-




Individual ampoules of THC (at a concentration of
1 mg/mL in methanol) and [2H3]THC (THC-d3) (0.1 mg/mL
in methanol) were purchased from LGC Promochem (Mol-
sheim, France). Cannabinol and cannabidiol were from
Lipomed (Arlesheim, Switzerland). All solvents were HPLC-
grade and from Merck (Darmstadt, Germany).
2.2. Specimens
Blank preserved oral fluid, used for the preparation
of negative controls, calibrators and quality control (QC)
samples was obtained from healthy volunteers and collected
with the Intercept collection device (OraSure Technologies,
Bethlehem, PA, USA) according to the manufacturer’s
instructions. Briefly, after gently wiping the collector pad
between gum and cheek for approximately 2 min (as a kind
of toothbrush), the device is placed in the supplied vial,
which contains a stabilising buffer solution, and sealed.
After centrifugation, the recovered fluid is transferred in
cryotubes and represents a mixture of the collected oral fluid
and the buffer in a proportion of approximately 1 to 2. The
device collects an average of 0.38 ± 0.19 (SD) mL with a
range of 0.05 to 0.8 mL of oral fluid and a dilution factor of
1 in 3 is arbitrarily accepted [6]. The tubes were sealed and
stored at −20 ◦C prior to analysis.
Authentic preserved oral fluid samples were collected by
the police at the roadside during roadblocks to intercept
drivers under the influence of drugs, using the same procedure
as described for the blank samples.
A third series of preserved oral fluid samples was obtained
with a similar protocol from nine healthy volunteers with a
history of cannabis use. Once a week and for two consecutive
weeks, subjects received either a placebo cigarette (contain-
ing cannabis where the THC had been previously extracted)
or a marijuana cigarette (containing 300 g THC per kilo-
gram weight). Oral fluid samples were collected 0.5 h before
and at various times after drug administration (0.25, 0.5, 1,
1.25 and 1.5 h). Thus, we obtained from each volunteer six
oral fluid samples in the placebo condition and six in the THC
condition. The study protocol was approved by the ethics
committee of the University Hospital of Maastricht in The
Netherlands.
2.3. Preparation of standard solutions and sample
extraction
An internal standard (IS) working solution of THC-d3
at a concentration of 10 ng/mL was prepared in methanol.
Working solutions of THC at different concentrations (1, 2,
4, 5, 8, 16, 32, 50, 100, 200 ng/mL in methanol) were used
for the preparation of calibrators and QC samples. Working
solutions were stored at −20 ◦C, and were prepared monthly.
The extraction procedure was carried out in 10 mL
disposable screw top vials of high quality glassware (Chro-
macol, Herts, UK) with 100 or 500 L of preserved oral
fluid specimen collected with the Intercept device. The pH
of the preserved oral fluid samples ranged between 6.0 and
7.0. Fifty microliters of the IS working solution and 4 mL
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of hexane were added; when only 100 L was used, an
additional 400 L of deionised water was added.
After mechanical shaking (30 min) and centrifugation
(10 min at 3000 × g), the organic phase was transferred to
a 5 mL disposable screw top vial (Chromacol) and then
evaporated to dryness at 40 ◦C under nitrogen. The extract
was reconstituted in 100 L of mobile phase and 20 L was
injected into the LC–MS-MS system.
2.4. LC–MS-MS
2.4.1. Chromatography
LC was performed using a Waters Alliance 2690 sepa-
ration module (Waters, Milford, MA, USA). Analytes were
separated on a XTerra MS C18 column (150 mm × 2.1 mm,
3.5 m) (Waters), eluted isocratically with 1 mM ammonium
formate–methanol (10:90, v/v), delivered at a flow rate of
0.2 mL/min. The total run time of the method was 8 min. All
aspects of system operation and data acquisition were con-
trolled using MassLynx NT 4.0 software.
2.4.2. Mass spectrometry
A Quattro Premier tandem mass spectrometer (Waters)
was used for all analyses. Ionisation was achieved using elec-
trospray in positive ionisation mode (ESI+). The optimum
conditions were: capillary voltage, 2.0 kV; source block tem-
perature, 120 ◦C; desolvation gas (nitrogen) heated to 280 ◦C
and delivered at a flow rate of 700 L/h.
In order to establish the appropriate multiple reaction
monitoring (MRM) conditions for the individual compounds,
solutions of standards [500 ng/mL, in 1 mM ammonium
formate–methanol (10:90, v/v)] were infused into the
mass spectrometer and the cone voltage (CV) optimised to
maximise the intensity of the protonated molecular species
[M + H]+. Collision-induced dissociation (CID) of each
protonated molecule was performed. The collision gas (ar-
gon) pressure was maintained at 0.35 Pa (3.5 × 10−3 mBar)
and the collision energy (eV) adjusted to optimise the
signal for the most abundant product ions, which were
subsequently used for MRM analysis. The transitions were
m/z 315.2 → 193.1 and m/z 315.2 → 259.3 for THC. The
former (and most prominent precursor-product transition)
was used for quantification and the latter transition used as a
qualifier. The transition for THC-d3 was m/z 318.2 → 196.1.
All aspects of data acquisition were controlled using
MassLynx NT 4.0 software with automated data processing
using the QuanLynx program (Waters).
2.5. LC–MS-MS assay validation
2.5.1. Linearity, limit of quantification (LOQ), precision,
accuracy and recovery
Quantification was performed by integration of the area
under the specific MRM chromatograms in reference to the
integrated area of its respective deuterated analogue.
Linearity was assessed when either 100 or 500 L of the
sample, collected with the Intercept device, was processed
and analysed using LC–MS-MS. When 100 L was used,
calibration curves ranged from 0.5 to 100 ng/mL (0.5, 1,
2, 4, 8, 16, 25, 50, 100 ng/mL) and from 0.1 to 10 ng/mL
(0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 5, 10 ng/mL) when 500 L of
preserved oral fluid was used. Standard response curves
were generated daily using a weighted (1/x) least-squares
linear regression model.
The limit of quantification (LOQ) was defined as the
concentration of the lowest calibrator which was calculated
to be within ±20% of the nominal value and with a %
relative standard deviation (RSD) less than 20% [19,20].
QCs were prepared for every run in blank preserved oral
fluid at a concentration of 2.5 and 25 ng/mL for 100 L
of sample and at a concentration of 0.5 and 2.5 ng/mL for
500 L of preserved oral fluid. Intra-assay precision was eval-
uated by replicate (n = 4) analysis of the two QC samples in
one run for each of both volumes of preserved oral fluid.
Inter-assay precision was evaluated by replicate analysis of
the QC samples in several experiments performed on eight
different days by two operators. A comparison of the calcu-
lated concentrations of the QC samples to their respective
nominal values, was used to assess the accuracy (bias) of the
method.
Recovery was estimated by comparing the response of a
5 ng/mL calibrator when the non-deuterated compound was
added before the extraction step (n = 3) with the response
obtained when the non-deuterated analyte was added after
sample preparation (n = 3). THC-d3 was added before the
extraction step in both conditions.
2.5.2. Stability of unprepared and prepared samples
Stability of THC in preserved oral fluid collected by the In-
tercept device was monitored in preserved oral fluid samples
spiked at the initial concentrations of 1, 10 and 100 ng/mL.
THC concentrations in the samples were either determined
immediately (control samples, n = 3) or following incubation
at room temperature or at 4 ◦C for a period of 24 h (n = 3)
or 48 h (n = 3) after preparation. Stability at each time point
was tested against a lower acceptance limit corresponding
to 90% of the mean of control samples by a one-sided t-test
(P < 0.05).
For an evaluation of freeze/thaw stability, a calibrator at
5 ng/mL was analysed before (control samples, n = 3) and
after three freeze/thaw cycles (stability samples, n = 3). For
each freeze/thaw cycle, the samples were frozen at −20 ◦C
for 24 h, thawed, and then maintained at ambient temperature
for 1 h. Stability was tested against a lower acceptance limit
corresponding to 90% of the mean of control samples by a
one-sided t-test (P < 0.05).
The stability of THC in the extracted sample (preserved
oral fluid initially spiked at 5 ng/mL) was investigated by
repeated injections of a mixture of five extracted samples
(maintained in the autosampler at 4 ◦C) over a period of 15 h.
Absolute peak areas were plotted as a function of injection
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time and the stability of the processed samples tested by re-
gression analysis. Instability of the processed samples would
be indicated by a slope that was significantly different from
zero (P < 0.05).
2.5.3. Assessment of matrix effects
To assess any potential suppression or enhancement of
ionisation due to the sample matrix, two types of experiments
were performed. In the first experiment, THC (5 ng/mL) was
added after extraction of either water or preserved oral fluid
i.e. before evaporation, and the peak responses obtained in
both conditions were compared. A two-sided t-test was used
to identify any significant differences (P < 0.05).
The second type of experiment involved a continuous post-
column infusion of a mixture of THC and THC-d3 (10 ng/mL
at a flow rate of 10 L/min) to produce a constant elevated
response in both MRM channels. The interference of this
constant response was monitored following the injection of
samples either prior to or after extraction of 100 or 500 L of
preserved oral fluid and compared to the response following
the injection of mobile phase only.
3. Results and discussion
The method was validated for linearity, LOQ, precision,
accuracy and analytical recovery by the analysis of spiked
preserved oral fluid samples, collected using the Intercept
device. Two sets of calibration standard samples (in 100 and
500 L of preserved oral fluid) were prepared for validation
of linearity. The linearity data are summarised in Table 1.
In each case, a weighted (1/x) linear regression line was ap-
plied. Linearity with a correlation coefficient r2 = 0.999 was
achieved in the range investigated: from 0.5 up to 100 ng/mL
when 100 L of preserved oral fluid was used and from
0.1 up to 10 ng/mL for 500 L of sample. Fig. 1 shows the
MRM chromatograms obtained following the analysis of a
sample spiked with THC and THC-d3 when either 100 and
500 L of preserved oral fluid was used. For both calibration
curves, the lowest calibrators, i.e. 0.5 ng/mL and 0.1 ng/mL
when using 100 or 500 L, respectively, of collected oral
fluid, satisfied the criteria for LOQ. It should be noted that
the mean resultant specimen volume, following dilution with
the preservative solution, varied around 1.2 mL even under
controlled conditions [8]. However, in reality, the volume is
often reduced in driving under the influence (DUI) cases due
to the stimulation of sympathetic nerves which results in the
production of a viscous and less abundant oral fluid. This is
the case particularly true for regular users of amphetamines
[10]. In addition, in these cases the possibility of other drugs
should be tested for. This necessitates optimal usage of the
minimal amounts of specimen provided. For these cases, the
LOQ when using only 100 L of oral fluid was sufficiently
low to meet the requirements of SAMSHA for oral fluid
testing (i.e. 2 ng/mL THC in undiluted oral fluid) [21].
However, in pharmacokinetic studies, where the detection
of THC over time often necessitates increased sensitivity
and a lower LOQ, this can be achieved very simply, by
using larger volumes of oral fluid. For example, when using
500 L of collected oral fluid, the LOQ was determined to be
0.1 ng/mL. Thus, the choice of sample volume will largely
depend on the application in addition to the requirements for
sensitivity.
These results are comparable with previous GC–MS-MS
reports [7,8]. The obtained LOQ for THC was lower than the
one reported by Concheiro et al. [18], primarily due to the
use of tandem MS instead of single MS. These authors used
undiluted oral fluid collected by spitting. Hence, when using
diluted oral fluid, collected with the Intercept device, a lower
LOQ is needed to meet the requirements of SAMSHA.
Selectivity of the method was achieved by a combination
of retention time, precursor and product ions. Quantification
was based on the most prominent product ion (i.e. quantifier);
confirmation of THC was evaluated through the presence of
the second product (i.e. qualifier). At the LOQ the qualifier
had a signal to noise ratio (S:N) > 10:1. The acceptance range
for the peak area ratio quantifier/qualifier was 2.36 ± 0.35 for
all analyses.
The intra-assay precision (repeatability) and inter-assay
precision (reproducibility) were highly satisfactory with all
relative standard deviations less than 6% (Table 2). Results
indicated that the accuracy of the assay was > 93%. Recovery
of the method was 85.6 ± 0.5%.
The stability of spiked samples (1, 10 and 100 ng/mL) was
monitored at 24 and 48 h at 4 ◦C and at room temperature.
No statistical significant differences could be observed for
the three different concentrations in both conditions. Also
no statistical differences could be noted for the stability of
spiked samples (5 ng/mL) during three freeze/thaw cycles.
In addition, the potential for any undesired stability of
the processed samples was tested. To this end, the stability
of THC was monitored by means of repeated injections of
extracted samples (5 ng/mL) over a period of 15 h, and by
plotting the absolute peak areas as a function of time. The
Table 1
Linearity and sensitivity data for THC in preserved oral fluid
Linearity data Sensitivity data
Volume oral fluid (L) Slopea Intercepta RSD of slopea r2 (range of five consecutive days) LOQ (ng/mL)
100 1.0635 0.0209 2.9 0.9993–0.9999 0.5
500 5.3976 −0.0009 4.1 0.9992–0.9999 0.1
Samples were prepared by the liquid–liquid extraction method as described in the text.
a Reported values are the mean of five determinations over five consecutive days.
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Fig. 1. MRM chromatograms obtained with a single injection of a 100 L extracted preserved oral fluid sample enriched with 5 ng/mL THC and 5 ng/mL
THC-d3 (A) and of a 500 L extracted preserved oral fluid sample enriched with 0.8 ng/mL THC and 1 ng/mL THC-d3 (B). The figure shows the response
for THC-d3 (top trace) and for the two transitions of THC (quantifier and qualifier, middle and bottom traces, respectively). Peak intensity is shown in the top
right-hand corner of each trace.
results indicated no significant instability over the course of
the experiment.
Insufficient sample clean-up can result in matrix effects,
leading to either suppression or enhancement of the analyte
response [22–24]. This can lead to variable sensitivities and
decreased precision and accuracy. Consequently, in the devel-
opment of any LC–MS(-MS) method, the potential for any
such ion suppression or enhancement should be assessed.
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Table 2
Precisiona and accuracy data for THC for the extraction of 100 and 500 L of spiked preserved oral fluid samples
Volume oral fluid (L) Concentration of
QC (ng/mL)
Intra-assay precision Inter-assay precision
Mean concentration
found (ng/mL)
RSD (%) Bias (%) Mean concentration
found (ng/mL)
RSD (%) Bias (%)
100 2.5 2.5 3.6 −1.0 2.4 2.9 −2.5
25.0 24.8 5.4 −0.7 24.0 5.4 −4.1
500 0.5 0.5 2.5 −2.4 0.5 4.1 −5.5
5.0 4.9 0.4 −2.0 4.7 3.8 −6.8
a Intra-assay precision was evaluated by the preparation and analysis of four replicates of a low and a high QC in a single assay for both volumes of oral fluid
used. Inter-assay precision was evaluated by the preparation and analysis of each QC over eight consecutive days.
The Intercept collector contains a variety of chemicals, i.e.
sodium chloride, sodium benzoate, potassium sorbate, bovine
gelatin, Tween 20, chlorhexidine digluconate and a blue dye,
some of which can interfere with the LC–MS-MS detection
signal. To assess this, we compared peak area responses ob-
tained when THC was added after the extraction of blank
preserved oral fluid with the responses obtained when THC
was added to an extract where the preserved oral fluid was
substituted with water. No statistically significant different
peak areas were observed.
Post-column infusion experiments (based on the method
described by Bonfiglio et al. [22]) were performed to provide
information of the effect of matrix throughout the course of
the whole chromatographic run and not just at the elution
time for the analytes. The effect on THC response obtained
following the injection of a mobile phase control is shown
in Fig. 2A. As expected, no changes in response were ob-
served. The effects on THC response obtained following the
injection of a sample prior extraction and after extraction of
100 and 500 L of preserved oral fluid are given in Fig. 2B,
C and D, respectively. The results confirm the usefulness
of the liquid–liquid extraction as a sample clean-up before
chromatography: a decrease of 100% in response starting
from ∼1.7 min was observed when no sample clean-up
was performed. A reduction of 50% was still noted at the
moment of elution of THC, probably due to the elution of
endogenous components. When injecting extracted samples,
this suppression was still apparent but restored by the
elution time of THC. In addition to THC, cannabidiol and
cannabinol are two components that are also present in the
Fig. 2. Evaluation of the effect on THC response of an injection of a mobile phase control (A), a blank sample prior to extraction (B) and the same sample
following the extraction of 100 and 500 L of preserved oral fluid (C and D, respectively). The shaded area indicates the elution position of THC.
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Fig. 3. LC–MS-MS analysis of an extracted 100 L blank oral fluid sample enriched with 5 ng/mL THC-d3 (top trace), THC and cannabidiol (middle trace)
and cannabinol (bottom trace). Peak intensity is shown in the top right-hand corner of each trace.
Cannabis sativa plant and may also be detected in oral fluid.
To evaluate their potential for interference, standards were
analysed using the developed LC–MS-MS method. This is
particularly important in the case of cannabidiol since this
component has the same molecular mass (and thus the same
protonated species) as THC and shows the same product ions
after CID. Cannabidiol eluted at 3.28 min and was chromato-
graphically resolved from THC. In contrast, cannabinol did
not produce any response in the monitored MRM channel
due to a different molecular mass. The appropriate MRM
transition for this component was m/z 311.2 → 223.1, as
determined by direct infusion experiments. Cannabinol was
demonstrated to elute at 4.38 min. Fig. 3 shows the MRM
chromatograms obtained following LC–MS-MS analysis of
an extracted 100 L blank oral fluid sample enriched with
5 ng/mL THC-d3, THC, cannabidiol and cannabinol.
The validated LC–MS-MS method was applied to the
analysis of 102 oral fluid samples collected with the In-
tercept from volunteers who had received either a placebo
cigarette or a marijuana cigarette. THC concentrations ob-
tained after smoking a single marijuana cigarette are shown
in Fig. 4. For these cases only the presence of THC had to
Fig. 4. Box- and whisker plots of THC levels in preserved oral fluid samples from nine healthy volunteers following smoking of a single marijuana cigarette.
Oral fluid samples were taken 0.5 h prior to smoking and at 0.25, 0.5, 1, 1.25 and 1.5 h after smoking. Concentrations plotted on the Y-axis are expressed as
ng/mL. The central box represents the values from the lower to upper quartile (25–75 percentile). The middle line represents the median. The horizontal line
extends from the minimum to the maximum value, excluding “outside” (not present) and “far out” values (cross marker) which are displayed as separate points.
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Fig. 5. Typical MRM chromatograms obtained following the analysis of two authentic preserved oral fluid specimens obtained from drivers in a roadside
setting. Concentrations were 5.7 ng/mL (A) and 50.8 ng/mL (B). The figure shows the response for THC-d3 (top trace) and for the two transitions of THC
(quantifier and qualifier; middle and bottom traces respectively). Peak intensity is shown in the top right-hand corner of each trace.
be confirmed, thus 500 L of oral fluid was used for the
analysis. For samples where the response exceeded the up-
per limit of the standard curve, reanalysis of only 100 L
was performed. At −0.5 h all specimens were negative for
THC, except for three subjects in which low concentrations
were found (0.2, 0.4 and 2.2 ng/mL). However, it should
be noted that in both the placebo and marijuana condition,
THC could be detected, probably due to incomplete removal
of THC for the preparation of the placebo cigarette. Mean
peak (±1 SD) THC concentration in the marijuana condi-
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Table 3
Results obtained applying the method to 48 preserved oral fluid samples
collected by the police at the roadside
Sample identity THC (ng/mL) Sample identity THC (ng/mL)
1 5.7 25 60.2
2 7.0 26 3.9
3 4.6 27 52.2
4 18.5 28 25.4
5 2.5 29 193.5
6 95.8 30 111.2
7 <LOQ 31 7.3
8 84.7 32 14.6
9 <LOQ 33 1.9
10 0.5 34 4.7
11 4.5 35 100.0
12 3.9 36 23.0
13 31.9 37 57.1
14 50.8 38 88.6
15 34.6 39 3.9
16 56.0 40 375.8
17 81.1 41 3.7
18 11.9 42 4.4
19 107.4 43 4.2
20 92.1 44 4.2
21 10.0 45 4.2
22 17.6 46 4.1
23 94.8 47 4.0
24 37.2 48 4.4
tion occurred at the first specimen collection (0.25 h) and
was 30.6 ng/mL (±21.6 ng/mL). Thereafter, THC concentra-
tions declined steadily to mean concentrations of 2.6 ng/mL
(±2.3 ng/mL). Overall, concentrations were quite variable;
this has also been reported by other authors [8] and may be
due to the lack of exact volume measurement of the collection
device. The Intercept device is a collection device on which
the specimen is absorbed onto a matrix, leading to variable
absorbed volumes.
The mean peak concentration is lower than the one re-
ported by Niedbala et al. using the same collection device
[8]. This could be due to the fact that the samples were only
analysed several months after sampling. During this time the
samples were conserved at −20 ◦C on the pad, i.e. without
prior centrifugation. However, no stability studies on this as-
pect were available from the manufacturer.
During roadside controls for drugged driving, the police
collected 48 authentic oral fluid samples for a confirmatory
analysis in the laboratory. In these cases only 100 L of
preserved oral fluid was used due to limited sample volume.
Fig. 5 shows typical MRM chromatograms of Intercept
samples obtained from two marijuana users. In Fig. 5A, the
presence of cannabidiol (at a retention time of 3.28 min) was
also noted. A summary of the quantitative results for the
positive samples is presented in Table 3. In these samples,
the median THC concentration was 13.3 ng/mL with a range
from 0.5 to 375.8 ng/mL. The measured THC concentrations
varied considerably and some samples had to be reanal-
ysed after dilution (one in five dilution with blank oral
fluid).
4. Conclusions
A fully validated LC–MS-MS method for the determina-
tion of THC in preserved oral fluid, collected with the In-
tercept device, was developed. The method offers the com-
bination of a very simple liquid–liquid extraction to avoid
ion suppression, a high recovery and excellent precision and
accuracy, when using either 100 or 500 L of collected sam-
ple. The method was successfully applied to Intercept sam-
ples collected at the roadside and collected after a controlled
study with cannabis.
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Abstract
We present a validated method for the simultaneous analysis of basic drugs which comprises a sample clean-up step, using
mixed-mode solid-phase extraction (SPE), followed by LC–MS/MS analysis. Deuterated analogues for all of the analytes of
interest were used for quantitation. The applied HPLC gradient ensured the elution of all the drugs examined within 14 min and
produced chromatographic peaks of acceptable symmetry. Selectivity of the method was achieved by a combination of retention
time, and two precursor-product ion transitions for the non-deuterated analogues. Oral fluid was collected with the Intercept1, a
FDA approved sampling device that is used on a large scale in the US for workplace drug testing. However, this collection
system contains some ingredients (stabilizers and preservatives) that can cause substantial interferences, e.g. ion suppression or
enhancement during LC–MS/MS analysis, in the absence of suitable sample pre-treatment. The use of the SPE was
demonstrated to be highly effective and led to significant decreases in the interferences. Extraction was found to be both
reproducible and efficient with recoveries>76% for all of the analytes. Furthermore, the processed samples were demonstrated
to be stable for 48 h, except for cocaine and benzoylecgonine, where a slight negative trend was observed, but did not
compromise the quantitation. In all cases the method was linear over the range investigated (2–200 mg/L) with an excellent intra-
assay and inter-assay precision (coefficients of variation<10% in most cases) for QC samples spiked at a concentration of 4, 12
and 100 mg/L. Limits of quantitation were estimated to be at 2 mg/L with limits of detection ranging from 0.2 to 0.5 mg/L, which
meets the requirements of SAMHSA for oral fluid testing in the workplace. The method was subsequently applied to the analysis
of Intercept1 samples collected at the roadside by the police, and to determine MDMA and MDA levels in oral fluid samples
from a controlled study.
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1. Introduction
A variety of body specimens other than urine, such as
saliva (oral fluid), sweat and hair have been used to docu-
ment drug exposure for pre-employment screening, in fo-
rensic toxicology laboratories and in clinical applications
[1–4]. The advantage of these samples over traditional
matrices like urine and blood is that collection is almost
non-invasive, relatively easy to perform, and may be
achieved under close supervision to prevent adulteration
or substitution of the sample. Tools for the detection of
drugs in alternative specimens often utilise traditional tech-
nology, though some limitations are imposed which require
special attention: the specimen volume or mass is often
small, the target analytes are different from urine and the
analyte concentration is lower than in urine [1–5].
Oral fluid can be extracted and analysed like other
biological fluids such as blood. In general, there will be
less interference from endogenous compounds than with
blood or urine [1]. Laboratory immunoassay procedures
(EIA) to screen for drugs of abuse in oral fluid have been
validated for cocaine [6,7] opiates [8,9] and cannabinoids
[10].Many reports on oral fluid refer to the commonGC–MS
procedures for certain classes of drugs in blood using
electron impact mode. These methods utilise the deuterated
analogues for parent drugs, e.g. D9-tetrahydrocannabinol
(THC) and cocaine and also for relevant metabolites, e.g.
6-acetylmorphine (6-AM) [1,4,5]. Due to the small sample
volume of oral fluid specimens, chromatographic procedures
using tandem mass spectrometry, either GC or LC, have
been developed for the detection of a single class of analytes
[11,12] or for the analysis of multiple classes of illicit drugs
simultaneously [13,14]. The high specificity and the
increased signal-to-noise in combination with short chro-
matographic run times and a potential to reduce sample
preparation because there is no need for derivatization, make
LC–MS/MS the technique of choice for high-throughput
confirmation of multiple illicit drugs in oral fluid samples.
One major issue that needs to be addressed is the choice
of sampling method and the influence of the collected matrix
on the LC–MS/MS analysis. Mortier et al. used liquid
chromatography quadrupole-time-of-flight mass spectrome-
try with electrospray ionisation to successfully determine
morphine, codeine, cocaine, benzoylecgonine and amphe-
tamines in oral fluid samples obtained by spitting and
subjected to solid-phase extraction (SPE). However, when
authentic samples collected with a specific device were
analysed, interferences were noticed compromising the
quantitative analysis [13]. Dams et al. investigated the
influence of oral fluid matrix components (samples collected
with a neutral Salivette1) during post-column infusion of
morphine, after different sample preparation steps [15].
The Intercept1 is a FDA approved sampling device that
is used on a large scale in the US for workplace drug testing
[11]. It is also used to collect oral fluid samples for con-
firmation analyses in the joint roadside study between the
European Union and the US to detect driving under the
influence of drugs [16]. The collection system contains
stabilizing salts, non-ionic surfactants for surface wetting
and antibacterial agents, and guarantees a good stability for
most illicit drugs and their metabolites during storage at
4 8C. However, these ingredients can also cause interfer-
ences, e.g. ion suppression during LC–MS/MS analysis in
the absence of a suitable clean-up method.
We have validated a newly developed LC–ESI–MS/MS
method combined with a routine SPE clean-up for the simul-
taneous quantitation of the major analytes which can be
detected after consumption of basic illicit drugs; the oral fluid
was collected using the Intercept1 device. The method was
applied to Intercept1 samples collected at the roadside and
after a controlled administration of MDMA to volunteers.
2. Materials and methods
2.1. Materials
Ammonium formate and ammonium hydrogen carbonate
were purchased from Sigma–Aldrich (Steinheim, Germany).
Tetrahydrofuran (chromatographic grade) and hydrochloric
acid (fuming, 37%) were from the same supplier. Formic
acid, ammonia solution (32%, extra pure), hydrochloric acid
solution (0.1N) and all other solvents (HPLC-grade) were
purchased from Merck (Darmstadt, Germany). Solid-phase
extraction (SPE) cartridges Oasis1 MCX (30 mg, 1 cm3)
were from Waters (Milford, MA).
Individual stock solutions of the drugs and their deuter-
ated analogues were purchased from LGC Promochem
(Molsheim, France). Stock solutions of amphetamine-d11,
methamphetamine-d5, MDMA-d5, MDA-d5, cocaine-d3,
benzoylecgonine-d8, morphine-d3, codeine-d6 and 6-acetyl-
morphine-d6 were obtained at concentrations of 0.1 g/L in
methanol or acetonitrile. Amphetamine, methamphetamine,
MDMA, MDA, cocaine, benzoylecgonine, morphine,
codeine and 6-AM were certified at a concentration of
1 g/L in methanol or acetonitrile. Separate working solutions
of the drugs, for tuning and selectivity experiments, were
prepared in the laboratory at a concentration of 1 mg/L in
methanol. A mixed working solution of non-deuterated
compounds at 4 mg/L in methanol was used for the pre-
paration of calibrators and QC samples within each run. A
mixed internal standard working solution of 1 mg/L was
prepared in methanol. Working solutions were stored at
20 8C, and were prepared monthly. To obtain the lower
concentrations needed for internal standardization and vali-
dation of each experiment, further dilutions in water were
prepared the same day.
2.2. Specimens
Oral fluid used for the preparation of blanks, calibrators
and QC samples was obtained from healthy volunteers and
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collected with the Intercept1 collection device (OraSure
Technologies, Bethlehem, PA) according to the manufac-
turer’s instructions. Briefly, after gently wiping the collector
pad between gum and cheek for approximately 2 min (as a
kind of toothbrush), the device is placed in the supplied vial,
which contains a stabilizing buffer solution, and sealed.
After centrifugation, the recovered fluid was transferred
in cryotubes and represents a mixture of the collected oral
fluid and the buffer in a proportion of approximately 1:2. The
device collects an average of 0.38  0.19 mL of oral fluid
and a dilution factor of 1 in 3 is arbitrarily accepted [11]. The
tubes were sealed and stored at 20 8C prior to analysis.
Authentic oral fluid samples were collected by the police
at the roadside during roadblocks to intercept drivers under
the influence of drugs, using the same procedure as described
for the blank samples.
A third series of oral fluid samples were obtained with a
similar protocol from 18 volunteers who received either
placebo or a high (100 mg) or a low (75 mg) dose ofMDMA.
Oral fluid samples were collected at 1.5 and 5.5 h after
administration of the drug. The study protocol was approved
by the ethics committee of the University Hospital of
Maastricht in The Netherlands.
2.3. Sample preparation
Twenty-fivemicroliters of concentrated hydrochloric acid,
50 mL of an internal standard working solution (at 0.2 mg/L)
and 750 mL of water were added to 250 mL of oral fluid
specimen collected with the Intercept1 device. After
conditioning with 1 mL of methanol and 1 mL of 0.1N
hydrochloric acid, the diluted oral fluid samples were applied
onto the SPE columns. Clean-up was accomplished with
successive 1 mL washes of 0.1N HCl, tetrahydrofuran and
a mixture of methanol and water (50:50, v/v). The cartridges
were dried by applying full vacuum for 5 min before elution
with 0.5 mLof5%ammonia inmethanol.After the extraction,
the elution solution was treated according to a variety of
different protocols: a simple dilution with 1 mL of water
which had been previously proposed [17]; a fairly rapid
and controllable concentration step to 50–100 mL, performed
in a vacuum centrifuge (Jouan RC 10.22) at 40 8C, followed
by addition of 950 mL of ammonium formate buffer (10 mM,
with 0.01% formic acid, pH 4.2) before injection onto the LC
system; complete evaporation of the elution solution
performed with and without adding 50 mL of a 5% hydro-
chloric acid solution in methanol before taking to dryness. In
the latter case thedry residuewas then reconstituted in1 mLof
a mixture of the ammonium formate buffer pH 4.2 and
methanol (95/5, v/v).
2.4. Chromatographic conditions
LC was performed using a Waters Alliance 2695 separa-
tion module. All aspects of system operation and data
acquisition were controlled using MassLynx NT 3.5 soft-
ware (Micromass UK Limited, UK). Analytes were sepa-
rated on a XTerra MS C18 column (2.1 mm  150 mm,
3.5 mm) (Waters) using a gradient elution with 10 mM
ammonium bicarbonate (pH 10) (A) and methanol (B), at
a flow rate of 0.25 mL/min. A gradient was carried out
starting from 30% B at 3 min, B was then increased to 50%
over the next 1 min. From 4 min to 12 min, B was linearly
increased to 75%. At 12 min, B was increased to 90% in
1 min before returning to its initial conditions within 0.1 min
and equilibrating for 6.9 min, which resulted in a total run
time of 20 min. An injection volume of 20 mL was used.
2.5. Mass spectrometry
AQuattro Ultima tandem mass spectrometer (Micromass
UKLimited, UK) fitted with a Z-Spray ion interfacewas used
for all analyses. Ionisation was achieved using electrospray in
the positive ionisation mode (ES+). The following conditions
were found to be optimal for the analysis: capillary voltage,
1.0 kV; source block temperature, 120 8C; desolvation gas
(nitrogen) heated to 350 8C and delivered at a flow rate of
800 L/h. The appropriate multiple reaction monitoring
(MRM) conditions for the individual analytes and their
respective deuterated analogues, were determined by direct
infusion into the mass spectrometer. The cone voltage (CV)
was adjusted to maximise the intensity of the protonated
molecular species [M + H]+ and collision induced dissocia-
tion of each protonated molecule was performed. Collision
gas (argon) pressure was maintained at 2.7  103 mbar and
the collision energy (eV) adjusted to optimise the signal for
the most abundant product ions, which were subsequently
used for MRM analysis.
2.6. Method validation
2.6.1. Selectivity, stability, recovery, assessment of
matrix effects
The ability of the analytical method to differentiate and
quantify the analyte in the presence of other components in
the matrix and of other target analytes was assessed by
including blank specimens from a different origin in every
run, and by injection of single analyte solutions and evalu-
ation of the MRM transition signal.
Analyte stability in the final extract was checked by
repeated injections of an extracted calibrator at 80 mg/L
over 48 h, and plotting of the absolute peak areas as a
function of time.
Recoveries were estimated by comparing the responses
of an 80 mg/L calibrator when the non-deuterated com-
pounds were added before the extraction step with those
obtained when the non-deuterated analytes were added after
sample preparation.
To assess any potential suppression or enhancement of
ionisation due to the sample matrix, two types of experi-
ments were performed. In the first experiment, standards
were added after the sample pre-treatment, i.e. just before
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injection and the peak responses were compared to those
obtained from a methanolic standard diluted in the same
volume of ammonium formate buffer. In addition, for an
assessment of the effects of untreated samples, the diluted
oral fluid samples that would normally be applied to the SPE
cartridge were also directly injected into the LC. The second
type of experiment involved a continuous post-column
infusion of a mixture of the analytes of interest and their
deuterated analogues (10 mg/L at a flow rate of 10 mL/min)
to produce a constant elevated response in each MRM
channel. The interference of this constant response was
monitored following the injection of samples either prior
to or after SPE clean-up.
2.6.2. Linearity, intra-assay and inter-assay precision,
accuracy
Quantitation was performed by integration of the area
under the specific MRM chromatograms in reference to the
integrated area of its respective deuterated analogue which
was added before the extraction procedure. Freshly prepared
working solutions of 0.02, 0.1, 0.4 and 1 mg/L in water were
used to prepare oral fluid calibrators at a concentration of 2,
10, 20, 40, 80, 120 and 200 mg/L. Standard curves were
freshly prepared with each batch of QC and authentic sam-
ples. Standard curves were generated using a least-squares
linear regression, with a 1/xweighting factor. Quality control
samples (QC) were prepared for every run in blank oral fluid
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Table 1
MRM transitions and conditions for all compounds and their deuterated analogues
Compound Precursor ion (m/z) Product ions (m/z) Cone voltage (V) Collision energy (eV)
Amphetamine 136.10 119.10, 91.00 20 9, 17
Amphetamine-d11 147.10 98.00 35 18
Methamphetamine 150.10 119.00, 91.00 20 9, 20
Methamphetamine-d5 155.10 92.00 20 20
MDA 180.05 105.00, 77.00 20 22, 30
MDA-d5 185.00 168.10 20 10
MDMA 194.05 163.05, 105.10 40 12, 25
MDMA-d5 199.10 165.10 40 13
Cocaine 304.15 182.10, 82.10 20 18, 28
Cocaine-d3 307.15 185.10 22 20
Benzoylecgonine 290.15 168.10, 105.00 45 20, 30
Benzoylecgonine-d8 298.10 171.00 45 20
Morphine 286.10 165.10, 152.00 75 40, 57
Morphine-d3 289.00 165.10 75 47
6-AM 328.10 165.00, 152.00 80 40, 70
6-AM-d6 334.20 165.10 75 40
Codeine 300.10 165.10, 128.10 70 43, 58
Codeine-d6 306.20 165.10 70 45
Italicised transitions were used for quantitation.
Table 2
Stability of 6-AM and cocaine in oral fluid samples following a variety of post-SPE protocols
Post-SPE protocols Results
pH Stability over 48 h
6-AM Cocaine
1 Dilution with water 11 Unstable Unstable
2 Concentration to 50–100 mL and dilution with water 8–9 Stable Unstable
3 Concentration to 50–100 mL and reconstitution in 0.95 mL
ammmonium formate buffer 10 mM; 0.01% formic acid)a
4–5 Stable Stable
4 Complete evaporation and reconstitution in 0.95 mL ammmonium
formate buffer 10 mM:0.01% formic acid)b
4-5 Stable Stable
5 Concentration to 100 mL, addition of 50 mL MeOH:HCl (95:5),
complete evaporation and reconstitution in 0.95 mL ammmonium
formate buffer 10 mM:0.01% formic acid)c
4–5 Stable Stable
a Regression analysis showed a slight negative trend for cocaine and, to a lesser extent, for benzoylecgonine over a period of 48 h. The decrease
in peak area was significantly different from zero (t-test, p < 0.05). For all other compounds, there was no significant change of the peak area.
b Loss of amphetamines has been reported in the evaporation process.
c This procedure extends the sample preparation considerably.
at a concentration of 4, 12 and 100 mg/L. Intra-assay preci-
sion was evaluated by replicate (n = 4) analysis of the three
QC samples in one run. Inter-assay precision was evaluated
by replicate analysis of the QC samples in several experi-
ments performed on four different days by two operators.
Comparing the calculated concentrations of all calibrators
and QC samples to their respective nominal values, provided
data on the accuracy of the method.
2.6.3. Limit of detection and limit of quantitation
The limit of quantitation (LOQ) was defined in this study
as the lowest calibrator with an acceptable relative uncer-
tainty (coefficient of variation 20% and an accuracy of
100  20%). The limit of detection (LOD) was estimated
from extracted oral fluid samples, spiked with decreasing
concentrations of the analytes, where the response of the
quantitative ion was equal to 10 times the response of the
blank extract.
3. Results and discussion
3.1. Method validation
The applied gradient ensured the elution of all the drugs
examined within 14 min and produced chromatographic
peaks of acceptable symmetry. Selectivity of the method
was achieved by a combination of retention time, precursor
and product ions.
With the exception of MDA, the most prominent pre-
cursor-product transitions were used for quantitation of the
non-deuterated compounds and the next most abundant,
used as qualifiers. For MDA an elevated background
response was noted when using the MRM transition based
on the most prominent product, i.e. m/z 180 > 163.
Improved sensitivity (based on signal-to-noise) was
achieved when the MRM transition utilised an alternative
product ion (Table 1).
For the corresponding deuterated analogues, only one
transition was monitored. Injection of single analyte solu-
tions did not produce interference in the other MRM chan-
nels.
One of the limiting factors of LC–MS(-MS) applications
is the potential presence of a matrix effect, leading to
suppression or enhancement of the analyte response. This
typically occurs as a result of insufficient clean-up of the
matrix, and although partly overcome by the use of deuter-
ated internal standards, it leads to variable sensitivities, and
decreased precision and accuracy. Dams et al. [15] observed
no signal suppression for morphine in oral fluid collected
with a Salivette1 after a simple dilution step, and a small ion
suppression effect after SPE (maximum 10–15%) in the ESI
mode. Protein precipitation resulted in suppression of 50–
70% in some areas of the chromatogram. The Intercept1
collector contains a variety of chemicals, i.e. sodium chlor-
ide, sodium benzoate, potassium sorbate, bovine gelatin,
tween 20, chlorhexidine digluconate and a blue dye, some of
which can interfere with the LC–MS/MS detection signal.
After direct injection of diluted spiked oral fluid samples
collected from seven individuals and analysed without SPE
clean-up, relatively small variations in the responses for
cocaine and benzoylecgonine (ranging from 12% suppres-
sion to 24% enhancement) were observed. In all cases there
was an enhancement in the responses for MDMA and
methamphetamine, which was very variable ranging from
2 to 62%. The most dramatic effect was the suppression of
the analyte signal for morphine and 6-AM (68–87%), and to
a lesser extent for codeine, amphetamine and MDA (33–
67%). The Oasis1 MCX (30 mg, 1 cm3) SPE cartridges
utilise mixed-mode (cation-exchange) sorbents, which pro-
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Table 3





Amphetamine 90.7  4.4 6.2
Methamphetamine 83.7  4.1 4.6
MDA 82.2  2.9 7.8
MDMA 76.6  2.3 1.9
Cocaine 93.1  0.7 +5.1
Benzoylecgonine 93.9  2.0 +12
Morphine 99.0  0.9 13
6-AM 91.8  1.6 9.8
Codeine 94.4  2.0 +3.4
Data represent the mean of four experiments with an 80 mg/L
calibrator.
Table 4
Equation of a typical calibration curve with coefficient of determination (r2), and the estimated limits of quantitation (LOQ) of the method
Compound Equation r2 LOQ (mg/L)
Amphetamine y = 1.0306x + 0.1952 0.999735 2.0
Methamphetamine y = 1.8859x + 0.0032 0.999279 2.0
MDA y = 0.4206x  0.0843 0.999731 2.0
MDMA y = 1.1554x + 0.0752 0.999598 2.0
Cocaine y = 1.0043x + 0.8846 0.999952 2.0
Benzoylecgonine y = 1.4007x + 0.2487 0.999781 2.0
Morphine y = 1.4769x + 0.0991 0.999467 2.0
6-AM y = 0.9387x + 0.1621 0.999717 2.0
Codeine y = 1.0836x + 0.0802 0.999288 2.0
vide effective sample clean-up for basic drugs. The pro-
posed SPE procedure takes approximately 35 min for a
batch of 20 samples and uses three washing steps for
selective clean-up of the different components. The
0.1N HCl solution locks the analytes and matrix onto
the sorbent using ion-exchange mechanisms and removes
any salts and weakly retained species. Tetrahydrofuran
was selected because of its water miscibility and because it
removes a significant fraction of surfactant material. The
third wash with methanol/water (50:50) removes any
remaining surfactants. The elution solution was chosen
to elute the analytes while retaining the strong organic
bases (antibacterial) from the preservative solution. After
the extraction, the elution solution was treated according
to a variety of different protocols summarised in Table 2.
Since pH is a crucial factor in the stability of cocaine and
6-AM, efforts were made to lower the pH of the injected
solutions. Stability of analytes was monitored by means of
repeated injections of extracted samples over 48 h, and
plotting absolute peak areas as a function of time. Eva-
poration of the eluate to approximately 50–100 mL and
reconstitution with 0.95 mL of an ammonium formate
buffer (10 mM:0.01% formic acid) was considered the
most suitable (Table 2).
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Fig. 1. Evaluation of the effect of the matrix on 6-AM and cocaine response by post-column infusion following an injection of a water-only
control (a and d) and a blank sample prior to SPE (b and e) and the same sample post SPE clean-up (c and f). The dotted areas indicate the elution
position for 6-AM and cocaine, respectively. Peak intensity is shown on the right-hand corner of each trace.
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Table 5
Intra-assay and inter-assay precision (expressed as variation coefficient) and accuracy (expressed as percent deviation) of the QC samples spiked
at a concentration of 4.0, 12.0 and 100.0 mg/L
Compound Intra-assay precision (n = 4) Inter-assay precision (n = 8) Accuracy
Low Medium High Low Medium High Low Medium High
Amphetamine 1.9 1.0 3.1 5.4 5.3 8.6 3.1 0.8 1.8
Methamphetamine 3.3 1.9 1.1 2.2 0.5 1.7 4.2 2.0 1.4
MDA 3.9 3.0 0.8 1.1 1.5 2.6 3.4 0.1 1.7
MDMA 1.8 1.3 4.5 5.7 5.0 4.9 5.7 1.0 0.6
Cocaine 1.9 1.2 1.2 4.3 5.3 1.8 5.1 1.8 0.6
Benzoylecgonine 1.0 1.2 0.9 5.0 12.6 2.3 1.4 1.3 0.1
Morphine 1.0 1.5 1.2 3.3 2.2 3.9 1.4 2.2 1.4
6-AM 2.3 2.6 0.3 4.2 3.2 3.1 1.5 1.0 1.6
Codeine 7.7 1.4 2.2 1.2 1.3 2.9 1.1 0.1 0.5
Table 7
Summary of oral fluid concentrations (mg/L) of cocaine (COC), benzoylecgonine (BE), 6-AM, morphine (MOR), codeine (COD), amphetamine
(AMP), MDMA and MDA in authentic samples from potentially intoxicated drivers
ID COC BE 6-AM MOR COD AMP MDMA MDA
1 >2000 >2000 238 725 107 – – –
2 26 146 – – – – – –
3 915 46 – – – – – –
4 – – – – – 802 – –
5 – – – – – 1329 – –
6 1726 1019 291 1063 132 – 3 –
7 – – – – – – 1198 15
8 22 < 2 – – – – 11 –
9 – – – – – 425 2 –
10 115 199 – – – 13 2 –
11 – – – – – 1797 151 15
12 12 63 – – – 75 1066 8
13 – – – – – 358 < 2 –
14 – – – – – 488 >2000 123
15 – – – – – 325 13 <2
16 >2000 >2000 – – – – – –
17 191 124 – – – 30 330 41
18 555 186 – – – – – –
19 72 140 – – – 41 598 33
20 – – – – – 745 – –
Table 6
SAMHSA proposed threshold concentrations for oral fluid testing laboratories
Drug classes Analytes Threshold concentrations (mg/L)
Screening test Confirmatory test
Amphetamines d-Methamphetaminea 160(1)/50(2) 160(1)/50(2)
d-Amphetamine 160(1)/50(2)
Cocaine Benzoylecgoninea 20 8
Opiates Morphinea 40 40
6-AM 4
Marijuana D3-Tetrahydrocannabinola 4 2(1)/4(2)
(1) Substance Abuse and Mental Health Service Administration. Mandatory guidelines for federal workplace drug testing programs. Draft #3.
December 2000. (2) Substance Abuse and Mental Health Service Administration. Mandatory guidelines for federal workplace drug testing
programs. Draft #4. September 2001.
a Target analyte for initial screen.
The results of the extraction recovery study are presented
in Table 3. Very high and reproducible recoveries were
obtained with this SPE procedure for all analytes.
No clear interferences were detected during the ana-
lysis of blank samples. Application of the SPE procedure
to selectively spiked samples (one compound and its
deuterated analogue), showed no detectable signal
(>LOD) in other MRM channels, except when 6-AM
was extracted. There was a clear response for morphine
and its deuterated analogue after extraction of 6-AM only
samples. The estimated concentration of the morphine
detected was on average 4.2  0.05% of the 6-AM con-
centration in the sample and remained unchanged for a
48-h injection time. As expected, the ratio of the 6-AM
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Fig. 2. The precursor-product transitions used for quantitation of (a) benzoylecgonine; (b) morphine; (c) 6-AM; (d) codeine; (e) MDA; (f)
amphetamine; (g) MDMA; (h) methamphetamine; and (i) cocaine in the 12 mg/L calibrator prepared by the routine SPE method. Peak intensity
is shown on the right-hand corner of each trace.
response to its deuterated analogue remained identical to a
non-extracted standard.
An assessment of the matrix effect after SPE clean-up is
presented as a percentage of ion suppression or enhancement
in comparison to a standard. The results are shown in Table 3
and clearly indicate that there is only a minimum effect on
ionisation due to the presence of the matrix. The post-
column infusion experiments were performed to assess
the effect of the matrix throughout the course of the whole
chromatographic run and not just at the elution time for the
analytes. The effect on the response for one of the most
severely affected compounds, i.e. 6-AM, and one of the least
affected compounds, i.e. cocaine, are given in Fig. 1. Fig. 1a
and d show the responses obtained in these channels follow-
ing an injection of a water-only control. The slight changes
observed in baseline correspond to the changes in the LC
gradient. The responses following the injection of a sample
prior to SPE and the same sample following SPE, are also
given. The results confirm the usefulness of the SPE method
as a sample clean-up before chromatography to obtain
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Fig. 3. Box-and whisker plots of MDMA (A) and MDA (B) levels in oral fluid samples collected with Intercept1 after a controlled
administration of a single dose ofMDMA. Concentrations plotted on the Y-axis are expressed asmg/L. The central box represents the values from
the lower to upper quartile (25–75 percentile). The middle line represents the median. The horizontal line extends from the minimum to the
maximum value, excluding ‘‘outside’’ (square marker) and ‘‘far out’’ values (filled square marker) which are displayed as separate points.
reproducible and reliable quantitative results for all com-
pounds without major interferences of matrix components.
Calibration curves were made for each compound by
plotting the peak-area ratios (compound/internal stan-
dards) against the concentration. A weighted (1/x) linear
regression line was applied for each compound. Linear
responses were obtained for all the compounds over the
range investigated (2–200 mg/L). Linearity, intra-assay
and inter-assay precision, and limits of quantitation are
summarised in Tables 4 and 5. Coefficients of variation at
the low (4 mg/L), medium (12 mg/L) and high (100 mg/L)
QC level were consistently below 10%, except in one case.
Fig. 2 shows an MRM chromatogram after extraction of a
medium QC sample. The limit of quantitation for all
analytes (Table 4) was sufficiently low to meet the require-
ments of SAMHSA for oral fluid testing in the workplace
(Table 6). Limits of detection were estimated to be
between 0.2 and 0.5 mg/L.
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Fig. 4. MRM chromatograms obtained following the analysis of an authentic oral fluid specimen obtained from a driver in a roadside setting. The
figure shows the response for the two transitions (qualifier and quantifier) of benzoylecgonine (a, b), morphine (c, d), 6-AM (e, f), codeine (g, h)
and cocaine (i, j). Peak intensity is shown on the right-hand corner of each trace.
For each compound two MRM transitions were
monitored to provide additional confidence in identification.
The ratio of these ions (qualifier ion to quantitation ion) was
calculated. For all of the compounds investigated, ion ratios
were found to be very reproducible with variation (as %CV)
less than 8%.
3.2. Samples
One hundred and eight oral fluid samples were collected
with Intercept1 from volunteers who received a single
representative dose of MDMA (75 or 100 mg), or placebo.
The quantitative results are presented as box-plots in Fig. 3.
Samples with a concentration above the linear range of the
calibration curve were diluted appropriately and re-analysed.
Concentrations of MDMAwere quite variable and generally
high, though not as elevated as in previous studies where the
same dose of MDMA was administered and samples were
collected by spitting [18,19]. The corresponding MDA
concentrations remained quite low, even at 5.5 h. To our
knowledge, this is the first study to report on typical concen-
trations of MDMA and MDA in oral fluid samples collected
with Intercept1 after a controlled administration and using a
validated method of analysis.
During roadside controls for drugged driving, the police
collected fifty-five authentic oral fluid samples for a con-
firmatory analysis in the laboratory. Fig. 4 shows the typical
MRM transitions of an Intercept1 sample of a mixed
cocaine/heroin user. The presence of 6-AM is an important
feature of oral fluid analysis in comparison to blood, and has
been demonstrated with this collection device in a
previously published paper [20]. In Table 7 a summary of
the quantitative results for the positive samples is presented.
The measured concentrations varied considerably and
several samples had to be re-analysed after a 1 in 10 dilution
with blank oral fluid and with water. Identical results were
obtained which indicated that the method was also applic-
able to a smaller sample size. The choice of sample volume
will largely depend on the application and the requirements
for sensitivity. For instance, Dams et al. [21] analysed oral
fluid samples collected from pregnant methadone mainte-
nance treatment participants using the Salivette1 device. In
contrast to the Intercept1 specimens, Salivette1 samples are
not further diluted, e.g. with stabilizing buffer prior to
analysis, however, nevertheless, in this population low me-
dian concentrations were reported, i.e. 7.5 mg/L morphine,
5.2 mg/L 6-AM, 3.4 mg/L benzoylecgonine and 6.4 mg/L
cocaine.
4. Conclusions
We have validated a method for the simultaneous ana-
lysis of the most prevalent basic illicit drugs and their
metabolites in oral fluid collected with Intercept1. The
method combined SPE with LC–MS/MS and provided a
thorough clean-up of the matrix to avoid ion suppression, in
combination with a high recovery, excellent precision and
accuracy in the linear range from 2 to 200 mg/L, using
250 mL of sample. The method was successfully applied
to Intercept1 samples collected at the roadside and after a
controlled administration of MDMA to volunteers.
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